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Preface to ”Metastatic Progression and 
Tumour Heterogeneity”
Tumor heterogeneity is one of the biggest current challenges for cancer therapy. 
Exciting developments in single-cell -omics, cellular tracking, and imaging, alongside the expansion 
of new tools to study patient samples enable a deeper understanding of the molecular mechanisms 
that drive tumor progression. These approaches have recently highlighted the broad inter- and 
intra-tumoral heterogeneity that exists amongst patient cohorts and across tumor streams, while 
longitudinal studies indicate that the diversity of malignant cell populations that make up primary 
tumors and metastases can evolve in space and time.
Furthermore, the cellular and molecular features of the tumor microenvironment, including 
immune cells, have to be taken into consideration for the understanding of tumor progression. 
Targeting both tumor cells and tumor microenvironment is also an exciting area of investigation, 
with new approaches such as immunotherapy now emerging as powerful treatment alternatives.
Thus, comprehensive analyses of tumor heterogeneity are essential to both improve the overall 
treatment of patients with cancer and further progress towards precision medicine. This Special Issue 
highlights some of the state-of-the-art technologies aiming to dissect the heterogeneity of malignant 
cells and their microenvironment and will cover some of the promising discoveries that are likely to 
improve cancer patients’ outcome.
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Abstract: Therapies that prevent metastatic dissemination and tumor growth in secondary organs
are severely lacking. A better understanding of the mechanisms that drive metastasis will lead to
improved therapies that increase patient survival. Within a tumor, cancer cells are equipped with
different phenotypic and functional capacities that can impact their ability to complete the metastatic
cascade. That phenotypic heterogeneity can be derived from a combination of factors, in which
the genetic make-up, interaction with the environment, and ability of cells to adapt to evolving
microenvironments and mechanical forces play a major role. In this review, we discuss the specific
properties of those cancer cell subgroups and the mechanisms that confer or restrict their capacity
to metastasize.
Keywords: metastasis; heterogeneity; plasticity; epithelial-to-mesenchymal transition; biomechanics;
circulating tumor cells (CTCs); extracellular vesicles; metastatic niche; epigenetics; CTC-clusters
1. Cancer Cell Heterogeneity: A Hierarchical Matter?
1.1. Cancer Origin and Evolution
A normal cell transforms into a cancer cell by accrual of multiple genetic mutations over time, which
ultimately lead to uncontrolled cellular proliferation. Genetic drift may arise from a combination of
germline or spontaneous mutations, exposure to environmental carcinogens, genome rearrangements,
and/or increased genome instability [1]. Those genetic changes can subsequently impact a cancer
cell’s epigenetic landscape by changing chromatin regulatory machinery or by aberrant expression of
transcription factors that normally drive cellular differentiation and specify cellular fate [2]. To add to
that complexity, the genomic/epigenomic drivers of a cancer can change over time. Standard-of-care
treatment for most solid tumors comprises a series of aggressive chemotherapies that, in combination
with aberrant cancer cell divisions and fluctuating microenvironmental landscapes, create opportunity
for cancer cells to further mutate, adapt, and evolve, often toward a more aggressive phenotype. In this
way, genetic and epigenetic modifications create phenotypic and functional heterogeneity [3] that fuel
tumor progression and, consequently, represent a major therapeutic obstacle [4].
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1.2. A Cancer Cell Hierarchy
Notwithstanding the genetic component to cancer development and progression, it is also well
established that epigenetic mechanisms can create functional heterogeneity in genetically identical
cancer cells, which is fundamentally important to tumor growth and metastasis. That notion is solidified
in the idea that genetically identical cancer cells can be hierarchically organized according to phenotype,
in this case, tumor-initiating potential [5–9]. At the top of the hierarchy sit the aggressive cancer
stem cells (CSCs, or tumor-initiating cells), which, in a manner akin to stem cell divisions in normal
tissues, self-renew to maintain the tumor-initiating cell pool or divide asymmetrically to produce
non-tumor-initiating cell progeny (Figure 1). The balance between self-renewal and differentiation is
determined by a combination of cell-intrinsic and environmental factors, which can dynamically impact
cellular heterogeneity observed within a tumor. Generally, a higher percentage of tumor-initiating
cells is associated with more aggressive and metastatic tumors [10,11]. With the unique capacity to
fuel tumor growth, to metastasize, and to resist therapeutic treatment, attempts to better identify and
functionally characterize those aggressive cells are of great interest.
 
Figure 1. Schematic overview of cancer cell phenotypic heterogeneity. Cancer cells with an identical
genetic background can be hierarchically organized according to cell phenotype. CD44Hi cancer stem
cells (CSC) are an aggressive cell type that have likely undergone a partial-epithelial-to-mesenchymal
transition (partial-EMT) to acquire multiple biological traits that enhance their tumorigenic and
metastatic potential. Cells residing in a CD44Hi CSC state sit at the top of the hierarchy, where they can
self-renew to maintain the aggressive CSC pool or, alternatively, undergo asymmetric divisions to form
more differentiated CD44Lo (non-CSC) progeny. In some cancer types, CD44Lo epithelial cells have the
potential to ascend the hierarchy and enter into the aggressive CD44Hi state.
The origins of tumor-initiating cells are not yet clearly defined; however, it has been hypothesized
that they may arise via oncogenic transformation of normal tissue stem or progenitor cells [12–14].
Alternatively, tumor-initiating cells may also arise via reversion of non-tumor-initiating cancer
cells into a tumor-initiating cell state [7,10,15]. That idea is conceptually important as it implies
that tumor-initiating cells can be continually replenished throughout tumorigenesis. Moreover,
it provides a mechanism for non-aggressive tumors to transition toward more aggressive and metastatic
disease. Accordingly, the characterization of signaling mechanisms that generate and maintain highly
tumorigenic, metastatic, and chemotherapy-resistant tumor-initiating cells should provide novel
avenues for therapeutic design. In that regard, the development of new technologies, such as single-cell
2
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sequencing [16,17] and barcoding-based functional assays [9,18–20], applied to clinically relevant
models, should be able to address these issues in the near future.
1.3. CD44: Defining Aggressive Cancer Cells
The use of membrane-anchored protein markers to distinguish subpopulations of aggressive
cancer cells has proven a useful tool in cancer research [21–25]. In a wide variety of solid tumors,
including those of breast [6], gastric [26], pancreas [27], ovary and colon [28–30], and also in blood
malignancies [31], residence in, or transition into the aggressive tumor-initiating cell state can be
monitored by high expression of the cancer stem cell marker CD44—where the nomenclature CD44Hi
represents cells enriched for that aggressive cancer cell phenotype [32–36]. The CD44 molecule can
exist in a variety of splice isoforms that are functionally important. Recent findings link the expression
of different CD44 isoform variants with cancer progression and specific tumor cell features, including
pro-survival signaling [37], cellular reprogramming [38], acquisition of migratory capacity [39],
and tumor initiation [40–42]. CD44 can also facilitate the arrest of circulating tumor cells prior to
extravasation [43]. Together, these findings emphasize the cellular and molecular heterogeneity that
exists within cancer cell populations, which belie the power of bulk population analyses to define
putative therapeutic options.
1.3.1. CD44Lo versus CD44Hi Cells: Epithelial versus Mesenchymal Cell States
Compared to the bulk tumor mass, the aggressive CD44Hi cancer stem cell subpopulation is often
associated with loss of epithelial characteristics and gain of mesenchymal traits [10,15]. Consistent with
those findings, activation of the epithelial-to-mesenchymal transition (EMT) program is one means by
which poorly aggressive CD44Lo epithelial cancer cells gain entrance into a more aggressive CD44Hi
cancer stem-like state [44–46]. The EMT transcription factors SNAI1 (snail family transcriptional
repressor 1), SNAI2, ZEB1 (zinc finger E-box binding homeobox 1), among others, are key mediators of
that process [47]. Indeed, ZEB1 also drives splicing of CD44 in a manner that promotes tumorigenicity,
recurrence, and drug-resistance [48,49]. Along with the acquisition of cancer stem-like traits, the EMT
also increases a cancer cell’s ability to invade and migrate, promotes cancer cell spread away from
the primary tumor, entrance into the circulation, and extravasation at a secondary site [50]. In line
with those findings, single-cell expression analysis of disseminated tumor cells isolated from breast
cancer patient-derived xenograft (PDX) models at early stages of metastatic disease display gene
expression profiles consistent with the EMT [17]. Additional studies in preclinical models also establish
a correlation between existence of mesenchymal CSC populations and metastatic burden, and that
inhibiting EMT-transcription factor expression abolishes tumor-initiation and metastatic potential of
aggressive cancer cells [51,52]. Moreover, loss of an epithelial phenotype and gain of mesenchymal
features correlates with poor clinical outcome in some tumor types [53–58].
1.3.2. Novel Markers to Define Metastatic Cells
The search for additional markers to refine the aggressive cancer stem cell population has revealed
that the CD44Hi cancer cell compartment is heterogeneous and encompasses a variety of phenotypic
cell states [6,59,60]. For example, expression of the marker CD24 has been used to distinguish between
different cancer cell phenotypes, where enhanced tumor-initiating potential correlates with residence
in a CD44HiCD24Lo state and the CD44HiCD24Hi cell state is further associated with tolerance to
chemotherapy [61]. In addition, a recent study showed a novel role for integrin β4 (CD104) in the
regulation of cell transitions across the epithelial–mesenchymal spectrum, where CD44HiCD104+ cells
reside in a more epithelial state than their CD44HiCD104− counterparts [60]. That study characterized a
CD104 expression ‘sweet spot’ for tumor-initiating potential that defined a CD44HiCD104+ intermediate
epithelial–mesenchymal state [60]. Furthermore, a follow-up study demonstrated that non-canonical
WNT signaling drives CD44Hi cells through the CD104+ to CD104− transition with a concomitant
shift from a partial-EMT state to a mesenchymal state. That phenotypic change is indeed associated
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with a significant decrease in tumor-initiating potential, suggesting that retention of certain epithelial
characteristics, i.e., a partial-EMT state, provides optimal tumorigenicity [54,62–66].
2. Cancer Cell Plasticity: Shaping Metastatic Fitness
We and others have shown that CD44Lo cell populations are not locked in their epithelial state,
rather they can transition into the aggressive CD44Hi state via activation of components of the EMT
program [15,33,35,44]. Those findings suggest that poorly tumorigenic CD44Lo cells may also have
the intrinsic potential to seed metastases by transitioning into a CD44Hi state, albeit with far more
biological effort than pre-existing CD44Hi cells. If true, CD44Lo cells may also be present at very early
stages of metastatic dissemination. Accordingly, while pre-existing CD44Hi cells are highly enriched for
metastatic potential, defining a tumor’s CD44Hi content at one specific time point may not adequately
capture the tumor’s true metastatic potential. Additionally, and although yet to be clarified, it has
been suggested that certain tumor cells are more suited to sense, compute, and respond to signals from
their microenvironment that initiate the EMT program [44]. Indeed, we have previously identified
that tumor cells maintaining the ZEB1 promoter in a bivalent chromatin configuration are highly
conducive to activating the EMT program, or part thereof. In contrast, tumor cells that maintain the
ZEB1 promoter in a repressed state are less likely to undergo the EMT [44]. Together, these studies
suggest that strategies designed to prevent cellular plasticity combined with strategies to eradicate
existing CD44Hi cells will be required to treat cancer effectively.
3. The Seed, the Journey, and the Soil: The Metastatic Cascade
Metastasis is initiated when cells migrate away from the primary tumor and invade into
neighboring tissue toward blood or lymphatic vessels. After vessel wall barrier transmigration
(intravasation), the invasive cells, now referred to as circulating tumor cells (CTCs), are exposed to a
variety of arduous conditions, including a novel microenvironment, exposure to new cell types and
signals, anchorage-independent growth, and shear forces from the blood flow. As such, survival in
the circulation poses an extremely harsh selection process that very few CTCs can withstand. While
CTCs are indeed detected in the majority of patients with carcinoma [67,68], it has been suggested
that as few as 1–4% of CTCs successfully complete the metastatic cascade and successfully form
metastatic foci [67–70]. That inefficiency suggests that CTC intrinsic features likely co-operate with
surrounding tumor stroma and vascular environments to determine overall metastatic success [71,72].
CTCs thus represent a minority subpopulation of a patient’s tumor, where the role of hemodynamic
forces, endothelial fitness, and blood cells are capital for tuning CTC metastatic potential. CD44Hi
tumor-initiating cells and the EMT program endow cancer cells with the very ability to survive these
arduous conditions. Indeed, studies analyzing CTCs in human patients are enriched for an EMT
phenotype [73,74].
3.1. Entering the Circulation, Off They Go
Tumor cells invade into their surrounding tissues toward the lymphatic and/or vascular circulation
as single mesenchymal or amoeboid cell types, or collectively as epithelial sheets or clumps [75,76].
A common way for tumor cells to gain access to the circulation is via disruption of tumor vasculature
integrity that enables transendothelial migration. That process is enhanced in the setting of
tumor-induced chronic inflammation [77], where endothelial cell integrity and selective permeability
are lost [78]. Endothelial disruption is predominantly caused by tumor infiltrating leukocytes, such as
neutrophils [79,80] and macrophages [81], that communicate with tumor cells to promote intravasation
by facilitating angiogenesis together with the breakdown and remodeling of the extracellular matrix [82].
In fact, macrophage depletion in mice completely abrogates breast cancer metastasis. Endothelial
integrity disruption also exposes extracellular matrix proteins such as von Willebrand factor (vWF),
collagen, or fibronectin, which in turn, recruit and activate platelets that act in concert to further tune
tumor cell intravasation [83,84] (Figure 2). Interestingly, and together with cytokines and growth
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factors secreted by the tumor stroma, activated platelets at tumor vessel disruption sites can directly
contribute to the initial invasive phenotype of tumor cells by the release of transforming growth factor
beta TGFβ [85,86]. Indeed, platelet-derived TGFβ can induce the EMT in tumor cells entering the
circulation [85,87].
 
Figure 2. From invasion into the circulation. Tumor cells can reach the vasculature and enter the
circulation as single circulating tumor cells (CTCs) or CTC clusters. The latter may show a variable
degree of complexity according to cell heterogeneity within the primary tumor (tumor mass A) and/or
the cells encountered during the process of intravasation and in the circulation, such as blood cells
(e.g., platelets, neutrophils) or due to encounters with tumor cells from a different primary site (tumor
mass B). Cancer cells within the primary tumor can reside in diverse stages of differentiation along an
epithelial-to-mesenchymal spectrum. Cells that display mesenchymal features may have enhanced
survival, proliferation, and invasiveness and express cancer stem-like markers, including the adhesion
molecules CD44 or plakoglobin. Homotypic interactions between tumor cells, mediated by CD44
among others, may lead to the formation of a CTC cluster. At the moment of intravasation, disruption of
endothelial integrity by invasive tumor cells exposes extracellular matrix proteins (yellow line) including
von Willebrand factor (vWF), collagen, or fibronectin, which recruit and activate blood platelets. In
turn, platelets secrete transforming growth factor beta TGFβ, among many other angiogenic and
pro-inflammatory factors that can induce tumor cells to undergo the EMT and induce a mesenchymal
phenotype in endothelial cells, thereby increasing endothelial permeability and the expression of Notch
ligands. Activation of Notch signaling in tumor cells supports survival and proliferation, mostly
on CSC populations. Once tumor cells have entered the circulation, activated or resting platelets
(unpublished observation) can bind to single CTCs or CTC clusters and support survival by protecting
them from shear stress as well as enhancing cell adhesion at distant sites of arrest.
Besides platelets, CTCs may also tune intravasation themselves and take advantage of the
endothelial microenvironment. For example, human breast cancer cells induce mesenchymal
characteristics in endothelial cells, as evidenced by upregulation of smooth muscle actin (ACTA2) and
fibroblast specific protein 1 (FSP1), a phenotype also detectable in human neoplastic breast biopsies.
Subsequently, the altered endothelial cells display enhanced survival, migratory, and angiogenic
properties and are in turn capable of improving tumor cell survival and invasiveness via the TGFβ
and Notch–Jagged1 signaling pathways [88]. Indeed, Notch ligands are frequently present on
5
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tumor-associated endothelial cells [89–92], and, independently of their roles in angiogenesis [93],
they can also activate Notch signaling in tumor cells, thus enhancing aggressiveness, survival, and
metastasis in diverse cancers [94–96]. Those advantages were precisely observed in CD44HiCD24Lo/−
CTCs [97]. Similarly, a CD133+ cancer-stem cell phenotype is induced by Notch signaling in colon
cancer [98]. Together, these observations indicate that the stem-like CTC phenotype may be enhanced
by endothelial cell crosstalk.
3.2. In Transit: Better Together
3.2.1. CTC Clustering
The phenotypic, morphological, and functional properties of heterogeneous tumor cell populations
at the primary tumor site, may lead to differential mechanisms of tumor cell shedding into circulation.
In this sense, single CTCs and/or collectively migrating clusters—ranging from two to 50 cells—are both
detected within the circulation of patients with metastatic solid cancers [99–102]. Some CTC clusters
have been characterized as polyclonal tumor cell groupings suggesting that 1) they may arise from
different tumor masses or metastatic foci [103,104] or 2) clustering does not necessarily occur prior to
departure from the primary site, but during intravasation [105,106], transit in the circulation [103,104],
or at the secondary arrest site [107] (Figure 3). Recent data derived from pre-clinical murine models
demonstrate that CTC clusters show a 23–50-fold increased metastatic potential over single CTCs and
are known to increase in number during disease recurrence and the development of chemotherapy
resistance [74,103].
 
Figure 3. From the circulation to extravasation. CTCs that survive the harsh conditions of the blood
microenvironment will eventually come into contact with, and arrest, on the endothelial cells lining
the blood vessels at the metastatic site. Adhesion to the endothelial cells depends on the adhesion
receptor repertoire of the tumor cells and in the case of heterotypic clusters, on the adhesion receptor
repertoire of accompanying cells, for example, neutrophils and platelets. In addition to their role
in adhesion, neutrophils and platelets can further enhance extravasation by increasing endothelial
permeability via TGFβ and vascular endothelial growth factor A (VEGF secretion. Endothelial arrest
predominantly takes place at sites where blow flow is low enough to allow stable adhesion to the
vasculature. After this point, higher flow profiles are needed to induce endothelial remodeling around
the arrested CTC, an essential process for successful extravasation. Clustering of polyclonal CTCs can
occur at the site of arrest and/or extravasation, together with blood cells.
6
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The mechanisms behind a CTC cluster’s enhanced metastatic fitness are currently under
investigation. One hypothesis suggests that differential expression of cell junction proteins may
play a relevant role, as cell–cell junctions are important regulators of cell phenotype and function.
Indeed, preserving cell–cell contacts protects clusters from anoikis [74] and enhances their survival and
colony-forming potential [103,106]. For example, knockdown of the cell junction protein plakoglobin
in mouse models abrogates CTC cluster formation and drastically inhibits lung metastasis [103].
Additionally, recent findings demonstrate that CTC clusters are enriched for cells with cancer stem
cell-like features [74,105], whereby intercellular homotypic interactions between the cancer stem cell
marker CD44 molecules enhance cluster formation [104]. Hence, intercellular cell–cell contacts within
the cluster, in addition to paracrine signals, may be key to the maintenance of that aggressive stem-like
cancer cell state. Furthermore, during development, loss of cell–cell junctions is an initiating step in the
EMT, while maintenance of cell–cell junctions is required to preserve the embryonic stem cell state and to
reprogram somatic cells into induced-pluripotent stem cells [108–110]. Consistent with those findings,
it has recently been shown that classic binding sites for pluripotency and proliferation-associated
transcription factors such as POU class 5 homeobox 1 (POU5F1/OCT4), SRY-box transcription factor 2
(SOX2), and Nanog homeobox (NANOG, are specifically hypomethylated in clustered CTCs [111] and
that pharmacological dissociation of CTC clusters reverts their methylation profile and suppresses
metastasis. Those findings suggest that the distinct differentiation states between single CTCs and CTC
clusters, driven in part by pluripotency factors, may account for differences in their metastatic potential.
The hypothesis that hypomethylation of pluripotency sites may account for the differential metastatic
potential of CTC clusters versus single CTCs is supported by data demonstrating that the DNA
methylation profile of CTC clusters is detected in primary breast tumors with poor prognosis [111].
However, the specific role of EMT in CTC cluster formation and the resultant enhanced metastatic fitness
remains unclear. For example, it has been shown that CTC clusters encapsulated by tumor-induced
blood vessels are highly metastatic by a Slug/Snail-independent mechanism [112]. Furthermore,
another report by using quantitative 3D histology at the cancer–host interface revealed that collective
migration is the predominant mechanism of cancer cell invasion, positioning single cell migration
as an extremely rare event [113]. These findings suggest that CTC-extrinsic mechanisms, such as
vascular patterning during tumor progression, can influence CTC clustering and shedding without a
compulsory phenotypic change toward the mesenchymal fate. As evidenced by a recent longitudinal
analysis of patient-derived single and clustered CTCs, the number and size of CTC clusters add
additional prognostic value to single CTCs’ enumeration alone [114]. Nevertheless, the mechanisms
involved in the generation of a certain number and/or size of CTC clusters are yet to be studied.
Interestingly, recent findings in this direction point to CTC plasticity as a key regulator of CTC-cluster
size. Indeed, the prevention of a full EMT transition and thus a hybrid epithelial/mesenchymal
phenotype, regulates the formation of large CTC clusters, suggesting that the balance between
intermediate epithelial/mesenchymal phenotypes improved the metastatic fitness of CTC clusters [115].
3.2.2. Interactions That Matter: Heterotypic Clustering
The metastatic fitness of CTCs may be regulated by their physical and functional interactions with
cell types other than cancer cells established at the primary tumor site or during their transit through the
circulation, thus creating not only polyclonal but also heterotypic clusters (Figure 2). These heterotypic
CTC clusters can include neutrophils [79,116], dendritic cells [117], or cancer-associated fibroblasts
derived from the primary tumor stroma [118] that accompany CTCs to their secondary site [119].
Those companions are likely to modify the phenotype and intravascular behavior of CTCs by diverse
means, including enhanced resistance to shear stress, EMT/MET induction, adhesion, survival, or
proliferation. Moreover, the variety of cytokines and growth factors arising from those heterotypic CTC
clusters may play a fundamental role in remodeling the distant niche during and after extravasation,
thereby facilitating colonization [119,120]. One well-studied heterotypic interaction is that of CTCs and
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blood platelets (Figure 3). The implication of blood platelets in cancer is a rather old song [121,122];
however, their role in metastasis is not yet completely understood.
In general terms, platelets have shown a pro-metastatic role in several mouse models [86,123–125],
and their number, size, and thrombotic properties have been linked to poor prognosis in human
cancers [83,84,126]. The most compelling evidence for pro-metastatic platelets is the inhibition
of metastasis by platelet depletion in experimental murine lung metastasis models [122,127,128].
Additionally, it is generally accepted that CTCs are able to bind, activate, and aggregate platelets
in a process called tumor cell-induced platelet aggregation (TCIPA) [129]. TCIPA has been shown
to correlate with the metastatic potential of CTCs [130,131] and to protect CTCs from shear stress
and/or immune system cytotoxicity by forming a physical shield or by releasing immunosuppressive
molecules [86,132]. The mechanism(s) involved in TCIPA-metastatic potential correlation are not yet
clear, as not all metastatic cells aggregate platelets [129,133–135]. In that sense, TCIPA involvement in
metastatic potential may have historically suffered from a lack of consensus about what TCIPA actually
is: The induction of homotypic clumps of activated platelets, or the formation of platelet–tumor cell
heterotypic clusters? In the later scenario, resting or low-activated platelets could bind and shield
cells without classic TCIPA occurrence (unpublished observation). Additionally, and contrary to
their well-established pro-metastatic role, specific platelets receptors have been shown to mediate
anti-metastatic effects [136,137], questioning their precise contribution to metastasis and suggesting a
spatiotemporal role of platelets in the metastatic cascade [138]. Nonetheless, heterotypic interactions are
likely to prove a key component of metastatic success and may be refined in the future to include platelet
binding to specific CTC populations where adhesive capacity is enhanced, and platelet-dependent
tuning of CTC–endothelial adhesion/extravasation.
Whether the effects of platelets on metastasis involve physical and continuous CTC–platelet
interactions whilst in the circulation and/or during extravasation remains an open question. Steric
interference of CTC–platelet interactions directed at the alpha2beta3 integrin expressed on platelets
does inhibit metastatic burden [139–141]. On the CTC side, the adhesion protein CD97 that is expressed
in several primary and metastatic cancers [142] has been shown to directly interact and activate
platelets. In turn, the lysophosphatidic acid (LPA) released by the platelets promotes experimental
metastasis [143,144] by a mechanism involving CD97–LPAR (LPA receptor) dimerization at the CTC
plasma membrane. LPA binding to CD97–LPAR heterodimer may also induce a pre-EMT invasive
phenotype via a RHO family GTPase signaling-dependent mechanism [145,146]. Other cell surface
antigens expressed on tumor cells can serve as adhesive receptors for platelets, including podoplanin:
CLEC2 [147], the HMGB1: TLR4 [148], and the CD24: P-selectin interactions [149]. Interestingly, CD24
knockdown decreases metastatic burden in vivo, whether this is due to changes in platelet interactions
remains to be determined [150,151]. Platelets may also support CTC survival and subsequent metastasis
by inhibiting anoikis in a Yes associated protein 1 (YAP1)-dependent manner [152]. They can also
tune endothelial fitness and favor adhesion to the vessel wall by activating the purigenic receptor,
P2Y2 [153,154] or by their natural ability to link to endothelial selectin P ligand (PSGL-1) [155,156],
highlighting the important spatiotemporal role of platelets during the metastatic cascade.
3.2.3. Going with the Flow: Biomechanics of CTCs Extravasation
In order to reach secondary sites, circulating tumor cells (CTCs) have to avoid the hostile blood
or lymphatic flow forces to arrest and stably adhere to the endothelium of the target organ [157,158].
CTC-extrinsic mechanisms such hemodynamic forces have been proven to be key in CTC endothelial
arrest and extravasation [43,159]. We have recently identified a threshold of hemodynamic forces that
allow stable arrest of CTCs in low-flow venous-like vascular regions, and active endothelial remodeling
in higher-flow regions. Endothelial remodeling is an essential event for successful CTC extravasation
(Figure 3). In this sense, endothelial fitness and crosstalk with CTCs at the extravasation site may define
the final metastatic outcome. Indeed, we have observed that only flow-activated endothelium shows
plasma membrane protrusions and accomplishes endothelial remodeling in vitro [159]. Others have
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additionally demonstrated that flow forces are able to regulate endothelial cell barrier function via
non-canonical Notch signaling [160], making endothelial cells more permeable to CTCs, and inducing
vascular cell adhesion molecule 1 (VCAM1) expression, leading to increased neutrophil infiltration
and metastasis [161]. Interestingly, the areas with endothelial remodeling show deposition of fibrillar
material and platelet recruitment [162,163], supporting a role for platelets in CTC flow-dependent
adhesion and/or extravasation processes. Whether CTC clusters equally extravasate by endothelial
remodeling in flow-permissive regions remains to be further elucidated. A recent study conducted
in the zebrafish embryo, that requires further validation, demonstrates that clusters of CTCs mostly
extravasate upon endothelium remodeling [164]. It has become evident that clustering increases
CTC resistance to shear stress and protects from immune cell clearance [103,165]. Furthermore,
the trajectories traveled by CTC clusters in the circulation are different to the paths of single CTCs,
in large part due to size and shape. Compact clusters flow closer to the endothelial barrier than linear
clusters or single CTCs and, thus, slowly [166,167], which increases their ability of adhering to the
endothelium [168]. Interestingly, the intrinsic differentiation state of a CTC cluster may also influence
its flow-dependent adhesive and biomechanical properties. It has been demonstrated that breast cancer
cells showing the stem-like CD44+/CD24−/ALDH1+ phenotype were significantly more deformable
than non-CSCs. In addition, more-deformable cells were found to roll with shear-independent velocities
in vitro [169]. Those findings have provided motivation to consider mechanical properties as a possible
biomarker for cancer cell stemness. Indeed, we have recently shown that CD44 plays a key role in
early endothelial arrest, as CD44 mediates the early weak-magnitude adhesion forces required for CTC
arrest at the endothelial wall [43]. Hence, the increased metastatic potential of CTC clusters could be
explained in part by a higher propensity to arrest on endothelial cells and to extravasate, which might
be directly linked to the cell deformability index of CTC clusters.
4. Secondary Organ Colonization: Shedders or Seeders?
Not all CTCs that reach a secondary site have the capacity to colonize it [170]. In an elegant study
utilizing barcoding clonal analysis of patient-derived xenografts, Merino et al. recently demonstrated
that the extent of clonal diversity at metastatic sites is highly dependent on continual shedding of
CTCs from the primary tumor. Hence, once the primary tumor is removed, clonal heterogeneity in
secondary organs is dramatically reduced [18]. It is thus possible that while a variety of heterogeneous
cancer cells may continually enter the circulation via active or passive processes at the primary tumor
site, only CTCs with tumor-initiating potential have the ability to efficiently seed metastases. This
idea is in line with the observation that cancer cells with high tumor-initiating/metastatic potential, for
example CD44Hi cells, are observed at low frequency in patient primary tumors (~15% of the cancer
cell population [6]).
There are likely other mechanisms by which poorly metastatic cells overcome their own metastatic
inefficiency, including that of subclonal co-operation. It has recently been shown that minor subclones
expressing interleukin 11 (IL11) and vascular endothelial growth factor D (VEGFD) within the primary
tumor can modulate the immune system in a manner that enhances polyclonal metastatic growth of
otherwise non-metastatic clones [171]. Those findings demonstrate how intra-tumor heterogeneity can
mechanistically progress disease to advanced stages [172] and highlight the complex and co-operative
interactions that contribute to metastatic success.
Metastatic Niche: A Driving Force or a Barrier?
Irrespective of whether cancer cells arrive at the secondary tumor site as single, clusters,
or polyclonal clusters of cells, there are still multiple extrinsic stresses that must be overcome in
order to generate a robustly growing metastasis (Figure 4). In 1889, Steven Paget proposed that
the ability of tumor cells to initiate secondary tumor growth largely depends on crosstalk between
metastatic tumor cells—the seeds—and the host microenvironment—the soil [173]. For a cancer cell
entering a secondary tissue, it is likely that the growth-supportive signals from the local stroma and
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interactions with other cancer cells are quite different to those formerly present at the primary tumor
site. Consequently, even a metastasis-competent disseminated cancer cell may be forced into a state of
senescence, apoptosis, or latency if it is not able to rapidly adapt to its new environment. The fate of a
disseminated cancer cell at the secondary site can be markedly influenced by location, where proximity
to the microvasculature niche is related to dormancy, an effect mediated by tissue specific mechanisms.
For example, cancer cell quiescence in the lung is mediated by thrombospondin 1 (TSP1) and bone
morphogenetic protein 4 (BMP4), whereas in the bone marrow, TSP1, BMP7, transforming growth
factor β2 (TGFβ2), and growth arrest-specific 6 (GAS6) induce and maintain quiescence [174,175].
 
Figure 4. Metastatic colonization. Cancer cells with the intrinsic potential (e.g., CSCs) to initiate a
secondary tumor must overcome multiple extrinsic stresses to establish a robustly growing metastasis.
Signaling in the secondary tumor environment (initiated by the innate/adaptive immune system, stromal
cells, or vasculature) can induce cells into a state of quiescence or dormancy. A permissive pre-metastatic
niche may be created by signals arising from the primary tumor (via primary tumor-derived extracellular
vesicles or polarization of the adaptive and/or innate immune systems) that enables cancer cells to
avoid or exit dormancy and subsequently proliferate to establish a metastatic colony.
Metastatic colonization can also be restricted by the immune system. In melanoma, disseminated
tumor cells enter into an immuno-induced dormant state following arrival at a secondary site [176].
Upon depletion of cytotoxic CD8+ T cells however, metastatic growth reactivates, indicating an active
role of the immune system in inhibiting tumor cell proliferation after dissemination. Similarly, in breast
and lung carcinomas, interaction between tumor cells and natural killer (NK) cells suppress NK
cell-activating ligands, a process that appears to be coupled with entrance into a quiescent state [177].
Our recent work demonstrated that the immune system can restrict metastatic growth by modulating
a cancer cell’s phenotype. In models of breast cancer, the primary tumor activated the innate immune
system such that macrophages at sites of metastasis inhibit metastatic outgrowth by locking cancer cells
in a stem-like state [178]. In that setting, interleukin 1 beta IL1B released by macrophages signals via the
interleukin 1 receptor type 1 (IL1R1) on the cancer cells to maintain high expression of ZEB1. Implicit
here is the notion that preventing CD44Hi cells from undergoing asymmetric divisions to produce their
highly proliferative epithelial CD44Lo progeny significantly inhibits metastatic growth. Conversely,
forcing cells to undergo a complete mesenchymal-to-epithelial transition (MET) at the metastatic site
can deplete the tumor of the tumor-initiating cells that sustain secondary tumor growth [179]. Together
those studies highlight the intricate balance between epithelial and mesenchymal cancer cell states and
their impact on tumorigenicity.
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In other instances, including the example of co-operative growth leading to robust metastasis [171],
the immune system can act in a manner that enhances secondary tumor growth. In that setting, a hypoxic
primary tumor microenvironment creates a pre-metastatic niche comprising CD11b+/Ly6Cmed/Ly6G+
immune suppressor cells that compromise NK cell cytotoxicity, thereby diminishing a key mechanism
for disseminated tumor cell elimination [180]. Additionally, recruitment of monocytes/macrophages
and neutrophils can promote tumor cell survival, colonization, and pre-metastatic niche establishment
in mice [181–183]. Neutrophils have been shown to enhance metastasis by grouping CTCs in
circulation through the formation of neutrophil traps (NETs)—nets of extracellular neutrophil DNA
fibers. In addition, neutrophil-derived leukotrienes were shown to be responsible for colonization at
sites of metastasis by selectively expanding a subpopulation of cancer cells that retain high tumorigenic
potential. Neutrophils can also remodel the host extracellular matrix to promote metastatic growth
and direct signaling that maintains aggressive metastasis-initiating phenotypes [171,182–184].
The EMT itself is another mechanism that can impart several advantages on disseminated tumor
cells during early stages of colonization. Tumor cells are subjected to high levels of oxidative stress
due to hypoxic conditions at the primary tumor site, in the circulation, and at secondary sites of
colonization [185]. Expression of EMT transcription factors can protect from the damaging cytotoxic
effects induced by oxygen radicals and DNA damage [186]. Furthermore, oxidative stress has been
linked with activation of the EMT [187], setting up a positive feedback loop that may enhance metastatic
cell survival under stressful conditions. The EMT also plays a key role in enabling disseminated
tumor cells to evade immune surveillance [188]. Accordingly, epithelial cells have been shown to
express high major histocompatibility (MHC) class I and low CD274 (PD-L1) levels, while more
mesenchymal carcinoma cell lines exhibiting EMT markers expressed low levels of MHC-I, high
levels of PD-L1 [189]. Indeed, ZEB1 can directly regulate PD-L1 levels [190,191]. Consequently,
epithelial tumors can be more susceptible to elimination by immunotherapy than corresponding
mesenchymal tumors [189]. Mechanisms of immune evasion attributable to the EMT may also include
downregulation of immunoproteasome subunits and consequently, downregulation of MHC class I
-bound peptides [192].
Another important determinant of metastatic success is the preparation of a favorable
pre-metastatic niche via primary tumor cell-derived extracellular vesicles (EV) [193]. A recent study by
Hoshino et al. showed that uptake of tumor-derived integrin exosomes by resident cells at secondary
sites determines organotropic metastasis. Exosomal expression of α6β4 and α6β1 is associated with
lung metastasis, while exosomal integrin αvβ5 was linked to liver metastasis. Reduction of those
distinct integrin complexes decreased exosome uptake and subsequently metastasis, via inhibition
of Src signaling and activation of pro-inflammatory signals in resident cells [194]. Additionally, our
recent work has shown that patrolling monocytes and endothelial cells are key cellular types in charge
of tumor EV uptake [195] and may therefore be early activators of the metastatic niche. Indeed, uptake
of metastatic tumor cell-derived molecules reprograms the resident normal tissue cells in a manner
that aids metastatic growth [196]. Clearly, interactions between the seed and soil are intricately linked
to metastatic success. Determining the mechanisms that define those interactions may form the basis
of future therapeutic strategies to inhibit metastasis.
5. Conclusions
Metastasis is not a linear process, rather, it is a highly dynamic interplay of intrinsic cellular
properties and extrinsic host factors that are constantly evolving throughout the course of tumorigenesis
to positively or negatively influence the metastatic process. We have discussed phenotypic traits that
promote a cancer cell’s ability to complete specific stages of the metastatic cascade, encompassing
the notion that there is not a single phenotypic state that equates with metastatic success. Instead,
it is likely that metastatic success lies in tumor cell’s ability to adapt its phenotype, at each step of
the cascade, to survive the variety of challenges encountered along its journey; including constant
turnover of transitional cellular states, interactions with host components and between different clonal
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populations. The extent to which a given cell/clone completes the metastatic cascade likely depends
upon its epigenetic, transcriptomic, and proteomic landscape, and whether it travels alone or with
companions. Those properties, in turn, determine how that cell processes and responds to incoming
signals. In some tumor types, it is likely that specialized cancer cells are equipped with most, if not all of
the biological traits required for metastasis. In less adept cancer cell populations, a favorable metastatic
niche environment, traveling with a support team, or a permissive environment created by the primary
tumor may be the prime determinants of metastatic success. Elucidating the prominent mechanisms at
play in different tumor types and subtypes will lead to more effective means to therapeutically target
and inhibit metastatic growth.
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Abstract: The adenoma-to-carcinoma progression in colon cancer is driven by a sequential
accumulation of genetic alterations at specific tumor suppressors and oncogenes. In contrast,
the multistage route from the primary site to metastasis formation is underlined by phenotypic
plasticity, i.e., the capacity of disseminated tumor cells to undergo transiently and reversible
transformations in order to adapt to the ever-changing environmental contexts. Notwithstanding the
considerable body of evidence in support of the role played by epithelial-to-mesenchymal transition
(EMT)/mesenchymal-to-epithelial transition (MET) in metastasis, its rate-limiting function, the detailed
underlying cellular and molecular mechanisms, and the extension of the necessary morphologic
and epigenetic changes are still a matter of debate. Rather than leading to a complete epithelial or
mesenchymal state, the EMT/MET-program generates migrating cancer cells displaying intermediate
phenotypes featuring both epithelial and mesenchymal characteristics. In this review, we will address
the role of colon cancer heterogeneity and phenotypic plasticity in metastasis formation and the
contribution of EMT to these processes. The alleged role of hybrid epithelial/mesenchymal (E/M)
in collective and/or single-cell migration during local dissemination at the primary site and more
systemic spreading will also be highlighted.
Keywords: colon cancer; Wnt signaling; tumor heterogeneity; phenotypic plasticity; EMT; hybrid
E/M; collective and single-cell migration; beta-catenin paradox
1. Introduction—Tumor Heterogeneity in Colon Cancer
Colon cancer is the third most commonly diagnosed malignancy and the second leading cause
of cancer-related death worldwide. It is predicted that its mortality burden will increase by 75% by
2040 [1]. Apart from its clinical impact, colon cancer also represents a unique study model to elucidate
the cellular and molecular mechanisms underlying tumor onset, progression towards malignancy, and
metastasis formation at distant organ sites [2].
It is generally accepted that primary colon carcinomas are heterotypic, i.e., they feature a
heterogeneous composition of epithelial cancer cells intermingled with lymphocytes, stromal fibroblasts,
endothelial, and other cell types from the micro- and macro-environment [3]. This heterogeneity is
matched by the diversity of parenchymal cancer cells encompassing a broad spectrum of morphologies,
gene expression profiles, and functional characteristics [4–6]. Likewise, heterogeneity within the
stromal compartment, i.e., the tumor microenvironment, has also been demonstrated [5,7].
Intrinsic, i.e., (epi)genetic, as well as extrinsic factors, such as spatial location within the tumor
(e.g., at the invasive front vs. tumor center), inflammation, and treatment history underlie the
observed intra-tumor heterogeneity. Consequently, different cellular subpopulations within the
primary tumor mass and its metastatic lesions are observed [8,9]. Next to ‘spatial’ heterogeneity,
‘temporal’ heterogeneity has also been demonstrated relative to changes in the (epi)genetic landscape
Cancers 2019, 11, 1368; doi:10.3390/cancers11091368 www.mdpi.com/journal/cancers23
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of colon cancer within individual tumors over time [10]. Of note, tumor heterogeneity is thought to
underlie the disappointing results of many currently employed anti-cancer therapies as it not only
supports tumor progression and metastatic dissemination but it also lies at the basis of the development
of therapy resistance and of overall poor clinical prognosis [11].
Metastasis formation is a process encompassing multiple steps: (1) Local tumor invasion across
the basement membrane into the surrounding stroma, (2) intravasation into the vasculature, (3)
survival in the circulatory system, (4) extravasation into the parenchyma of the distant organ, (5)
colonization into a distal organ, and (6) re-initiation of proliferation to form macroscopic metastases [12].
In order to successfully complete this challenging series of events, the most important feature of the
metastasizing cancer cell is the capacity to adapt to the ever-changing environmental contexts by
undergoing reversible changes in its cellular identity. This ‘Dr. Jekyll and Mr. Hide’ feature of migrating
cancer cells is often referred to as phenotypic plasticity [13] and is controlled by epigenetic mechanisms
which regulate, among other processes, epithelial-to-mesenchymal transition (EMT) and the reverse
mesenchymal-to-epithelial transition (MET) [14].
A variety of chromatin remodeling complexes such as Polycomb and NuRD, play a central
role in the transcriptional regulation of EMT-related transcription factors (EMT-TFs) and micro
RNAs (miRs) by determining the accessibility of regulatory DNA elements and positioning of
nucleosomes [15,16]. In addition, post-translational histone modifications which modulate chromatin
folding and influence recruitment of regulatory proteins and control gene expression [17]. Accordingly,
contextual EMT-promoting signals epigenetically modify the repression of epithelial genes and
consequently drive the transition of cells into more mesenchymal-like states. These are epigenetically
sustained unless the presence of EMT-promoting signals is discontinued leading to the reversion to
more epithelial phenotypes [15].
Notwithstanding the considerable body of evidence in support of the role played by EMT/MET in
metastasis, its rate-limiting function, and the detailed underlying cellular and molecular mechanisms,
and the extension of the necessary morphologic and epigenetic changes are still a matter of
debate [14,18,19]. Rather than leading to a complete epithelial or mesenchymal state, the EMT/MET
programs generate migrating cancer cells displaying intermediate phenotypes featuring both epithelial
and mesenchymal characteristics. These hybrid E/M cancer cells have been the focus of much attention
in the most recent scientific literature as they are likely to be metastable and as such very efficient in
causing metastasis [20].
Here, we will address the role of tumor cell heterogeneity and phenotypic plasticity in colon
cancer metastasis formation and the contribution of EMT to these processes. The alleged role of hybrid
E/M in collective and/or single-cell migration during local dissemination at the primary site and more
systemic spreading will be highlighted.
2. The Adenoma-Carcinoma Sequence in Colon Cancer: The β-Catenin Paradox
Colon cancer arises and progresses through a well-defined series of histologic stages along which
normal colonic epithelial cells transform in stepwise fashion into precursor lesions which eventually
evolve to increasingly more invasive and malignant stages. This sequence, often referred to as ‘the
adenoma-carcinoma sequence’, features a gradual accumulation of genetic alterations in specific tumor
suppressors and oncogenes generally regarded as the main underlying and driving forces in the
progression of colonic adenomas towards malignancy [21].
The initiating and rate-limiting event in the vast majority of sporadic colon cancer cases is
represented by the constitutive activation of canonical Wnt signaling through loss of function mutations
at the APC (adenomatous polyposis coli) tumor suppressor gene. Alternatively, gain of function or
‘activating’ mutations in Wnt agonists such as the β-catenin (CTNNB1) oncogene have functionally
equivalent consequences, i.e., the ligand-independent and constitutive signaling activation of the
pathway [2]. The reason for the pivotal role of the Wnt/β-catenin signal transduction pathway in
colon cancer onset mainly resides in its functional role in the intestinal crypt of Lieberkühn where
24
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it regulates the homeostatic equilibrium between stemness, proliferation, and differentiation [22].
In the bottom third of the crypt, where stem cells reside, Wnt signaling is particularly active due
to signals from the surrounding stromal environment. Moving along the crypt-villus axis however,
Wnt is progressively less active in a decreasing gradient inversely proportional to the grade of
differentiation of the epithelial lining [23]. Here, in the absence of canonical Wnt ligands such as Wnt3a,
intracellular β-catenin levels are controlled by the formation of a multiprotein “destruction complex”
encompassing protein phosphatase 2A (PP2a), glycogen synthase kinase 3 (GSK3β) and casein kinase
1α (CK1α), and the scaffold proteins adenomatous polyposis coli (APC), and Axin1/2. This complex
binds and phosphorylates β-catenin at specific serine and threonine residues, thereby targeting it for
ubiquitination and proteolytic degradation by the proteasome [23] (Figure 1a). In the presence of Wnt
ligands instead, i.e., in the stem cell compartment, co-activation of the Frizzled and LRP5/6 (low-density
lipoprotein receptor-related proteins) receptors prevents the formation of the destruction complex
thus resulting in the stabilization and consequent translocation of β-catenin from the cytoplasm to the
nucleus. Here, β-catenin interacts with members of the TCF/LEF family of transcription factors and
modulates the expression of a broad spectrum of Wnt downstream target genes with cellular functions
ranging from stemness to proliferation [23] (Figure 1a). Consequently, loss- and gain-of-function
genetic alterations in APC and β-catenin respectively, result in the constitutive signaling of β-catenin
to the nucleus [2].
 
Figure 1. The (a) Wnt/β-catenin signal transduction pathway and the (b) β-catenin paradox in colon
cancer. (a) Illustration of the canonical Wnt signaling in homeostasis. Left panel: In the absence of
Wnt ligands, intracellular β-catenin levels are controlled by a destruction complex encompassing
protein phosphatase 2A (PP2a), glycogen synthase kinase 3 (GSK3β) and casein kinase 1α (CK1α),
adenomatous polyposis coli (APC), and Axin1/2. This complex binds and phosphorylates β-catenin at
serine and threonine residues, thereby targeting it for ubiquitination and proteolytic degradation by
the proteasome. Right panel: In presence of Wnt, co-activation of the Frizzled and LRP5/6 (low-density
lipoprotein receptor-related proteins) receptors prevents the formation of the destruction complex
leading to the stabilization and consequent translocation of β-catenin from the cytoplasm to the nucleus.
Here, β-catenin interacts with members of the TCF/LEF family of transcription factors and modulates the
expression of a broad spectrum of Wnt downstream target genes. Adapted from [24]. (b) The β-catenin
paradox in colon cancer. β-catenin IHC analysis of the invasive front of a colon carcinoma show marked
nuclear β-catenin accumulation in the proximity of the stromal microenvironment. In contrast, the
majority of tumor cells localized inside the tumor mass are characterized by membrane-bound and
cytoplasmic β-catenin staining. Scale bar: 50 μm.
This genetic model predicts that the vast majority of colon cancers, initiated by the constitutive
activation of Wnt signaling, should feature nuclear β-catenin localization throughout the entire tumor
mass. However, extensive immunohistochemical analysis of sporadic colon cancers has contradicted
25
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this prediction. In fact, only a minority of colon cancer cells, non-randomly distributed along the
invasive front of the primary mass and of quasi-mesenchymal morphology, show nuclear β-catenin
accumulation. In contrast, the majority of more differentiated (epithelial-like) tumor cells localized
inside the tumor mass are characterized by an apparently normal (membrane-bound) subcellular
distribution of β-catenin together with increased cytoplasmic staining [25] (Figure 1b). This “β-catenin
paradox” is generally explained by the fact that the APC and β-catenin mutations are necessary for
the constitutive activation of the pathway though insufficient for nuclear β-catenin accumulation and
full-blown Wnt signaling [24] (Figure 1b). The latter is only achieved in colon cancer cells located at
the invasive front where they are exposed to stromal cues capable of further promoting the nuclear
translocation of β-catenin from the cytoplasm [26].
Of note, the same heterogeneous β-catenin distribution, with nuclear staining in less differentiated
cells located in closer proximity to the microenvironment and membranous staining in more
differentiated cells in the center of the lesion, has also been observed in colon cancer metastases [27].
The reacquisition of epithelial features at the metastatic sites is required for cancer cell proliferation,
as mesenchymal-like cells are generally hindered in their proliferative activity and are therefore not
able to underlie the expansion of the metastasis.
Hence, different levels of Wnt signaling activity between the tumor center and the invasive
front are likely to account for the ‘spatial’ intra-tumor heterogeneity and to underlie distinct Wnt
downstream cellular effectors such as proliferation and EMT leading to tumor growth and invasion,
respectively [28]. These observations have led to the hypothesis according to which, apart from its
role in colon cancer initiation, Wnt signaling and the consequent downstream EMT activation, also
underlies the onset of migrating cancer stem cells (mCSC) at the invasive front of the primary lesion
which locally invade the tumor microenvironment and eventually form distant metastases [29].
This paracrine—and presumably epigenetic—control of local invasion and metastasis also offers
an explanation to the so-called “progression puzzle” [30], i.e., the lack of main genetic and expression
differences between matched primary tumors and metastases as reported in colon cancer and other
tumor types [31–33]. This suggests that although the adenoma-carcinoma progression at the primary
site is clearly driven by the sequential accumulation of genetic mutations at key genes, the multistage
route from dissemination into the tumor microenvironment to metastasis formation is underlined by
phenotypic plasticity, i.e., the capacity of circulating tumor cells (CTCs) to undergo transient phenotypic
changes to adapt to the ever-changing cellular contexts en route to distant organ sites. As previously
and eloquently proposed by Thomas Brabletz and collaborators, EMT and its reverse program MET
play pivotal roles in regulating phenotypic plasticity of CTCs [29].
In the next section, we will discuss the current understanding of the role of EMT in local invasion
and metastasis.
3. Epithelial to Mesenchymal Transition in Local Invasion and Metastasis
As pointed out in the previous section, tumor cells within primary and metastatic tumor masses,
as well as CTCs, display substantial phenotypic heterogeneity representing various intermediate
stages of the EMT program [34,35]. EMT is a developmental program exploited by carcinoma
cells to switch from their epithelial state, featuring cell–cell contacts and apical–basal polarity,
to more motile and invasive quasi-mesenchymal phenotypes with spindle-like morphology and
front-back-end polarity. During cancer invasion, EMT provides cells with the ability to produce,
interact with, and digest the surrounding extracellular matrix (ECM), detach from the primary
tumor, and invade into the surrounding tissue [14]. In addition to promoting cellular migration
and invasion, the transient phenotypic changes associated with formation of the mesenchymal state
during EMT have been associated with the acquisition of stem-like properties, resistance to therapy,
and immune suppression [36–39]. The epigenetic, and as such reversible nature of EMT is crucial
as the reverse mesenchymal-to-epithelial (MET) process allows migrating cancer (stem-like) cells to
regain proliferative and epithelial characteristics to colonize distant organ sites [14]. The initiation and
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execution of EMT are orchestrated by a set of transcription factors (i.e., ZEB1/2, SNAIL1/SLUG, and
TWIST1/2) and miRNAs (e.g., the miR200 family) [40]. Hallmarks of EMT include the silenced expression
of integral members of epithelial cell adhesion structures such as adherens- and tight-junctions, and
desmosomes, and/or proteins involved in cytoskeleton (re)organization and in cell-matrix adhesion.
Next, EMT-TFs can also activate the expression of mesenchymal cell markers resulting in changes in
cell morphology, enhanced migratory properties, and ECM remodeling. EMT is induced by cytokines
and growth factors secreted from the tumor microenvironment in response to metabolic changes,
hypoxia, innate and adaptive immune responses, and treatment by cytotoxic drugs [40]. In addition,
the mechanical composition and properties of the ECM also play an important role in EMT regulation.
Both shear stress of cancer cells and increasing matrix stiffness in the microenvironment activate EMT,
tumor invasion and metastasis [41–43]. In turn, as noted before, EMT also stimulates the composition
and mechanics of the ECM, thereby forming a tightly controlled feedback loop that is often dysregulated
in cancer.
As mentioned above, colon carcinomas display nuclear β-catenin accumulation at the invasive
front simultaneously with the acquisition of mesenchymal-like morphologic features [24]. In this
respect, it has been shown that EMT can be activated downstream of canonical Wnt/β-catenin signaling
as GSK3β kinase activity inhibition stabilizes SLUG, thereby initiating EMT [44]. Alternatively,
active Wnt signaling also inhibits SNAIL1 phosphorylation, leading to increased protein levels of
this transcriptional repressor of E-cadherin, EMT initiation, and local invasion [45]. In colon cancer,
overexpression of the Wnt ligand Wnt3a is associated with EMT and cancer progression. Accordingly,
Wnt3a overexpression in both in vitro and in vivo models was shown to induce SNAIL expression thus
promoting EMT, an effect that is abrogated by the Wnt antagonist Dickkopf1 (Dkk1) [28].
More recently, the intestinal microbiome has also been shown to contribute to EMT. A variety
of enterotoxins secreted by microbes, including Bacteriodes fragilis, Fusobacterium nucleatum, and
Enterococcus faecalis have been demonstrated to alter normal cell–cell adhesion by interfering with
E-cadherin function [46–48]. F. nucleatum adheres through FadA (Fusobacterium adhesion A), an adhesion
protein, to E-cadherin in colon cancer cells. The FadA/E-cadherin interaction leads to activation of
β-catenin signaling and of oncogenic and inflammatory responses [48]. Interestingly, Fusobacterium
and its associated microbiome (including Bacteroides, Selenomonas, and Prevotella) are sustained in distal
metastases and mouse xenografts of primary colorectal tumors. Treating tumor-bearing mice with the
antibiotic metronidazole reduced the amount Fusobacterium and abrogated cancer cell proliferation
and growth [49].
3.1. Role of EMT in Metastasis under Debate
EMT is often defined by the respective down- and up-regulation of epithelial (e.g., E-cadherin,
catenins, and cytokeratins) and mesenchymal markers (e.g., vimentin, fibronectin, and N-cadherin) by
the above-mentioned ZEB1/2, SNAIL1/SLUG, and TWIST1/2 transcription factors (EMT-TFs). However,
no single transcription factor (TF) or downstream target can universally define EMT throughout
different cancer types and cellular contexts. Distinct EMT-TFs are likely to act in a tumor- and
dosage-specific manner and as such differentially repress or enhance the transcription of specific
downstream target genes. From this perspective, the recent debate on whether EMT is an essential
requirement for metastasis to occur [14,50] reflects the complexity of the network of transcription
factors and their downstream targets in the activation of the EMT program. Two provocative studies,
in particular, have raised questions on the relative importance of the role played by EMT along the
multistep sequence of events leading to metastasis. Fischer et al. (2015) employed in vivo mesenchymal
GFP reporters to study EMT onset in the MMTV-PyMT mammary cancer model. Notwithstanding
the observed mesenchymal expression within the primary lesions, albeit in low proportion, and its
enrichment in CTCs, GFP-positive tumor cells did not contribute to distant metastases [18]. Moreover,
Zeb1/2 inhibition by miR-200 overexpression did not reduce lung metastasis incidence. In a second
study by Zheng et al. (2015) it was shown, by taking advantage of a pancreatic ductal carcinoma
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mouse model, that genetic ablation of Snail1 or Twist1 did not affect dissemination and lung metastasis
development [19]. The latter is in contrast with a later study by Krebs et al. (2017), showing that Zeb1
downregulation in the same pancreatic cancer models negatively affects the formation of precursor
lesions, tumor grading, invasion, and metastasis [51]. Additionally, other studies using different cancer
mouse models point to a key role of Snail1- and Twist1-driven EMT in metastatic colonization [52–54].
Although compelling, the Fischer et al. (2015) and Zheng et al. (2015) studies are mainly based on
the analysis of individual transcription factors and downstream targets in specific tumor models [39,40]
and cannot as such be used to discard EMT’s role in metastasis against an overwhelming body of
experimental evidence from the scientific literature. Several TFs are known to cooperate in eliciting
EMT and in controlling the extension of the execution of the trans-differentiation program. Also,
EMT-TFs are known to act in a cooperative and context-dependent fashion, and loss of individual
factors in specific organ sites may well not suffice to initiate EMT and facilitate metastasis formation.
The same is true for the employed mesenchymal markers the expression of which cannot be employed
as universal readouts of EMT activation [14,50].
3.2. Hybrid E/M Phenotypes and Partial EMT: Many Shades of Gray
As mentioned above, the transient and reversible nature of EMT represents an essential feature
for a metastatic lesion to develop [52,54,55]. Recent experimental evidence indicates that EMT, rather
than acting as a binary switch where cells transit between fully epithelial and mesenchymal states,
generates a broad spectrum of intermediate E/M stages where cells co-express both types of markers [14]
(Figure 2). These partial EMT states are metastable and as such confer to the cancer cell enhanced
phenotypic plasticity, an essential hallmark of the migrating/metastatic cancer (stem) cell [14].
 
Figure 2. Epithelial to mesenchymal transition (EMT). Schematic overview of epithelial (E) cells
transitioning to mesenchymal (M) phenotypes through an intermediate E/M state, and vice versa.
EMT can be induced by various stimuli and is dependent on the environmental context.
Two recent studies, in particular, have highlighted the relevance of partial EMT in metastasis.
In a mouse model of pancreatic ductal adenocarcinoma (PDAC), Aiello et al. (2018) sorted primary
tumor cells according to their membranous expression of E-cadherin (Cdh1). Additional RNAseq
and protein analysis of Cdh1-negative cancer cells revealed the presence of two distinct groups of
tumors: while the first resulted from the transcriptional downregulation of E-cadherin (and of other
epithelial markers), the second and major group showed E-cadherin expression both at the mRNA and
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protein levels. However, rather than being presented at the membrane, E-cadherin was internalized in
recycling endosomes [34]. These two distinct E-cadherin negative and EMT-competent subpopulations
of tumor cells were also earmarked by different invasive and metastatic behavior. Whereas cancer
cells featuring a complete EMT (i.e., E-cadherin downregulated at the transcriptional level) invaded
the tumor microenvironment mostly as single cells, cells with internalized E-cadherin in a partial
EMT state (E/M) migrate collectively as multicellular clusters which are also found in the blood of
the pancreatic cancer mouse model [34]. Of note, it has also been shown that the different degrees of
epithelial-mesenchymal plasticity affect the tumor cells’ metastatic organotropism, i.e., their capacity
to metastasize a spectrum of different organ sites [56].
In a second study, Pastushenko et al. (2018) employed a mouse model of squamous cell
carcinoma (SCC) and, by taking advantage of the different expression levels of the CD106, CD61, and
CD51 cell-surface markers, identified six distinct EpCAM-negative tumor cell subpopulations, each
characterized by a different degree of EMT. The different SCC subpopulations, encompassing both
fully mesenchymal (complete EMT) and hybrid E/M subtypes (partial EMT), were characterized by
distinct chromatin landscapes and gene expression profiles. Similar EMT-heterogeneity was also found
in mouse models for metaplastic and luminal breast cancer [35]. Although the tumor-propagating
capacity of hybrid E/M EpCAM-negative SCC cells was found to be comparable with that of their fully
mesenchymal equivalents, those with a partial EMT phenotype showed increased CTC multiplicities
and metastasis formation at distant organs [35]. Overall, partial EMT seems to confer increased
phenotypic plasticity to the cancer cells especially when it comes to regaining epithelial characteristic
(by MET), an essential requirement for metastasis formation at specific organ sites [14]. Of note,
HNSCC (head and neck squamous cell carcinoma) cells with partial EMT are preferentially localized at
the invasive front of the primary tumors in close proximity to CAFs (cancer-associated fibroblasts) [57],
reminiscent of the “β-catenin paradox” in colon cancer [24].
The elucidation of the molecular mechanisms underlying partial EMT is still in its early days.
Nonetheless, the different intermediate E/M phenotypes are likely to be driven by specific epigenetic
and transcriptional modifications. Kröger et al. (2019) isolated subpopulation tumor cells stably
residing in a hybrid E/M state from both in vitro and in vivo models using a human immortalized and
transformed mammary epithelial cell line. These E/M tumor cells were characterized by upregulation
of the SNAIL EMT-TF and of canonical Wnt-signaling. Ectopic ZEB1 expression resulted in a fully
mesenchymal transformation of the E/M cells accompanied by a reduction of their tumorigenic potential
and a switch from canonical to non-canonical Wnt signaling [58].
Apart from SNAIL, other transcription factors including NUMB, GRLH2, and OVOL have been
proposed to act as ‘phenotypic stability factors’ which promote, control, and stabilize the hybrid E/M
state, possibly by interfering with the core EMT decision-making circuit [59,60].
As mentioned above, the cancer cell’s ability to revert back from EMT-induced phenotypes is
critical for metastasis formation in distant organs and full mesenchymal transformation may result in
the irreversible loss of MET capacity [58,61,62]. For example, activation of TGF-β signaling triggers
EMT in carcinoma cells in a dosage-dependent fashion. Upon short-term treatment, the induced
EMT is reversible. However, prolonged exposure of cancer cells to TGF-β result in more stable and
irreversible transitions even upon ligand withdrawal [62].
Next to the specific expression signatures of EMT-related transcription factors and their
downstream signaling pathways driving hybrid E/M and fully mesenchymal states in cancer cells,
the existence of other alternative EMT-programs with distinct outcomes has been proposed [34,56].
Overall, it is still unclear whether hybrid E/M cells represent a metastable population or are
just captured in a time frame transitioning from the epithelial to mesenchymal phenotype. Also,
it remains uncertain which context-dependent environmental factors and downstream signaling paths
are responsible for driving heterogeneous phenotypic fates during tumor progression. Nonetheless,
as mentioned earlier, ample experimental evidence clearly indicates that the hybrid E/M cells state
is involved in the collective invasion, migration, and dissemination of tumor cells en route to form
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distant metastases. In the next sections, we will portray the role of EMT in collective cell invasion into
the local tumor stroma and dissemination as CTC-clusters, when compared with single migrating
cancer cells that complete the full EMT-program.
4. Single versus Collective Cell Migration
The initial detachment of the cancer cell from the primary mass and its invasion in the surrounding
stromal microenvironment represent critical and rate-limiting steps in the metastatic cascade responsible
for 90% of deaths in patients with malignancies [12,63]. In order to invade, cancer cells employ distinct
invasion modalities: single (amoeboid or mesenchymal invasion) and collective cell migration. Of note,
cancer cells can switch between these invasion modes, an important feature when it comes to the
development of anti-invasive and anti-metastatic therapies [64].
4.1. Single Cell Migration
Cancer cells lacking interactions with neighboring tumor cells can detach from the primary mass
and migrate individually into the microenvironment. There are two different mechanisms of single-cell
invasion, namely amoeboid and mesenchymal migration [64]. The involvement of one of these two
modes is dependent on the rigidity of the cell-matrix adhesions, the tumor cell’s capacity to remodel
the extracellular matrix, and the contractility of the cytoskeleton [65]. In amoeboid invasion, an
EMT-independent mechanism, cancer cells have a characteristic rounded cell shape. Here, migration
relies on the contractility of cortical actomyosin, promoted by the Rho/ROCK signaling pathway [66].
The proteolysis-independent actomyosin contractility results in membrane blebbing, i.e., the formation
of membrane protrusions that enable cancer cells to squeeze through gaps within the ECM [66,67].
In contrast, during mesenchymal single-cell invasion, cells adopt an elongated spindle-like phenotype
with front-back polarity as a result of EMT [68,69]. Additionally, cells that engage the mesenchymal
mode are dependent on the activity of enzymes such as matrix metalloproteinases (MMPs) and serine
protease seprase that degrade the ECM and, as tumor cells invade, progressively create channels
which can be used for the cells lagging behind the leading ones [70]. Interestingly, inhibition of ECM
remodeling leads to amoeboid migration with cancer cells squeezing through pre-existing pores by
actomyosin contractility [67]. Of note, MMPs are generally regarded as integral members of the EMT
program. In hepatocellular carcinoma (HCC), upregulation of the EMT-TF Snail not only repressed
E-cadherin transcription but also increased expression of MMP-1, MMP-2, MMP-7, and MT1-MMP
leading to accelerated invasion [71,72]. Alternatively, several ECM components and even MMPs can,
in some cases, act as EMT initiators [73,74]. Induction of MMP-3, also known as stromelysin-1 (SL-1),
in the mammary epithelium resulted in cleavage of E-cadherin leading to removal of E-cadherin and
catenins from adherens junctions, downregulation of cytokeratins, upregulation of vimentin and of
endogenous MMPs [73].
Although single-cell invasion is linked to tumor cells undergoing the full EMT-program leading
to suppression of E-cadherin and induction of vimentin [68,69], there is evidence that partial EMT, i.e.,
the retention of epithelial features, can also feature single-cell migration [75,76]. Additionally, cancer
cells can switch between amoeboid and mesenchymal states spontaneously or through changes in
ECM composition [67].
4.2. Collective Cell Migration and the Role of EMT
In collective cell migration, cancer cells retain intact cell–cell adhesions while invading the tumor
microenvironment, the vasculature, and distant organ sites [77]. A variety of migration modalities
feature collective cell migration, ranging from narrow linear connected cell strands to broad sheets or
compact cluster/budding of cells [77]. Unlike single-cell migration resulting from fully mesenchymal
cells, the role of EMT in collective migration is subtler. Recently, using a Drosophila melanogaster model
of colon cancer, it was shown that the Snail homolog Sna can activate partial EMT in tumor cells
leading to their collective invasion through the basement membrane and muscle fibers [78]. Additional
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evidence pointing at the correlation between hybrid E/M and collective cell migration lies in the onset of
‘leader’ cells at the invasive margin that are selected to guide other ‘following’ cancer cells [79]. These
leader cells show a bi-phenotypic state with mesenchymal features as altered polarity and development
of protrusions at their front. Yet, they also maintain attachments to their follower cells at their rear
end. The follower cells, on the other hand, retain apical–basal polarity and migrate taking advantage
of the pulling force generated by leader cells [80]. Knockdown of the epithelial marker cytokeratin
14 in leader cells is sufficient to block collective migration suggesting that the hybrid E/M state is
mandatory for establishment of the leader cells [79]. The onset, activity, and maintenance of leader
cells are coordinated by environmental stimuli, i.e., the local increase of compression [81], soluble
factors, and chemokines [82], but is also controlled within the collective tumor group by autocrine
or juxtacrine fashion. Of note, also in this case several MMPs are expressed at the leading edge to
facilitate ECM degradation and to create a migration path for the cell clusters [83].
Notably, non-cancer cells can also contribute to collective cell migration. The movement of cancer
cells can be conducted by migratory stromal cells such as fibroblasts [84,85]) or macrophages [86,87].
Labernadie et al. (2017) demonstrated that cancer-associated fibroblasts (CAFs) exert a physical
force on cancer cells that leads to their collective migration. This intercellular force transduction
is achieved by the formation of heterophilic adhesion complexes between N-cadherin on the CAF
membrane and E-cadherin on the cancer cell membrane [85]. Moreover, CAFs are also a source of
ECM-degrading proteases such as MMPs thereby creating micro tracks used by cancer cells to migrate
through [84]. In addition to degrading the ECM, CAFs also secrete growth factors and chemokines
that generate chemotactic gradients to direct cell migration [88]. Last, cancer cells can ingest exosomes
secreted by CAFs thereby activating intracellular pathways known to trigger EMT [89]. In colon
cancer, CAFs release exosomes containing miR-92a-3p and promote invasion and chemotherapy
resistance. miR-92a-3p directly binds to FBXW7 and MOAP1 thereby activating Wnt-induced EMT
and mitochondrial apoptosis [89].
Overall, single and collective cell migration share some of the underlying mechanisms (e.g.,
cell–cell and cell-matrix communication, and the establishment of a migratory polarity). Moreover,
during invasion tumor cells can switch between different modes of migration depending on intrinsic
(cell adhesion) and extrinsic cues (ECM composition and density). In general terms, a complete EMT is
associated with single-cell migration, whereas collective cell migration seems to result from partial
EMT. Nonetheless, the mechanisms underlying the role of EMT in determining the invasion modalities,
the intercellular communication among invading cells, and the tumor microenvironmental cues leading
to collective migration are yet poorly defined. This is further complicated by the fact that invasion
modalities are likely to be cell type-, tissue-, and time-dependent. The plasticity of cancer cells to
switch between different invasion modes is a key feature and a putative target for the development of
novel therapeutic strategies [90].
5. Circulating Tumor Cells
Circulating tumor cells (CTCs) are defined as those cancer cells disseminated from the primary
tumor mass and intravasated into blood vessels which are thought to underlie metastasis at distant
organ sites [91]. CTCs have been identified at different multiplicities in many carcinomas including
colon, breast, prostate, lung, bladder, and gastric cancer, while they are extremely rare in healthy
individuals or in patients with non-malignant disease [91]. However, even in cancer patients,
CTCs are extremely rare and, accordingly, their prospective isolation and characterization have
proven to be a challenge [91]. Heterogeneity also exists among CTCs, possibly reflecting the above
discussed intra-tumor heterogeneity. Likewise, the existence of both single CTCs, as well as CTC
clusters comprising multiple (from few to hundreds) cells, has been well established in the scientific
literature [92,93]. Of note, CTC clusters are not exclusively composed of epithelial cancer cells but are
often intermingled with immune cells, cancer-associated fibroblasts, tumor stroma, and platelets [94–98].
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In addition to this heterogeneity, CTCs and CTC clusters have been captured that express both epithelial
and mesenchymal features [93,99–101].
5.1. Single CTCs versus CTC Clusters
Single CTCs disseminate into distant organs upon EMT [14]. However, the discovery of CTC
clusters has raised questions on the relative role of EMT in local invasion and systemic dissemination
from the primary tumor mass. CTC clusters are defined as a group of 2–3 or more tumor cells that travel
as a group through the bloodstream [91]. In 1954, Watanabe showed that, by injecting bronchogenic
carcinoma cells in the jugular vein of recipient mice, tumor clumps, in contrast to single cells, were able
to form metastasis [102]. Accordingly, aggregated colon cancer cells also showed increased metastatic
efficiency in the liver when compared with single cells after intra-portal injection in rat [103]. These
initial observations, however, did not explain how and where CTC clusters are formed. More recently,
it has been demonstrated that CTC clusters do not derive from the intravascular aggregation of single
CTCs or from proliferating single CTCs, but rather from clumps of primary tumor cells that collectively
detach from the primary mass and enter the vasculature as CTC clusters [104–106]. Moreover, it was
also shown that the metastatic capacity of CTC clusters was up to fifty-fold higher when compared
with single CTCs [104]. Genome-wide single-cell DNA methylation analysis demonstrated distinct
methylomes between CTC clusters and single CTCs in human breast cancer patients. CTC clusters
were shown to be hypo-methylated at stemness- and proliferation-associated transcription regulators
including OCT4, NANOG, SOX2, and SIN3A, and hyper-methylated at Polycomb target genes [107].
Lastly, the presence of circulating tumor micro emboli in peripheral blood of patients with cancer
arising from colon, breast, and lung was predictive of poor survival [104,108,109].
5.2. CTC Cluster Heterogeneity
The heterogeneous composition of CTC clusters encompassing parenchymal cancer cells together
with immune cells, cancer-associated fibroblasts, tumor stroma, and platelets, seems to reflect the
heterogeneity of the primary tumors they originate from [94–98]. The presence of non-malignant cells
within CTC clusters contributes to their improved survival and metastatic capacity. Normal epithelial
cells undergo cell anoikis upon the detachment from the extracellular matrix (ECM), which establishes
an important defense mechanism to prevent abnormal growth in inappropriate places. However, EMT
can circumvent anoikis in individual cells during dissemination and metastasis [110]. The transition of
single CTCs to a mesenchymal phenotype results in the expression of adherence-independent survival
signals that compensate for the loss of attachment to the ECM [111]. Alternatively, CTC clusters may
prevent tumor cell anoikis by retaining epithelial cell–cell interactions and thus contributing to the
activation of survival stimuli [104,105]. Next, the non-malignant cell microenvironment can protect
CTC cells from immune cells [112,113], shield cells from mechanical stress, and promotes adhesion to
the endothelium [114,115]. It also has been shown that platelets can induce EMT in CTCs via TGF-β
and NF-κB signaling while enhancing their metastatic potential [97]. Thus, secretion of growth factors
and cytokines by the non-cancer cells may represent an additional survival advantage for the CTC
clusters in the vasculature. Last, yet another advantage of the CTC clusters when compared to single
CTCs is the capacity of remodeling the microenvironment at the metastatic site, thereby facilitating
colonization [95].
5.3. EMT in CTC Clusters
Next to the heterogeneity of CTC clusters in terms of cell lineage composition, the degree of
EMT activation among the parenchymal cancer cells within CTCs can also vary considerably. CTC
clusters display epithelial cell–cell interactions as shown by the retention of expression of several
epithelial-specific genes such as K5, K8, K14, E-cadherin, P-cadherin, and plakoglobin in metastatic
breast CTC clusters [116]. Accordingly, knockdown of plakoglobin, a member of the catenin protein
family and homologous to β-catenin, led to disaggregation of the CTC clusters, thereby compromising
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metastasis formation [104]. Also, disruption of K14 expression negatively affected the expression of key
downstream effectors in metastatic niche remodeling and metastasis survival, leading to compromised
efficiency in metastasis formation [105]. However, CTC clusters with predominant hybrid E/M or
fully mesenchymal features have been observed in human colon, prostate, lung, and breast cancer
patients [93,99–101]. At least one-third of cancer cells from within CTC clusters derived from colon
cancer patients were negative for cytokeratin expression [100]. In breast cancer, CTC clusters show
shifts in their EMT status according to treatment modalities with predominant mesenchymal expression
patterns during cancer progression and/or in refractory disease [93] (Figure 3). This dynamic EMT
profile allows for cellular plasticity and adaptation to the diverse cellular contexts encountered by
CTCs during dissemination and metastasis formation, and to different treatments regimes. The latter
is also of relevance for the use of prognostic epithelial markers of CTCs likely to fail to detect cancer
cells that have undergone EMT. Additional mesenchymal CTCs markers are needed for more accurate
prognostic studies [117].
 
Figure 3. EMT features in single circulating tumor cells (CTCs) and CTC clusters from a metastatic
breast cancer patient. (a) Longitudinal monitoring of EMT features in CTCs. The Y-axis indicates the
number of CTCs per 3 mL of blood. The patient was monitored over time (X-axis) during treatment
with inhibitors targeting the PI3K and MEK pathways (months 1–8), followed by chemotherapy with
Adriamycin (8–12). The color-coded quantification bars indicate the EMT status of the CTCs based
on RNA-ISH (in situ hybridization) analysis at each indicated time point. P = disease progression;
R = tumor response. (b) RNA-ISH analysis of EMT markers in CTCs derived from patients with
metastatic breast cancer. Green dots represent epithelial (E) and red marks mesenchymal (M) markers.
Scale bar: 5 μm. Adapted from [93].
As mentioned above, alternative EMT-programs accounts for different CTC phenotypes.
Aiello et al. (2018) suggested that single CTCs arise from cancer cells that have completed a full
EMT-program, whereas tumor cells characterized by partial EMT tend to present as clusters resulting
from collective migration [34]. However, it has been demonstrated that, next to those mainly composed
by CTCs, cell clusters have been isolated from colon cancer patients which consist of endothelial cells
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without any genetic aberrations found in their matched primary tumor of origin. These cell clusters
were positive for both epithelial and mesenchymal markers and are thought to result from the direct
release of clusters from the tumor vasculature due to impaired neo-angiogenesis [118].
6. Partial EMT, Collective Cell Migration, and Metastasis: Therapeutic strategies
Metastasis formation involves the successful completion of a sequential series of challenging
steps. Phenotypic plasticity refers to the key feature of the metastasizing cancer cell to adapt to the
environment where it resides through reversible changes of its cellular identity [13]. This ‘Dr. Jekyll
and Mr. Hide’ feature of migrating cancer cells is controlled by epigenetic mechanisms which regulate
E-to-M and M-to-E transitions (EMT and MET) [14]. However, EMT cannot be regarded as a binary
process as it generates hybrid E/M cancer cells encompassing a range of intermediate stages. Partial
EMT has been correlated with collective cell migration and with the presence of CTC clusters with
enhanced metastatic potential in the peripheral blood of cancer patients [119]. Moreover, the unaffected
CTC clusters multiplicity upon chemotherapy is indicative of treatment failure in colorectal cancer [120].
From this perspective, the elucidation of the underlying intrinsic and extrinsic mechanisms is bound to
lead to the development of novel therapeutic and even preventive strategies based on the targeting of
cell–cell and/or cell-matrix interactions and the disruption of CTC clusters. Gkountela et al. (2019)
tested a library of approximately 2500 FDA-approved compounds and identified Na+/K+ ATPase
inhibitors able to disaggregate derived CTC clusters derived from breast cancer patients into single
cells. Mechanistically, Na+/K+ ATPase inhibition in tumor cells leads to an increase of intercellular
Ca2+ concentration and to the consequent inhibition of formation of cell–cell junctions. In an in vivo
xenograft model using NSG mice injected with patient-derived breast cancer cells in their fat pad,
treatment with the Na+/K+ ATPase inhibitor ouabain resulted in a marked reduction of CTC cluster
formation together with the increase of single CTC multiplicity. Although the size of the primary tumor
was unaffected upon ouabain treatment, the overall number of metastatic lesions, corresponding to the
number of CTC clusters, was reduced [107].
An alternative approach towards the development of therapeutic strategies based on CTC clusters
may be represented by inhibition of platelet function. Platelets make integral part of CTC clusters where
they are thought to protect the cancer cells from shear stress and immune attacks [121]. Acetylsalicylic
acid (i.e., aspirin) inhibits platelet function by acetylation of cyclooxygenase (COX) thereby preventing
arachidonic acid (and prostaglandin) production and consequently resulting in irreversible inhibition
of platelet-dependent thromboxane formation. Based on this, aspirin has been employed as an
anticoagulant for the prevention of thrombosis [122]. In experimental cancer models and clinical trials,
inhibiting the interaction between cancer cells and platelets have been shown to hamper tumor cell
survival, growth and metastasis formation [123,124].
Notwithstanding the above promising and innovative therapeutic strategies based on CTC
clusters, their allegedly high degree of plasticity—as a mechanism to escape targeted treatment—is
also likely to result in therapy resistance. Nonetheless, future research towards the identification of
novel therapeutic targets to lower the risk of CTC cluster formation is expected to improve the efficacy
of cancer treatment in the long run.
7. Final Remarks and Conclusions
EMT contributes to a considerable degree of cellular heterogeneity in both primary tumors and
metastatic lesions as it affects a broad spectrum of cellular functions beyond the transitions between
epithelial and mesenchymal states associated with enhanced invasive and metastatic abilities. Changes
in stem cell behavior, escape from apoptosis and senescence, ECM and tumor-microenvironment
remodeling, and resistance to cytotoxic treatments are only a few among the broad spectrum
of downstream EMT effectors which contribute to intra-tumor cell heterogeneity with profound
implications for cancer therapeutics, especially in the decade of personalized treatments [11].
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In fact, EMT is thought to play key roles in each and every step of the metastatic cascade including
intra- and extravasation [125], and the colonization of distant organ sites [126,127]. For the sake of
brevity, these latter aspects are not discussed in this review. The observed broad spectrum of EMT
effectors may well reflect the pleiotropic functional roles of the EMT-TFs such as ZEB1 [128] that go
well beyond the E to M (and vice versa) trans-differentiation, and include angiogenesis, remodeling of
the tumor microenvironment, immune escape, mechanotransduction, and possibly many more.
The identification and elucidation of the complex network of intrinsic and extrinsic mechanisms
driving EMT at “just-right” (E/M) levels to trigger collective migration, generate CTC clusters and
successfully metastasize distant organ sites represent the major future research challenge in the
translation of our fundamental understanding of metastasis into therapy. From this perspective,
single-cell epigenetic and transcriptomic analysis will provide powerful approaches to address this
challenge. These high-resolution techniques will be key to elucidate the heterogeneous composition of
malignancies including the identification of distinct and rare cell types arising transiently in time and
at specific locations within tumors. Moreover, single-cell profiles will help to investigate the variability
among individuals, disease states, microenvironments, and treatment history.
Overall, the realization of the importance of epigenetics and the elucidation of the mechanisms
underlying transient changes in the cellular identity of individual circulating and metastasizing tumor
cells will lay the basis for the development of novel treatment modalities. These will complement the
current ‘personalized cancer medicine’ mainly directed at somatic gene mutations arisen at the primary
site and unlikely to be rate-limiting in the clinical management of a more advanced malignant disease.
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Abstract: Fluidity in cell fate or heterogeneity in cell identity is an interesting cell biological
phenomenon, which at the same time poses a significant obstacle for cancer therapy. The mammary
gland seems a relatively straightforward organ with stromal cells and basal- and luminal- epithelial
cell types. In reality, the epithelial cell fates are much more complex and heterogeneous, which is
the topic of this review. Part of the complexity comes from the dynamic nature of this organ: the
primitive epithelial tree undergoes extensively remodeling and expansion during puberty, pregnancy,
and lactation and, unlike most other organs, the bulk of mammary gland development occurs late,
during puberty. An active cell biological debate has focused on lineage commitment to basal- and
luminal- epithelial cell fates by epithelial progenitor and stem cells; processes that are also relevant to
cancer biology. In this review, we discuss the current understanding of heterogeneity in mammary
gland and recent insights obtained through lineage tracing, signaling assays, and organoid cultures.
Lastly, we relate these insights to cancer and ongoing efforts to resolve heterogeneity in breast cancer
with single-cell RNAseq approaches.
Keywords: mammary gland; breast cancer; cell fate; heterogeneity; 3D cultures; organoids; signaling;
single-cell RNAseq
1. Introduction into Mammary Gland Structure, Function and Early Development
The mammary gland is comprised of many different interacting cell types. Epithelial cells form a
primitive structure early during embryonic development, which later form the nipple and a ductal
network that expands into the fat pad. These epithelial ducts are surrounded by fat cells, and become
innervated with a variety of stromal cells including endothelial cells, immune cells, and fibroblasts [1].
Maturation of the gland is regulated at first by mesenchymal interactions, and later by hormone and
growth factor receptor signaling during puberty and pregnancy. Mammary epithelial cells assemble
into their normal morphology between E16-E18 (embryonic day), forming a bilayered duct with an
inner lumen [2]. Together, the mammary epithelial subtypes interact to carry out the organ’s functions.
After pregnancy, mature epithelial cells can later differentiate into alveolar cells and subsequently
produce milk proteins.
Mammary epithelial cells (MECs) typically form a bilayered epithelium and can be broadly
separated into two distinct compartments: an inner layer of luminal and outer layer of basal MECs.
However, additional heterogeneity exists within both luminal and basal MECs. Luminal populations
are often sub classified based on hormone and growth factor receptor status. The basal epithelium
contains a subset of so-called myoepithelial cells that lie along the outside of the ductal epithelial tree
and assist in the motility of milk protein along the lumen. The MEC system also contains subsets of
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basal and luminal stem and progenitor cells, which will be covered in greater detail later. For example,
within the luminal compartment a population of luminal progenitor cells can go on to form ductal
or alveolar cells. In addition, basal cells contain a subset of mammary stem cells (MaSCs) forming a
small, heterogeneous, and to date poorly defined population that drive development, repair and organ
reconstitution when transplanted into epithelium-cleared fat pads of recipient mice [3].
Puberty is the most dynamic and striking period during the development of the mammary
gland. The rudimentary duct undergoes significant expansion, resulting in the formation of bulbous
multilayered structures called terminal end buds (TEBs) [4] (Figure 1). TEBs are the proliferative
centers that drive elongation, bifurcation, and branching until the entirety of the mammary fat pad is
filled, thereby creating the mature epithelial tree [5]. The TEB contains cap cells, a rapidly growing and
dividing progenitor cell population that later goes on to form the tree’s outer myoepithelial layer [6].
 
Figure 1. Schematic of mouse mammary gland development during puberty. During puberty, the
rudimentary duct undergoes significant expansion, resulting in the formation of bulbous multilayered
structures called terminal end buds (TEBs). These TEBs are the proliferative centers that drive elongation,
bifurcation, and branching of ducts until the entirety of the mammary fat pad is filled, thereby creating
the mature epithelial tree.
2. Luminal Cells and Luminal-Specific Progenitors
The luminal compartment contains different mature, differentiated cell populations with specified
functions as well as progenitor-cell populations that are each distinguished by specific gene and
extracellular ligand profiles.
Several classifications of luminal cells exist within the mammary gland. Luminal cells are
segregated based on functional, morphological, and expression profiling evidence. Histologically,
luminal cells can be broadly separated into two types: ductal and alveolar. Mature ductal
cells can be either estrogen receptor (ER) positive or negative, and feature the following marker
expression profile: CD49floCD29loCD24+CD14−EpCAMhic-kit−Sca1+CD61−CD49b− [7], in which
the CD numbers and other markers represent different gene products. Mature alveolar cells
are always estrogen receptor (ER) negative and can be more precisely characterized through
a CD49floCD29loCD24+CD14−EpCAMhiSca1loCD61− expression pattern. Alveolar cells can be
distinguished by their secretory morphology and histologically by the accumulation of milk
proteins within.
Transcription factors have been demonstrated to drive luminal cell fate commitment throughout
development. The Elf5 (E74-like factor 5) transcription factor is one of the major drivers of luminal
cell specification and differentiation. Elf5 is able to directly repress Slug (Zinc Finger Protein
SNAI2) transcription, thereby blocking basal cell determination and promoting luminal cell fate [8,9].
Progesterone acts on mature, progesterone receptor-positive cells and induces expression and secretion
of the chemokine RANKL (Receptor activator of nuclear factor kappa-B ligand) that subsequently, in a
paracrine manner, induces progenitor cells to express Elf5 [10]. The transcription factor Gata-3 (GATA
binding protein 3) is another key regulator of luminal cell identity. Gata-3 expression is important for
the maturation of luminal progenitor cells into mature ductal and alveolar cells [11]. Stat5a (Signal
Transducer and Activator of Transcription 5A), a transcription factor activated by activated by ligands
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including prolactin, growth hormone, and EGF (Epidermal Growth Factor) drives the expansion of
luminal progenitors and subsequent differentiation into alveolar cells [12].
Luminal progenitor populations can be distinguished using many of the above extracellular
markers. For example, ductal progenitors are CD61+, CD49b+, CD14+, and c-kit+ whereas their mature
counterparts are negative for the surface expression of these proteins [13–15]. Sca-1 (Spinocerebellar
ataxia type 1) expression can be used to separate ductal progenitors from alveolar progenitors since
alveolar progenitor cells lack membrane expression of the protein. It should be noted that expression
of these extracellular receptors is not ubiquitous between mouse model lines. Neither c-kit nor CD61
are expressed in mammary epithelial cells derived from C57BL/6 mice, while they are both found in
MECs from FVB/N mice [16]. The fate and biology of these luminal progenitor cell populations has
been further characterized by lineage tracing experiments, which we will discuss in Section 4.
3. Basal Cells and Progenitors
Unlike luminal cells, the factors that control and label different basal cell populations are
less clear. Both stem cells and bipotent progenitor cells have been identified within the broader
basal cell lineage. The use of extracellular markers to distinguish these discrete populations,
however, has not yet yielded clear profiles. Mature myoepithelial basal cells are typically
CD29hiCD49fhiCD24+EpCAMlo/med [7]. The undifferentiated population that is enriched for MaSCs is
believed to be CD49fhiCD29hiCD24hiEpCAMlo/medSca1−. Markers that are specific for a restricted basal
cell progenitor have not been identified and neither have specific markers for a restricted myoepithelial
cell progenitors. Luminal progenitors are thought to arise from an early basal cell population.
Several epithelial-mesenchymal transition (EMT) factors have been identified as molecular
regulators of the basal/MaSC population. The transcription factor Slug is a key for the basal/MaSC
lineage as it suppresses luminal cell fate. Slug-deficient mice have delayed ductal morphogenesis and
aberrantly express luminal signature genes in basal cell populations [17,18]. The transcription factor
Sox9 cooperates with Slug to suppress luminal fate and exogenous expression of these two factors
can convert differentiated luminal cells into MaSCs with long-term mammary gland-reconstituting
ability [18]. Tumor protein TP63 loss blocks the formation of the primitive epithelial duct [19]. Perhaps
one of the strongest drivers of basal cell identity, p63 overexpression in luminal cells leads to an identity
shift from luminal to a basal phenotype [20]. Notch1/3 signaling has been reported to down-regulate
TP63 expression as basal progenitors restrict to a luminal cell fate [21]. The transcription factor p53, on
the other hand, restricts basal/MaSC renewal and drives differentiation [22].
4. Lineage Tracing to Identify Restricted and Bipotent Progenitor Cells
Lineage tracing is a powerful tool to observe and track the function of adult-, stem- and
progenitor-cells during normal homeostasis, and various studies have utilized this approach to shed
light on the lineage hierarchies of the MECs. K8-creER targeted cells exclusively differentiate into
luminal cells when observed in vitro [23]. MECs marked with this label are maintained in small
numbers following several rounds of growth and differentiation. Elf5, a well-studied luminal progenitor
cell gene, was utilized in a separate study to trace this restricted progenitor population throughout
pubertal development [24]. Elf5-expressing cells exclusively produced mammary epithelial cells with
a luminal identity and were a major driver of branching morphogenesis [24]. In 2014, Rios et al.
confirmed that these Elf5-expressing cells were short-lived and restricted progenitors, as the positive
cells could not be detected in the mammary glands of lineage tracer mice after 20 weeks [24]. Combined,
these findings show that there may exist both short- and long-lived progenitor cells that exclusively
mature into luminal subtypes.
Lineage tracing studies were performed in order to hone-in on the exact nature of mammary
progenitor populations. In 2011, van Keymeulen et al. established that all mammary epithelial lineages
are derived from cytokeratin-14 (K14) expressing embryonic progenitors [23]. Following this population
throughout puberty revealed that K14+MaSCs promote basal expansion and maintenance. MaSCs
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expressing K8 promoted luminal cell expansion and maintenance throughout puberty. When cultured
in vitro these restricted progenitors maintain their identity, while only basal cells display multipotency
in transplantation and reconstitution assays [23]. Rios et al. used lineage-tracing experiments to
identify a cytokeratin 5 (K5) expressing bipotent progenitor population [24]. K5-positive cells labeled
at the onset of puberty contributed to the formation of both mature luminal and myoepithelial cells.
5. Three-Dimensional Spheroid Cultures
In the late 1980s and early ′90s, three-dimensional (3D) cultures were instrumental in the discovery
of the cell biology of mammary gland development and breast cancer. We term these classical
three-dimensional spheroid cultures in our review, as these did not yet focus so much on the function
and preservation of stem cells through Wnt signaling. We will cover more on Wnt signals and organoids
later. For an excellent overview with historic perspectives on the development of these 3D culture
platforms we refer you to a review by Drs Simian and Bissell [25]. Essential for these revolutionary
in vitro approaches was the isolation of gel from the matrix of chondrosarcomas in 1977 by Orkin
and colleagues [26] that is now commonly known as Matrigel (Figure 2). For example, these classical
3D spheroid cultures revealed that a 3D basement membrane [27] impacts the response of a series
of human breast-tumor cell lines at different stages of progression, cultured within a physiological
context [28]. Importantly, the 3D aspect of these cultures revealed new discoveries, such as bidirectional
cross-modulation of integrin and EGFR (Epidermal Growth Factor Receptor) signaling, that were not
present in artificial 2D cultures [29].
 
Figure 2. Schematic of three-dimensional spheroid cultures of mammary gland tissue. The discovery
of Matrigel by Orkin and colleagues [26] enabled cell biological studies by many research groups with
three-dimensional (3D) spheroid cultures of mammary gland tissue in vitro. Plating of digested MEC
clusters aided the identification of restricted luminal- or basal-cells and bipotent progenitors in 3D,
while further digestion into single mammary epithelial cells and plating into colony-forming assays
provided information on the proliferative capacity.
Classical 3D spheroid cultures also aided identification of restricted luminal- or basal-cells
and bipotent progenitors. In vitro experimentation confirmed that, the restricted differentiation
potential of both luminal cells and basal, myoepithelial cells can be maintained, given specific culture
conditions [30]. In mammosphere assays, single MECs can be cultured short-term in ultra-low
adherence plates to generate mammospheres. These assays interrogate the function and clonogenic
capacity of MaSCs. Mammosphere cultures could generate MEC colonies with either restricted
unipotent differentiation potential or a bipotent stem-like phenotype, suggesting the existence of
unipotent- and bipotent-progenitors [31]. Isolated single mammary epithelial cells can also be plated in
Matrigel pellets in a colony-forming assay (Figure 2). Single MECs are able to seed into the surrounding
matrix and clonally expand. The number of colonies that are able to form, as well as the size of the
colonies, provides a representation of the proliferative capacity of progenitor cells within the total
MEC population. Similarly, only MaSCs with self-renewal potential are able to survive non-adherent
conditions. The number of mammospheres that are able to form can be used as a proxy to quantify
MaSC activity. Use of these platforms has allowed for new insights into the mechanisms by which
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ductal morphogenesis is directed, particularly with regard to the role of different growth factor
receptors, which we discuss next.
6. EGFR Family and Ligands
The EGFR family consists of EGFR (ErbB1/Her1), ErbB2/Her2, ErbB3/Her3, and ErbB4/Her4. ErbB
receptors can both homo- and heterodimerize, with 10 possible combinations-six heterodimers and four
homodimers. There is a high level of homology between kinase domains of the four EGFRs (~60–80%)
with divergence occurring predominantly in the C terminus (shared identity is only ~10–25%). ErbB
proteins have tissue specific expression, though they are commonly expressed together. EGFRs are
found in several epithelial cell types such as the lung, intestine, and the breast. ErbB2 has no known
ligands (Table 1), but frequently dimerizes with the other three EGFR members because of its unique
and extended interaction loop [32]. ErbB3 is kinase dead, its cytoplasmic domain unable to initiate
phosphorylation cascades. ErbB3 is able to trans phosphorylate its own intracellular domain to assist
heterodimerization, as well as allosterically activate other EGFRs, however [33].




















EGF: Epidermal Growth Factor; TGF: Transforming Growth Factor; AREG: Amphiregulin; EPG: Epigen; BTC:
Betacellulin; HB-EGF: Heparin-binding EGF-like growth factor; EPR: Epiregulin; NRG: Neuregulin; EGFR: Epidermal
Growth Factor Receptor; ErbB: Erythroblastic leukemia viral oncogene homolog; Her: Human epidermal growth
factor receptor.
Up to 13 different ligands have been found to bind EGFR family proteins: EGF, HB-EGF,
transforming growth factor (TGF), amphiregulin (AREG), epiregulin (EREG), epigen (EPG), betacellulin
(BTC), and neuregulins 1–6 (NRG) [34–36]. Ligand binding induces phosphorylation at tyrosine residues
on the cytoplasmic domain [37]. EGF and TGF are the key ligands for EGFR and ErbB3/B4 preferentially
bind neuregulins. The EGFR family members and their preferred ligands can be found in Table 1.
Evidence suggests that EGFR phosphorylation and the duration and amplitude of signaling events are
influenced by the binding of different ligands. This results in divergent cellular responses. For example,
AREG is more potent in stimulating ductal elongation compared to EGF [38]. These ligand-specific
nuances are important during development and cancer and we will cover some of the cancer-specific
nuances of EGFR signaling in Section 10.
7. EGFR during Mammary Gland Development
The vast majority of what is understood about the EGFR family’s role in mammary development
comes through the use of genetic mouse models. Egfr-deficient mice perish just after birth, which
complicated deciphering the exact nature of EGFR during mammary organogenesis [39,40]. Luetteke
et al. generated Waved-2 mice to circumvent this problem. The Waved-2 allele has a point mutation near
EGFR’s cytoplasmic kinase domain that reduces activity; it is hypomorphic [41]. Waved-2 mice have
defective mammary development with diminished branching and a reduction in ductal invasion [42,43].
Use of a dominant negative EGFR protein using the mammary-specific MMTV promoter confirmed
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its role during pubertal development. Mice with the dominant negative EGFR display reduced
proliferation and inhibited duct maturation [44]. Egfr’s importance in the stroma was confirmed via
the generation of mixed tissue recombinants from transplanting neonatal epithelial cells from wild
type or egfr-deficient mice [43,45,46].
Perturbations in other EGFR family genes also result in dramatic mammary developmental
phenotypes. Specifically, deficiency in the ErbB2–4 results in impaired ductal outgrowth during
puberty. Deletion of ErbB2 shunts ductal outgrowth [47,48]. ErbB2 also controls terminal end bud
(TEB) formation through its regulation of cellular compartmentalization. In summary, despite many
studies into the role of EGFR proteins in the mammary gland, the exact nature of each member has not
been fully elucidated. Stromal and epithelial expression of the EGFR family is critically important at
all stages of mammary development. A better understanding of EGFR and its downstream effectors is
needed to create a clearer picture of the signals and processes that regulate the complex process of
mammary organogenesis.
8. EGFR Signal Strength, Downstream Effector Kinases, Cell Fate
Mammary epithelial cells are organized into a developmental hierarchy based on extracellular
receptor and gene expression patterns. The exact nature of these populations, and the factors that
balance their proliferation with differentiation, are not well understood. Recent evidence has emerged,
however, that EGFR signaling in MECs may be a key player in better defining this hierarchy as depicted
in Figure 3.
 
Figure 3. Schematic of the developmental hierarchy in the mammary gland. It should be explicitly
stressed that Figure 3 is a model. In this hierarchy, mature luminal cells and mature basal cells are
maintained by lineage-restricted, unipotent progenitors, which are replenished by multipotent stem
cells that are present during embryogenesis.
In 2011, a report by Pasic et al. began to decipher EGFR’s potential role in controlling MEC
fate decisions during development. An ex vivo organoid model was utilized using cells taken from
normal human breast tissue. They observed that different EGFR ligands could elicit discrete cell
fate decisions. EGF stimulation of human breast organoids initiated a significant expansion of the
basal (myoepithelial) population. Conversely, AREG stimulation drove organoids towards a luminal
(ductal) cell fate. Interrogation of the downstream effector revealed that this deviance in cell fate
decisions was due in part to the strength of downstream MEK-ERK signals, in which stronger activation
EGFR-Ras-MEK-ERK selectively expanded the basal cell population and weaker activation drives
luminal expansion [49].
Mukhopadhyay et al. expanded our insights into this initial model in 2013 [50]. Using an
hTERT-immortalized human stem/progenitor cell pool, they observed similar cell fate decision changes
that were dependent on the strength and duration of EGFR signals. Once more, it was observed that
stimulation with the weak agonist AREG promoted luminal cell fate and a strong agonist (TGFα)
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drove cells towards a basal cell identity. In contrast to the data presented in Pasic et al. [49], however,
Mukhopadhyay et al. found that EGF stimulation did not drive MaSCs down a specific lineage [50].
The addition of U0126, an inhibitor against the MEK-ERK pathway, significantly reduced differentiation
into CD49floEpCAMhi and EpCAMlo cells [50]. Taken together, it appears that the duration and
amplitude of EGFR signals affects MEC fate choices.
Since many of the signaling effectors triggered by the EGFR lay downstream of Ras, it is of interest
to consider the strength and duration of Ras activation as the cell fate determination factor. A historic
study reported that nuances in receptor-Ras signaling can affect cell fate in a PC-12 cell line system.
Stimulation of rat adrenal carcinoma cells (PC-12) with different EGFR ligands produced altered cell
fate. In the PC-12 system, EGF is a weaker agonist compared to the strong nerve growth factor (NGF).
EGF stimulation led to a short pulse of Ras-MEK-ERK activation and cell proliferation, while NGF
stimulation elicited prolonged Ras-MEK-ERK signals, exit from the cell cycle and differentiation [51].
Since that report in 1995, very little work has followed up on this, perhaps because it is challenging to
couple quantitative biochemical measurements to cell fate decisions, especially in in vivo studies.
9. EGFR and Other Receptor Tyrosine Kinases Signaling and Ductal Morphogenesis
Ductal morphogenesis is the process in which the mammary epithelium invades the fat pad
during puberty to form a fully branched ductal epithelial tree. It is known to occur in a somewhat
stochastic process, regulated by the combinatorial input of diverse signals. The stochastic aspect is
perhaps best exemplified by the fact that there are substantial differences between mammary glands of
mouse littermates. This has led the field to conclude that predetermined genetic control of pubertal
development is not a possibility, unlike in the development of other epithelial tissues [52]. Development
is dictated by mechanical factors and molecular signals from the surrounding stroma [53]. As a result,
maturation of the breast is context-dependent.
The pubertal developmental process is initiated in large part by the expression of ovarian
and pituitary hormones [54]. These signals cooperate to facilitate growth and communication
between epithelial and stromal cells. Genetic knockout of estrogen receptor alpha (ERα) leads to
incompletely developed mammary ductal trees, and exogenous administration of estrogen in mice
lacking ovaries rescues ductal morphogenesis [55,56]. Estrogen facilitates stromal cell expression of
hepatocyte growth factor (HGF) and epithelial expression of amphiregulin (AREG) [57,58]. AREG
can communicate with the epidermal growth factor receptor (EGFR), whose expression is essential on
mammary stromal cells [46]. Estrogen’s collective functions serve to regulate local cell growth during
pubertal development.
Estrogen is not the only steroid hormone important for pubertal mammary gland development,
however. In fact, estrogen alone is insufficient to restore ductal morphogenesis when other input (like
from the pituitary gland) is missing. Exogenous administration of growth hormone, normally produced
by the pituitary gland, can restore the impaired branching phenotype of pituitary gland-deficient
mice [59]. Growth hormone induces stromal insulin-like growth factor 1 (IGF1) expression, which
binds to IGFR on epithelial cells [60]. Together growth factor and IGF1 act as global regulators of
ductal morphogenesis.
Several growth factor receptors and receptor tyrosine kinases (RTKs) are involved in the integrated
signaling environment that directs mammary morphogenesis. Fibroblast growth factors (FGF) and their
receptors (FGFRs) are critically important for growth and branching. FGF2 and FGFR2 in particular
shape the profile of ductal outgrowth and MEC proliferation. Genetic deletion of fgfr2 disrupts
ectodermal and placode formation during embryonic mammary organogenesis [61]. Mammary
epithelial cells lacking fgfr2 have a proliferative disadvantage when compared to their wild-type and
fgfr2-heterozygous counterparts, and are depleted within TEBs [62]. Mice with inducible deletion of
fgfr2−/− reveal a similar phenotype; proliferation is significantly attenuated and TEBs are completely
absent from the glands [63]. In summary, fgfr2 is a key regulator of luminal epithelial cells and it plays
a specific role in the TEBs of elongating ducts.
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The EGFR family of signaling proteins plays a pivotal role in directing pubertal mammary gland
development in conjunction with FGF and FGF2. In brief, perturbations to each of the four EGFR
family members result in developmental defects. In ex vivo culture, FGF2 addition can rescue growth
and branching in EGFR-null 3D spheroids [45]. Mice with dominant negative EGFR display reduced
proliferation and inhibited duct maturation [44]. Deletion of ErbB2 shunts ductal outgrowth [47,48].
ErbB2 also controls TEB formation through its regulation of cellular compartmentalization. ErbB3
deficiency results in small TEBs and increased branch density with decreased TEB size as a result in
an increase in apoptosis, controlled via observed changes in the PI3K (Phosphoinositide 3-kinase)
signaling pathway. Anti-apoptotic transcription factor Bcl-2 is reduced in ErbB3−/− mice [64]. Mice
deficient for ErbB4 have defect occurring later in breast development, specifically during the formation
of milk-producing luminal cells [65].
10. ERFR in Breast Cancer and Oncogenic PI3K Signals That Switch Fate
Dr Schlessinger put forth an elegant and simple model for EGFR activation with EGF as an
external signal leading to the conversion of a monomeric receptor to a ligand-induced dimer [66],
which served as a framework for further studies. The EGFR dimer turned out to be an asymmetric
structure in which one EGFR kinase domain in a dimer acts as an allosteric activator for the other [67],
which subsequently paved the way to mechanistically understand how a catalytically inactive Her3
can facilitate the activation of other EGFRs, such as Her2 [68]. Her2 overexpression is frequently found
in breast cancer and typically associated with poor prognosis; a Her2/Her3 heterodimer operates as
an oncogenic unit that drives breast cancer proliferation [69], with the phosphorylated tyrosines in
the intracellular tail of the catalytically inactive Her3 functioning as adapter scaffolds for intracellular
kinases such as PI3K (Phosphoinositide 3-kinase) and PLC (Phospholipase C).
Whereas it is clear that the EGFR family plays a role in mammary gland development and
maturation as well as breast cancer, a lot less is known about the specific effector kinase pathways
that lie downstream of the receptor families such as the EGFR. Elegant imaging studies revealed
that levels of phosphorylated ERK kinases (a type of MAPK) are highest in MECs near the front of
elongating ducts whereas levels of phosphorylated Akt kinase were equal throughout and Huebner
et al. proposed a model of receptor-induced proliferation leading to highly motile cells with high
phospho-ERK [70]. Two thought-provoking studies relate cell fate choices to aberrant PI3K signals in
the context of breast cancer. Cell fate, heterogeneity, and cell lineage conversions are aspects that are
of great relevance to cancer as these impact the tumor type and also often responses to therapy [71].
PIK3CA (Phosphoinositide 3-kinase p110 alpha) with a histidine to arginine mutation at position 1047
(H1047R) is a frequent mutation occurring in human breast cancer and expression of PIK3CA(H1047R)
in lineage-committed basal Lgr5-positive and luminal keratin-8-positive cells led to dedifferentiation
into a multipotent stem-like state [72]. Furthermore, the tumor cell of origin influenced the frequency
of malignant breast tumors, linking (heterogeneous) cell fate to cancer aggressiveness [72]. Van
Keymeulen et al. reported similar results in their studies in the context of loss of the tumor suppressor
p53; expression of PIK3CA(H1047R) in basal cells (keratin K5-CreERT2 driver) gave rise to luminal-like
cells and expression in luminal cells (K8-CReERT2) resulted in basal-like cells before progressing into
invasive tumors [73]. Therefore, the rules that are thought to exist in normal unipotent progenitors
(see Figure 3) appear alter when cells express PIK3CA(H1047R), which brings up a bigger question.
What aberrant biochemical signals are capable to induce crossover of basal- and luminal-cell fates and
drive further increases in heterogeneity and fluidity between mammary epithelial cells?
11. The Mammary Stem Cell Conundrum: More Questions than Answers
While there is a general consensus about some of the factors that mark and or regulate the MaSC
population, the field has been left with more questions than answers when trying to specifically define
MaSCs [74]. For example, the estimates for stem cell frequency, derived from calculating the number
of mammary repopulating units, varies dramatically. Estimates for MaSC frequency range from 1
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in every 100 total cells to 1 in every 4900 [75–77]. Extracellular markers used to sort MaSCs have
proven insufficient to exclusively identify MaSC populations, but rather, only identify populations
within which MaSCs are enriched [78–80]. The embryonic stem cell marker Oct4 (Octamer-binding
transcription factor 4) has been found to label human mammary stem cells, but is insufficient to
specifically separate MaSCs from other progenitor cells [81,82].
Some progress has been made towards separating MaSCs from mature myoepithelial and basal
progenitors by using transgenic mouse models. MaSCs residing in the terminal end bud (TEB) cap
cells exclusively express the phosphatase s-Ship [83], but MaSCs during pubertal development are not
just found in cap cell populations. Lgr5, given its well-known role in intestinal epithelial populations,
became of interest as a potential marker of the MaSC population [84]. Again, the Lgr5 story is unclear
with opposing results of studies that use slightly different approaches. Whether Lgr5+ cells have
increased repopulating activity and whether they trend towards quiescence or self-renewal has not
been clearly delineated. The exact nature and potential of Lgr5+ and Lgr5-negative MaSC populations
is an ongoing field of research [85–87]. The Lgr5 question is emblematic of the larger picture that
MaSCs are a highly heterogeneous population. Isolating a basal population enriched for MaSCs from
fetal mice revealed a distinct stem cell identity. Fetal-derived MaSCs display augmented clonogenic
potency and repopulating efficiency when compared to their adult stem cell counterparts [88]. Further,
these fetal MaSCs expressed unique extracellular receptor pattern, one that has features of both basal
and luminal cells, which was also different from pubertal MaSCs [89]. The heterogeneity is further
compounded when looking at adult mammary glands. Adults MaSCs have been found to display
“lineage priming,” in which restricted differentiation programs exist within seemingly pluripotent and
self-renewal competent stem cells [90,91]. Recent RNAseq studies have begun to further subdivide the
MaSC pool. In 2017, Pal et al. found an early progenitor subset marked by CD55 that exists between
basal and luminal cells [92]. In sum, the spatial-, temporal-, and functional-heterogeneity of MaSCs
has made their study complicated and bolstered the importance of finding new regulatory factors.
In summary, in vitro and in vivo findings suggest that breast epithelial cells can be arranged into
a developmental hierarchy (Figure 3), but it should be explicitly stressed that this is just a model. In
this hierarchy, mature luminal and myoepithelial cells are maintained by lineage-restricted progenitors,
which is replenished by the MaSC population [93]. Bipotent progenitors exist within this hierarchy,
but the exact placement is unclear and has therefore been excluded. Extracellular ligand expression
and transcription factor regulation has served as the basis for the construction of this model. The
extraordinary complexity of the mammary stem cell population has complicated a clear understanding
of the drivers for epithelial cell fate decisions.
12. Organoids to Assess Stem- and Progenitor-Potential
Organoids are miniature, three-dimensional, in vitro tissue cultures that retain stem cell function,
and are generated from pieces of tissue (Figure 4). Organoids have been instrumental to study stem
cell biology of epithelial cell lineages [94,95]. They have gained traction as ideal platforms to screen
for biomarkers, obtain personalized predictive/prognostic information, and test novel therapeutic
strategies and rational drug design [96–98]. Organoids and classical mammosphere cultures are similar
in that both are in vitro 3D cultures of cells (Figures 2 and 4). However, organoids typically depend
more on the extracellular matrix and may display more self-organization and spatially restricted
lineage commitment [99].
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Figure 4. Pipeline of mammary gland organoid cultures. Submerging the Matrigel droplet with growth
medium containing Wnt and R-Spondin ligands enables sustained maintenance of stem cell function
and allows for functional studies on mammary stem cells (MaSCs) in these 3D cultures.
Furthermore, organoids can be cultured indefinitely and can be cryopreserved, whereas classical
mammosphere cultures generally survive for shorter time periods [100]. Indeed, several different
mammosphere cultures media cocktails have been applied in the past, but for many of these studies the
goal was not to sustain growth long term. For example, Mroue and Bissell used growth media containing
insulin transferrin selenium (ITS) and fetal bovine serum (FBS) for mammospheres generated from
mouse mammary glands, but cultures were not sustained for long periods of time in this study [101].
It should be noted that the use of FBS in organoid culture is challenging since the exact composition is
unknown and components can vary from batch-to-batch. Ewald et al., used growth media containing
ITS supplemented with FGF2 and cultures were grown and assessed for a couple of days [102].
A crucial part of successfully culturing organoids (Figure 4) is to preserve stem cell function
over long periods of time. The Wnt pathway has been shown to play an important role in stem
cell maintenance [103]. In the canonical Wnt pathway, Wnt proteins bind to Frizzled (FZD) and
LRP (lipoprotein receptor-related protein) receptors. Dickkopf (DKK) is a ligand that binds to
LRP6 with high affinity [104]. Wnt binding to FZD and LRP receptors results in increased levels
of β-catenin, which translocate into the nucleus to form a transcriptionally active complex with
Tcf factors (T cell factor) [105,106]. In the absence of Wnt signals, Tcf transcription factors bind to
Groucho repressors [107–109] and as such Tcf factors act as switches to turn on Wnt target genes [110].
Intriguingly, one of the β-catenin/Tcf target genes is the extracellular receptor Lgr5 [111]. R-spondins
are ligands for Lgr5 (Leucine-rich repeat-containing G-protein coupled receptor 5), and can associate
with the Frizzled/LRP Wnt receptor complex to enhance the Wnt signal [112]. Structure-based design
and subsequent production of surrogate Wnt ligands that are hybrid molecules combining the DKK
and Wnt ligands proved clever tools to sustain canonical Wnt signaling in combination with R-spondin
ligands and support efficient organoid growth [113].
In addition to surrogate Wnt and R-spondin ligands, EGF and Noggin are required to indefinitely
expand organoids [114]. Furthermore, additional components can be added to the organoid
medium to help maintain organoid cultures. These include fibroblast growth factor (FGF) 7, FGF10,
Activin like kinase inhibitor (A83-01), SB202190 (p38 mitogen-activated protein kinase inhibitor),
and nicotinamide [115]. Neuregulin 1 (Nrg1) is required for morphogenesis and differentiation
of the mammary gland [116]. Addition of Nrg1 to organoid culture medium resulted in higher
efficiency of mammary organoid generation [114]. Rho kinase inhibitor (Y-27632) was found to induce
indefinite proliferation in vitro in normal and tumor epithelial cells [117] and addition of Y-27632 to
organoid culture medium improved organoid culture conditions [114]. In Section 6 we discussed the
heterogeneity and complexity of the stem- and progenitor- cell population in the mammary gland with
Lgr5+ and Lgr5− cells and different characteristics in fetal-, puberty-, and adult-stages. We anticipate
that successful mammary gland organoids will require complex but clearly defined (growth) factor
medium and that systematic application of standard operating protocols (SOPs) will propel the field’s
efforts of organoid and cell heterogeneity forward.
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13. Reconstructing Mammary Epithelial Cell Types and States Using Single-Cell Genomics
Advances in next generation sequencing and microfluidic-based handling of cells and reagents
now enable us to explore cellular heterogeneity in an unbiased manner using various single-cell
genomics modalities to profile genomic features in individual cells [118]. The current scientific
knowledge about the MEC system is largely limited to data generated by bulk profiling methods, which
only provide averaged read-outs that generally mask cellular heterogeneity. This averaged approach is
particularly problematic when the biological effect of interest is limited to only a subpopulation of cells
such as stem/progenitor cells, which may comprise only minor subsets of the total number of cells in a
tissue. However, over the very recent years several studies emerged that utilized single-cell genomics
approaches for unbiased identification of the cell types and states within the MEC compartment.
Among the genomics modalities available to date, single-cell RNA sequencing (scRNAseq) is the
most advanced and most widely accessible to the research community, and has recently been applied
to both human and mouse mammary epithelial samples (Figure 5). A recent study using a combination
of microfluidic- and droplet-enabled single-cell transcriptomics pipelines revealed that the human
breast epithelium contains three very distinct types of cells that each contain additional distinct cell
states [119]. Based on these data, the human epithelium contains one basal and two luminal cell types,
namely a hormone-responsive and a secretory type of luminal cells. The secretory luminal cell type was
previously called luminal progenitors and generally expresses markers such as ELF5 (E74-like Facotr 5)
and KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, CD117). Within basal cells,
further distinctions can be made based on expression of myoepithelial markers (e.g., ACTA2, Actin
Alpha 2, Smooth Muscle). Pseudo temporal analysis of the differentiation trajectories in this dataset
defined a continuous lineage that seamlessly connected the basal and two luminal cell types, which is
in line with the concept that basal and luminal cell types are maintained by an integrated system of
stem and progenitor cells.
 
Figure 5. Pipeline of scRNAseq to resolve cellular heterogeneity with novel sequencing techniques.
Processing mammary gland tissue of breast cancers into single-cell droplets coupled to single-cell RNA
sequencing (scRNAseq) and data analysis (e.g., tSNE plots) allows for high resolution investigation of
different cell types on the basis of individual cell transcriptome.
The mouse mammary epithelium at post-pubertal stage generally revealed a comparable cell type
and state composition with some differences in terms of marker genes expressed in each cell type.
Pal et al. [92] used scRNAseq of isolated mouse MECs to define three main cell types, namely basal
(marked by Krt14, Keratin 14), secretory luminal or also called luminal progenitors (L-sec; marked
by Elf5) and mature, hormone-responsive luminal cells (L-HR; marked by Prlr, Prolactin receptor).
In addition to the main cell types, intermediate states were identified marked by expression of both
luminal and basal genes, which could be indicative of transitional cell states between luminal and basal
cells and thus support the notion of one continuous lineage trajectory that maintains all MEC cell types.
Another similar study focused on the differentiation dynamics of the mouse mammary epithelium
during various developmental stages of adult virgin, pregnant, lactating and involuting mammary
gland using scRNAseq, which defined the lineage hierarchies as a differentiation continuum rather that
discrete differentiation stages [120]. The most elusive cell type remains the MaSC, which so far did not
emerge as a distinct cluster in either human or mouse single-cell transcriptomics analyses, although a
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subset of basal cells in both human and mouse cells expresses the putative MaSC markers PROCR
(Protein Coding, CD201) or LGR5 [119,120]. It remains to be determined whether more sophisticated
analysis tools such as single-cell potency analysis [121], or higher sequencing depth per cell and
larger cell numbers are required to unambiguously define the MaSC as a distinct cell type (Figure 5).
Recent years have also seen the emergence of studies that applied scRNAseq to unravel complexity of
breast cancer [122,123], including the immune environment of breast tumors [124,125], and response
to Herceptin therapy that targets EGFR2 (Her2) [126]. More is certainly to come as scRNAseq and its
analysis becomes more mainstream and affordable.
In addition to gene expression programs, the epigenetic makeup of the cell is a critical determinant
of cellular identity that is not detectable in scRNAseq data. Recent technological advances now
allow for profiling chromatin accessibility using the Assay for Transposase-Accessible Chromatin
using sequencing (ATACseq) to reconstruct cis/trans regulatory elements associated with cellular
identity [127]. Further adaptation of this pipeline enabled single-cell-level ATACseq to profile cellular
heterogeneity on an epigenetic level both using massively parallel [128] and combinatorial indexing
methods [129]. This approach has recently been applied to elucidate transcriptional regulators of the
fetal mammary gland developmental lineages showing that fetal MaSCs can be separated into basal-like
and luminal-like lineages, suggesting an early lineage segregation prior to birth [130]. Another study
utilized a combination of single-cell ATAC and RNA sequencing isolated mammary epithelial cells
to reveal the spectrum of heterogeneity within the MEC system in the adult stage [131] Interestingly,
a distinct luminal progenitor cell state within the secretory luminal cell type emerged in chromatin
accessibility analysis that was clustering separately in transcriptomics data. By integrating single-cell
transcriptomics and chromatin accessibility landscapes, this work further identified novel cis- and
trans-regulatory elements that are differentially activated in the epithelial cell types and the newly
defined progenitor cell state. Taken together, these single-cell genomics studies provide invaluable
resources that may serve as reference atlases to map out how the system goes awry during diseases
such as cancer in unprecedented resolution.
14. Conclusions
In summary, cartoons such as the one depicted in Figure 3 in our review give the impression of
simple and clean cell lineage choices with well-defined trajectories of cell development in unipotent
manners. In reality the mammary gland, and therefore breast cancer, is much more complex and
cellular heterogeneity is obvious. The pair of studies using expression of oncogenic PIK3CA(H1047R)
in different mammary epithelium cell subsets give particularly striking examples of crossover between
basal- and luminal- cell fates and the possibility of dedifferentiation into a multipotent stem-like
state [71,72]. It is not difficult to imagine how such fluidity in cell identity may greatly impact how
breast cancer patients respond to specific types of therapy in the clinic. Fortunately, technology is
constantly evolving. For example, studies that assess the potential of cell populations with organoids
coupled to characterization of the transcriptional landscape at the single-cell level are starting to emerge
(Figure 6). Intelligent combination of organoids, mouse models, scRNAseq, ATACseq, lineage tracing,
CyTOF (mass cytometry by time-of-flight), and other novel technology platforms will be required to
comprehensively understand cell heterogeneity in the mammary gland and breast cancer.
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Figure 6. Organoids, scRNAseq, and other technologies to resolve cellular heterogeneity. Combination
of different platforms such as organoids and scRNAseq but also mouse models, lineage tracing, and
patient-centric assays will likely each make important contributions to resolve cellular heterogeneity in
the mammary gland and in breast cancer.
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Abstract: Pancreatic Ductal Adenocarcinoma (PDAC) is a particularly insidious and aggressive
disease that causes significant mortality worldwide. The direct correlation between PDAC incidence,
disease progression, and mortality highlights the critical need to understand the mechanisms by which
PDAC cells rapidly progress to drive metastatic disease in order to identify actionable vulnerabilities.
One such proposed vulnerability is epithelial mesenchymal plasticity (EMP), a process whereby
neoplastic epithelial cells delaminate from their neighbours, either collectively or individually, allowing
for their subsequent invasion into host tissue. This disruption of tissue homeostasis, particularly in
PDAC, further promotes cellular transformation by inducing inflammatory interactions with the
stromal compartment, which in turn contributes to intratumoural heterogeneity. This review describes
the role of EMP in PDAC, and the preclinical target discovery that has been conducted to identify
the molecular regulators and effectors of this EMP program. While inhibition of individual targets
may provide therapeutic insights, a single ‘master-key’ remains elusive, making their collective
interactions of greater importance in controlling the behaviours’ of heterogeneous tumour cell
populations. Much work has been undertaken to understand key transcriptional programs that drive
EMP in certain contexts, however, a collaborative appreciation for the subtle, context-dependent
programs governing EMP regulation is needed in order to design therapeutic strategies to curb
PDAC mortality.
Keywords: pancreatic cancer; epithelial mesenchymal plasticity; target discovery; review
1. Pancreatic Cancer, Tumour Heterogeneity, and Carcinoma Vulnerabilities
Pancreatic cancer (PC) is the fourth most common cause of cancer-related deaths in Western
societies, with 57,000 new cases annually, resulting in nearly 46,000 deaths in North America alone [1].
The most common type of PC is Pancreatic Ductal Adenocarcinoma (PDAC), which arises in the ductal
epithelium of the exocrine tissue responsible for secreting pancreatic digestive juices. Late detection
combined with early metastatic spread have limited gains in overall survival relative to other cancers
such that PDAC mortality has the potential to surpass that of both colorectal and breast cancers by
2030 [2]. PDAC research therefore aims to define better diagnostic markers and novel therapeutic
avenues, however is significantly complicated by the clinical heterogeneity present both within
and between patient tumours. This emphasises the need for more integrative approaches aimed at
developing a better understanding of targetable processes in PDAC tumourigenesis.
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Cancer is a genetic disease caused by the accumulation of somatic mutations, resulting in a
functional imbalance between tumour suppressive and oncogenic signals [3]. While transformed cells
retain characteristics of the host to efficiently avoid being detected as foreign by the immune system,
many aberrant phenotypes caused by genetic mutations and dysregulated signaling potentially render
these cells susceptible to selective therapeutic interventions. Extensive examinations of the molecular
traits of PDAC aimed at identifying such vulnerabilities have been conducted to date. Indeed, genomic
and transcriptional profiling of patient tumours as part of large-scale studies by the The Cancer Genome
Atlas (TCGA) and International Cancer Genome Consortium (ICGC) have allowed for insights into the
scale of inter-tumour heterogeneity in a breadth of patient cohorts [4–6].
These studies have identified four major genetic aberrations common to pancreatic
tumours [7–9]. 90% of tumours carry gain-of-function mutations in KRAS2, activating proliferative
and cell survival pathways, whilst 95% contain either partial or complete inactivating mutations in
CDKN2A, contributing to loss of cell cycle regulation, furthering proliferation. TP53, responsible for
responding to DNA damage and inducing apoptosis, is altered in 60% of cases. SMAD4 inactivation is
also common in pancreatic cancer development, and is found in 50% of patient cancers, disrupting the
tumour suppressive signals of TGFβ, aiding proliferation [10]. As well as these four common driver
mutations, genomic sequencing of tumours has identified an additional panel of consistently mutated
genes [6]. These genetic mutations implicate pathways often dysregulated in cancer, including KRAS,
TGFβ, WNT, NOTCH, ROBO/SLT, G1/S, SWI-SNF, and chromatin/DNA/RNA modification and repair.
Transcriptional profiling of PDAC tumours has allowed researchers to define discrete regulatory
mechanisms within these networks that are associated with particular prognostic indices in different
molecular subtypes of PDAC, which include squamous, pancreatic progenitor, immunogenic and
aberrantly differentiated endocrine/ exocrine tumours [6]. Such classification schemes may provide
clinical value by aiding in patient treatment regimen selection and planning [11], however, to date
they have provided limited clinical value due to lack of targetable phenomena. It is important to
note that while these studies have aimed to characterise changes within carcinoma cells, the excessive
presence of desmoplastic stroma may confound these results. Indeed, microdissection of the tumour
from its associated stroma has allowed the retrospective re-evaluation of large-scale transcriptional
profiling efforts, highlighting the overwhelming contribution of stromal contamination to many such
studies. Deconvolution based on laser capture microdissection and RNASeq profiling of 60 matched
tumour/stroma pairs suggested that ICGC and TCGA samples contained stromal fractions of 46%
and 55%, respectively, highlighting difficulties in deriving definitive conclusions from whole tumour
analyses [12].
Such studies are invaluable as a means of understanding the intertumoural heterogeneity that
exists between patients, and they form a strong set of public data that have been analysed to better
appreciate the diversity of tumour presentation [13]. An increasing focus on single cell analytic
technologies has yielded exciting opportunities to understand the contributions that individual cells
make towards intratumoural heterogeneity, tumour progression, and patient outcomes [14,15]. These
studies highlight the need for efforts aimed at distinguishing the heterogeneous nature of a tumour’s
biology from that of the surrounding host tissue in which it propagates, so as to be better able to exploit
cancer specific vulnerabilities [16].
As such, it is not surprising that the interactions between neoplastic epithelial cells and host
myofibroblast and stellate populations, which can promote stromal inflammation, are increasingly
being recognised. This desmoplastic reaction, which accounts for up to 90% of PDAC tumour volume,
has pro-tumourigenic properties by leading to increased tissue stiffness and hypoxia as well as by
providing physical barriers to both immune surveillance and chemotherapeutic penetrance [17–19].
The fibrillar collagen, hyaluronic acid and fibronectin rich extracellular matrix (ECM) deposited by
stromal cells contains many soluble cytokines and growth factors secreted by both cancer and stromal
compartments and contributes to both tumour initiation and progression [20–23]. Resident cells
are forced to interact within this dynamic tumour microenvironment and are subject to stimuli that
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influence cell phenotypes in both stromal and carcinoma components. Such stimuli may propagate the
invasion and dissemination of carcinoma cells by inducing epithelial mesenchymal plasticity (EMP),
and thus this process is considered an important vulnerability that, when effectively targeted, may
curb tumour progression [24,25].
2. EMP and PDAC Progression
EMP is often separated into two distinct but related processes—the forward process of
epithelial-mesenchymal transition (EMT), and the reverse process of mesenchymal-epithelial transition
(MET) [26]. These programs serve to describe the plasticity within epithelial cells that enables them
to dedifferentiate into a more motile mesenchymal state, thereby allowing them to more effectively
migrate. EMP is thought to play a significant role in several stages of tumour formation [27] and
progression [28]. Initially, this plasticity allows tumour cells to detach and migrate from their site of
origin (invasion), gaining access to lymphatic and blood vessels (intravasation), and then penetrating
distant sites (extravasation), to form metastases.
A litany of reviews regarding different facets of EMP in PDAC, have been written, including those
focused on molecular mechanisms of EMP regulation and metastasis [29–36], the role of epigenetic
regulation [37], therapy development and resistance [38–42], microRNA regulation [43,44], and cancer
stem cell generation [45–49]. This review thus focuses on some of the ongoing controversy surrounding
in vivo evidence of EMP and the limitations of current approaches, highlighting the need to integrate a
greater diversity of published EMP molecular regulators.
Development of PDAC frequently progresses undetected, remaining asymptomatic until it
becomes an advanced stage of disease. Non-invasive precursor lesions formed either by epithelial
proliferations or mucinous cysts in the pancreatic ducts, termed pancreatic intraepithelial neoplasia
(PanINs), or intraductal papillary mucinous neoplasms (IPMNs), respectively, mark the onset of a
histologically definable neoplasm in PDAC [50]. Such neoplasms, namely PanINs, progress through
stages of dysplasia within the ductal epithelium, giving rise to the most common form of PDAC,
pancreatic ductal adenocarcinoma (PDAC). The full breadth of factors that contribute to the invasive
and metastatic behaviour of PDAC are vast. In this form of PDAC, there is very little latency between
primary tumour formation and local and distant metastasis, implying that PDAC carcinoma cells may
be readily equipped to invade and disseminate from a very early stage of development [51,52].
Invasive regions of human carcinomas are typically characterised by the presence of
tumour-derived, fibroblast-like cells expressing mesenchymal markers such as vimentin, fibronectin
and N-cadherin, with decreased expression of epithelial adhesion molecule E-Cadherin and increased
nuclear beta-catenin relative to surrounding cells [53–57]. Decreased expression of E-cadherin has been
shown to correlate with invasive and undifferentiated PDAC [58]. Furthermore, PDAC patients with
tumour cells that express decreased E-cadherin and higher amounts of vimentin, s100A4, fibronectin
and SNAI1 are more likely to have distant metastases, lymph node invasion and lower overall
survival [54,59–62]. The EMP inducing transcription factor (TF) TWIST1 has been shown to be
upregulated in PDAC compared to match normal tissues [63], and SNAI1 mRNA levels in PDAC fine
needle aspirates are significantly correlated with lymph node and perineural invasion as well as with
poorer survival [64]. A mediator of transforming growth factor beta (TGFβ) signaling, SMAD3, was
also shown to accumulate in the nucleus of PDAC samples, and was correlated with higher grade
tumours and lymph node metastasis, indicating a role for TGFβ in driving EMP in vivo [65]. Solitary
infiltrating cancer cells displaying low E-cadherin and increased vimentin expression have proven to
be significant prognostic indicators in resected clinical specimens from PDAC patients [66]. Tumour
budding cells in PDAC have been observed with increased levels of ZEB1 and ZEB2, and reduced
levels of E-cadherin and β-catenin, indicative of EMP mediated local invasion. ZEB2 overexpression
in tumour-stroma associated cells also correlated with pathological assessment of tumour size, and
lymph node metastasis [67]. Such striking pathology provides some of the clearest evidence for the
role of EMP in PDAC progression.
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While this clinical evidence strongly supports a role for EMP in mediating cancer invasion, the
inability to accurately follow carcinoma epithelial dedifferentiation in vivo has led to some debate
surrounding the extent of its role in tumour progression [68,69]. Such debate has necessitated the use
of genetically engineered mouse models (GEMMs) to trace the role of EMP in cancer progression,
specifically the pancreatic epithelium conditional Kras/P53 mutant (PKCY) mice Lineage labelling
of epithelial cells in this spontaneous PDAC model has allowed researchers to track these cells as
they adopt mesenchymal properties and migrate away from the primary tumour into the circulation,
seeding liver metastases [70]. In one study, EMP was detected in 42% of labelled PDAC epithelial cells,
as assessed by the expression of EMP markers Zeb1 or Fsp1 and/or lack of E-cadherin. These cells were
mostly observed in regions of inflammation, supporting the idea that EMP is driven by inflammatory
interactions within the tissue microenvironment. Interestingly, some labelled epithelial cells that had
undergone EMP displayed evidence of delamination and fibroblast morphology prior to tumour
formation, and were otherwise indistinguishable from host stromal cells [70]. This is supportive of the
very early, integral role that EMP may play in PanIN formation prior to tumour development.
Further studies in this same PDAC mouse model have shown that suppression of EMP via the
knock-out of Twist1 or Snai1 TFs does not reduce metastasis, despite the decreased expression of EMP
markers and increased cell proliferation as evidence for EMP ablation [71]. Equivalent numbers of
lineage labelled epithelial cells were found in circulation and in metastases regardless of Twist/ Snai1
knockout, suggesting that other mechanisms are involved in PDAC cellular invasion. PDAC cells do
not possess a strong epithelial phenotype however, and may thus be insensitive to the loss of Snail TFs,
which are potent repressors of epithelial programs but are less efficient in inducing mesenchymal
properties. This possibly explains why Snail is dispensable for EMP and metastatic progression in
this model [71,72], and points towards alternative mechanisms of EMP induction that may be driving
factors in this PDAC system.
Indeed, there is evidence that the Zeb1 TF is largely responsible for driving EMP in this GEMM
model of PDAC development [73]. Zeb1 ablation in PDAC cells was not found to affect Twist1 expression,
however it was associated with decreased Zeb2, Slug and a slight reduction in Snai1 expression. Zeb1
depleted tumours were better differentiated, indicating less local invasion, and showed significantly
reduced metastasis when compared to control PDAC mice [73]. This is in direct contrast to depletion
of Twist1 or Snai1, which did not affect metastasis in this model system, highlighting the importance of
recognising the context and tissue specific drivers of EMP.
Subsequent investigations aimed at overcoming the limitations of identifying single EMP
regulatory TFs has shown that lineage labelled cancer cells are able to metastasize without expression
of αSma or Fsp1, both of which are thought to be robust markers of EMP activation in this model [74].
Indeed, larger metastatic nodules were found containing exclusively cells that had never expressed
αSma or Fsp1, while micrometastatic clusters of 3–5 cells were shown to have undergone EMP. Such
evidence, combined with the fact that Zeb1 depletion in previous studies resulted in only a 50%
reduction in metastasis underscores the pitfalls of seeking to identify individual master regulators and
markers of such a complex process. Adding to this complexity, the emerging importance of hybrid
EMP phenotypes, in which the expression of both epithelial and mesenchymal markers may occur at
levels that are insufficient to drive the reporter constructs used in such lineage tracing models, adds a
further technical challenge [75–77].
More recent attempts to understand EMP in individual PDAC cells has shown the activation
of EMP transcriptional programs within certain subsets of tumour cell populations [14]. This study
highlighted a clear role for cytokines from the stromal compartment in inducing EMP in certain PDAC
cell lines, and indicated that EMP activation could be observed in discrete tumour gland subunits with
prognostic utility. These models have provided considerable insights into the diverse mechanisms of
PDAC development, and highlight that there are context-dependent EMP programs involved in both
local invasion and metastatic dissemination that require further examination [72,78].
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3. In Vitro EMP Models and Exogenous Stimuli
While GEMMS, in particular the PKCY model of spontaneous PDAC formation, are currently
the gold standard for studies of the biology of EMP in tumourigenesis, in vitro studies form the
basis for the majority of our current molecular understanding of intracellular events which occur in
EMP. Many publicly available and in-house generated cell lines are used to study PDAC, but only
a very limited number of these undergo well-characterised, stimulus-driven transitions that mimic
the pathophysiological induction of EMP. This is perhaps consistent with the limited number of EMP
events witnessed in in vivo models, highlighting the difficulties of studying such a dynamic process.
EMP is modulated by TGFβ, receptor tyrosine kinases (RTK) ligands, WNT ligands, interleukins,
hypoxia via HIF1α signaling, as well as HIPPO, NOTCH signaling. Their mechanisms and specific
impact on downstream EMP targets have been comprehensively reviewed elsewhere, however our
understanding of their subtleties is on-going [79,80]. TGFβ acts as a tumour suppressor in normal
tissue and early stage disease by regulating cell proliferation and inducing apoptosis through canonical
signaling pathways, however this activity is lost as cellular transformation progresses [81–85]. Indeed,
TGFβ is a potent activator of EMP in PDAC cells when its tumour suppressive signals are disrupted
through SMAD4 mutations, found in 50% of PDAC tumours [81,86]. Similarly, activating KRAS
mutations found almost ubiquitously in PDAC cooperate with TGFβ signaling to hyperactivate
downstream RAS/RAF MAPK pathways to induce EMP [87]. While TGFB activates the greatest
number of EMP signaling pathways, and may thus be considered a major driver in PDAC, the
activation of additional pathways shown in Figure 1 by RTK, WNT and interleukin ligands may
provide additional layers of crosstalk. Activation of SMAD, MAPK, PI3K, STAT, and NFκB pathways
are commonly demonstrated in PDAC EMP research, however the relative extent to which each
pathway governs EMP is unclear, as many studies evaluate these pathways independently [29,88–94].
These complex pathways ultimately serve to influence transcriptional programs that co-operate
directly and indirectly to control the plasticity that exists between epithelial and mesenchymal
phenotypes of carcinoma cells (Figure 1). Of note is the increasing recognition for the role of long
non-coding RNAs (LncRNA) and micro-RNAs (miRNA) in EMP regulation. Among the cells that do
undergo EMP-like transitions, there is a degree of selectivity for the ligands that are able to activate
these EMP programs, and this is reflected in the limited number of commercial cell lines that are
commonly manipulated within the field. This is consistent with the level of heterogeneity reported in
PDAC, and suggests discrete differences in steady state signaling, which may predispose a given cell’s
response or resistance to exogenous stimuli.
 
Figure 1. Simplified overview of cooperating signaling pathways in EMP.
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EMP is induced by stimuli shown within arrows on the left in order of potency. These signals
activate signal transduction pathways that cooperate directly and indirectly to translocate signals to
the nucleus (braced) to regulate EMP transcription factors, long non-coding RNAs (LncRNA), and
micro RNAs (miRNAs).These factors then modulate EMP by discrete regulation of epithelial (Red Box)
and mesenchymal (Green box) cellular properties, which in turn influence migration and invasion.
Transforming growth factor (TGFB) activates the greatest number of these pathways, including direct
cytoskeletal regulation by RhoA, aswell as canonical SMAD and non-canonical p38/JNK, MEK/ERK
MAPK pathways and PI3K/AKT. Receptor tyrosine kinase (RTK) signaling is induced by binding
of growth factor (GF) ligands such as EGF, IGF, FGF, HGF or VEGF and activates RAS/MEK/ERK,
PI3K/AKT/NFκB and downstream SRC pathways. WNT signaling also modulates EMP by downstream
stabilisation of B-catenin and subsequent nuclear translocation for EMP program activation by TCF/LEF
transcription factors. Interleukins (ILs) can also induce EMP programs via STAT3 signaling. Additional
mediators of EMP include Hypoxia, Hedgehog, Notch and Integrin signaling (not shown), and
highlight the context dependent activation of EMP from micro-environmental cues.
While most studies rely upon knockdown and over-expression approaches to demonstrate the
function of proteins in the context of cell migration, proliferation and EMP transitions, relatively few
studies have investigated these targets in the context of the physiological induction of EMP in response
to exogenous stimuli. Among PDAC cell lines, L3.6pl cells have been shown to respond to VEGF
treatment [95], while the inflammatory cytokines TNF-α and IL-1β drive EMP in PaTu 8988T and
AsPC-1 cells via Hedgehog signaling [96]. Collagen 1 also stimulated L3.6pl and BxPC-3 cells to become
more invasive through interaction with DDR1 [97], and BMP2 was able to elicit a similar response
in BxPC-3 cells [98]. PANC-1 cells are a well characterised model of inducible EMP, first shown by
Ellenrieder et al to undergo a bidirectional change in response to TGFβ alongside CAPAN-1, COLO-357,
IMIM-PC1 [99], HPAF-II, and CAPAN-2 cells [100]. PANC-1 cells have since been repeatedly modelled
with regard to their EMP response, which has been shown to be inducible in response to TGFβ, TNF-α,
HGF, or hypoxia through differing mechanisms [101–104]. SNAI1 appears to be a major driver in
this model, being heavily regulated at the transcript and protein level, despite modest changes in
E-cadherin and Vimentin proteins [105]. EMP is thus invariably the result of exogenous stimuli that
activate discrete but conserved cellular pathways through novel intermediates that are an ongoing
focus of basic cancer cell biology research.
4. Pre-Clinical Discovery of EMP Targets
As a result of the complexities of discerning cancer biology from native processes in vivo, the
use of cell lines derived from primary tumours are a valuable means of modelling the molecular and
phenotypic properties of cancers. Extensive investigation has been performed using gene silencing and
overexpression approaches to evaluate the role that particular molecules have in regulating or effecting
the EMP phenotypes of PDAC cells, however a concise summary of novel targets in the PDAC EMP
field has to date been lacking. Thus, this review provides an exhaustive overview of such research as a
platform for their integration, and progressive evaluation. The function of these candidate molecules
can be broadly separated into secreted/soluble products (Table 1), receptors (Table 2), other membrane
associated proteins (Table 3), cytoskeletal adaptors (Table 4), kinases (Table 5), intracellular mediators
(Table 6), transcription factors (Table 7) and post transcriptional controllers (Table 8). The candidates
shown were selected by searching Pubmed for the terms ‘pancreatic’ and ‘epithelial’, and articles
investigating a novel candidate’s impact on EMP phenotypes were manually curated. These effectors
have been characterised to varying extents for their influence on invasion, migration, xenograft tumour
growth, prognostic associations, and impact on known EMP signaling pathways. The proposed
mechanisms of candidates and assays used to assess such effects are shown within tables and may be
used to gauge where further support may be warranted to confirm and extend such findings. Due to
the inherent variation in models used, the statistical power granted by IHC for varying sized patient
cohorts with accompanying clinical information, and the level of EMP as a primary context, it is difficult
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to draw direct conclusions regarding pivotal significance within the field and clinical importance
from such singular studies. Candidate expression in primary patient material that correlated with
lymph-node metastasis are shown in bold within tables, and provide the best surrogate for their role in
EMP mediated invasion, and include membrane bound proteins IGFBP2, ITGB4, CEACAM6 [106–108].
The use of IHC to capture dynamic EMP processes may be limited however, as shown in the case of
LIN28B, where its expression is both induced by TGFβ and high in PDAC tissue, despite its role to
suppress the pro-EMP non-coding RNA LET7a [109,110]. Such studies highlight both the utility and
limitations of the links between in vitro assays and clinical material, and emphasise the need for both
wider cohorts of patient material for validation and the development of GEMM models to strengthen
findings in a standardized manner.
Figure 2 illustrates the proposed activity of some of these novel candidates, and how they may
positively or negatively regulate discrete EMP signaling pathways. Of note are several candidates
that converge to positively regulate EMP migratory phenotypes through FAK/Src and FAK/PI3K
signaling, including the 5HT receptor and mucins, as well as EEF2K, USP22, and ZIP4. Their complete
mechanisms of action and prevalence in PDAC tissue remain to be elucidated, however their inhibition
may curb carcinoma invasion by blocking FAK activation and subsequent EMP modulation. Similarly,
candidates participating in stability of EMP signaling and TF activity provide targets to modulate
the EMP process specific for carcinoma cells. AURKA kinase has been shown to participate in a
positive feedback loop with stabilization and activity of TWIST1, while PEAK1 and NES have been
implicated in stabilization YAP/TAZ and SMAD TF activity. The discovery of discrete EMP regulation
and development of combinatorial inhibitors may provide the opportunity for more personalized
therapeutic approaches to curb metastatic disease.
 
Figure 2. Simplified overview of the proposed mechanisms of novel candidates.
EMP and cell migration (GREEN boxes) is induced through cell surface proteins (ITG, 5HTR, MUC,
BLT2, SEMA3C, RTK, TGFβR) (RED) to activate signaling pathways (ORANGE boxes, blue arrows).
These pathways are influenced by novel mediators (BLUE boxes) through activation (GREEN arrows)
or inhibition (RED T) of known signaling members, however complete mechanisms of action
remain to be elucidated. For full details, evidence of proposed mechanism and references of novel
mediators, see tables below. Note signaling pathways shown have had intermediates removed for ease
of visualisation.
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5. Conclusions
Overall, investigation of the fundamental biology of EMP aims to combat local and metastatic
invasion by providing a better understanding of the processes that allow cancer cells to dissociate
from their epithelial adhesions to spread. EMP is a prominent driver of PDAC progression, thus
highlighting the importance of our understanding of the subtleties of its regulation. The ability of EMP
programs to direct cancer cells towards a drug resistant and migratory lineage capable of seeding local
and distant recurrence presents a significant barrier to current treatment regimens. Therefore, the
identification of new candidate molecules regulating these processes are crucial to inform targeted
therapies and provide insights into the vulnerabilities of heterogeneous populations of tumour cells
present in PDAC.
It is clear from this ever-growing list of EMP effectors in PDAC cells alone, that much work
remains to delineate their collective interactions within and beyond our current understanding on
EMP signaling pathways. While candidates have been shown to play roles in aspects of EMP signaling
and associated phenotypes, significant support is required for their mechanisms of action to make
concrete conclusions about their directive actions in cancer. Our understanding of receptor mediated
canonical signaling through PI3K/AKT, MAPK, NFκB and other well studied cell cycle pathways has
required decades to tease apart, and the subtleties of EMP programs provides a similar challenge. Open
source integrative tools such as Reactome [200], WikiPathways [201], String [202], and Cytoscape [203]
provide platforms for researchers to combine such analyses to build upon our current understanding
and fill knowledge gaps in the field of cancer biology. In this way, progress may be made to better
understand and discover properties that may be modulated in concert to control EMP in cancer.
In vitro and xenograft tumour modelling and manipulation of target molecules often demonstrates
a role in cancer cell migration and tumour formation, however stronger evidence for their physiological
role in regulating EMP, metastasis and therapy resistance may require GEMMs. The use of in vivo
manipulation of PDAC GEMM models using targeted CRISPR approaches may be such a route towards
a system that better recapitulates the spontaneity and heterogeneity of human tumours [204].
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Abstract: Tumor blood vessels supply nutrients and oxygen to tumor cells for their growth and
provide routes for them to enter circulation. Thus, angiogenesis, the formation of new blood vessels,
is essential for tumor progression and metastasis. Tumor endothelial cells (TECs) that cover the inner
surfaces of tumor blood vessels reportedly show phenotypes distinct from those of their normal
counterparts. As examples, TECs show cytogenetic abnormalities, resistance to anticancer drugs,
activated proliferation and migration, and specific gene expression patterns. TECs contain stem-like
cell populations, which means that the origin of TECs is heterogeneous. In addition, since some
abnormal phenotypes in TECs are induced by factors in the tumor microenvironment, such as hypoxia
and tumor cell-derived factors, phenotypic diversity in TECs may be caused in part by intratumoral
heterogeneity. Recent studies have identified that the interaction of tumor cells and TECs by juxtacrine
and paracrine signaling contributes to tumor malignancy. Understanding TEC abnormality and
heterogeneity is important for treatment of cancers. This review provides an overview of the diversity
of TECs and discusses the interaction between TECs and tumor cells in the tumor microenvironment.
Keywords: tumor endothelial cell; metastasis; heterogeneity; angiocrine factor
1. Introduction
Cancer is one of the leading causes of death in most of the advanced countries, and the main cause
of cancer death is distant metastasis. Hematogenous metastasis is still incurable, although patient
survival has improved. Understanding and overcoming tumor progression and metastasis are crucial
in cancer therapy. Tumor tissues require oxygen and nutrients to grow, and these are supplied by
blood flow to the tumor. Without neovascularization, most tumors may become dormant at a diameter
of 2–3 mm [1]. Blood vessels support tumor cell expansion by providing the routes from intravasation
in primary tumors to extravasation in distant organs. Tumor blood vessels play an important role in
tumor growth and dissemination.
Antiangiogenic therapy was proposed by Dr. Folkman [1]. Since solid tumors are dependent on
neovascularization for their growth, Folkman suggested that the prevention of neovascularization
may restrict tumor growth to a very small diameter [1]. Angiogenic inhibitors such as bevacizumab,
a humanized anti-vascular endothelial growth factor (VEGF) antibody [2], have been used for the
past 15 years. Because VEGF is known as a permeability factor [3–5], antiangiogenic therapy not
only suppresses the growth of tumors, it also normalizes blood vessel structures and improves the
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delivery of oxygen and drugs, which potentially affects both radiotherapy and chemotherapy [6,7].
However, the clinical benefits of antiangiogenic therapies have been limited, resulting in slight
improvements in prognosis, such as enhancing progression-free survival [8]. In addition, resistance
to antiangiogenic therapy has emerged because of the complex interaction between tumor cells and
stromal cells, including endothelial cells (ECs), which allows for tumor cells to escape these targeted
therapies [9].
Tumor endothelial cells (TECs) that cover the inner surfaces of tumor blood vessels are the primary
targets of antiangiogenic therapy. Several reports have demonstrated that TECs are abnormal, and their
abnormality is one of the causes of resistance to antiangiogenic therapy. In addition, TECs show
intertumoral and intratumoral heterogeneity in terms of communicating with the surrounding tumor
microenvironment. Reviewing how to overcome cancer from a TEC perspective, we focus on the
abnormality and diversity of TECs, incorporating a discussion regarding the interaction between TECs
and tumor cells in the tumor microenvironment.
2. Abnormalities of TECs
2.1. Tumor Blood Vessels and Normal Blood Vessels
At the organ level, the vasculature in the tumors from which TECs originate has an atypical
morphology described as “abnormal” in terms of structure and function. Vasculature in normal
nondiseased organs has an organized hierarchical structure that supports the efficient distribution of
blood and its components to cells [10]. The order of blood flow in the normal vessels is from arteries
to arterioles, and subsequently to capillaries, postcapillary venules, and lastly veins. In terms of
function, tumor blood vessels do not support a sequential pattern of blood flow due to the chaotic
order of organization.
The formation of tumor blood vessels from existing ones, called angiogenesis, occurs in response
to the proangiogenic stimuli, including VEGF, basic fibroblast growth factor (bFGF), placental growth
factor, and angiopoietin, among others that are produced by the tumor cells [11,12]. Hypoxia [13] and
acidity [14], which are commonly associated with the tumor microenvironment, also can stimulate
VEGF production in tumors. The abundance of VEGF and/or the other angiogenic factors in the
tumor microenvironment sustains a continuous process of angiogenesis, leading to the formation
of tumor blood vessels with various structural defects [12]. These tumor blood vessels are tortuous,
highly permeable, and dilated, and show differential coverage and a loose association of perivascular
cells along the vessels and weakened EC junctions [15,16].
Another important contribution to the abnormal phenotype of tumor vasculature is the insufficient
control of the angiogenesis process. It has been documented that there exists an imbalance in
the expression of the angiogenesis stimulators and inhibitors [17,18]. Furthermore, it was recently
demonstrated that uncontrolled glycolysis in TECs due to an upregulated expression of glycolysis genes,
including the enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), contributes to
structural deformities observed in tumor blood vessels [19].
These abnormal structural changes make tumor blood vessels highly permeable compared with
normal vessels. Proteins and fluids leak out of the vessels into the extracellular environment and create
a high tumor interstitial pressure [20,21]. In addition, the expanding tumor population exerts more
pressure on the blood vessels, causing some portions to collapse. Concomitantly, blood flow to certain
portions of the tumor is cut off, leading to hypoxia [22], a switch to glycolytic metabolism in some
tumors, and an increase in tumor acidosis. Hypoxia in tumors further induces tumor aggressiveness
through epithelial-mesenchymal transition, resulting in tumor metastasis [23].
2.2. Differential Characteristics of Tumor and Normal Endothelial Cells
Endothelial cells (ECs) in blood vessels are the primary cells in blood vessel formation, and in a
similar way as tumor blood vessels show alterations compared with the normal vessels, the resident
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endothelial cells in tumor blood vessels are also different. Compared with normal endothelial cells
(NECs), TECs differ in their genetic makeup, protein expression, and functional output (Figure 1).
Figure 1. TEC abnormality. Soluble factors and extracellular vesicles released from tumor cells, CAFs
and TAMs, induce endothelial cells in pre-existing blood vessels to initiate angiogenesis to form tumor
blood vessels. In the process, the NECs are transformed into TECs in the formed tumor vessels.
Additionally, hypoxia and ROS in the TME may contribute to the TEC phenotype. TECs have higher
proliferative and migration abilities as compared to the NECs. They have an abnormal karyotype
characterized by various chromosomal abnormalities and aneuploidy. The genetic changes that occur
lead to the upregulated expression of proangiogenic genes e.g., VEGFA and angiocrine factors such
as biglycan, which induces angiogenic function in the TECs and may also affect the tumor cells.
Furthermore, the upregulation of stemness genes such as MDR1 and ALDH lead to the development of
a drug resistant phenotype in the TECs. ROS, reactive oxygen species; TEC tumor endothelial cells;
NEC, normal endothelial cell; CAF, cancer-associated fibroblast; TAM, tumor-associated macrophages;
TME, tumor microenvironment.
We have previously reported that human renal TECs show various percentages of aneuploidy as
compared to NECs [24]. Similarly, in murine TECs the karyotype indicated the presence of larger nuclei
and more aneuploidy than in NECs. Within the nuclei in the TECs were chromosomal aberrations,
including missing whole or portions of chromosomes, translocations, and abnormal centrosomes
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characterized by larger sizes and excess numbers than in NECs [25]. These observations indicate that
generally TECs have chromosomal instability.
At the molecular level, TECs express angiogenesis-sustaining genes; for example, receptors such
as VEGFR-1, VEGFR-2, and VEGFR-3, angiopoietin receptor tie-2, and an upregulated expression
of angiopoietin 1 and VEGF-D compared with NECs [26]. With these genes, TECs exhibit a strong
response to the respective angiogenic factors for the receptors [27,28]. In addition, we have also
previously reported that TECs show an upregulated expression of nonconventional angiogenic factors
such as biglycan [29], lysyl oxidase (LOX) [30], and pentraxin 3 (PTX3) [31]. Furthermore, TECs have
been described as being “activated” and “chronically inflamed” [32]; they express adhesion molecules
ICAM-1, VCAM-1, and E-selectin [27], through which they interact with proinflammatory and
tumor cells.
In performing angiogenesis, both human and murine TECs are highly proliferative [28], self-sustaining,
and are not dependent on serum for proliferation the way that NECs are [26]. Differentially expressed in
FDCP 6 homolog (DEF6) and PTX3 play a role in regulating EC proliferation [31,33], and their expression
in TECs could partly account for how TECs regulate and sustain continuous proliferation. The migration
ability of TECs is also higher than that for NECs [28,34]. We have demonstrated that some genes
upregulated in TECs are important for TEC migration. For example, we showed that interrupting LOX
and biglycan, which were upregulated in isolated TECs, decreased migration and tube-forming ability
and caused morphological changes in the TEC [29,30]. Pharmacological LOX inhibition in vivo also led to
a decrease in tumor metastasis [30]. Moreover, murine TECs maintain their biological characteristics after
longer periods of cell culture than do NECs [28].
The exposure of tumor cells to the hypoxic tumor microenvironment induces the expression of
stemness genes [35]. Provided that TECs are exposed to a similar microenvironment, some studies
have identified the upregulated expression of stemness genes such as stem cell antigen-1 (Sca-1) [28],
MDR-1 [36], and ALDH [37] in the TECs. We have shown that the expression of MDR-1 [36] and
ALDH in TECs that are derived from highly metastatic melanoma, for example, induces in the TECs a
property of drug resistance to the drug paclitaxel [37]. Another study, involving TECs derived from a
human hepatocellular carcinoma, showed that the CD105+ TECs acquired resistance to 5-fluorouracil
(an anticancer drug) and sorafenib (an antiangiogenic drug) as compared to the CD105+ NECs or
human umbilical vein endothelial cells (HUVECs) [38].
3. Heterogeneity of TECs
3.1. Different Roles in ECs during Angiogenesis
Angiogenesis starts in response to cues in injury or pathological condition. VEGF and other
proangiogenic factors stimulate quiescent ECs and activate to adopt angiogenic phenotype. Three types
of cells, namely tip, stalk, and phalanx cells, are known to coordinate the sprouting of capillaries from
pre-existing vessels. Migrating tip cells lead the nascent vessel sprouts at the forefront. Proliferating
stalk cells trail the tip cells and elongate blood vessels [39]. Acquiescent phalanx cells form continuous
monolayers, forming a tight barrier. These specializations of ECs are transient and reversible by
altering the balance between proangiogenic factors, such as VEGF, and suppressors of EC proliferation,
such as Dll4-Notch activity [40,41]. Tip cells migrate in response to the VEGF gradient, while stalk
cells that proliferate are dependent on the VEGF concentration [42]. Phalanx cells secrete soluble Flt1
(VEGFR-1), which neutralizes VEGF activity to end angiogenesis [43].
These ECs differ in their metabolism [44,45]. Since angiogenic sprouting is metabolically
demanding [46], ECs rely on glycolysis [44], which is stimulated by the regulator PFKFB3. ECs can
interchange their position depending on their metabolic condition during angiogenesis. Stalk cells
overtake the tip cell position when they express higher levels of PFKFB3 [44]. This specialization is one
of the heterogeneities of ECs in a tumor microenvironment.
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3.2. Origin of TECs
Angiogenesis is the process of sprouting from a pre-existing vessel, while vasculogenesis is
mediated by the mobilization of precursor cells, such as endothelial progenitor cells (EPCs) from bone
marrow. EPCs were named by Asahara et al., who isolated from adult peripheral blood mononuclear
cells showing the same characteristics as the embryonic angioblasts [47–49]. Although the identity and
the contribution of EPCs in tumors are controversial and are still under discussion, several studies have
shown that EPCs are incorporated into newly formed tumor blood vessels [50–53]. The surface markers
of EPCs are classically expected to express CD34, VEGFR-2, and CD133 [49]. Numerous studies have
aimed to target EPCs to develop novel therapeutic strategies, since EPCs or circulating endothelial
precursor cells contribute to tumor angiogenesis [50,51].
ECs are heterogeneous [54]; for example, the EC structure and function are different depending
on vascular size, which is described in terms of the macrovasculature, including arterial and venous,
and in terms of microvascular capillaries [55]. Morphology and marker expression in ECs show
differences depending on the EC origin [56,57]. Organ-specific or tissue-specific phenotypes in ECs
have also been reported [55,58,59]. ECs show heterogeneity in structure and function, and in time and
space [60]. TEC heterogeneity can be caused by the surrounding endothelial heterogeneity, with an
activating angiogenic switch.
The concept that tumor cells could generate TECs was introduced by some groups of investigators.
Streubel et al., demonstrated that chromosomal aberrations were shared by B-cell lymphoma cells and
TECs, which means that TECs in B-cell lymphomas are in part tumor related [61]. In glioblastomas,
some studies reported that glioblastoma stem cells may give rise to TECs [62–64]. Ricchi-Vitiani
et al., showed that various TECs in glioblastoma carry the same genomic alteration as tumor cells,
which indicates that some TECs have neoplastic origin [62]. Want et al., also demonstrated that
members of a subpopulation of TECs share the same somatic mutations as glioblastoma cells, and that
the stem-cell-like CD133+ fraction includes a subset of CD144-expressing cells [63]. Soda et al.,
demonstrated that tumor cells directly transdifferentiate into CD31+CD34+ ECs, which may play
a role in resistance found toward anti-VEGF therapy [64]. On the contrary, another study showed
that glioblastoma cells give rise to pericytes rather than to ECs, using lineage tracing with pericyte-
or EC-specific promoter-driven fluorescent reporters [65]. The study reported that such an event
wherein glioblastoma stem cells give rise to ECs may be very rare because ECs rarely carry the cancer
genetic mutations, as other groups of investigators have demonstrated [65–67] Transdifferentiation to
ECs in tumors may occur in other cell types. In multiple myeloma, tumor-derived pleiotrophin and
macrophage colony-stimulating factor stimulate monocytes to induce the expression of EC markers,
and the cells become transdifferentiated into ECs that incorporate into tumor blood vessels [68].
Since Fernandez et al., demonstrated that monocyte-derived immature dendritic cells behave as
endothelial-like cells in the presence of specific cytokines such as VEGF [69,70], it has been proposed
that dendritic cells may possibly transdifferentiate into TECs in a cytokine-rich tumor microenvironment.
These variations could lead to TEC diversity.
3.3. Stem Cell Population in TECs
TEC heterogeneity and diversity have also been reported at functional and molecular levels [71].
TECs upregulate aldehyde dehydrogenase (ALDH) expression. There are two populations in TECs,
such that some have high ALDH activity and some have low. ALDHhigh TECs formed more tubes on
Matrigel and sustained the tubular networks longer, with the upregulation of VEGFR2 expression,
than ALDHlow TECs did [72]. The ALDHhigh population was resistant to fluorouracil (5-FU) in vitro
and in vivo, with upregulation of stem-related genes compared with ALDHlow TECs [37]. Naito et al.,
reported that vascular-resident stem/progenitor-like ECs, which form a minor population in tumors,
contribute to tumor angiogenesis. Because of their ability to efflux Hoechst 33342 dye, they are termed
side population cells, and cause drug resistance [73]. These reports suggested that the heterogeneity of
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ECs in tumor tissues may be a mechanism contributing to resistance to anticancer and antiangiogenic
therapy (Figure 2).
Figure 2. TEC heterogeneity in the tumor microenvironment. TECs are derived from multiple
cells. TECs acquire their specific characteristics by several factors in the tumor microenvironment.
These variations could lead to TEC diversity.
3.4. The Effect of Tumor Microenvironment on TEC Heterogeneity
The heterogeneity of TECs in highly metastatic tumors and in tumors with low metastasis has
been also described [34]. TECs derived from highly metastatic tumors display activated proliferation
and migration with the upregulation of proangiogenic factors [34]. TECs in highly metastatic tumors
show a stem-like phenotype with an upregulation of stem cell markers, such as CD90 and Sca-1,
and a high ability to form spheres [34]. These data suggested that the microenvironment surrounding
TECs, including tumor cell phenotype and metastatic potential, affects TEC characteristics and induces
heterogeneity among TECs.
TECs acquire their specific characteristics in the tumor microenvironment during tumor
angiogenesis. One of the factors in tumor microenvironment is hypoxia. It is well known that
tumors are hypoxic [74]. Since the tumor blood vessel pattern is nonhierarchical and disorganized
due to the excessive VEGF causing high permeability, which in turn results in an insufficient blood
supply, tumor blood vessels are also sometimes exposed to hypoxia. Hypoxia induces the expression
of hypoxia-inducible factor-1 alpha and transcribes several molecules, such as VEGF-A. In highly
metastatic tumors, TECs are exposed to hypoxia and the expression of VEGF-A is high compared
with TECs in tumors with low metastasis [34]. Hypoxia induces the accumulation of reactive oxygen
species (ROS). We have previously demonstrated that ROS induces some TEC marker expression in
ECs [75]. TECs show chromosomal instability [24,25], and the abnormalities are accumulated in TECs
in highly metastatic tumors [34] or ALDHhigh TECs [72]. One of the causes of cytogenic abnormality in
TECs was excessive VEGF [76] and ROS [77]. These factors in the tumor microenvironment induce
abnormalities and heterogeneity in ECs.
Tumor-derived soluble factors and microvesicles/exosomes are also among the causes of
abnormalities in TECs. TEC marker expression was induced by tumor-derived soluble factors.
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For example, the expression of CXCR7 [78], biglycan [79], and MDR1 [36] was upregulated by soluble
factors derived from highly metastatic tumors. Tumor-derived microvesicles induce a proangiogenic
phenotype in ECs via endocytosis [80]. TECs acquire their specific characteristics by several factors in
the tumor microenvironment.
Previous studies have demonstrated that endothelial-to-mesenchymal transition (EndMT) can occur in
cancer [81]. EndMT is recognized as a unique source of cancer-associated fibroblasts (CAFs). These CAFs
coexpress the EC marker CD31, along with one of the mesenchymal markers, FSP1, or αSMA [81].
Transforming growth factor β (TGFβ) is known to induce EndMT [82]. Conversely, recent studies
demonstrated that ECs resist specific conversion to alpha-SMA+myofibroblast-like cells when the cells
are challenged with TGFβ through secretion of bFGF [83]. TGFβ and bFGF could oppose and cooperate
with each other during EndMT via Elk1 [84]. These data suggest that EndMT is another mechanism
producing TEC heterogeneity.
4. The Role of TECs in Cancer Progression
Tumors often become more malignant and aggressive progressively, step by step. In a primary
tumor, tumor cells increase and gain malignant potential, and tumor cells invade the surrounding
stroma and extracellular matrix (ECM). At the metastatic phase, tumor cells intravasate into vessels
and reach distant organs [85]. Tumor stromal cells such as CAFs or immunosuppressive cells
contribute to tumor progression [86], and TECs also play crucial roles at these steps, in addition to
supplying oxygen and nutrients by blood flow. The upregulated expression of VEGF receptors may
contribute to the rapid response of TECs to VEGF to facilitate disorganized blood vessel formation,
through which tumor cells could get into the blood stream. Upregulation of adhesion molecules
in TECs gives tumor cells scaffolds to invade between TECs, which lead to extravasation to drive
metastatic dissemination [87]. In addition, TECs provide a number of inductive factors named
“angiocrine factors” (Table 1), and these factors stimulate tumor growth and tumor cell migration [88].
TECs produce various molecules such as endothelin-1, bFGF, TGFβ, interleukin (IL)-6, and IL-8 as
paracrine mediators of prostate cancer progression [89]. Other angiocrine factors, including IL-6,
IL-3, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage-CSF (GM-CSF), IL-1,
and nitric oxide, promote leukemic cell proliferation. In addition, Jag1 derived from TECs activates
Notch2 in lymphoma cells to promote tumor invasiveness [90]. CXCR7 on TECs is involved in
tumor growth and angiogenesis [78,91,92]. CXCR7 regulates CXCL12-CXCR4-mediated tumor cell
transendothelial migration [93]. Platelet-derived growth factor (PDGF) signaling plays a crucial role in
inhibitor of differentiation 4 (ID4)-mediated regulation of ECs and Glioma-initiating cells by promoting
the PDGF-NOS (nitric oxide synthase)-ID4 signaling axis. These effects maintain cancer stemness and
promote tumor angiogenesis [94]. In addition, TECs downregulate tumor-suppressive factors such as
Slit2. Slit2 is one of the tumor-suppressive angiocrine factors that is negatively regulated by the EphA2
receptor on ECs [95].
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Table 1. Angiocrine factors produced by tumor endothelial cells.
Angiocrine Factors Functions Refs
Angiopoietin-2 (Ang2) Recruit innate immune cells [96]
Basic fibroblast growth factor (bFGF) Organogenesis and tumorigenesis [89,97]
Biglycan Stimulate tumor cell intravasation [79]
Bone morphogenetic protein-2, 4 (BMP2, 4) Tumorigenesis [98]
Calcineurin Vascular stabilization and promotemetastatic outgrowth [99]
C-X-C motif chemokine 12 (CXCL12) Tumorigenesis and tumor progression [100,101]
Endothelin-1 Promote tumor growth [102]
Granulocyte colony stimulating factor (G-CSF) Promote leukemic cell proliferation [103]
Granulocyte macrophage colony stimulating
factor (GM-CSF) Angiogenesis [104]
Insulin growth factor binding protein-7
(IGFBP7) Tumor-suppressive checkpoint [105]
Insulin growth factor-1 (IGF1) Stimulate chemoresistance andangiogenesis [105,106]
Interleukin-3 (IL-3) Promote leukemic cell proliferation [103]
Interleukin-6 (IL-6) Macrophage activation and tumorprogression [107]
Interleukin-8 (IL-8) Angiogenesis and tumor progression [108]
Jagged-1 (Jag1) Promote tumor invasiveness andchemoresistance [90]
laminin α4 (LAMA4) Tumorigenesis [109]
Lysyl oxidase (Lox) Angiogenesis and stimulate tumor cellintravasation [30]
Nitric oxide (NO) Tumorigenesis [110]
Platelet-derived growth factor (PDGF) Angiogenesis and tumorigenesis [94]
Placental growth factor (PGF) Angiogenesis and tumorigenesis [111]
Pentraxin 3 (PTX3) Stimulate TEC proliferation [31]
Slit2 Tumor suppression [95]
Suprabasin Angiogenesis [112]
Transforming growth factor beta (TGF-β) Tumorigenesis and tumor progression [113]
Vascular endothelial growth factor-A (VEGFA) Angiogenesis and autocrine loop [114]
Moreover, TECs stimulate tumor cell intravasation and metastasis. Wieland et al., demonstrated that
Notch1 in TECs activates the migration of tumor cells and promotes intravasation. Endothelial Notch1
promotes lung metastasis with neutrophil infiltration. In addition, TECs frequently express elevated
Notch1 in human tumor tissues, including melanoma, breast carcinoma, lung adenocarcinoma,
serous ovarian carcinoma, and colorectal carcinoma, and this expression correlates with poor
prognosis [115]. ALK1 in TECs is also involved in tumor metastasis. ALK1 expression in TECs
is an independent prognostic factor for metastasis of breast cancer [116]. The oxygen-sensing prolyl
hydroxylase domain protein 2 (PHD2) in TECs is involved in vessel shaping. Haplodeficiency of PHD2
did not affect vessel density or lumen size, however, it normalized the endothelial lining and vessel
maturation in tumors, which leads to the reduction of tumor cell intravasation and metastasis [43].
We have shown that biglycan, a small leucine-rich repeat proteoglycan, was remarkably upregulated in
TECs and facilitated the migration of toll-like receptor-expressing tumor cells, which increased circulating
tumor cells and lung metastasis [79]. Endothelial calcineurin have a unique function, which does not
affect primary tumor growth, but activates the outgrowth of metastases [99]. These studies suggested
that TECs actively promote tumor cell progression and metastasis.
Drugs for anticancer treatment include cytotoxic drugs and molecular targeting drugs. In most
cases, these drugs gradually become ineffective in cancer treatment, and this is considered to be
caused by tumor cells acquiring drug resistance. It is generally known that tumor cells acquire drug
resistance via phenotypic changes, such as increased drug transporter expression [117]. On the contrary,
TEC characteristics also cause drug resistance. Renal cell carcinoma-derived TECs are resistant to
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vincristine [26], and hepatocellular carcinoma-derived TECs are resistant to 5-FU and adriamycin [36,38].
TEC-derived Jag1 confers Notch-dependent chemoresistance in lymphoma cells [90]. TECs have
acquired resistance to anticancer drugs via the upregulated expression of ATP-binding cassette
transporters, similar to cancer stem cells [36,118]. TECs also play a role as a molecular checkpoint
in chemotherapy. IGFBP7 expressed by TECs suppresses IGF1R signaling and the stem-cell-like
property of tumor cells. Chemotherapy triggers TECs to suppress IGFBP7, and the upregulation of
IGF1 activates the FGF4-FGFR1-ETS2 pathway in TECs and accelerates the conversion of tumor cells
to chemoresistant tumor stem-like cells [105]. The drug resistance property of TECs also serves to
promote tumor survival. Residual TECs in drug-treated tumors will restore angiogenesis in the more
resistant tumor cells that have survived antiangiogenic therapy.
In recent years, tumor immunity has been noted as an important factor for anticancer treatment,
and immune checkpoint inhibitors have become key drugs for antitumor immunity [119,120]. ECs play
an important role in controlling immune cell entry into tissues with chemokines and adhesion
molecules [121]. In tumor tissues, the abnormalities of TECs suppress T-cell trafficking and function
and cause an immune-suppressive environment [122]. For example, the high expression of VEGF
and other growth factors reduces endothelial ICAM-1 and VCAM-1 expressions in tumor tissues,
causing the lymphocyte–endothelial interactions to become inefficient [123]. VEGF and prostaglandins
induce CD95 (FasL) expression on TECs, leading to apoptosis of activated anticancer CD8+ T cells.
In contrast, regulatory T cells that suppress antitumor immune responses are protected by antiapoptotic
genes, such as Bcl2 and Bclxl, and these cells can selectively migrate into tumor tissues [124].
Upregulation of CD73 on TECs reduces effector T-cell homing, whereas anti-CD73 antibodies can
restore efficacy of antitumor immunotherapy and decrease tumor angiogenesis [125,126]. In addition,
PD-L1, which is a negative regulator of T-cell activation, is expressed in TECs. PD-L1 blockade
enhances tumor vascular normalization during anti-VEGF therapy [127]. Macrophage also plays
an important role for tumor immunity. TECs are one of the major sources of IL-6 in glioblastoma.
Angiocrine IL-6 induces arginase-1 expression and promotes macrophage alternative activation [107].
Thus, vascular normalization is a promising concept in anticancer treatment and can potentially
improve the outcome of immunotherapies [128–130].
5. Conclusions
In this review, we addressed the abnormality and heterogeneity of TECs to understand their roles
in the tumor microenvironment. The functions of ECs in newly formed blood vessels in tumor tissues
are not only to transport nutrients and oxygen for tumor survival and growth, but also to actively
promote tumor progression and chemoresistance.
Antiangiogenic therapy has been widely used in many types of tumors; however, since it is now
clear that TECs are heterogeneous, to overcome and regulate tumor angiogenesis is a difficult and urgent
task. To understand the complex situation in the tumor microenvironment, companion diagnostics to
monitor vascularization is required. In addition, both angiogenesis and vasculogenesis need to be
targeted to regulate aberrant excessive blood vessels. Targeting multiple growth factors as combination
therapy have shown improved outcomes, but the therapeutic effects are sometimes not enough.
Another therapy, such as combination with immunotherapy or targeting EC metabolism is expected to
normalize tumor microenvironment to cure cancer disease.
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Abstract: Breast cancer is a remarkably complex and diverse disease. Subtyping based on morphology,
genomics, biomarkers and/or clinical parameters seeks to stratify optimal approaches for management,
but it is clear that every breast cancer is fundamentally unique. Intra-tumour heterogeneity adds
further complexity and impacts a patient’s response to neoadjuvant or adjuvant therapy. Here,
we review some established and more recent evidence related to the complex nature of breast cancer
evolution. We describe morphologic and genomic diversity as it arises spontaneously during the
early stages of tumour evolution, and also in the context of treatment where the changing subclonal
architecture of a tumour is driven by the inherent adaptability of tumour cells to evolve and resist the
selective pressures of therapy.
Keywords: breast cancer; genomics; intra-tumour heterogeneity; metastasis; subclonal diversity;
treatment resistance
1. Introduction
That breast cancer is heterogeneous is beyond all doubt. We now count at least 20 histological
subtypes of invasive breast cancer, defined by morphologic growth patterns and cytological
appearance [1] and three broad biological subtypes, based on the expression of diagnostic biomarkers
(oestrogen (ER) and progesterone (PR) receptor positive; HER2 positive; and triple negative (lacking
hormone receptors and HER2). The ‘big data’ revolution has dramatically enhanced our appreciation
of the molecular heterogeneity of breast cancer, further stratifying the disease into biologically and
clinically meaningful subtypes, including six or more intrinsic subtypes (normal, claudin-low, luminals
A and B, HER2 enriched and basal) [2–5]; four triple negative molecular subtypes (basal-like 1, basal-like
2, mesenchymal and luminal androgen receptor) [6]; and, ten integrative clusters captured by combined
transcriptional and DNA copy number profiling [7]. Adding to this, the diversity of extra-tumoral
components such as the tumour matrix and immune infiltrate is substantial and so it is easy to imagine
that no two breast cancers will respond to therapy, or potentially progress to metastasis in quite the
same way.
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The recent advances in genomics technology is providing elaborate detail to the somatic architecture
of breast tumour genomes, and with it, unprecedented insight into the mechanisms at play driving
tumour development, adaptation and progression in response to treatment. Next generation sequencing
technology has built on foundational knowledge created by candidate gene sequencing and comparative
genomic hybridisation to provide very high depth, targeted gene panel sequencing for identifying
targetable mutations and subclonal mutations; whole exome sequencing (WES) for comprehensive
mutational analysis of all coding sequences; and whole genome sequencing (WGS) for an unbiased
survey of all coding and non-coding sequences to capture the full repertoire of genetic alterations,
encompassing single nucleotide variants (SNVs), small insertions and deletions (indels), copy number
alterations (CNAs) and structural variants (SVs). Most somatic genetic alterations are perceived
to provide little or no advantage to the neoplastic cells in which they arise (passenger mutations),
however some enhance or inhibit the activity of cancer genes, and hence are termed driver mutations.
One of the great powers of WGS is the ability to use the large numbers of SNVs, indels, CNAs and
SVs to call mutational signatures and the analysis of these ‘genomic scars’ reveal great insight into
the causative factors driving an individual cancer [8–12]; i.e., the exogenous carcinogenic processes,
defective endogenous cellular processes or germline predisposition that have played a significant role
in the aetiology of an individual cancer.
Here we outline how the molecular genetic analysis of tumour genomes has shed light on the
inter- and intra-tumour heterogeneity exhibited by breast cancer; we elaborate on the concepts of
cancer drivers and clonal evolution linked directly to the diverse morphological characteristics of the
disease; and the complex processes of metastasis.
2. Genomic Diversity of Primary Breast Cancer
There are several landmark studies that have characterised the genomic landscape of invasive
breast cancers [10,11,13–16]. It is increasingly clear that each breast cancer is genomically distinct, with a
high level of diversity in the overall number of individual genetic alterations (SNVs, indels, CNAs,
SVs), the cancer genes affected, and the global patterns of mutations captured by mutational signatures.
Most breast cancers have relatively low numbers of SNVs and indels, compared to other
cancer types, however, approximately 20% of tumours are associated with defective homologous
recombination (HR) double strand break repair (e.g., in particular those arising in BRCA1, BRCA2,
PALB2, RAD51C germline mutation carriers), and these exhibit high rates of SNVs and indels. Further,
a minority of tumours (<10%) exhibit hypermutator phenotypes, for instance in tumours associated
with defective base excision repair (e.g., MUTYH inactivation), mismatch repair (e.g., MSH2, PMS2,
MLH1 inactivation) or APOBEC cytidine deaminase activity mutational signatures [8,9,12,14,17–19].
From an architectural point view, some breast cancers have ‘simple’ genomes (e.g., tumours
with the 1q gain and 16q deletion pattern of alterations), whilst other tumours exhibit complex
arrays of structural variants involving interchromosomal rearrangements and high level amplification
of major oncogenic driver genes (e.g., including ERBB2/HER2, CCND1, ZNF703/FGFR1, MYC);
and tumours associated with defective HR repair exhibit extremely high levels of chromosomal
instability [7,9,13,14,20,21].
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A meta-analysis of breast cancer sequencing studies has established that there are at least 147 breast
cancer driver genes [22]. Approximately three driver gene mutations are found per tumour [14] and
there are a multitude of combinations possible [23]. Some are mutated or altered at high frequency (e.g.,
TP53, PIK3CA, MYC, CCND1, ERBB2) whilst most are affected infrequently, with only 39/147 (26.5%)
of these driver genes being altered in 5% or more of the TCGA breast cancer samples (Figure 1A).
Further, some genes exhibit a strong genotype/phenotype relationship and so when altered they
contribute to the resulting molecular and phenotypic lineage that subsequently develops. For instance,
the distribution of driver mutations differs between ER positive and ER negative tumours [14], including
the most common driver genes, PIK3CA and TP53, respectively. This is also evident in familial breast
cancer, where the inheritance of a pathogenic germline driver mutation is also strongly related to
the resulting tumour phenotype: ER-negative in BRCA1-associated tumours (with high frequency
of TP53 mutations); ER-positive in BRCA2, ATM and CHEK2-associated tumours; HER2-positive in
TP53-carriers; and E-cadherin negative and lobular growth pattern in CDH1-carriers [19,24–29].
Some driver mutations manifest more frequently in morphologically distinct tumours and some
are pathognomonic for special histological types of the disease (Figure 1B–D). Elegant examples
of this occur in rare breast cancer special types; for example secretory carcinomas arise due to the
highly recurrent oncogenic driver created by a balanced t(12;15) (p13;q25) translocation creating an
ETV6-NTRK3 fusion gene; similarly the MYB-NFIB translocation (t(6;9) (q22–23; p23–24)) is a key
driver in the development of adenoid cystic carcinomas of the breast. Both these tumour types are
low-grade, typically of a triple negative phenotype and have counterparts in other tissues (e.g., salivary
gland) driven by the same translocations [30–34].
Invasive lobular carcinoma (ILC) is the most common special histological type of breast cancer,
defined by a characteristic diffuse growth pattern, with discohesive neoplastic cells. The archetypal
alteration in ILC involves dysfunction of the epithelial cell adhesion complex involving E-cadherin and
its binding partners β-catenin and P120-catenin. E-cadherin is encoded by the gene CDH1, which is
inactivated in ~65% of ILC by gene mutation and loss of heterozygosity. Building on formative work
by others, the recent large TCGA study [15], Desmedt et al. [35] defined the unique genomic features
of ILC compared to invasive breast carcinoma of no special type (IBC-NST or IC NST, previously
called invasive ductal carcinoma, IDC) through a deep characterisation of the TCGA breast cancer
multi-omic data and the targeted mutation profiling of a large cohort of ILC. In addition to CDH1
mutations, the only other highly recurrent oncogenic driver was PI3KCA (43–48%), with a plethora of
low frequency (<15% of cases) driver mutations affecting FOXA1, TBX3, ERBB2, ERBB3 and PTEN
that were enriched in ILC relative to IC NST, while GATA3 and TP53 mutations were enriched in IC
NST relative to ILC. TP53 mutations occur at significantly different frequencies between ER+ and ER−
tumours, and so the TP53 mutation finding is likely driven by the presence of ER negative tumours
in the IC NST cohort. Metaplastic breast cancers are at the other end of the histological spectrum
to ILC; they are a rare and heterogeneous special tumour type, which exhibit metaplastic change
to squamous and/or mesenchymal elements; tumours are high grade and are associated with an
overall poor outcome. Although generally triple-negative, they have a high frequency of PIK3CA
mutations [36–38], and indeed have the unusual co-occurrence of PIK3CA and TP53 driver mutations
in some instances [36].
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Figure 1. Genomic alterations across breast cancers. (A) Frequency of genomic alteration (mutation and
copy number variation) in the 147 breast cancer driver genes across the TCGA pancancer breast cancer
dataset (n = 1033); and stratified by oestrogen receptor (ER) status (in magnified plot): ER positive,
n = 795; ER negative, n = 238. Top ten most frequently mutated genes in (B) Invasive Carcinoma-No
Special Type (IC-NST) [15]; (C) Invasive Lobular Carcinoma (ILC) [15]; and, (D) Metaplastic breast
cancer [36–38].
3. Subclonal Genomic Diversity in Primary Breast Cancer
Multi-region sequencing of an individual tumour gives intriguing insights into the subclonal
nature of the disease (Figure 2A). The level of subclonal heterogeneity identified across a cohort of
50 breast cancers was variable [39]: most cases had a driver mutation that was shared by all regions
sequenced (i.e., an early founder driver gene mutation, and indicating an evolutionarily conserved
lineage); about half the cancers showed limited variation in the mutations identified across different
regions sequenced, whereas for three tumours there was profound subclonal diversity. Sub-clonal
driver mutations (e.g., in TP53, PIK3CA, PTEN, MYC amplification) were identified in a subset of
tumour regions sequenced. Subclonal driver alterations have been previously evident, but not to
such detail, through more standard in situ techniques in the diagnostic setting, i.e., breast tumours
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with heterogenous ERBB2 amplification. The geographical expansion of mutant subclones was often
confined to 1–3 adjacent regions, but interestingly in some cases, mutationally distinct subclones
were found to be growing admixed with one another. Cases studied pre- and post- neoadjuvant
chemotherapy or targeted therapy revealed evidence that treatment can dramatically alter the clonal
make-up of a tumour [39,40].
Eirew and colleagues [41] studied mutations and subclonal dynamics using patient-derived
xenograft (PDX) models, and demonstrated that engraftment and subsequent propagation of patient
samples led to selective changes in subclonal frequencies. Notably, independent grafts of the same
tumour resulted in reproducible expansion of specific subclones that were presumably ‘fitter’ in
this new environment [41]. These striking findings recapitulates the clonal diversity observed in
patient samples, but also highlights the idea that human tumour cells in PDX models are dynamic and
continually evolve in response to the pressures they are subjected to.
Mixed ductal lobular carcinomas are a unique histological subtype of breast cancer; like metaplastic
breast cancers they elicit morphological evidence of intra-tumour heterogeneity, this time
showing tumour regions with both ductal and lobular-like differentiation. Multi-region exome
sequencing supplemented by copy number profiling of cases exhibiting distinct morphological
components demonstrated these were clonally related tumour regions as opposed to being collision
tumours [42]. In contrast to the above studies, where topographically defined regions were analysed,
here morphologically defined populations of cells representing the different growth patterns (ductal
and lobular, including associated pre-invasive lesions) were isolated by microdissection and analysed.
In individual cases, all lesions shared precise genetic alterations as likely early events in tumour
development; all cases also exhibited private mutations unique to a morphological lineage (e.g., TBX3),
suggesting they may be important in the separate evolution from a common antecedent [42].
This theory is supported by data from an analysis of multiple invasive tumours from patients
with multifocal breast cancer, using targeted gene sequencing analysis, supplemented by low coverage
WGS to identify structural and copy number variants [43]. Here, all lesions within an individual case
were morphologically identical and expressed the same biomarker profile (same grade, ER and HER2
status). In two thirds of cases, all lesions shared precise genetic alterations, whilst the remaining cases
shared no common mutations, from the panel of 360 genes analysed, but they shared structural/copy
number variants. Thus, all cases exhibited compelling evidence for the multifocal invasive tumours
having a common clonal origin, and for there being subclonal, parallel/branched evolution occurring
prior to invasion into the tissue stroma.
4. The Early Clonal Nature of Breast Cancer—Going Back to the Beginning
The early stages of breast neoplasia are defined by a plethora of morphologically characterised
lesions which reside within the ductal tree. The frequency with which such morphologically distinct
lesions co-existed in the same specimen gave credence to the idea that lesions were evolutionarily
related (later supported by molecular evaluation). Ductal carcinoma in situ (DCIS) and lobular
carcinoma in situ (LCIS) are genetically advanced lesions and direct precursors to invasive cancer.
Columnar cell lesions (CCL), flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH) and
atypical lobular hyperplasia/lobular neoplasia (ALH/LN), among others, are considered ‘earlier’ steps
along the multistep pathway to breast cancer development. Each of these lesions harbour genetic
alterations and are considered clonal neoplastic proliferations; CCL harbour both DNA copy number
alterations and gene mutations, including an usually high rate of PIK3CA mutations (54%) [44–46].
Likewise, ADH may be considered a genetically advanced precursor lesion [47].
The role these lesions play in the evolution of ER-positive and ER-negative disease types has
been well described [34,48–51] (Figure 2B). Early hypotheses for the evolution of ER-positive breast
cancer, in particular, was that of a linear progression from CCL to ADH to DCIS to IDC. Yet the level
of intra-tumoural heterogeneity seen within precursor lesions of an individual specimen points to a
more complex situation. For instance, within a surgical specimen both DCIS and LCIS can exhibit
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morphological (e.g., different grades/level of differentiation) and biological (e.g., variable expression
of ER, PR, HER2, Ki67) heterogeneity as well as evidence of subclonal genomic diversity [52–54];
these lesions can also co-exist, even admixed within the same duct (Figures 2C and 3). Whilst a linear
process of evolution might occur, there is more likely a complex array of parallel/branching clones
evolving within the normal ductal structure, and that this probably arises from an underlying bed of
genetic instability already present in normal breast epithelium (Figures 2 and 3).
Figure 2. The morphological and molecular evolution of breast cancer. (A) Hypothetical schematic
showing how the mutation of cancer genes drives the clonal and subclonal evolution of cancer (adapted
from [55]). Key early driver genes impact the subsequent lineage and tumour type that arises, including
mutations in PI3KCA in ER+ tumours, CDH1 in lobular lineage, TP53 in high grade ER- tumours,
ETV6-NTRK3 and MYB-NFIB translocations in secretory and adenoid cystic carcinomas respectively.
(B) the multistep model of breast cancer showing morphological stages of development from normal
epithelium. This simplified model is based on the evolution of ER positive and ER negative breast cancer,
as portrayed in more detail elsewhere [49–51]; evidence derived from morphological evaluation and
the frequency with which lesions are co-localized, as well as molecular evidence showing co-localized
lesions share identical mutations indicating clonal relatedness. (C) Cartoon to illustrate how this might
arise in a ‘sick lobe’, that is a clonal outgrowth of apparently morphologically normal-looking epithelial
cells (green), which harbour early genetic changes. In some areas of the lobe, the earliest morphologically
abnormal changes may appear in some terminal duct-lobular units (lobule) as columnar cell lesions.
These lesions are considered precursors of ADH (light blue cells) and DCIS (purple cells), which arise
in lobules and may travel down ducts. The mutation or loss of CDH1 (E-cadherin) triggers the
evolution of the ’lobular lineage’ (sky blue cells) as ALH then LCIS (lobular neoplasia); these cells
may travel down ducts underneath the normal epithelial lining (pageotoid spread). Both LCIS and
DCIS are genetically advanced lesions and so likely exhibit sub-clonal mutations. As these neoplastic
cells can travel along ductal structures then this means invasion can occur at multiple sites giving
rise to multifocal invasive disease (ILC, IC NST), which continues to undergo subclonal change.
CCL: columnar cell lesion; ADH: atypical ductal hyperplasia. ALH: atypical lobular hyperplasia,
APH: atypical apocrine hyperplasia; DCIS: ductal carcinoma in situ; LCIS: lobular carcinoma in situ;
IC NST: invasive carcinoma no special type; ILC: invasive lobular carcinoma; MDL: mixed ductal
lobular carcinoma; MGA: microglandular adenosis.
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Figure 3. Illustrating morphological and molecular heterogeneity. Low power, haematoxylin and eosin
stained sections of two tissue blocks from the same surgical specimen (scale bar = 2 mm). Both blocks
are widely affected by breast disease with cystically dilated ducts, in situ carcinoma and invasive
carcinoma. The three images in the lower panel are high power views of the same sections stained for
E-cadherin (scale bar in middle image = 0.5 mm). Left picture shows cells of LCIS (E-cadherin negative)
that have grown and then expanded underneath normal epithelial cells lining a duct (pagetoid spread),
adjacent to E-cadherin positive, invasive cells of IC NST. Middle picture shows adjacent ducts in a
complex branching network, one duct populated by DCIS (E-cadherin positive), two smaller ducts by
LCIS and two other ducts co-involved by cells of DCIS and LCIS (DCIS/LCIS). Right picture showing
ducts separately involved by DCIS or LCIS, plus an area of invasive cancer (ILC, E-cadherin negative).
The individual components of this case were previously analysed by whole exome sequencing and all
lesions were shown to be clonally related with early, common diver mutations identified in BRCA2 and
TBX3, ‘lobular’ lineage-specific mutations including in CDH1 and ‘ductal’ lineage-specific mutations
including in NF1 (see [42]). DCIS: ductal carcinoma in situ; LCIS: lobular carcinoma in situ; IC NST:
invasive carcinoma no special type; ILC: invasive lobular carcinoma.
Molecular analysis of morphologically complex cases has given great insight into this diversity.
Topographically mapped single cell sequencing has elegantly demonstrated that most copy number
alterations identified in invasive cancer arise in DCIS; and that clonal diversity observed in invasive
cancer is driven in large part by existing clonal diversity present within DCIS, whereby distinct
subclones may escape from the ductal tree to seed polyclonal invasive disease (neoplastic cells escaping
from different regions of the ductal tree could seed apparently multifocal invasive cancer) [54,56]
(Figure 2C). Weng and colleagues [57] also explored these relationships in detail using massively
parallel sequencing of normal epithelium, various low-grade proliferative and pre-invasive lesions and
associated invasive cancer. Using the somatic mutations to resolve phylogenetic relations between the
lesions, the authors revealed a fascinating and complex hierarchy between lesions within individual
cases; while IC NST and DCIS were always linked by a shared mutational history; CCLs were either (i)
closely related to this DCIS/IC NST lineage with numerous shared somatic mutations, (ii) distantly
related to this lineage owing to sharing very early mutations but subsequently evolving down a
parallel pathway, or (iii) arose quite independently with no mutations detectable or no mutations in
common to higher grade lesions analysed. Interestingly, PIK3CA mutations arise frequently but quite
heterogeneously within this early stage of disease, including in normal epithelium. Sometimes these
mutations are discordant between lesions examined, or are present in CCL but not in synchronous in
situ and invasive lesions [45,57], suggesting such early driver events may enhance cellular proliferation,
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on a background of which other driver mutations may (or may not) arise to trigger progression (or not)
to more advanced lesions.
Recent sequencing has revealed an amazing level of genetic instability in ‘normal’ cells of various
tissues, caused by environmental exposure or local pathological processes related to tissue injury [58–61].
There is a growing wealth of evidence suggesting the same is true in breast tissue, acting as a primer for
neoplasia. Indeed, morphologically normal epithelium adjacent to tumour harbours a higher level of
genetic instability relative to reduction mammoplasty tissue, particularly when normal is within 1 cm
of tumour; furthermore normal epithelium from cancer-free patients who carry a pathogenic germline
mutation in BRCA1 or BRCA2 also acquire an elevated level of chromosomal instability compared to
controls [57,62–66]. In the case of germline mutation carriers, haploinsufficiency for genes with clear
roles in DNA damage response (such as BRCA1 and BRCA2) is likely to underpin the predilection
to acquire genomic alterations in cells prior to morphological abnormalities being observed [67–69];
in non-carriers the genetic instability may be arising as part of a field cancerisation or ‘sick lobe’ effect,
in which a duct/lobe or a proportion of a lobe is clonally affected by genetic instability and hence the
entire lobe is ‘at risk’ of further genetic instability and oncogenic activation [70]. Indeed, this might
explain the observation of multiple atypical proliferations (e.g., CCL, ADH, LCIS, DCIS) co-existing
across the same specimen (Figures 2C and 3).
5. Genomics and Clonal Dynamic Changes During Metastatic Progression
Metastatic dissemination is the cause of most cancer-related deaths, therefore, the goal to develop
a deep understanding of the mechanisms of metastasis cannot be understated. Large scale sequencing
projects of metastatic samples from breast cancer patients, and the analysis of matched cases of the
primary tumour and distant metastasis or multiple metastases from an individual have started to
reveal important advances in knowledge of clonal progression and treatment resistance.
In many cases the growth pattern (histological type), the expression of phenotypic biomarkers
and the molecular subtype of the primary tumour remains quite stable during progression of disease.
Genomic data reveal a high concordance in the mutations and in particular copy number alterations
between matched primary and metastatic tumours [71–75]. Thus, there is a clear clonal ancestry
during progression, and the early molecular drivers of behaviour and phenotype (e.g., mutations
in TP53, PIK3CA, CDH1, GATA3, amplification of MYC, CCND1, ERRB2/HER2) remain prevalent
drivers in metastatic deposits [71–74,76–80]. Despite this, significant intra-patient heterogeneity
develops during progression, even in the absence of systemic therapy; this occurs to a greater
extent in progression to distant metastases relative to local lymph nodes and is exacerbated by the
selective pressures applied during adjuvant therapy [73,77,81–84]. Changes in tumour phenotype or
in the intrinsic molecular subtype during progression occurs in around 30% of patients (most often
involving the down regulation of PR, but may also involve ER and less frequently a change in HER2
status) and may occur in a non-random manner at specific metastatic sites (e.g., lung, liver and bone
metastases) [85–88]. To further complicate matters, the phenotype of different metastases within a
patient can be heterogenous [83,86,89–92].
Compared to early breast cancer, distant metastases tend to harbour a higher mutation burden
and more frequent alterations to driver genes that may confer resistance to chemotherapy or targeted
therapy, in particular endocrine therapy [74,75,78–80]. Most notably, activating mutations in ESR1
and amplification of the ESR1 gene region (6q25.1) are rarely observed in primary disease, but are
prominent and critical drivers of resistance observed in around 20% of metastases arising following
endocrine therapy [73,74,78–80,93,94]. Enrichment of mutations in TP53, GATA3, KMT2C, AKT1, NF1,
PTEN, ERBB2, FGFR4, or amplification of 7p11.2 (EGFR), 8q24 (MYC), 11q13.3 (CCND1) and 20q13.2
(AURKA) may also underpin endocrine therapy resistance as they are more frequently identified in
ER+/HER2− breast cancer metastases compared to ER+/HER2− primary tumours; many of these
gene mutations are mutually exclusive to ESR1 mutations, emphasising their potential equivalence in
driving resistance [78–80,95].
118
Cancers 2020, 12, 848
Mutational signatures found in the primary tumour are also found in metastases; but as with
individual gene mutations, the frequencies of individual mutation signatures may also change, with an
enrichment in signatures associated with APOBEC enzymatic activity and homologous recombination
deficiency being higher in metastases than in primary tumours [75,78,82]. Evidence suggests the
acquisition of APOBEC signature maybe a driver of intra tumour heterogeneity and endocrine
resistance [17,84,96,97].
The genomic analysis of matched primary and metastatic samples has revealed fascinating
insight regarding the evolution of metastatic disease [73,75,82–84,86,90,98–100]. Such efforts reveal,
for example, that driver mutations that are enriched in metastasis are indeed rarely found in the matched
primary tumour, indicating they arose either in a small subclone not sampled when the primary tumour
was sequenced, or they occurred during the metastatic process after cells had disseminated from the
breast (i.e., treatment induced mutations) [39,73,79,80,82,101]. Indeed, mutations in ESR1, ERBB2
and NF1 were significantly enriched in ER+/HER2− tumours post hormone treatment compared to
tumours from ER+/HER2− untreated patients [80].
The genetic relationship between multiple metastases within a patient is exceedingly complex
but accruing sequencing data and phylogenetic analysis suggests that all metastases within a patient
are genetically related, arising from a common ancestral clone. However, subclonal divergence
of metastases is invariably observed within patients: driver and non-driver gene mutations are
heterogeneously accumulated in different metastases, subsets of metastases may therefore be more
closely related to each other than they are to other metastases, and heterogenous tumour phenotypes
(ER positive and ER negative) often coincide with this divergent history [75,84,90].
The data supports various models of progression; evidence for both linear and parallel models are
evident, in which multiple metastases may arise from a single seeding event from cells disseminating
from the primary tumour, or indeed metastases may be seeded from already established metastases in
a more linear fashion. The longer the time span between diagnosis of primary tumour and that of
the metastases, then the larger the divergence in genetic make-up of the metastases, as expected [98].
Further, in patients with advanced disease at the time of diagnosis, there is evidence of multiple seeding
events from the primary tumour, or even from different parts of the same primary tumour [84,98].
An important finding arose through the analysis of the variant allele frequency of shared mutations
between metastases or between the primary tumour and resulting metastases: subclonal mutations
remained subclonal in the resulting tumour, indicating that metastases were seeded by heterogeneous
collections of disseminated cells as opposed to being seeded by a single cell or a single clone (monoclonal
origin) [75].
6. Capturing Intra-Tumour Heterogeneity in Tissue or Liquid Biopsy
Predicting the extent of intra-tumour heterogeneity in primary or metastatic disease may provide
valuable diagnostic insight into improving the management of patients undergoing neoadjuvant or
adjuvant therapy, respectively. This may provide a framework for understanding likely response to
chemotherapy or targeted therapy in these settings. As described above, it is clear that tumours may
develop and progress on a linear, monoclonal trajectory, with little diversity in phenotype. A single
biopsy of the primary tumour or a metastatic deposit may therefore be sufficient to capture the most
functionally important alterations to determine therapy.
However, tumours that exhibit intra-tumour heterogeneity and hence with parallel/branching
models of progression at play, are more likely to harbour subclones with innate treatment resistance or
metastatic capability, or to harbour the capability to evolve in response to treatment to develop resistance.
Capturing this level of intra-tumour heterogeneity at diagnosis maybe challenging, but could encompass
the recording of a heterogeneity score with regards to morphology and biomarker expression/molecular
subtype. Pathologists already record the presence of mixed growth patterns or grades, or the diversity
across a tumour for the expression of ER, PR, HER2. Comprehensive sequencing of the entire primary
tumour to characterise the subclonal architecture of a mass is not feasible, but evidence suggests that
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sequencing of two different regions of the tumour provides meaningful information to record clonal
heterogeneity and to identify targetable genomic alterations [40].
There has been some reluctance to biopsy metastatic disease in the past, but it has great value in
the era of molecular evaluation and the potential offerings for precision medicine. Various studies have
demonstrated the feasibility in performing molecular testing on metastatic biopsies [71,79], but this
approach is only possible if the metastasis is accessible and may not be appropriate when a patient has
multiple organs involved.
Alternative approaches to examine tumour heterogeneity or for capturing important phenotypic
or genomic alterations have advanced significantly in recent years. Circulating tumour cells (CTCs)
and cell-free tumour DNA (ctDNA) [102–104] are shed into the circulation from both primary and
metastatic tumour deposits. Such liquid biopsies are very accessible, and very amenable to repeat
sampling while the patient is on treatment to monitor disease. They are, therefore, of great potential
benefit in capturing phenotypic heterogeneity or driver mutations acquired or enriched for during
treatment; and they are not biased by tumour sampling.
Increased concentration of CTCs in early [105,106] and metastatic [107–110] breast cancer is
associated with poor prognosis. The application of single cell analysis technologies to PDX models has
shown that CTCs are continuously released by the primary tumour, however only a proportion of
clones have the capacity to seed a metastatic deposit, and as such the utility of CTCs in predicting
the characteristics of subsequent metastases may be limited [111]. Nevertheless, analysis of CTCs
can capture phenotypic heterogeneity of the tumour of origin, for example in the expression of ER,
HER2 and androgen receptors [112–114], and also of biological processes driving metastasis such as
dynamic changes in epithelial and mesenchymal composition [115,116]. Clusters of CTCs, which may
show intermediate epithelial/mesenchymal properties [115,117], demonstrate higher metastatic capacity
than single cells [118–121]. Genomic analysis of single CTCs reveals important heterogeneity in the
mutation of various driver genes (e.g., PIK3CA, ESR1, KRAS, PTCH1, NOTCH1) reflecting the presence
of discrete subclonal mutations within the tumour of origin and/or the presence of genomic alterations
driving resistance/metastasis [122–127].
To illustrate clinical utility of the serial evaluation of molecular heterogeneity within single CTCs,
Paoletti and colleagues comprehensively profiled single CTCs in a patient with metastatic lobular
carcinoma who progressed following chemotherapy [124]. They demonstrated the presence of four
alterations (CDH1 and TP53 frameshift mutations; PIK3CA and SOX2 amplifications) in CTC samples
at baseline and progression. However, high-level MYCN amplifications were only identified in CTCs
sampled at progression, likely conferring treatment resistance. Similarly, the development of mutations
and splice variants within ESR1 identified in single CTCs of metastatic patients on endocrine therapy
also correlated with the onset of endocrine resistance [124,126,128,129].
ESR1 mutations are also readily detected in ctDNA [130–133], and in fact, ctDNA represents a
more sensitive method of detection compared to CTCs [129]. ctDNA is released from tumour cells
undergoing apoptosis, necrosis and phagocytosis. Like CTC analysis, ctDNA provides an opportunity
for non-invasive molecular testing, akin to the non-invasive prenatal testing (NIPT) in pregnancy,
for monitoring patients on therapy. In early breast cancer, the detection of ctDNA in patients undergoing
neoadjuvant chemotherapy correlated with tumour grade and stage and a slow (versus rapid) drop of
ctDNA levels after one cycle of chemotherapy was associated with a shorter disease-free survival [134].
The detection of minimal residual disease was also demonstrated in patients who continued to have
detectable ctDNA PIK3CA mutations after surgery [135]. In the metastatic setting, the mutational status
is highly concordant between ctDNA and tumour tissue [136,137] with additional private mutations
identified in some cases [137].
Serial ctDNA mutation analysis can help characterise the dynamic evolution of subclonal mutations
in real time [138–140] and hence represents a powerful approach for the prospective analysis of patients
on targeted therapy and the early detection of tumour subclones with resistance capability. This has
been demonstrated in the setting of endocrine therapy (various types of ESR1 alterations, including
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mutations, rearrangements and amplifications), CDK4/6 inhibition with endocrine therapy (ESR1,
RB1 and PIK3CA mutations) and anti-HER2 therapy (copy number variations in the ERBB2 gene
as well as increase in TP53 or PI3K/AKT/mTOR pathway mutations) [131,132,141,142]. Importantly,
and reflecting the inter-metastasis molecular heterogeneity described above, ESR1 mutations identified
from either CTC or ctDNA from an individual patient are often heterogenous, suggesting that distinct
subclones develop in parallel and utilise overlapping mechanisms of resistance [124,131].
7. Clinical Implications and Utility in Breast Cancer
Many major centres around the world operate routine cancer sequencing programs integrating
clinical applications with research, and commonly using targeted panels of cancer genes [143] for triaging
patients into clinical trials for targeted therapies. For example; Dana Farber Cancer Centre /Brigham
and Womens’ Cancer Centre (BWCC) offers the ‘Profile’ study wherein cancer gene panel testing may
help doctors enrol a patient in a clinical trial or choose the right combination of FDA-approved targeted
therapies. Memorial Sloan Kettering Cancer Centre has been pioneering ‘basket trials’ implementing
the use of their in-house MSK-IMPACT panel sequencing assay [144], where trial inclusion is based on
mutation status rather than disease origin. UC San Diego Moores Cancer Centre uses the Foundation
One panel and has matched 45% of BC patients to a ‘personalised’ therapy [145,146], however it should
be noted that most of these matches were ERBB2 amplifications to HER2 therapies and the applicability
of this panel outside of ERBB2 in breast cancer is uncertain. Increasing numbers of tools are emerging
to facilitate the matching of alterations and therapies, including for example, PanDrugs [147], while the
MD Anderson program [148] is feeding back ‘sequence-drug’ matching data into the public arena
through their Precision Cancer Therapy interface.
By the end of 2015, 39 gene targets with matched FDA-approved therapies were noted in
an extensive review of precision oncology [149] while the OncoKB resource [150] details 20 genes
(42 alterations) as FDA-recognised biomarkers (Level 1 evidence) and 10 genes (22 alterations) as
Level 2 (standard of care; predictive of response in breast cancer or another indication). In breast
cancer, ERBB2 amplifications (targeted with anti-HER2 therapies) and PIK3CA mutations (targeted
with Alpelisib + Fulvestrant) are the only Level 1 biomarkers as noted by OncoKB, while inactivating
mutations of BRCA1 and BRCA2 are classed as Level 2 biomarkers for intervention with talazoparib
and olaparib. Increasing data therefore supports the clinical application of genomics to inform
therapeutic intervention in breast cancer. Whole exome and whole genome sequencing will be
required to account for the diversity of genes mutated in breast cancer [14,151] as well as larger scale
alterations and mutation signatures that may predict treatment response. It is now clear, through
mutation signature analysis, that hallmarks of defective DNA damage repair (specifically homologous
recombination which BRCA1/2 mediate) are indicative of dysfunctional BRCA1/2 [8,10]. A weighted
model (HRDetect) can detect BRCA1/BRCA2-deficient samples using WGS data [9]. The HRDetect
algorithm was independently validated, and its association with platinum response in advanced breast
cancer demonstrated, where a high HRDetect score was associated with clinical improvement on
platinum therapies [152,153]. Recent research has applied a functional HR assay (RECAP) to breast
cancer samples and demonstrated that 29% of HR-defective tumours were not BRCA-related [154],
although the researchers themselves classify this approach as pseudo-diagnostic.
The introduction of immune checkpoint inhibitors (ICI) has revolutionised therapeutics across
a number of advanced solid tumours. While a subset of patients displays a durable response,
the implementation of a robust biomarker has been challenging. Tumour mutation burden (TMB) is
now emerging as a diagnostic biomarker for ICIs such as PD-1/PD-L1 inhibitors [155,156]. It is now
possible to calculate TMB from panel sequencing data [157], not just exome or genome sequencing,
and with time we expect to see a rationalisation of diagnostic ‘cut-offs’. Small molecular inhibitors of the
PI3K/AKT/mTOR pathway are fast approaching the clinic. The pan-AKT inhibitor, AZD5363, is potent
and sensitivity is predicted by PIK3CA mutations [158]. The SOLAR trial [159] investigating the mutant
PIK3CA inhibitor, alpelisib, demonstrated that a combination of alpelisib with fulvestrant prolonged
121
Cancers 2020, 12, 848
progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced
breast cancer.
The application of these genotype–phenotype relationships in the clinical context of heterogeneity
remains to be rationalised. Tumour heterogeneity exclusive of a histological subtype is not standardly
reported; for example, ER positivity is recorded in a binary fashion with a low cut-off for positivity.
Whether drugs are used sequentially to target residual clones, or in combination for simultaneous
targeting will depend on myriad factors including the application of robust biomarkers of sensitivity
to the therapy and the extent of intra-tumour heterogeneity.
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Abstract: Unlike bulk-cell analysis, single-cell approaches have the advantage of assessing cellular
heterogeneity that governs key aspects of tumor biology. Yet, their applications to circulating tumor
cells (CTCs) are relatively limited, due mainly to the technical challenges resulting from extreme rarity
of CTCs. Nevertheless, recent advances in microfluidics and immunoaffinity enrichment technologies
along with sequencing platforms have fueled studies aiming to enrich, isolate, and sequence whole
genomes of CTCs with high fidelity across various malignancies. Here, we review recent single-cell
CTC (scCTC) sequencing efforts, and the integrated workflows, that have successfully characterized
patient-derived CTCs. We examine how these studies uncover DNA alterations occurring at multiple
molecular levels ranging from point mutations to chromosomal rearrangements from a single
CTC, and discuss their cellular heterogeneity and clinical consequences. Finally, we highlight
emerging strategies to address key challenges currently limiting the translation of these findings to
clinical practice.
Keywords: single-cell analysis; cellular heterogeneity; circulating tumor cells
1. Introduction
The concept of intratumoral heterogeneity (ITH), first described in 1982 by Fidler and Hart [1], has
been expanded to include genetic, phenotypic and functional heterogeneity within tumors comprising
diverse malignant and non-malignant subpopulations. With accumulations of mutations in DNA
damage checkpoint control genes and DNA repair genes, divergent cancer clones may evolve and
propagate over time through selection processes driven by constantly changing microenvironment and
by the use of therapy [2,3]. In addition to genetic heterogeneity in clonal mutations and subclonal de
novo mutations, functional heterogeneity related to developmental pathways and epigenetic programs
and spatial variability in tumor microenvironment contribute to ITH, which governs key aspects of
tumor biology, including tumor invasion, metastasis, and drug resistance [2].
Recent years have also seen the contribution of non-malignant cells, such as stromal fibroblasts,
immune cells, bone-marrow-derived cells, mesenchymal stem cells, and endothelial cells, to ITH within
a tumor. Malignant and benign cells interact locally through a complex network of extracellular matrix
(ECM) and the related components, collectively termed as matrisome, which has been linked to tumor
Cancers 2019, 11, 1595; doi:10.3390/cancers11101595 www.mdpi.com/journal/cancers133
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progression, response to adjuvant therapy, and immune system [4–7], driving tumor phenotypes
supporting their metastatic competence. The tumor cells can be shed passively (through corrupted
blood vessel) and/or actively (through epithelial–mesenchymal transition (EMT)) from tumors into the
circulation, referred to as circulating tumor cells (CTCs), in which only a minority of cell populations
survive under the physiological blood flow and succeed in early colonization phases [8]. Despite the
low frequency of occurrence, CTCs allow for repeated sampling, which is not clinically practical for
tissue biopsy, and may thus be an excellent tool for assessing tumor heterogeneity and for revealing
clonal diversity underlying resistance to treatment [9].
The prevalence of phenotypic plasticity involving programmed death-ligand 1 (PD-L1) [10],
stemness [11], drug resistance [12], and EMT [13], within CTC populations has fueled investigation
of cellular heterogeneity using single-cell high-throughput enrichment and sequencing platforms
over the past five years. Emerging single-cell RNA sequencing (scRNA-seq) data further suggest
that CTCs may interact with hematopoietic cells or platelets in blood through direct and/or indirect
routes, adding another layer of heterogeneity [14]. Bulk-cell approaches traditionally deployed in
existing CTC literature, however, have provided insights into cellular processes averaged throughout
the enriched blood sample, which largely comprises leukocytes, or white blood cells (WBCs). The
leukocyte contamination is inevitable in any given primarily enriched sample due in part to extremely
rare CTCs occurring at a frequency of ~1 in 107 WBCs in blood from a cancer patient [15] and the
relatively low cell capture efficiency of existing cell sorting technologies, which are further limited to
isolating only certain CTC subpopulations (refer to the Section 2.1 for further details). It is therefore
essential to reach single-cell resolution to precisely characterize CTCs at the genomic level and further
to investigate the clinical impact of cellular heterogeneity present within CTC populations.
2. Methods and Technologies
Despite technical challenges, single-cell CTC (scCTC) analyses have so far revealed genomic
variations specific to each CTC, including mutations that are not yet present in the Catalogue of
Somatic Mutations in Cancer (COSMIC) database [16–20] or subclonal alterations that are not easily
discernible from tissue biopsies [16,17], cells of origin of cancer (e.g., bone marrow-derived multiple
myeloma) [21], or with bulk-cell approaches [22], providing comprehensive landscape of evolving
tumor cells. Such private genomic variations shared by CTCs may represent “CTC phenotypes”,
including intravasation competency, increased migration/motility, enhanced cell–cell interactions,
variation in energy metabolism, interaction with platelet and blood immune cells, resistance to anoikis,
and resistance to therapy [19,23]. Single nucleotide variations (SNVs) and/or copy number variations
(CNVs) in these putative precursors of metastasis present early in clonal evolution or in tumor
progression may be excellent targets for therapeutic intervention. Examined below are scCTC DNA
sequencing studies that have successfully assessed DNA alterations in patient-derived CTCs across
various cancer types (Table 1).
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2.1. CTC Enrichment
Once collected, blood samples are subjected to CTC enrichment using density gradient
centrifugation, 2D/3D microfiltration, microfluidic devices, or immunoaffinity-based technologies
(Figure 1; refer to Ref. [14] for detailed summary and comparison of existing CTC enrichment
technologies). While CellSearch® remains the choice of primary enrichment tool in scCTC sequencing
studies, such immunoaffinity-based enrichment technology relying on epithelial cell surface markers
(e.g., EpCAM or CKs) have varying capture efficiency depending on the degree of EMT, stemness, and
the resulting differentiation cell state. EpCAM+CK+ cells have also been detected by CellSearch® in
patients with benign diseases, but in lower frequency compared to the cancer group [54]. Clinical data
supporting the metastatic competence of EpCAM− CTCs in numerous studies [34,55] have further
fueled the transition in the field to the development of label-free approaches leveraging on biophysical
properties of CTCs (e.g., size, density, stiffness).
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4. Single-Cell DNA Sequencing
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Figure 1. The standard workflow and existing technologies for scCTC sequencing. CTCs are primarily
enriched from a whole blood sample, and are isolated as single cells for subsequent downstream
molecular analyses. For genomic analysis of whole genome/exome, whole-genome amplification
(WGA) is performed and amplified DNA products are QC-checked prior to sequencing.
One of our pioneering efforts in developing such marker-independent technology was the
application of inertial microfluidics using spiral microchannels, in which depth and width of each
channel can be designed to control the positioning of cells or microparticles in suspension via Dean
flow fractionation (DFF). Our technology, so-called ClearCell® FX, enriches intact and viable CTCs
from the peripheral blood of cancer patients in a fully automated and high-throughput fashion, with
a reported >80% sensitivity and specificity in detecting CTCs from clinical samples (refer to [56] for
further details on the system). Mechanobiologically inspired enrichment platforms achieve high
sensitivity and are not limited to certain CTC subpopulations, yet the purity of enriched samples may
be compromised due to their size distribution overlapping with leukocytes, as observed in breast,
colorectal, and prostate cancer [57]. To best interrogate CTCs and their cellular heterogeneity, cell
enrichment technology should thus be carefully selected for unbiased capture and recovery of different
CTC subpopulations.
2.2. Single-Cell Isolation
CTC enrichment technologies are used in conjunction with microscopic micromanipulators (e.g.,
Eppendorf Transfer Man NK2/4 micromanipulator, CellCelectorTM), laser capture microdissection
(LCM) [26], microfluidic devices [44], or DEPArrayTM to recover putative CTCs as single cells. Enriched
cells are often fixed and stained with the nucleic acid dye DAPI and monoclonal antibodies specific to
epithelial cell surface marker cytokeratin (CK) and leukocyte marker CD45, and manually selected by
the trained and skilled operator based on DAPI and CK positivity and CD45 negativity. Morphology
137
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of the captured cells (e.g., cell shape, size) are concurrently assessed to identify cells having 4 to 40 μm
diameter, round or oval shape, and/or high nuclear/cytoplasm ratio [37,39,49].
Even though dozens of CTCs might have been captured in CTC enrichment step, only very
few single CTCs (<10 CTCs) have been isolated and transferred successfully to a PCR tube per
sample [4,19,49]. Such low recovery rate could be attributed to apoptotic CTCs, which are often
excluded from the isolation in most scCTC sequencing studies. Consistent with the classic definition of
apoptosis, these cells are defined as CK+CD45- CTCs with non-intact nuclei having DAPI pattern of
chromosomal condensation and/or nuclear fragmentation and blebbing [52]. Given that low burden of
apoptotic CTCs has been associated with poor prognosis and aggressive phenotypes across several
cancer types [52,58], characterization of CTC apoptosis in situ may facilitate the development of new
platform for real-time monitoring of antitumor drug efficacy.
2.3. Whole-Genome Amplification (WGA)
WGA is an active area of development with wide applications to study rare tumor cells or
single-celled organisms, such as bacteria and archaea. There exist different WGA approaches based on
specific, degenerate, and/or hybrid primers: Linker-adapter PCR (LA-PCR), interspersed repetitive
sequence PCR (IRS-PCR), primer extension preamplification (PEP-PCR), degenerate oligonucleotide
primed PCR (DOP-PCR), displacement degenerate oligonucleotide primed PCR (D-DOP-PCR), multiple
displacement amplification (MDA), single primer isothermal amplification (SPIA), and multiple
annealing and looping-based amplification cycles (MALBAC; refer to ref. [59] for a comprehensive
summary on working principles and characteristics of each WGA method).
Briefly, LA-PCR and IRS-PCR methods utilize specific primers, each amplifying digested DNA
litigated to adapter fragments and repeating sequence elements, respectively, while the rest of the
methods, such as PEP-PCR, DOP-PCR, and D-DOP-PCR, are based on the use of degenerated primers.
MDA has been commonly applied to single-cell sequencing of microorganisms as well as patient-derived
CTCs. It employs a unique polymerase with strong strand displacement activity (e.g., phi29 DNA
polymerase), which can amplify fragments of up to 100 kb with high replication fidelity compared
to purely PCR-based (e.g., Taq polymerase) methods [59]. MALBAC has been proposed as a hybrid
PCR/MDA method, relying on two relatively error-prone DNA polymerases, Bst DNA polymerase and
Taq DNA polymerase, for isothermal strand displacement and PCR, respectively. Each WGA technique
has its own advantages and limitations in terms of sensitivity, specificity, uniformity, and amplification
bias. For example, while LA-PCR, DOP-PCR, and MALBAC may be the choice of method for detection
of CNVs but not SNVs, MDA (REPLI-gTM) has proven to be most sensitive in detecting mutations at a
single-base resolution compared to LA-PCR methods (GenomePlexTM, Ampli1TM) [60].
The challenge is that the yield of amplified DNA varies significantly across CTCs, where the success
rate of amplification ranges from 11% to 100% [24,61], and WGA step itself is subjected to coverage
biases and errors, such as preferential allelic amplification, GC bias, dropout events, and nucleotide
copy errors [60]. To account for such variability, studies have established an additional QC step prior
to in-depth sequencing to probe only CTCs with yields of DNA greater than negative controls [24] or
a fixed concentration level [27] or those showing specific bands corresponding to targets of interest
on the Agilent 2100 Bioanalyzer [19,29]. The author-defined QC assays have also been developed to
identify CTCs suited for single-cell targeted sequencing and analysis. For example, genome integrity
index (GII), which is determined from detectable PCR bands corresponding to three Mse fragments and
KRAS fragment, has been proven to be predictive of successful analysis of sequence-based molecular
changes, including point mutations, gene amplifications, and CNVs [30,36,42].
2.4. Sequencing and Profiling
Amplified DNA samples are subjected to library preparation and quantification. To date, scCTC
studies have most commonly employed next-generation sequencing (NGS), Sanger sequencing, single
nucleotide polymorphism (SNP), and array comparative genomic hybridization (aCGH) platforms,
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and conventional PCR technologies to analyze somatic SNVs, structural variations, (SVs), CNVs, and
chromosomal breakpoints and rearrangements for whole exome/genome or selected cancer-associated
genes, often comparatively with matched primary tumors and/or metastatic tissues or disseminated
tumor cells (DTCs).
In the library QC step, the sequencing depth, percentage of area covered, homogeneity of coverage,
and/or SNP densities are assessed to only select high-quality CTC libraries based on author-defined
assessment techniques, such as autocorrelation analysis [24] and Lorenz curves [26]. Fluorimetric
assays (e.g., Fluorometer) and analytical tool provided by the sequencing platform (e.g., Torrent Suite)
may also be used to quantify DNA samples and to assess the performance of sequencing runs and
the quality of generated data, respectively [19,31,37]. In some cases, the variants identified by NGS
were specifically selected and further validated by Sanger sequencing [31,45] or digital droplet PCR
(ddPCR) [36] using the same samples.
The sequence queried in single CTCs in prior studies vary from small-scale mutations (<1 kb) to
large-scale mutations (1 kb–100 Mb). Targeting larger regions may come with the trade-off of increased
number of false variant calls and sequencing costs and reduced number of individual cells to be sequenced [62].
Nevertheless, whole-genome sequencing (WGS) allows new discoveries of genomic variations occurring
even in non-coding regions that may add significant values to the analysis of rare tumor cells.
3. CTC Heterogeneity and Clinical Impact
While resolving cellular heterogeneity, single-cell approaches may link specific CTC subpopulation
programs to cancer cell phenotypes, metastasis, patient outcomes, and drug resistance, as demonstrated
by recent studies. Examined below are genomic aberrations commonly analyzed in CTCs and their clinical
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Figure 2. Summary of genomic alterations found in scCTC sequencing studies.
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3.1. Single Nucelotide Variation (SNV)
3.1.1. PIK3CA
PIK3CA is a gene harboring major driver mutations in many cancer types [63,64]. Its mutational
status has increasingly been recognized as a promising predictor of resistance to targeted therapies [65].
In breast cancer, tumors harboring PIK3CA mutations are often resistant to HER2-based therapy [66–68],
and are less likely to achieve pathologic complete response to anti-HER2 treatments [69,70]. Though
limited to the analysis of EpCAM-expressing CTCs, scCTC studies have applied targeted sequencing
approaches to examine mutational hotspots, most commonly in exon 9 and 20 [16,18,28,30,35,37,48,71].
The assessment of pre-existing resistant clones through scCTC analysis prior to the administration of
HER2-based therapies has been suggested to be of clinical significance for patients harboring CTCs
with HER2 amplification and double-mutant PIK3CA/HER2 [30]. Longitudinal monitoring of therapy
response through HER2 mutational analysis of CTCs in this subset of patients will be of particular
clinical interest, given the known drug efficacy of PIK3CA pathway inhibitors in patients with HER2+
primary tumors [72],
PIK3CA mutational status in CTCs indicative of resistance against HER2-targeted therapy has
been demonstrated for HER2− metastatic breast cancer patients screened for German multicentric
phase III trial (i.e., DETECT III study) harboring HER2+ CTCs [35]. Further, studies have noted a
high degree of intrapatient cellular heterogeneity and discordant PIK3CA status between CTCs and
matched primary tumors [18,28,35,36], of which PIK3CA was one of two genes (among >2200 COSMIC
mutations analyzed) frequently mutated in CTCs, cfDNA, and matched primary tumor in HER2-
breast cancer [36]. PIK3CA mutation has also been implicated in drug resistance of EGFR tyrosine
kinase inhibitor (TKI) treatment. Notably, a lung cancer patient harboring PIK3CA mutation in almost
all CTCs (7/8 CTCs) but not in primary tumor (low abundance) had progressive disease and presented
distant metastasis after one month of treatment with erlotinib. Early detection of such resistant cells in
such a less invasive way may thus be tremendously useful in drug selection.
3.1.2. TP53
TP53 is a tumor suppressor gene frequently mutated in most human cancers [73]. TP53 mutations
have functional implications in key molecular events in tumor progression, such as EMT [74],
stemness [75], cancer prognosis, and survival outcomes [76]. Highly heterogeneous TP53 mutational
status was observed across individual CTCs in prostate [24], lung [43], colorectal [16], and breast
cancer [29,31,36,38,41]. In metastatic prostate cancer, ubiquitous TP53 mutations were found among
multiple foci of the primary tumor and metastases, suggesting divergent cancer evolution from a single
ancestor cancer [24].
In breast cancer, TP53 harbored the highest number of mutations across CTCs [31]. Mutant TP53
p.R273C has been associated with cisplatin chemotherapy resistance [77]. Concurrent mutations of RB1
and TP53 genes were also found in the majority of CTCs from a lung cancer patient who experienced a
phenotypic transition from adenocarcinoma to small-cell lung cancer (SCLC) [43]. Notably, dramatic
clinical response was observed in this patient upon etoposide-cisplatin treatment, which is a standard
chemotherapy for SCLC patients [78,79]. These studies altogether highlight how scCTC profiling may
provide an early signal of phenotypic transition in tumor to guide new therapeutic regimen.
3.1.3. EGFR
Despite promising efficacy of EGFR in multiple cancer types [80], prediction of response against
EGFR inhibition still remains ambiguous. The mere assessment of EGFR expression at the DNA or
protein level using bulk primary tumor samples has not been an ideal indicator for predicting the
response to anti-EGFR drugs [81,82]. Whole-exome sequencing of lung CTCs revealed specific INDEL
in the EGFR gene (p.Lys746_Ala750del) shared by primary tumors and metastases, which could be
targeted with TKIs [43]. In our earlier work, we reported highly sensitive detection of EGFR mutations
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(T790M and L868R) in microfluidically enriched CTCs, which showed a complete concordance of
mutation status with matched primary tumors in non-small-cell lung cancer (NSCLC) patients [44].
Similarly, an integrated method using a magnetic sifter (MagSifter) and nanowell system has been
described for accurate detection of EGFR (del19, T790M, and L868R) mutations in CTCs from lung
cancer patients [22]. Notably, RT-qPCR readings of bulk blood samples did not reach detectable level
to be analyzed for same mutations in this study [22].
3.1.4. KRAS
KRAS, one of the genes involved in the EGFR signaling pathway, may have predictive value of
clinical response to anti-EGFR therapies, such as cetuximab [83], panitumumab [84], and gefitinib [85].
Patients exhibited mutational disparity between CTCs and matched primary tumors and/or across
individual CTCs in breast [36], colorectal [47–49], and multiple myeloma [24], and breast cancer [36].
This may explain the variable response to anti-EGFR treatment in these cancer patients. Similarly, a
highly varying degree of concordance in KRAS mutational status between CTCs and primary/metastatic
lesions was observed, reflecting intratumoral heterogeneity of point mutations in KRAS occurring in
48–76% of various cancers [86].
3.1.5. BRAF
Another mutation predictive of response to EGFR-inhibiting therapy is BRAF, which is associated
with a very poor prognosis particularly in colorectal cancer and melanoma [87]. Further, the predictive
values of V600E and V601E mutations have been demonstrated for the use of RAF kinase inhibitor
(vemurafenib) and MEK inhibitor (trametinib), respectively, in BRAF-mutated melanomas [50,88].
Somatic missense mutations in BRAF have been found in approximately 10% and 60% of colorectal
tumors and melanoma lesions, respectively [50,89]. Single-cell genomic characterization of CTCs across
these cancer types have revealed highly heterogeneous BRAF status across CTCs [47,48,50,51], with
disparities in BRAF mutations to the corresponding primary tumor [47,50]. While such considerable
heterogeneity observed in these selected genes might be the result of newly acquired mutations in
CTCs, it is likely that these mutations were missed by single sector-based tissue biopsies. Through the
additional deep sequencing of tissue samples, other groups indeed found mutations that were initially
unique to CTCs in the primary tumors and metastases at subclonal level [16].
3.2. Microsatellite Instability (MSI)
Defective DNA mismatch repair (MMR) machinery leads to hypermutation and instability in
nucleotide repeat sequences [90]. MSI is an established prognostic [91–93] and predictive marker [94,95]
in many cancer types. In colorectal cancer (CRC), tumors with high-level MSI, or MSI-H phenotype
account for ~15% of metastatic disease [96], and have distinct pathologic and clinical features [97].
MSI typing may serve as a predictor of benefit from adjuvant 5-fluorouacil chemotherapy for
non-MSI-H CRC patients [95,98]. The standard MSI assessment recommended by the National Cancer
Institute/International Collaborative Group/HNPCC (NCI/ICG-HNPCC) involves the examination of
two mononucleotide repeats and three dinucleotide repeats in tumor and non-tumor adjacent normal
tissues [99].
A comprehensive genomic study of CRC identified microsatellite stable (MSS) tumor harboring
MSI CTCs, through aCGH, mutational profiling, and MSI analyses at the single-cell level [47]. Of note,
immunohistochemical (IHC) expression analysis of DNA MMR proteins (i.e., MLH1, MSH2, MSH6,
and PMS2) in multiple sectors obtained from matched primary tumor and metastatic lesions did not
indicate MSI-H status in this patient. Such discordance was also found in mutational profiles, where
mutations in key genes such as KRAS and TP53 were detectable only in CTCs but not in the tumor.
Given that contaminating stromal cells or surrounding non-tumor cells in the tissue may obscure MSI,
single-cell approaches will be essential for MSI typing.
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3.3. Copy-Number Variation (CNV)
With the advent of SNP/aCGH arrays and NGS technologies, identification and characterization
of CNVs in primary and metastatic tumors have provided insight into the role of CNVs in cellular
functions and cancer pathogenesis [100–102]. Gain of oncogenes and loss of tumor suppressors are
frequent drivers of tumor progression, and are closely associated with therapeutic responses [103].
In CTCs, genome-wide CNVs were found to be highly reproducible from cell to cell within the same
individual and across different lung cancer patients with same pathological subtypes [43,45]. This is
consistent with homogeneity found in CTCs from SCLC [42,46] and colorectal cancer patients [45].
While harboring a substantial number of genomic aberrations, CTCs exhibit concordant changes
in chromosomes observed in matched primary and/or metastatic tumors, supporting their malignant
origin, but to different extents across individual CTC, as demonstrated in colorectal [45,47], breast [40],
and bladder [52] cancers. For example, phylogenetic analysis of CNV profiles identified homozygous
deletion of a chromosomal region containing the tumor suppressor gene, PTEN, in CTCs and lymph
node metastases, but not in primary tumor, suggesting that such CTC subsets might have metastasized
in colorectal cancer [45].
A unique signature of recurrent CNVs specific to CTCs was also found in breast cancer, consisting
of genes and miRNAs related to CTC phenotypes, such as resistance to anoikis, TGFβ signaling,
and metastasis [23]. This copy number signature clustered patients into two groups, independent
of subtype, revealing distinct functional or metastatic features in different populations. Gain of
a chromosomal region harboring the HER2 gene was further consistently observed across CTCs
regardless of HER2 status of matched primary tumors in this study, suggesting a potential role of HER2
amplification in CTC biology. Notably, HER2 amplification associated with the degree of chromosomal
changes was identified in another multi-scale scCTC study, where a significantly higher number of
genomic rearrangements was observed in breast CTCs with HER2 amplification than those without
amplification, whereas no such change was seen for PIK3CA mutations [30].
CNV profiling of CTCs could potentially be used as a tool for risk stratification. CNV-based
classifiers that can assign SCLC patients as chemosensitive or chemorefractory have been
developed [42,46], one of which have been validated in an independent patient cohort [42]. The two
patient groups stratified by these classifiers were found to have significant different progression-free
survival (PFS) and/or overall survival (OS), demonstrating prognostic and predictive value of CTC
CNV profiles [42,46]. Further, apheresis-acquired, CK+ CTCs harboring >10 chromosomal alterations
were associated with risk of early metastasis [32]. Better therapeutic strategies may also be inferred
from sequential single-cell characterization of CNV changes in CTCs over the course of treatment;
MYC amplification occurred along with AR protein expression and AR amplification in a prostate
cancer patient progressing through targeted therapy [27]. While direct targeting of MYC proves to
be difficult, scCTC data suggest that co-targeting of c-Myc in conjunction with AR may serve as an
alternative path to prevent the emergence of drug-resistant subclones.
3.4. Chromosomal Breakpoints
In addition to focal CNV analyses, whole genome-wide CNV profiles have been extensively
analyzed in bulk primary tumors. They are often associated with therapeutic resistance against
platinum-based chemotherapy and PARP inhibitors [104]. Large-scale state transition (LST), which
is defined as the number of chromosomal breaks between adjacent regions of at least 10Mb, is one
of surrogates of such large-scale genomic instability. Significantly higher and heterogeneous LST
scores were observed in CTCs from metastatic castration resistant prostate cancer (mCRPC) patients
compared to cancer cell lines and WBCs from healthy donors, implying unstable CTC genomes at
the single-cell level [25]. The ability to assess genomic instability with LST scoring could potentially
improve risk stratification for therapeutic strategies.
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3.5. Chromosomal Rearrangement
Two SVs common in all CTCs and both primary and metastatic tumors were found in prostate
cancer [26]: TMEM207 in chr3, which facilitates tumor invasion, migration, and metastasis [105,106],
and chr13-chr15 translocation. An extensive assessment further revealed heterogeneous status of SVs
involving tumor suppressor genes, such as BRCA2, RB1, and PTEN, which are common in prostate
cancer [107]. Heterogeneous status of PTEN SVs in single CTCs may suggest the acquirement of
variations at different time-points, as PTEN point mutations emerges as a late event during cancer
evolution [108]. Parallel transcriptomic profiling for detecting such SVs encoding oncogenes or tumor
suppressors that carry founder mutation will further allow discovery of novel fusion products.
4. Longitudinal Studies
While it has long been recognized that CTC count could serve as a robust predictor of patient
outcomes in breast, prostate, and colorectal cancers [36,39,109–112], CTC enumeration at a single
time point alone may not provide sufficient information in terms of treatment regimen. Alternatively,
phenotyping of CTCs with morphometric parameters and protein expression has been shown to be
better correlated with therapy response [27,113]. Another major advantage of CTC profiling is the
feasibility to analyze longitudinal samples to study mechanisms related to acquired resistance to
therapy (Figure 3). Yet, such analyses may be challenging in the absence of evident de novo global
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Figure 3. scCTC DNA sequencing for longitudinal monitoring of therapy response.
Selection of patients for targeted therapy has been based on the IHC detection of protein of interest
and/or fluorescence in situ hybridization-based analysis of gene-level alterations, typically in known
oncogenes, using primary tumor tissues. An underlying assumption is that only marker-positive
patients will respond to mutant oncogene-targeted therapy. These treatments may include vemurafenib
(BRAF inhibitor) for melanoma patients with V600E/V600K mutation in the BRAF gene [114], Neratinib
(HER2 TKI) [115], trastuzumab (HER2 antibody) [116] and pertuzumab (HER2 antibody) [117] for
breast cancer patients with amplification and/or overexpression of the HER2 gene, and erlotinib (EGFR
TKI) for non-small cell lung cancer patients with exon 19 deletion or L858R mutation in the EGFR
gene [118].
Such oncogene-targeted therapies, however, should carefully be applied in the clinical settings.
IHC detection of EGFR expression in bulk tumor tissue alone, for example, may not be an ideal tool
for prediction of response to gefitinib [119]. Discordance in genomic profiles between primary and
recurring/metastatic tumors [120–122] attributed to clonal changes, sampling error in clonal selection,
and/or technical flaws in the assay has complicated the decision-making process in treatment selection.
Repeat biopsy for marker reassessment does not guarantee improved accuracy, nor is it without
false-negative readings [123].
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Varying genomic status of oncogenes has thus been re-evaluated with CTC pools over the course
of therapy. Studies have examined the feasibility of detection of HER2+ CTCs in patients with HER2–
primary tumors [124,125] and that of KRAS-mutated CTCs in patients with nonmutated colorectal
primary tumor and mutated metastases [89]. Notably, it was found that treatment with trastuzumab,
an anti-HER2 antibody traditionally prescribed for patients with HER2+ primary tumor, was shown to
be effective in improving survival outcomes of patients with HER2− tumor by eliminating CK+HER2+
CTCs [126]. This was the first study that clearly demonstrated the potential of CTCs to effectively
monitor evolving mutational landscape reflecting time-varying changes in drug susceptibility. Since
then, several prospectively conducted studies have been carried out to facilitate the phenotyping and
genetic characterization of CTCs as targeted-therapeutic intervention in metastatic cancer [127].
Longitudinal genomic data on SNVs and CNVs have so far been obtained in scCTC studies where
CTCs were collected in a sequential manner during the course of treatment in lung [42,43] and prostate
cancer [17]. A unique set of somatic CNV variations distinct from those observed in response to
standard chemotherapy, was identified in single prostate CTCs at the time of targeted therapy failure,
inferring rapidly evolving genomic organization and the emergent putative-resistant clones [27]. In
another study where single-cell characterization was done before and during treatment for a breast
cancer patient, while CTCs revealed distinct mutational profiles at different time points, all CTCs
harbored mutation in the HER2 gene (p.V777L), regardless of sampling time, indicating resistance to
HER2-targeted treatment in this patient. Interestingly, the best treatment response to chemotherapy
with capecitabine and vinerolbine was observed in a patient who had the highest number of mutated
genes and sequence variants in single breast CTCs [31].
Not all longitudinal studies, however, have demonstrated a clear association between CTCs and
metastatic status. PIK3CA mutational status in majority of breast CTCs (7 out of 9 blood draws)
sequentially sampled over time was not reflective of bone and lung metastases while DTCs achieved
100% concordance in a patient with progressive metastatic breast cancer [28]. Such highly discordant
results, however, may be attributed to EpCAM-based approach employed in this study for CTC
enrichment, missing out de-differentiated EpCAM− or mesenchymally shifted CTCs, all of which may
be major constituents of putative metastatic founders [4].
5. Challenges and Emerging Technologies
Clearly, recent CTC studies have uncovered new perspectives in tumor biology and cancer
management, through the application of rare cell sorting and single-cell sequencing technologies.
Practically, however, there are challenges and technical errors associated with the developed workflows
presented in this work.
5.1. Fresh-Frozen Versus Formalin-Fixed
Immunoaffinity-based enrichment technologies, including CellSearch®, involve a fixation step,
which makes use of fixatives to stabilize whole blood for up to 96 h. Yet, fixed CTCs may be not
suitable for RNA-based measurements, ex vivo culture and expansion, drug screening, and xenograft
model-based functional studies, for compromised cell viability and degraded RNAs. Alternatively,
multiparametric flow cytometry or FACS can be used to keep viable CTCs, which can further be
expanded ex vivo to generate patient-derived 3D-spheroids, as demonstrated in prostate and breast
cancers [17,34]. DEPArrayTM and microfluidic technologies can also be used to isolate viable CTCs for
subsequent molecular screening on a cell-per-cell basis.
To preserve cell viability, peripheral blood sample should be delivered on ice immediately to the
laboratory once collected from a cancer patient. RNA degradation occurs within 2–4 h, and sample
processing >5 h after the blood draw may result in >60% loss in CTC yield [128]. Similar to tissue
acquisition of solid lesions, these requirements impose practical challenges in hospitals and labs,
particularly for longitudinal cohort studies. Nevertheless, emerging technologies may be applied
to CTCs to circumvent such issues, through the use of nuclear RNA or preservation protocol that
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retains cell viability and RNA quality for up to 72 h for single-cell transcriptomic profiling. Studies
have demonstrated high concordance between nuclear RNA and whole cell RNA in the expression of
cell-type specific and metabolic modeling genes [129], and that between fresh and preserved blood in
detecting cancer-specific transcripts [128]. Alternatively, frozen-optimized scRNA-seq protocols (e.g.,
Nuc-seq) may be applied to CTC profiling, which will be particularly useful for serial monitoring of
previously inaccessible tissues [2].
5.2. Increasing Number of CTC Libraries
Among all the steps, WGA was found to be the most error-prone step in performing scCTC
sequencing, with allele dropout (ADO) being a significant source of failure for scCTC sequencing [53].
Such prevalent limitations may be overcome if the amount of DNA template is increased. For example,
it has been suggested that at least 10 CTCs are required to reliably detect point mutations in KRAS from
pancreatic CTCs [53]. Similarly, sequencing multiple independent libraries of CTCs has been proposed
to improve sensitivity in determining variants and to better represent bulk library from a matched
primary tumor in prostate cancer [24]. The development of WGA methods providing improved
uniformity in genome-wide coverage of the amplified DNA may further facilitate reproducible and
accurate sequencing for clinical use.
Alternatively, highly sensitive CTC enrichment technologies may be applied to scCTC sequencing
studies to capture, assumedly, all CTCs present in blood so as to generate more DNA templates.
Recently, methods of performing single-cell CNV analysis of CTCs acquired by apheresis was described
in prostate and breast cancers [17], where CTCs harvested from an apheresis (mean volume = 59.5 mL)
achieved approximately 90-fold increased yield (CTC count = 12,546) [17]. Extrapolation analysis
further indicated that CTCs might be concentrated along with the mononuclear cell populations during
diagnostic leukapheresis (DLA), thereby enhancing CTC detection frequency even in nonmetastatic
cancer patients, as compared to standard CTC blood tests processing a volume of 1–10 mL of peripheral
blood [32].
In recent years, scRNA-seq technologies coupled with massively parallel microfluidics have
enabled high-throughput analysis of mouse retinal cells [130], human macrophages [131], embryonic
stem cells [132], and peripheral blood mononuclear cells (PBMCs) [133]. Their application to CTCs,
however, has been relatively limited due to the inefficiency of bead-cell pairing and the inevitable
contamination of blood cells even in primarily enriched samples [134]. To overcome these limitations,
Cheng et al. have recently developed Hydro-seq, which enable high-throughput contamination-free
scRNA-seq of CTCs from breast cancer patients, uncovering cellular heterogeneity in metastasis and
therapy related genes [134]. Having the scale-up capability while achieving high cell-capture efficiency
and high-fidelity single-cell sequencing results, these technologies will play an increasingly important
role in future studies aiming to generate more accurate and reproducible data at high throughput with
low cost.
5.3. Multidimensional Measurements
While others have attributed the appearance of CK+CD45+ cells to false-positive CK+ staining
of WBCs [32], such “double-positive” cells may have functional roles or clinical implication within
circulation given their occurrence at a much lower frequency in healthy blood samples [135]. Similarly,
the exact role of apoptotic CTCs (e.g., CK+CD45− cells with abnormal chromosomal patterns and/or
nuclear fragmentation), PD-L1+CD45− cells, and CK–CD45− cells in metastasis is not yet fully clear.
Technologies enabling joint profiling of multiple modalities from the same individual cell may
provide accurate means to understand clinical implication on the occurrence of these specific CTC
subpopulations in circulation.
The high definition-CTC (HD-CTC) is an exemplary technology that facilitates real-time single-cell
characterization of morphometric (i.e., cell roundness, cell area, AR subcellular localization) and
protein expression changes in AR for prostate cancer [27]. Similarly, the functional EPISPOT assay,
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which is now named EPIDROP, allows simultaneous single-cell analysis of proteome and secretome
of viable CTCs or of CTC clusters [136]. Such functional assays or microfluidic technologies, which
have been successfully applied to patient-derived CTCs for analysis of genome [44], transcriptome [4],
proteome [137], metabolome [138], and secretome [139] at the single-cell level, may further be integrated
into the framework for deriving multidimensional data. Along with the increasingly available genomic
data derived from tissue biopsies spanning diverse cancer types [140,141], the combined analysis of
tissue and liquid biopsies may further uncover new insights into tumor heterogeneity and provide
additional clinical information, as recently shown in lung cancer [4].
6. Conclusions
Recent scCTC studies have focused on how best to (1) identify and isolate extremely heterogeneous,
fragile, and rare CTCs in a highly specific and unbiased manner, (2) discriminate false negatives and
detect actionable mutations, and (3) relate the findings to clinically meaningful outcomes that could
not have been caught by a tissue biopsy. Emerging data pointing towards the prevalence of CTC
subpopulations and their differing metastatic potential have further stimulated studies aiming to
identify and genetically/phenotypically characterize such premetastatic subsets of CTC populations
that are favored to be liberated from primary tumors, survive in the bloodstream, and succeed in the
early colonization phases.
While past efforts in deconvoluting the complex nature of CTCs have been largely ineffective
with bulk-cell analysis, single-cell approaches are beginning to unmask cellular heterogeneity of
CTCs and their clinical significance, providing a foundation for liquid biopsy in the clinic. As we
continue to develop sensitive CTC enrichment technologies and generate more sequencing data
from patient-derived CTCs, clinicians will continue to find a better way to apply liquid biopsies,
possibly (1) at initial diagnosis, for prognostication, (2) after tumor resection, for assessment of residual
disease, and (3) after adjuvant therapies, for prediction of early recurrence or relapse. With mounting
molecular evidence suggesting prognostic value of CTC-derived biomarkers predictive of response to
chemotherapy, targeted therapy, and immune checkpoint inhibitors, we anticipate that, in the near
future, liquid biopsies will become a routine screening and monitoring of cancer patients.
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Abstract: Metastatic tumors are the primary cause of cancer-related mortality. In recent years, interest
in the immunologic control of malignancy has helped establish escape from immunosurveillance as a
critical requirement for incipient metastases. Our improved understanding of the immune system’s
interactions with cancer cells has led to major therapeutic advances but has also unraveled a previously
unsuspected level of complexity. This review will discuss the vast spatial and functional heterogeneity
in the tumor-infiltrating immune system, with particular focus on natural killer (NK) cells, as well as the
impact of tumor cell-specific factors, such as secretome composition, receptor–ligand repertoire, and
neoantigen diversity, which can further drive immunological heterogeneity. We emphasize how tumor
and immunological heterogeneity may undermine the efficacy of T-cell directed immunotherapies
and explore the potential of NK cells to be harnessed to circumvent these limitations.
Keywords: tumor heterogeneity; natural killer cells; tumor mutation burden; immunotherapy
1. Introduction
Recent advances in our understanding of cancer, driven by the development of sophisticated
biochemical and molecular techniques, have highlighted the complex and heterogenous nature of
this disease. Within individual tumors, significant differences in the molecular and phenotypic
profiles may arise from tumor cell-intrinsic or extrinsic factors. Genomics has provided the most
extensive insights to date about tumor-intrinsic variations, with sequencing studies revealing a large
extent of clinically-relevant intra-tumor heterogeneity [1–3]. Thus, next generation sequencing of
multiple tumor types identifying the association between increased clonal heterogeneity and higher
pathological stage and/or worse prognosis [4]. Moreover, genetic heterogeneity has also been identified
across patients, and the incidence of clinically actionable mutations differs significantly between
tumors arising from different tissue or cell types, amongst patients with the same class of tumor,
and between matched primary and metastatic tumors within the same patient [5–8]. Non-genetic
determinants of heterogeneity have also garnered significant interest, as even genetically identical
cells may harbor unique chemosensitivity profiles [9]. This points towards the role epigenetic
modifications [10–12] and metabolic reprogramming [13], in dictating the functional variation observed
within individual populations.
Tumor cell extrinsic factors, such as the cellular and structural elements of the tumor
microenvironment (TME), are also known to influence tumor heterogeneity. For instance, the spatial
arrangement of cells with receptor tyrosine kinase amplifications in glioblastoma has been shown
to correspond with degree of vascularization in the local TME [14]. Similarly, in melanoma patients,
the extent of subclonal divergence from the mutational profile of the primary tumor is dependent
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on the metastatic site [15], suggesting an influence of the local microenvironment. Perhaps the
most important component of the TME are the immune cells. Whilst the tumor-sculpting role
of the anti-cancer immune response has long been recognised, conflicting reports exist on the
impact of this immunoediting on tumor heterogeneity. The selective pressure of the immune
response has been shown to profoundly reduce sub-clonal diversity via the targeted elimination
of immunogenic cell variants [16], recent evidence indicates that the adaptive immune response
may in fact potentiate genomic instability [17], thus promoting the rise of novel subclones thereby
increasing tumor heterogeneity. As heterogeneity within the immune or tumor cell compartments could
conceivably impact the efficacy of immunotherapies, there is a vital need to improve our understanding
of the relationship between the two.
2. Spatial, Functional, and Temporal Heterogeneity of Immune Cell Infiltrates
Tumor cells develop in a dynamic niche; individual tumor cell subpopulations not only compete
and cooperate with each other, but also with the surrounding TME and its constituent immune cells.
Single-cell sequencing studies have confirmed that tumors may be populated by a vast and diverse
array of immune components: innate leukocytes, such as natural killer (NK) cells and mast cells;
phagocytes, such as macrophages, neutrophils, and dendritic cells; and adaptive effectors, including
naïve, memory, and effector B- and T-lymphocytes [18]. It is clear that the degree of immune infiltration
and the composition of this infiltrate can vary markedly across tumor types [19] and stages [18], as
well as between patients with the same tumor type [20,21]. Similarly, whether synchronous metastases
within a single patient regress or progress has been associated with their distinct immune profile [22].
Within a tumor, complexity is further compounded by the differing spatial distribution of immune
effectors between the core and invasive fronts, as well as within the adjacent tertiary lymphoid
structures [23,24].
However, as increased infiltration of CD8+ T-cells is prognostic for better outcome in numerous
tumor types [25–28], traditional scoring of tumor immunogenicity has been based upon the degree
of T-cell inflammation alone. Immunologically ’hot’ tumors, such as melanoma and non-small cell
lung cancer (NSCLC), present with a high degree of T-cell permeation, whereas tumor-infiltrating
lymphocytes (TILs) are scarcely observed in ’cold’ tumors, such as ovarian, prostate, and pancreatic
cancers. More recently, a third immunologically ’altered’ phenotype has been proposed, denoting cases
where peri-tumoral sites are densely inflamed with immune cells which lack the ability to infiltrate into
the tumor [29]. As the T-cell inflamed gene expression profiles of ’hot’ tumors have been strongly linked
with positive response to checkpoint blockade therapies [30,31], significant attention has been focused
on developing therapeutic strategies which can convert immunologically ’cold’ or ’altered’ phenotypes
into ’hot’ environments [32–34]. Yet, as the immune contexture may vary across non-adjacent tumor
regions, it should be emphasized that many tumors may not be universally ’hot’ nor ’cold’.
To address this disparity, the Immunoscore method proposed by the Galon group incorporates
spatial context into its immunological quantitation metric, computed by the ratio of memory CD3+
and cytotoxic CD8+ TILs at the tumor centre and invasive margins. In colorectal cancer (CRC), this
index has been validated as an independent prognostic marker which performs better than both
Tumor-Node-Metastasis (TNM) staging and microsatellite instability (MSI) status [35–37] and an
in vitro diagnostic assay has been made clinically available for assessing relapse risk in Stage II and III
CRC. Yet, there is substantial evidence that quantification varies between non-adjacent areas of tumor
biopsies [38–40], suggesting that single biopsies may not be representative of the broader infiltrating
immune landscape. Pertinently, a phenomenon termed Immunoskew has been documented, whereby
a minority of tumor regions are densely infiltrated with TILs despite an otherwise barren TME [41].
Determining whether Immunoskew extends to other immune cell populations, and identifying the
specific intra-tumor differences which drive this differential infiltration pattern, are worthy areas for
future study.
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Beyond TILs, the contribution of other cell types to tumor immunogenicity should not be
overlooked. NK cells are inversely correlated with cancer incidence [42,43] and intra-tumoral NK
cell infiltrates have been identified as a positive prognostic marker in multiple solid cancers [44–48]
and haematological malignancies [49]. Additionally, NK cells are supremely important in the control
of metastasis. A wealth of in vivo studies have demonstrated that mice depleted of NK cells via
pharmacological inhibition [50–52] or genetic knockout [53] are more vulnerable to metastasis than
their NK cell-proficient counterparts. The same is true for mice reconstituted with NK cells deficient in
cytotoxic molecules, such as perforin and interferon-γ (IFNγ) [54,55] or activating receptors [56–59].
This notion has been confirmed in a clinical study of CRC liver metastases, where increased frequency
of intra-tumoral NK cells was the variable most significantly (p = 0.01) associated with better overall
survival, performing better than other clinical parameters including TNM stage, number/size of
metastases, and frequency of infiltrating CD3+ lymphocytes [60]. Additionally, there is strong evidence
supporting the role of NK cells in the clearance of putative cancer stem cells [61–64], suggesting that
NKs may promote long-term recurrence-free survival.
The discordance in immune infiltrate between primary and metastatic tumors is more pronounced
in metachronous than synchronous tumors [24,65,66] indicating that temporal changes also contribute
to tumor heterogeneity. The composition of immune infiltrates is also known to change as tumors
progress, with one study in CRC reporting an increased prevalence of innate immune cells and
decreased number of most T-cell lineages in more advanced tumor stages [18]. The latter may
be particularly important when considering the age-associated decline in lymphocyte number and
function [67], particularly given that the majority of new cancer diagnoses are made in those over the
age of 65.
Above all, a limitation of current techniques that quantify immune infiltrates is that they frequently
do not assess functionality. Recent evidence suggests that infiltration alone may not be sufficient to elicit
anti-tumor responses, as effector cells can be relegated to the peritumoral stroma and therefore lack the
direct cell contact required for target cell destruction [68–70]. Similarly, the efficacy of each immune cell
population may be influenced by the immunoregulatory cytokines produced by neighboring cell types.
For example, infiltrating cytotoxic lymphocytes may be restrained by various immunosuppressive cell
types, including myeloid-derived suppressor cells [71], Tregs [33,72–74], and tumor-associated (TA)
fibroblasts [68,75–77], which are diversely distributed across cancer types. Conversely, traditionally
immunosuppressive cells can act beneficially depending on the surrounding tumor context [78,79].
3. Tumor Cell-Driven Immunological Heterogeneity
The observation that increased TIL fractions have positive prognostic value in numerous tumor
types has culminated in the harnessing of this subset for immunotherapy, primarily in the form of
immune checkpoint inhibitors. Whilst strikingly effective in tumor types, such as melanoma, renal
cell carcinoma (RCC), and NSCLC, the efficacy of immune checkpoint therapies is highly variable
across solid malignancies. For example, in CRC, positive therapeutic responses to T-cell directed
checkpoint inhibitors are limited to approximately 30% of patients with MSI, which represents 5% of
all patients [80]. Whilst the exact molecular mechanisms which underpin this resistance remain elusive,
emerging evidence suggests that broad spectrum of clinical responses could be partially attributable to
immunological heterogeneity. As well as differences in immune infiltration and interaction of immune
cell types, there are multiple tumor cell intrinsic factors, such as the secretome, receptor–ligand profile,
and neoantigen repertoire, which can drive immunological heterogeneity (Figure 1).
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Figure 1. Tumor and immunological heterogeneity. Tumor-intrinsic drivers of heterogeneity (upper
left) include diversity in: the degree of tumor vascularization or hypoxia (1), which determines whether
the local tumor microenvironment (TME) will support or suppress anti-tumor immune cells; the
variable expression of neoantigens (2) and ligands (3), which facilitate interaction with various immune
cell types; and the secretion of soluble factors (4) (which may also be produced by the immune cells
themselves) that may promote or restrain the action of nearby immune cells. Immune cell contributions
to heterogeneity (bottom right) include: the type and density of infiltrating versus excluded immune
cells (5); modulatory interactions between co-localised immune cell types (6); the balance of activating
versus inhibitory receptors (7); effector cell distribution between the invasive margin (IM) and central
tumor (CT) (8); and the overall balance between pro- and anti-tumor effectors (9).
3.1. Secretome Heterogeneity
Infiltrating immune cells can be conditioned by the soluble factors secreted by nearby tumor
cells. Tumor cells can directly foster an immunosuppressive TME via the production of enzymes and
metabolites including indolamine 2, 3-dioxygenase (IDO) [81,82], lactic acid [83] and prostaglandin
E2 [68,84]. As metabolically heterogeneous regions are detectable within discrete tumors [13], it is
conceivable that these immunosuppressive metabolites may be irregularly distributed. Although such
mediators are directly implicated in the dampening of T- and NK cell activity, their immunomodulatory
effects are not reflected in routine clinical immunohistochemistry, where the focus is on assessing the
presence or absence of lymphocytes, not their activation state.
There are multiple reports of tumor-derived cytokines, such as transforming growth factor-β1
(TGF-β1) suppressing cytotoxic effector functions [85–87], frequently acting via the downregulation of
activating receptors [88–90]. As TGF-β1 production is exacerbated in hypoxic conditions, it follows
that hypoxic tumor cells show heightened resistance to NK cell-mediated killing [91–93]. In response
to hypoxia, accumulation of immunosuppressive adenosine and subsequent signaling via the A2A
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adenosine receptor has been shown to potently inhibit T- and NK cells [94,95]. This tumor-protective
effect is abrogated in hyperoxic conditions [96,97], suggesting that supplemental oxygen could
be a useful co-adjuvant for immunotherapy. Due to the disorganized vascularization of growing
tumors, tumor cells may be irregularly exposed to hypoxia [98]. Interestingly, this intermittent
hypoxic conditioning has been shown to enhance inflammatory responses as compared with chronic
hypoxia [99–101]. However, this phenomenon has also been shown to enhance tumor growth and
promote radiotherapy resistance in in vitro and in vivo models [102]. Thus, more research interrogating
the role of intermittent hypoxia in the context of the TME would be valuable.
Additionally, there is mounting evidence that different immune cell subtypes, particularly NK cells,
may exhibit tropisms for different tumor types. Human NK cells develop from CD34+ hematopoietic
progenitors in the bone marrow and critically rely on interleukin-15 (IL-15) transpresentation for
maturation into two functionally distinct mature NK cell subsets in the periphery [103,104], divided
based on CD56 expression. Approximately 90% of circulating NK cells exhibit the CD56dim phenotype,
which primarily function as cytolytic effectors via production of perforin and granzyme B. Conversely,
the immunoregulatory CD56bright subset is charged with production of type I pro-inflammatory
cytokines (IFNγ, Tumor necrosis factor (TNF)α, GM-CSF, IL-10, IL-13) and preferentially reside
in the secondary lymphoid organs. In breast cancer [105] and gastrointestinal stromal tumours
(GIST) [44], tumor-infiltrating NK cells are primarily of the poorly cytotoxic CD56bright subtype,
whereas glioblastomas are preferentially infiltrated by CD56dim NK cells [106], and conflicting tropisms
have been reported in NSCLC [107,108]. Such differences in NK cell homing may also be associated with
the extent of hypoxia in the TME, as hypoxia-induced upregulation of chemokines C-X-C chemokine
receptor type 4 (CXCR4) and CCR7 has been shown to favor migration of the CD56bright subset [109].
Intriguingly, this is unlikely to be explained by chemokine profile alone, as NK cell infiltration in CRC
is scarce despite elevated expression of chemokines that attract CD56bright (CXCL9, CXCL10, CCL3,
CCL4) and CD56dim (CXCL8, CXCL1, CXCL5, and CXCL12) subsets in tumor tissue as compared with
adjacent normal mucosa [69].
3.2. Receptor–Ligand Heterogeneity
Through somatic recombination, the adaptive immune system is able to generate immunoglobulin
and T-cell receptor (TCR) repertoires which span millions of antigens. Disparate receptor repertoires
also exist within the NK cell compartment and underpin their functional heterogeneity. NK cell effector
functions are tightly controlled by a complex network of activating and inhibitory receptors, and the
ability of NK cells to eliminate target cells and produce cytokines relies upon the integration of signals
from both types. Activating receptors, such as the natural cytotoxicity receptors (NKp30, NKp44,
and NKp46) and NKG2D, recognise stress-induced ligands which are upregulated in response to
DNA damage or viral transformation (“induced-self” recognition) [110,111]. Conversely, inhibitory
receptors comprising the highly polymorphic killer cell immunoglobulin-like receptor (KIR) family
work to prevent the aberrant targeting of healthy host cells by engaging “self” molecules, such as major
histocompatibility complex class I (MHC-I), glycoproteins, and cadherins, and accordingly targeting
those that have lost expression of these molecules (“missing-self” recognition).
Whilst NK cell receptors are preformed and, therefore, do not undergo the rearrangements
characteristic of B- and T-cell receptors, a remarkable degree of NK cell diversity is conferred by the
combinatorial expression of different NK receptors. Utilising a mass cytometry panel of 28 NK cell
receptors, Horowitz et al. successfully detected up to 30,000 distinct NK cell phenotypes within a
healthy individual. Such heterogeneity may in part be explained by the multiple factors which can
regulate NK cell receptor repertoires, including host-genetics [112,113], epigenetic regulation [114] and
previous viral infection [115–117].
The KIRs are the most heterogeneously expressed family of receptors. KIRs are encoded
by 15 highly polymorphic genes clustered in the leukocyte receptor complex on chromosome
19q13.4 [118]. CD56dim NK cells express between 7 and 11 KIR family members; the presence
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or absence of individual KIR genes in each haplotype generates considerable genotypic diversity,
which is compounded by differing allelic frequencies within each gene. Such heterogeneity is of
clinical importance, as KIR-mismatch is a prerequisite for the graft-versus-leukaemia effect of allogenic
NK cell transfer [119–121] and specific KIR genotypes have been associated with better responses to
combination immunotherapies in neuroblastoma patients [122,123]. Similarly, three splice variants
of the activating receptor NKp30 have been identified and the relative abundance of activating
versus inhibitory isoforms has been associated with clinical outcome in neuroblastoma [124] and
gastrointestinal sarcoma [44]. In the latter study, expression of inhibitory NKp30c as the most abundant
isoform was the only independent prognostic factor for overall survival, whose overexpression was
traced to a single nucleotide polymorphism in the natural cytotoxicity receptor-3 (NCR3) gene [44].
Importantly, numerous in vitro studies have demonstrated the ability of tumor cell lines to
differentially regulate the receptor repertoires of NK cells [62,63,125]. Coordinated patterns of receptor
dysregulation have similarly been documented in tumor-infiltrating as compared with peripheral NK
cells. Reduced expression of activating receptors (including NKp30, NKp46, NKp80, CD16, DNAX
accessory molecule-1 (DNAM-1) and NKG2D) has been documented in lung carcinoma [108], breast
cancer [105] and acute myeloid leukaemia [126]. In each case, functional analysis of these patient-derived
NK cells revealed that tumor-associated NK cells are poor producers of IFNγ and have an impaired
ability to degranulate, although these studies did not investigate whether these defects impacted
clinical outcome. Conversely, upregulation of the CD96/NKG2A inhibitory receptor complex has been
observed in renal cell [127] and associated with poor prognosis in hepatocellular [128] carcinomas.
Immune cell responsiveness is not only determined by the balance of receptors present on a given
cell, but also by the various ligands expressed by the target cell. For instance, a recognised mechanism
of tumor escape in is the shedding of soluble ’decoy’ ligands for NK cell activating receptors, including
BCL2-associated athanogene 6 (BAG-6) [129,130] and B7-H6 [131]. Interestingly, a genome-wide
knockout screen performed by Klein and colleagues [132] identified loss of B7-H6 as the sole event
which increased resistance of the chronic myeloid leukaemia cells to NK cell killing. Yet, recent
studies investigating the functional consequences of NKG2D ligand shedding have challenged the
idea that soluble ligands are exclusively immunosuppressive; in human cancers, shedding of MHC
class I polypeptide related sequence A (MIC-A), a low-affinity NKG2D ligand, facilitates immune
evasion [133,134]; however, shedding of the high-affinity murine analogue, MULT-1, enhances NK cell
activation and tumor rejection [135].
Another major mechanism by which tumors evade immune destruction is up-regulation of
immune checkpoint ligands, such as CD80/86, 4-1BBL, and OX40-L. Immune checkpoints are a
broad group of inhibitory pathways and co-receptors with the primary purpose to restrict the
duration and amplitude of an immune response, thereby minimizing collateral damage to healthy
tissues [136]. Immune checkpoints primarily regulate T-cell responses, although checkpoint expression
has been documented in B cells, NK cells and professional antigen-presenting cells (APCs) [136].
In the context of cancer, chronic antigen exposure coupled with engagement of inhibitory immune
checkpoint ligands on tumor cells results in effector T-cell exhaustion, wherein T-cells undergo
profound impairment of proliferation, cytokine production and cytotoxicity. Even in hostile immune
environments densely infiltrated with cytotoxic T-lymphocytes, checkpoint ligand expression impinges
upon tumor clearance [137]. Programmed Death Ligand 1 (PD-L1) has attracted particular attention in
that its expression is associated with poor prognosis in multiple cancers [138–141]. Indeed, six of the
seven FDA-approved immune checkpoint inhibitors target the PD-1/PD-L1 inhibitory axis [142]. PD-L1
expression by tumor cells is a strong predictive biomarker for response to PD-L1 blockade [143], although
positive therapeutic responses to have been reported PD-L1-knockout mice [144] PD-L1-negative
patients [145]. This suggests that whilst PD-L1 positivity enriches for responders, combining PD-L1
expression with other predictive factors, such as MSI status, may increase our confidence in patient
selection. Indeed, even in tumors classed as PD-L1-positive, individual tumor cells vary widely in
terms of PD-L1 expression [66,146]. Individual research groups set thresholds for ligand positivity
160
Cancers 2019, 11, 1217
ranging from 1–50% [147] and in tumors classed as checkpoint-positive, negative-staining cells may be
ignored during clinical decision making despite their likely influence on treatment efficacy. Likewise,
ligand profiles are labile in response to therapy; conventional chemotherapeutics increase expression
ligands for the NK cell activating receptors NKG2D and DNAM-1 in multiple myeloma [148] and
ovarian cancer [149] cells.
There is also some degree of binding promiscuity involved in receptor–ligand interactions.
An array of NK cell receptors with opposing functional roles compete for binding of CD155 (PVR) ligand,
including activating DNAX accessory molecule-1 (DNAM-1) and inhibitory T-cell immunoreceptor
with Ig and ITIM domains (TIGIT) [150]. CD96-CD155 ligation is primarily considered an inhibitory
checkpoint in the NK-mediated control of metastasis [151], however an activating role for CD96 has
also been reported via promoting target adhesion [152]. Such complexity demonstrates how the
interplay between immune cell receptors and ligands should be assessed as a network rather than at
the single molecule level, and how such assessment should take into account spatial heterogeneity
rather than focus on limited areas.
3.3. Neoantigenic Heterogeneity; A Challenge for T-cell Directed Immunotherapies
Just as the ability of the immune system to recognise and destroy invading pathogens or foreign
particles relies on the ability to distinguish self from non- or altered-self, the genetic marks carried
by tumor cells provide a diverse set of antigens that the immune system can use to detect malignant
cells amongst their normal counterparts. Accordingly, T-cell directed immunotherapies have currently
proven most efficacious in cancer types with high average tumor mutation burden (TMB) [153,154].
Whilst clinical responses to immune checkpoint blockade in cancer types with traditionally low TMB
have been reported, these are generally restricted to virally-induced cancers, such as Merkel cell
carcinoma and human papilloma virus-positive head and neck squamous cell carcinoma (HPV+
HNSCC), which show enhanced T-cell infiltration due to the presence of viral antigen [155,156].
Similarly, MSI has been identified as a pan-cancer predictive marker for checkpoint inhibitors [157,158],
as MSI tumors harbour DNA mismatch-repair defects and thus present with 10–100 fold greater TMB
than genomically stable tumors [159]. MSI tumors also have higher TIL density as compared with
their microsatellite stable (MSS) counterparts, due primarily to their increased frequency of mutated
neo-epitopes recognisable as non-self [160]. Neoepitope load is predictive of clinical outcome in
bladder cancer [161], multiple myeloma [162], melanoma [163], and ovarian cancer [163,164], and there
several reports of cytotoxic T-cells recognising epitopes derived from single point mutations [165–167].
Accordingly, heightened TMB is associated with more diversified expansion of T-cells [168] and greater
infiltration of neoantigen-specific clonotypes [169].
Neoepitope targeting is an appealing therapeutic avenue in that the lack of neoepitope expression
in healthy cells ensures that neoepitope-specific T-cells are not impinged by central tolerance, thereby
conferring greater specificity and less toxicity. To this end, multiple studies are currently investigating
the possibility of targeting neoepitopes with for personalised immunotherapy (see Türeci et al. [170]
2016 for a complete list of completed and ongoing trials). Yet, a barrier to the clinical applicability of
these strategies inheres in the tremendously diverse range of antigenome landscapes observed between
patients. In a recent pan-cancer analysis where almost one million unique neoantigens were identified,
only 24 were conserved in at least 5% of patients in one or more cancer types [171]. Similar results have
been reported in analyses of individual cancer types [172,173]; of note, a cohort study from The Cancer
Genome Atlas (TCGA) in CRC (n = 598) revealed that only 4% of predicted neoepitopes were shared by at
least two patients [174]. This complexity is compounded by the substantial diversity across patients with
respect to human leukocyte antigen (HLA) haplotypes required for antigen presentation. This may be
particularly important as, unlike membrane-associated checkpoint molecules, the majority of tumorigenic
mutations affect genes which encode for intracellular proteins [175] and are therefore only recognizable
by CD8+ T-cells following antigen processing and presentation in the context of MHC-I.
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There is also strong evidence supporting the existence of neoantigenic heterogeneity within
individual tumors. In lung adenocarcinoma, post-surgical recurrence has been associated with an
increased proportion of branched neoantigens, defined as those not homogenously detected throughout
the tumor [21]. Importantly, TCR sequencing of 45 tumor regions in these patients demonstrated that
the majority of T-cell clones were topographically restricted, and that intra-tumor heterogeneity in TCR
repertoires positively correlated with predicted neoantigen variety. Together, these findings suggest that
regional differences in T-cell infiltration may be driven by spatially distinct neoantigen profiles, which
may have important consequences for the development of therapies which target single neoantigens.
There is also accumulating data suggesting that neoantigens are not equally ’potent’ in their ability to
elicit T-cell effector functions, highlighting that assessing neoantigen quality may be more important
than their quantity. Recent work has demonstrated that qualitative neoantigen prediction models,
where fitness is conferred by a higher probability of TCR-recognition, have surpassed quantitative
models in their ability to stratify for survival [176,177].
4. Neoantigen-Independent Strategies for Immunotherapy
Evidently, neoantigenic heterogeneity presents a formidable challenge in the development of T-cell
based immunotherapies. To circumvent this striking degree of variability, clinical attention has been
directed towards targeting non-mutated antigens that show heightened tumor specificity, including
cancer germline antigens (CGAs). Unlike patient-specific neoepitopes, non-mutated antigens arise from
comparatively well-defined mechanisms and are thus more likely to be conserved across patients. CG
antigens are proteins that are exclusively expressed by germ cells which can be aberrantly re-expressed in
multiple cancers, including the archetypal melanoma antigen (MAGE), synovial sarcoma X-chromosome
breakpoint (SSX), and oesophageal squamous cell carcinoma (ESO) families. Expression of CG antigens
is epigenetically modulated, being frequently induced following hypomethylation of CpG islands
and covalent histone modifications [178]. Due to their absence on healthy somatic cells, CGAs have
garnered substantial interest as therapeutic targets. However, development of CGA-directed therapies
has been hampered by their low prevalence. Indeed, Kerkar et al. [179] report that only 2–3% of
common epithelial cancers uniformly express New York-ESO-1 (NY-ESO-1).
An alternate strategy has been to target TA antigens that, despite basal expression in healthy
cells, are preferentially expressed by transformed cells. One class of TA antigens are the differentiation
antigens, which are homogenously expressed by cells of a given tissue type or cell lineage and
consequently, by all malignant cells arising therefrom. Given that these antigens are concomitantly
expressed in healthy tissues, therapeutic efficacy is generally accompanied by ’on-target’ toxicity.
For example, adoptive cell transfer directed against the metastatic melanoma differentiation antigens
gp1000 and melanoma-associated antigen recognised by T cells (MART-1) resulted in regression in
30% of patients, though these individuals frequently experienced uveitis and hearing loss due to
destruction of melanocytes in the eye and ear [180]. Similarly, targeting carcinoembryonic antigen
(CEA) overexpression in metastatic CRC induced regression but also severe inflammatory colitis [181].
Harnessing NK Cells for Innate Immunotherapy
In recent years, NK cells have emerged as alternative candidates for immunotherapeutic
development. Certainly, the MHC-I unrestricted manner of NK cell responses may render this
subset a more promising candidate for immunotherapy, as they may overcome the restricted benefit of
antigen-specific T-cells in tumors with high mutational diversity. NK-based therapies may prove a
new frontier in the treatment of immunologically ’cold’ or refractory tumors, given that the one of the
most common mechanisms of immune escape employed by tumor cells is downregulation of MHC-I
machinery [182]. Similarly, defects in genes implicated in antigen processing and presentation have
recently been identified as key drivers of acquired resistance to immune checkpoint therapies [183].
Additionally, NK cell cytotoxicity may be triggered following engagement of ligands upregulated by
transformed cells in response to epithelial-mesenchymal transition, such as MIC-A/B and ULBP1-3 [184].
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The latter renders NK cells particularly apt in the eradication of early metastatic cells. Importantly,
NK cell receptors are preformed and thus do not require prior sensitisation, clonal expansion and
co-stimulatory signalling required for T-cell responsiveness, thus allowing for more rapid cytotoxic
responses. Whilst adoptive transfer of HLA-mismatched NK cells induces graft-versus-tumor effects,
these cells do not contribute to dose-limiting graft-versus-host disease (GvHD) and may even play a
protective role by dampening alloreactive T-cell responses [185,186].
Although no therapies directed specifically at NK cells have been approved in the clinic to date,
such promising data suggests that a next wave of therapeutic advances could come from targeting
this cell type (Table 1). In phase I/II clinical trials, monoclonal antibodies targeting NK cell inhibitory
receptors, such as NKG2A [187] and the KIR family [188], have been shown to bolster NK cell-mediated
cytotoxicity. Chimeric antigen receptor (CAR) NK cells directed against CD19 [189,190], CD2 subset-1
(CS-1) [191] and epidermal growth factor receptor (EGFR) [192,193] have also shown efficacy in
xenograft models. To improve specificity, Bi-Specific Killer cell Engagers (BiKEs) have been developed
which co-target the CD16 low affinity IgG receptor (FcγRIII) and epitopes expressed by malignant
cells, such as CD33 [194] and EpCAM [195]. BiKEs have been shown to mediate NK cell cytotoxicity,
which is markedly enhanced following the incorporation of a modified human IL-15 crosslinker to
generate a tri-specific moity (TriKE; [196]. Yet, these approaches all still rely on tumor cell expression
of the selected target and may therefore show limited success in eliminating heterogenous tumor cell
populations. Addressing this challenge, CAR T-cells have been engineered to co-express members of
the natural cytotoxicity receptor (NCR) family of NK cell activating receptors (including NKp46 [197],
NKp44 [198], and NKp30 [199]. These ’hybrid’ CARs avoid the obstacle of MHC-restriction but retain
the long-term persistence of adoptively transferred T-cells, endowing cytotoxic T-cells with an NK
cell-like pattern of recognition. It is through such innovations, which consider the complexity of tumor
cell heterogeneity and acknowledge that immunotherapy may not be a ’one size fits all’ approach, that
we may draw the greatest clinical benefit.
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5. Concluding Remarks
Whether driven by immune cell-intrinsic or tumor-induced factors, it is clear that a vast scope
of immunological heterogeneity exists across human cancers. Incorporating our understanding of
this heterogeneity into clinical studies may improve our ability to further stratify patients who are
candidates for immunotherapy and aid in the design of rational combination therapies directed against
heterogeneously expressed targets thereby complementing existing therapeutic strategies, such as
those targeting PD-L1. Additionally, further research exploring the influence of TMB on the infiltration
and effector functions of non-antigen restricted mediators, specifically NK cells, could inform new
therapeutic strategies harnessing the innate immune compartment.
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Abbreviations
Common cell types and acronyms used throughout this manuscript.
CD56bright natural killer (NK) cell
Immunoregulatory subset (~10%) of NK cells producing type I
pro-inflammatory cytokines
CD56dim NK cell
Cytotoxic subset (~90%) of NK cells characterized by high production of
perforin and granzyme B.
Chimeric antigen receptor (CAR)
Chimeric proteins that fuse an extracellular tumor antigen-targeting domain
with a lymphocyte (T- or NK cell)-activating intracellular moiety.
Bi-/Tri-specific killer cell engager (Bi-/TriKE)
Advanced biologicals engineered to express antibody domains capable of
binding multiple unique antigens (e.g., 2 antigens /Bi- or 3 antigens/Tri on
NK cells and tumor cells to promote NK cell activation and binding to
tumor cells)
Killer cell immunoglobulin-like receptor (KIR)
Large family of highly polymorphic NK cell receptors (also expressed in a
subset of T-cells) which regulate cytotoxicity by engaging “self” molecules,
such as MHC-I.
Major histocompatibility complex class I (MHC-I)
Multi-protein complex expressed by all nucleated cells in mammals. MHC-I
presents peptide fragments (derived from self, non-self and neo-antigens) to
cytotoxic T-cells.
Natural cytotoxicity receptor (NCR)
Family of type I transmembrane proteins which, when stimulated, trigger
NK cell degranulation and cytotoxicity; most tumor-associated NCR ligands
are unknown.
Neoantigen-dependent killing
Peptides arising from tumor mutations are presented to T-cells in the
context of MHC-I, triggering clonal expansion of cytotoxic T-cells which
specifically target tumor cells expressing the cognate neoantigen.
Neoantigen-independent killing
Cytotoxicity which does not require priming by a specific antigen; NK cell
cytotoxicity is antigen-independent and therefore not restricted to tumor
cells that express the cognate neoantigen.
Microsatellite instability (MSI)
Type of genetic instability arising from defective DNA mismatch repair,
resulting in a hypermutated phenotype.
Tumor-infiltrating lymphocyte (TIL)
Lymphocyte which has migrated from the peripheral blood into a solid
tumor; This term often refers to tumor-infiltrating cytotoxic CD8+ T-cells.
Tumor mutation burden (TMB)
Number of mutations per coding area of a tumor genome; high TMB is
associated with better responses to checkpoint immunotherapy.
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Abstract: Inflammation is now recognized as a hallmark of cancer. Genetic changes in the cancer
cell are accepted as the match that lights the fire, whilst inflammation is seen as the fuel that feeds
the fire. Once inside the tumour, the immune cells secrete cytokines that kick-start angiogenesis to
ferry in much-needed oxygen and nutrients that encourage the growth of tumours. There is now
irrefutable data demonstrating that the immune contexture of breast tumours can influence growth
and metastasis. A higher immune cell count in invasive breast cancer predicts prognosis and response
to chemotherapy. We are beginning now to define the specific innate and adaptive immune cells
present in breast cancer and their role not just in the progression of invasive disease, but also in the
development of pre-invasive lesions and their transition to malignant tumours. This review article
focusses on the immune cells present in early stage breast cancer and their relationship with the
immunoediting process involved in tumour advancement.
Keywords: breast cancer; immune microenvironment; DCIS; ADH
1. Introduction
The immune system protects the host from pathogens and toxic, allergenic or foreign substances.
It is broadly classified into two lines of defence: innate immunity and adaptive immunity. Innate
immunity is comprised of the initial immune response, occurring within hours of encountering a
foreign antigen, and is antigen-independent (non-specific). On the other hand, adaptive immunity is
antigen-dependent and pathogen-specific, but requires approximately 4-7 days to mount a full active
response. It is well accepted that the immune system has an integral role in shaping the evolution of
cancer through the process of immunoediting. Testament to this, immunotherapy now forms part of
some cancer treatments, rallying the body’s immune system to fight cancer. Checkpoint inhibitors, for
example, have been developed to target and block the immune checkpoint proteins CTLA-4, PD-1
and PD-L1, which are upregulated on tumour cells and immune cells and restrict the immune system
from attacking the tumour. The checkpoint inhibitor therapies reactivate the T cells, leading to durable
responses and long-term survival in lung cancer and melanoma. Here we discuss the role of the
immune system in breast cancer (BCa), including invasive cancers and the pre-invasive in-situ lesions,
where recent work shows the innate and adaptive cells are already activated.
2. Lesions of the Breast
Carcinoma of the breast can arise from either the lobular or the ductal epithelium. Lobular
carcinomas are less prevalent than ductal, accounting for 4–10% of diagnoses from breast biopsies [1].
Before BCa reaches the invasive stage at which point it can spread to the rest of the body, it is referred
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to as a pre-invasive lesion (Figure 1). In pre-invasive lesions, the cancerous cells are confined to the
ducts or lobules from which they originate and have not yet broken the basement membrane [2]. The
pre-invasive lesions in ductal carcinoma are categorized as either atypical ductal hyperplasia (ADH)
or ductal carcinoma in situ (DCIS). It can be difficult to histologically distinguish ADH lesions from
that of low-grade DCIS, as the lesions look similar and ADH is mostly identified through failing to
meeting the diagnostic criteria for DCIS [3,4]. Ducts exhibiting abnormal proliferation that receive a
diagnosis of ADH are partially or completely filled with uniform and polarized cells. These cells are
hyperchromatic, and the extent of proliferation is greater than that found in usual ductal hyperplasia [4].
Ducts affected by ADH are small, typically defined as less than or equal to 2 millimetres (mm) in
size, and are usually found alone or in small, clustered foci [3]. Not all ADH lesions will progress to
carcinoma [5], however women with a diagnosis of ADH are four times more likely to develop BCa [6].
Figure 1. Stages of breast cancer development. Tumour cell initiation and expansion within the
mammary ducts characterises atypical ductal hyperplasia (ADH). This progresses to ductal carcinoma
in situ (DCIS), which is identified as a complete filling of the mammary duct with tumour cells. Once
the myoepithelium is breached and tumour cells escape beyond the mammary duct confinement, the
cancer is classified as an invasive ductal carcinoma [7].
DCIS lesions are characterized into low, intermediate, and high grade. The grades are distinguished
by cellular features including the presence of calcifications and necrosis within the duct, the regularity
and uniformity of the cells and their nuclei, and the extent of proliferation causing distortion of the
duct [8]. Irregularity of the tumour cell nuclei, mitotic figures, and the extent of necrosis within the
duct all dictate higher lesion grading [9]. DCIS lesions are typically surgically removed, but their
diagnosis confers a risk of both DCIS recurrence and progression to invasive disease. This occurs for
each DCIS grade, however the risk of recurrence or progression is highest in the high-grade lesions,
and lowest in the low-grade lesions [10–13].
Tumours are characterized as invasive ductal carcinoma (IDC) once the cells are no longer confined
to the affected duct, but have broken through the basement membrane and subsequently have invaded
the surrounding stroma [2]. The presence of hormone or growth factor receptors can divide the invasive
cancers into distinct subtypes. These include estrogen receptor-positive (ER+), human epidermal
growth factor receptor 2 (HER2)-positive, and triple negative (TNBC) BCa [14]. TNBC expresses neither
hormone nor growth factor receptors. BCa can also be classified by molecular characteristics into
luminal (which can be ER+ or ER− and also ER+HER2+), or HER2+ (which expresses amplification of
the human epidermal growth factor receptor 2 (HER2) gene, but are negative for ER). Finally, there are
2 subtypes that lacks all growth factors and are referred to as Basal and Claudin low [15].
3. The role of the Immune System in Cancer
Alongside the traditional hallmarks of cancer such as unregulated cell growth and apoptosis
evasion, immune-manipulating mechanisms are also considered pivotal characteristics of cancer
cells [16]. Tumours have the ability to influence their immune microenvironment either by
exerting immunosuppressive signalling, evading immune recognition, or fuelling tumour-promoting
inflammation as a means of driving cancer progression. Given the appropriate conditions,
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leukocyte activation initiated by mutated cells can advance neoplastic transformations into malignant
tumour cells [16].
This gives rise to the cancer immunoediting hypothesis. Here, it is postulated that the immune
system exerts both host-protective and tumour-stimulating actions [17]. Cancer immunoediting
is multifaceted and composed of three fundamental phases: elimination, equilibrium and escape
(Figure 2) [18]. Initially, tumour-specific antigens are recognised by the innate and adaptive arms of the
immune system and elicit a pro-inflammatory response [18]. The cancer immunosurveillance network
acts in cohesion to eliminate developing tumour cells, thereby preventing further tumourigenesis.
Tumours only progress to the equilibrium phase if immunosurveillance is unsuccessful or impaired.
Subsequently, cancerous cells persisting habitually in equilibrium with their microenvironment are
more equipped to mutate and produce new populations of tumour variants [18]. Modifications to
tumour cells can allow them to ultimately employ immunosuppressive mechanisms, thus evading
and essentially escaping the immune system in the final phase [18]. These immunologically sculpted
tumours grow with fewer selective pressures, actively induce an immunosuppressive microenvironment
and become evident clinically.
Figure 2. The three phases of cancer immunoediting. Normal cells transition to tumour cells
expressing specific tumour antigens, calreticulin, and NKG2D ligands if subject to oncogenic mutational
transformation. Elimination is the first phase of cancer immunoediting, where the cells of the innate
and adaptive immune system are recruited to the site of the tumour antigens and attempt to destroy
tumour cells via immune attack mechanisms (including secretion of cytokines IFNγ, IFNα, IFNβ, IL-12
and TNF). Any persisting tumour cells enter the second phase, equilibrium, where selection pressures
instigate new tumour cell genetic variants. These genetic modifications allow tumour evasion of the
immune system and promotion to the third phase, escape, where tumour cells progressively develop
and become clinically detectable as a palpable mass. Immune evasion is influenced by factors including
tumour cell PD-L1 upregulation, secretion of immuno-inhibitory cytokines (IL-6, IL-10, TGFβ and
MCSF) and recruitment of inhibitory immune cells (M2 macrophages, Regulatory T (TReg) cells and
Myeloid-derived suppressor cells (MDSCs)) that abrogate immune-mediated tumour cell killing via
inhibition of Natural Killer (NK) cells and CD8+ T cells. Tumour cells also experience a downregulation
of tumour antigen, calreticulin and NKG2D ligands, so are less susceptible to immune recognition [19].
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4. The Innate and Adaptive Immune System
The immune system is an organism’s natural defence mechanism that provides protection from a
plethora of pathogens, infections and diseases. Immune regulation is tightly controlled, which enables
appropriate recognition and response to foreign threats whilst avoiding unwanted inflammation
towards healthy tissue and the body’s natural microbial flora. The immune system is composed of
a dynamic network of cells, tissues and organs that broadly function in two lines of defence: innate
and adaptive immunity [20]. This division of the immune system is tailored directly towards the
pathogenic threat encountered, and also confers immunological memory where long-lasting protection
against the specific pathogen is established [20]. Both arms of the immune system are emerging to play
key roles on BCa development and progression.
5. Tumour Infiltrating Lymphocytes (TILs) and BCa
Tumour infiltrating lymphocytes (TILs) are immune cells that have migrated to the tumour tissue
and the local microenvironment. This population is indicative of an immune response generated by
the patient against the malignancy. In TNBC and HER2+ disease in particular, the presence of TILs has
been shown to correlate with a good prognosis and good response to chemotherapy. The relationship
has not been as definitely proven for ER+ disease, indicating that the luminal subtypes may be less
immunogenic than the others. This indicates that simple TIL counts are not as effective as a prognostic
marker in these tumours [21–23]. TILs have also been found to be a prognostic indicator for higher
rates of pathological complete responses (pCRs) to neoadjuvant chemotherapy [24–27].
Whilst TILs can be present within or around the tumour, TIL assessment is primarily concerned
with stromal TILs counted in H&E-stained tumour sections as stated by The International TILs
Working Group. While TILs in each compartment together constitute the population of lymphocytic
infiltration and may contribute to prognostic significance, the majority of TILs are found in the stroma.
Intratumoural TILs are difficult to quantify and low concordance between different scorers of the same
sample have been reported [28]. To quantify the number of stromal TILs, the guidelines state that one
should count the proportion of TILs in the stromal compartment in the visual field. Experts in the field
have developed guidelines and tutorials for assessing TILs in invasive cancers and metastases, as well
as DCIS lesions.
6. The Immune Regulation in Invasive BCa
TILs have been found to be elevated in primary invasive cancers compared to metastases. The
TIL populations across BCa in general are predominantly made up of T lymphocytes, and in particular
CD8+ cytotoxic T lymphocytes (CTLs). Due to this fact, CD8+ cells are a robust immune prognostic
marker for the outcome of BCa patients, particularly the TN and HER2+ subtypes, because they
represent an active, adaptive immune response to the neoantigens on the surface of the tumour cells
and correlate positively with improved survival [29].
CTLs have the capacity to differentiate further into tissue-resident memory T (TRM) cells that
exist within the breast tissue without recirculating systemically. TRM cells express high levels of
immune checkpoint molecules that contribute to tumour elimination and have been shown to be
actively involved in BCa immunosurveillance. TRM status has been shown to be an even greater
prognostic marker than CD8+ cells alone, and is significantly associated with improved TNBC patient
survival [30]. The T helper cells present during acute inflammation are predominantly T helper cell
type 1 (Th1) polarized and secrete cytokines such as IFNγ, TNFα and IL-2 which act to limit tumour
growth, promote antigen processing and presentation, and activate macrophages. The T helper cells
present during chronic inflammation and cancer are type 2 (Th2) polarized and express IL-4, IL-5, IL-6,
IL-10 and IL-13 which inhibit T cell-mediated cytotoxicity [31]. T regulatory lymphocytes (Tregs) are
characterised as T lymphocytes which are both CD4+ and FOXP3+ and have immunosuppressive
functions. Tregs normally help to protect against autoimmunity [32]. In the context of breast carcinomas,
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these immune cells are largely agreed to contribute to the pro-tumour immune response and assist the
tumour in subsequent immune escape, so are thus associated with a poor prognosis [21,33]. These
lymphocytes allow the progression of the tumour by expressing inhibitory factors that inhibit the
anti-tumour Th1 response [33].
In addition to T cells there are many other immune cell types that infiltrate breast cancers including
macrophages, NK cells, and dendritic cells (DCs) (Figure 3) [19,34,35]. In brief, CD4+ T helper, CD8+
CTLs, NK cells, M1 macrophages, and DCs are protective against tumour growth [36]. Conversely,
CD4+ FOXP3+ Th2 cells, M2 macrophages, and myeloid-derived suppressor cells (MDSCs) can drive
tumour growth [36].
Figure 3. The immune microenvironment of invasive ductal carcinoma. Subsets of the immune system
can elicit both tumour-promoting and tumour-suppressing effects. Immune inhibition of tumours
is largely driven by the activity of CD8+ T cells, CD4+ T cells, Tissue-resident T (TRM) cells, B cells,
Natural Killer (NK) cells, M1 macrophages and dendritic cells (DC). The tumour-fighting immune
landscape produces cytokines that inhibit tumour development (including IFNγ, TNFα, IL-1β, IL-2
and IL-12). CD8+ T cells and NK cells also secrete cytotoxic granules that trigger tumour cell apoptosis.
Similarly, B cells secrete tumour-specific antibodies that target tumour cells for elimination. In contrast,
the immune stimulation of tumours is promoted by Regulatory T (TReg) cells, M2 macrophages
and Myeloid-derived suppressor cells (MDSCs), which act to suppress their anti-tumour immune
counterparts and facilitate tumour growth. These cells release immuno-inhibitory pro-tumour cytokines
(TGFβ, VEGF, IL-6, IL-8 and IL-10) [37–41].
Tissue-resident macrophages are typically found along the ductal system in the stroma of the
normal breast, and are present prior to the development of any malignancy [42,43]. These are some of
the first immune cells to encounter tumour cells when they begin to form a hyperplastic or neoplastic
growth. The macrophages associated with tumours are referred to as tumour associated macrophages
(TAM) and their infiltration accompanies a worse prognosis in many cancers [44,45]. TAMs in invasive
BCa have been shown to express higher levels of the transcription factor hypoxia-inducible factor
2α (HIF-2α) in comparison to macrophages from the normal breast [46]. HIF-2α along with HIF-1α
from the tumour cells [47] activate the expression of vascular endothelial growth factor (VEGF) which
stimulates angiogenesis [48,49]. By vascularizing an early tumour, the TAMs ensure that the tumour
receives the nourishment it requires for malignant growth and metastasis. In support of this positive
feedback, microvessel density and VEGF expression have been found to be significantly correlated
with TAM density in IDC [50].
Cytokines from the tumour microenvironment are also key players in this process, as they can
induce phenotypic changes in macrophages. IL-10 and TGF-β switch the macrophages from an M1-like
(proinflammatory or classically activated) state to an M2-like (anti-inflammatory or alternatively
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activated) state. M1 macrophages elicit anti-tumour immune signaling and are associated with
tumour killing capacity. Conversely, M2 macrophages exert pro-tumour effects and are associated
with fibrosis and the production of matrix proteins [51] as well as angiogenesis, metastasis, and the
suppression of adaptive immunity [52,53]. Human BCa cell lines cultured in vitro are able to polarise
macrophages towards the M2 phenotype [54]. In BCa patient samples, M2 macrophages in the stroma
correlate with the presence of a lesion [54]. Retrospective studies of preserved human tumours have
demonstrated that M2 macrophages are significantly associated with poor prognosis in both ER- and
ER+ tumours [21].
MDSCs are a collection of progenitor and immature myeloid-lineage cell types which serve as
a brake on immune system activation [55]. High levels of MDSCs have been identified as a poor
prognostic marker for many cancers, and most likely participate in the pro-tumourigenic pathway
through the suppression and inhibition of the host anti-tumour immune response [55,56]. BCa patients
have higher circulating MDSC counts than their normal-matched counterparts [57]. Greater quantities
of MDSCs isolated from the blood of these patients correlated with poor prognosis, and when cultured
with T cells in vitro they were able to significantly inhibit proliferation of the lymphocytic population
in comparison to MDSCs derived from normal subjects [57]. Looking at early-stage breast cancer,
patients with greater neutrophil (a type of MDSC) counts had a higher neutrophil to lymphocyte ratio
and were more likely to relapse [58].
DCs express MHC Class II and can present their antigenic peptides to CD4+ T cells. They prime
tumour specific effector T cells to attack the tumour and are thought to play an important role in
shaping the host response to the cancerous cells. DC maturation and survival are impaired in invasive
tumours and the infiltration of plasmacytoid DCs (pDCs) in primary BCa is correlated with poor
clinical outcome. This indicates that pDCs contribute to BCa progression [59].
Natural killer (NK) cells are unique in that they have both innate and adaptive immune
properties [60]. NK cells participate in the anti-tumour immune response through the production of
pro-inflammatory cytokines, which recruit and induce proliferation of other immune cells [61]. NK
cells can also directly mediate anti-tumour immunity by killing the tumour cells themselves without
prior sensitization, so therefore play an active role in cancer immunosurveillance [62,63]. However, the
ability of NK cells to recognize and kill tumour cells is impaired in cancer patients, as tumour NK cells
exhibit an inhibitory phenotype characterised by the expression of inhibitory markers [64–66]. In BCa
patients, NK cell dysfunction correlates with tumour progression and invasiveness [65,67].
B lymphocytes are CD20+ adaptive immune cells which confer humoral immunity through the
production and secretion of antibodies, which are made of the protein immunoglobulin and recognise
specific tumour-antigens. Antibodies bind to these antigens and can inhibit the functionality of the
receptor or ligand they are bound to. Additionally, antibodies can signal to other cancer-killing cells
that they are bound to a tumour cell, thereby activating them to eliminate tumour cell populations [68].
B cells participate in immunity alongside the T cell response through their ability to present antigen
and co-stimulatory molecules to these lymphocytes [69]. Furthermore, B cells can be found in the breast
milk secreted by the lactating normal breast [42,43]. In IDC, B lymphocytes and immunoglobulin gene
expression signatures have been associated with a favourable prognosis in retrospective studies [70,71].
Though this supports an anti-tumour role for B cells and antibodies, other studies have associated
them with poor prognostic factors in BCa. Human BCa cells can induce a regulatory phenotype in B
cells, instigating production of transforming growth factor beta (TGF-β), a cytokine that stimulates
CD4+ T cells to become immunosuppressive T regulatory cells [72].
Although not strictly an immune cell, fibroblasts are present within the stromal microenvironment
of the breast and serve to produce the extraceullular matrix (ECM) proteins (in particular collagen).
They can also manufacture and respond to cytokines, allowing them to cooperate with the immune
cells within the stromal microenvironment. However, fibroblasts can control epithelial cell polarity,
proliferation, and to some extent, tumourigenic potential. Cancer associated fibroblasts (CAFs) have
been shown to drive increased tumour growth compared to normal fibroblasts [73]. They contribute
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to cancer cell survival and progression by secreting high levels of nutrient-rich ECM proteins, or
ECM-degrading proteases. These can promote persistent chronic inflammation within the tumour
microenvironment and inducing the epithelial mesenchymal transition (EMT) of tumour cells [74–77].
CAFs have the capacity to produce pro-inflammatory cytokines. These CAF-secreted cytokines
disrupt the normal cytokine balance to stimulate tumour growth by initiating angiogenesis and
inhibiting CTLs. CAFs have been shown to secrete high levels of the pro-inflammatory cytokines
IL-1β, IL-8, IL-10, tumour necrosis factor-alpha (TNFα), monocyte chemoattractant protein-1 (CCL2),
stromal derived factor-1 (CXCL12) and interferon-beta (IFNβ) [78,79]. The importance of the CAFs in
cancer growth has been highlighted by genetic analyses showing that their gene expression profiles
are very different to normal breast fibroblasts. Moreover, the expression profiles of CAFs taken from
tumours with poor (increased recurrence and shorter disease-free survival) versus good (reduced
recurrence and longer disease-free survival) outcome are also very different [80]. The good-outcome
fibroblasts were enriched for immune modulators such as those involved in the Th1 immune response.
This includes expression of T cell receptor complexes (CD8a, CD247, CD3D), MHC class I protein
binding and granzyme A/B activity. The poor-outcome stroma had increased levels of hypoxia and
angiogenesis and decreased chemokines that stimulate NK migration and T cell survival [80].
7. Immune Regulation of DCIS
The pre-invasive DCIS stage of BCa also exhibits significant immune infiltration. Gorringe and
colleagues showed that TILs are present in high grade DCIS lesions, with smaller numbers also
observed in low and intermediate grade lesions [81]. A global study of 53 mastectomy samples
demonstrated that T cell, B cell and macrophage levels were all elevated in DCIS compared with the
normal breast and remained elevated across subsequent cancer progression [82]. Similarly, neutrophils
have been found to be significantly higher in the breast of women with DCIS than in the normal
breast [83]. Clinical research assessing specific subsets of immune cells in DCIS has indicated that
CD68+ macrophages (in particular the M2 macrophages), CD4+ T cells and CD20+ B cells were
elevated in the high-grade DCIS cases compared to low [84].
CAFs are also thought to play a role in the transition of DCIS to IDC via their secretion of
factors which modify the surrounding stromal matrix. When fibroblasts sourced from the normal
breast or IDC were injected alongside a DCIS cell line in xenografts, the IDC-derived fibroblasts
(or CAFs) elicted a significant increase in tumour weight whilst normal fibroblasts had no effect on
xenograft progression [85]. One mechanism through which CAFs may be accomplishing this in early
BCa development is through the production of IL-10, which not only stimulates M2 polarisation of
TAMs but additionally serves to modulate T cell and NK cell phenotypes [54,86]. Osula et al. have
demonstrated that CAFs significantly upregulate expression of IL-6 in comparison to their normal
counterparts. By culturing these fibroblasts with DCIS cell lines, Osula and colleagues revealed
that DCIS cells grow faster, and that this growth is inhibited with treatment of an IL-6 neutralising
antibody [87]. Paracrine IL-6 signalling between malignant cells and pro-tumour fibroblasts may thus
be influential in the progression of DCIS to IDC.
Recurrent DCIS describes the reappearance of additional DCIS lesions after the primary diagnosis
and treatment and/or progression to invasive disease [9]. The highest risk of DCIS recurrence correlates
with patients displaying both low T cell numbers and elevated macrophages [84]. Of these recurrent
cases, immunosuppressive CD206+M2 macrophages were also prevalent, thus suggesting that their
anti-inflammatory effects may abrogate tumour-fighting T cell functions in these early lesions [84].
Illustrating the pro-tumourigenic role of macrophages, mouse models transplanted with pre-invasive
breast cancer cell lines have shown that metastatic progression is inhibited when the macrophages are
depleted prior to transplantation [88]. When directly compared with invasive BCa, the inflammatory
response to the malignant cells in DCIS is highly active. There are significantly more CTLs in DCIS
expressing granzyme B and IFNγ, marking these cells as activated, effector cytotoxic T cells [83]. In the
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same study, the diversity of T cell receptor clonotypes were found to be significantly higher in DCIS
than in IDC.
During a chronic infection, CD8+ T cells undergo a hierarchical loss of function and increase the
expression of coinhibitory receptors in a process called exhaustion. Importantly, targeting coinhibitory
receptors such as PD-1 and CTLA-4 using monoclonal antibodies, alone or in combination, has proven
to be effective in restoring the function of exhausted T cells. When DCIS and IDC were compared, the
T cell immunoglobulin and ITIM domain (TIGIT) co-inhibitory receptor was found to have higher
expression in T cells from DCIS patients compared to HER2+ and TNBC IDC. However, PD-L1 was
almost undetectable in DCIS and increased in IDC. CTLA-4 was also higher in T cells from IDCs
compared with DCIS [83]. Together this indicates that the immune microenvironment becomes
suppressive during invasive progression. but that each of the checkpoint molecules may play a
distinct role.
8. Immune Regulation of Hyperplasia
The immune regulation of early hyperplastic breast tumourigenesis is understood to a considerably
lesser degree than that of DCIS. Limited published data exists surrounding the immune infiltrate in
ADH of the breast. Gorringe and colleagues have shown that in DCIS a higher Fraction of Genome
Altered compared to normal (measured by copy number variation analysis) correlates with a higher
infiltration of TILs in DCIS [81]. They have not yet assessed TIL numbers in ADH compared to the
normal breast, but have shown that ADH lesions exhibit aneuploidy, loss of heterozygosity, gross
chromosomal rearrangement (such as amplifications and large-scale deletion) and methylation changes.
This indicates that the genomic changes present may activate the immune system early. In support of
this, human studies in endometrial cancer have demonstrated that significant immune involvement
enhanced the proliferative rate of hyperplastic tissue [89]. In particular, macrophage numbers and
the inflammatory cytokines they produce were significantly associated with early malignancies
and tumourigenesis.
Whilst the immune composition of ADH has not yet been explored, increased CD4+ T cells, CTLs
and B cells have been observed in lobules with lobulitis [90]. Similarly, normal breast tissue from
women with high breast density (which confers a 4-6-fold increased risk of BCa) exhibits increased
macrophages, DCs, B cells and CD4+ T cells. High-density tissue also disaplayed increased IL-6
and IL-4 secretion, thereby suggesting pro-tumour Th2 polarization [91]. The lack of information in
hyperplastic lesions may be due their small size (≤2 mm) [92–94] and close relationship to low grade
DCIS. This means the ADH samples are only collected for diagnostic purposes and not research. It is
also notable that there is a lack of concordance amongst pathologists in differentiating low-grade DCIS
and ADH [94]. Further analysis of the immune landscape of pre-invasive lesions including ADH will
hopefully reveal whether the microenvironment assists at this earliest stage of tumour escape from
immune regulation.
Fibroblasts may also play a role in the earliest stages of tumour growth. This notion has been
suggested by work demonstrating that stromal-specific inactivation of TGFβ-RII leads to pre-invasive
prostate cancer lesions in mice [95], and that stromal phosphatase and tensin homolog (PTEN) loss
can drive BCa growth [96]. In addition to stimulating the growth of early hyperplastic cells, CAFs
may participate in the loss of epithelial characteristics of ductal lesions. Fibroblasts isolated from
ADH-affected breast tissue exhibited an activated phenotype mirroring that of CAFs isolated from DCIS.
When cultured with the BCa cell line MCF-7, these ADH-associated fibroblasts induced decreased
expression of the epithelial protein e-cadherin and increased expression of the mesenchymal protein
vimentin [97]. This indicates that even when precursor cells are merely hyperplastic, activation of
fibroblasts under appropriate conditions may prime the lesion towards malignant transformation.
186
Cancers 2019, 11, 1375
9. Immune-Based Therapies for BCa Growth and Progression
As mentioned above, it is well-established that in both IDC and DCIS, high numbers of stromal
lymphocytes serve as a good prognostic factor in TNBC and HER2+ disease. This opens the door to
potentially utilize immunotherapies to mobilize the immune system against BCa. The PD-1/PD-L1
inhibitory pathway is one of the most intensively investigated avenues in the development of
immune-based therapeutics. PD-L1 is known to be expressed by primary and metastatic IDCs and has
been identified as a poor prognostic indicator in these patients [98–100], likely serving to downregulate
the T cell response to tumour cells. As TNBC has limited successful therapies, anti-PD-L1 therapy
represents a promising new treatment option. In vivo models of TNBC demonstrate that treatment with
antibodies targeting PD-L1 expressed on tumour cells reduces tumour volume whilst increasing tumour
immunogenicity [101]. PD-L1 inhibition has additionally been investigated for use in DCIS. Expression
of the immunosuppressive ligand is far less common in this earlier stage, though when expression
is observed, it is most commonly in HER2+ lesions [81,102]. Several trials are currently underway
investigating the use of anti-PD-L1 therapies both alone and in combination with HER2-specific
treatments, as reviewed by Ubago et al. [103].
Combination immunotherapies have also been proven as potentially efficacious novel TNBC
treatments. TNBC often upregulates activity of MEK, which contributes to an overactivation of the
Ras/MAPK pathway and thus serves as a poor prognostic indicator for recurrence and survival in these
patients. However, T cells also use MEK signaling for proliferation, activation, and differentiation,
so simply inhibiting MEK activity reduces the potential utility of recruiting the immune system.
When MEK inhibition was combined with agonist antibodies to activating receptors on T cells, or
with anti-PD-1/PD-L1 therapies, survival and tumour size significantly improved in xenograft TNBC
models [101,104].
Immunotherapies tend to particularly target T cells and the adaptive immune response. Innate
immunity represents an alternative route through which to pursue immune-based therapies. One
such novel therapy is anti-CSF1R, which inhibits the receptor found on TAMs responsible for their
recruitment and M2 activation as pro-tumourigenic immune cells. Mixed data exists concerning the role
of CSF1R inhibition and tumour growth in mice, with some studies demonstrating significant reductions
in tumourigenesis and others showing limited effectiveness or stimulated cancer metastasis [105,106].
This avenue of innate immune modulation in cancer therapies therefore remains somewhat elusive,
and requires further research to shed light on any possible therapeutic benefits.
10. Conclusions
The role of the immune microenvironment in BCa is becoming clearer. Infiltrating immune cells
in invasive lesions are predominantly T lymphocytes, and in particular CTLs. The CD8+ CTLs are
now viewed as a robust immune prognostic marker for the outcome of TN and HER2+ BCa patients.
There are additional innate and adaptive cells that infiltrate BCa or remain in close proximity in the
stromal microenvironment. CD4+ T helper, CD8+ CTLs, NK cells, M1 macrophages, and DCs are
likely protecting against tumour growth whilst the CD4+ FOXP3+ Th2 cells, M2 macrophages, and
myeloid-derived suppressor cells (MDSCs) simulate tumour growth. The cytokines present at the
tumour site are also key players in this process, often controlling the infiltration as well as activation
and polarization state of the immune cells. CAFs have altered gene expression profiles and function
compared to normal breast fibroblasts and can drive increased tumour growth by aiding cancer cell
survival and progression and by secreting high levels of nutrient-rich ECM proteins, or ECM-degrading
proteases. Less is known about the pre-invasive stages of BCa development including DCIS and ADH.
However, TILs are present in high-grade DCIS lesions, less so in low- and intermediate-grade lesions.
Those pre-invasive lesions with the highest risk of recurrence correlates have been show to exhibit
low T cell numbers and elevated macrophages. The TIL numbers at this time may be correlated with
the level of genetic changes that are measured within the lesions. As ADH lesions already exhibit
significant genetic changes (aneuploidy, loss of heterozygosity, gross chromosomal rearrangement
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and methylation changes) it is expected that the immune system will already be activated and in
hyperplastic endometrial cancer this has been shown. As we increase our understanding of the earliest
stages of BCa development and the interaction with the immune system, we will begin to define
whether immune therapies can be delivered earlier for better disease control.
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Abstract: Endometrial carcinosarcoma (ECS) represents one of the most extreme examples of tumor
heterogeneity among human cancers. ECS is a clinically aggressive, high-grade, metaplastic carcinoma.
At the morphological level, intratumor heterogeneity in ECS is due to an admixture of epithelial
(carcinoma) and mesenchymal (sarcoma) components that can include heterologous tissues, such
as skeletal muscle, cartilage, or bone. Most ECSs belong to the copy-number high serous-like
molecular subtype of endometrial carcinoma, characterized by the TP53 mutation and the frequently
accompanied by a large number of gene copy-number alterations, including the amplification of
important oncogenes, such as CCNE1 and c-MYC. However, a proportion of cases (20%) probably
represent the progression of tumors initially belonging to the copy-number low endometrioid-like
molecular subtype (characterized by mutations in genes such as PTEN, PI3KCA, or ARID1A), after the
acquisition of the TP53 mutations. Only a few ECS belong to the microsatellite-unstable hypermutated
molecular type and the POLE-mutated, ultramutated molecular type. A common characteristic
of all ECSs is the modulation of genes involved in the epithelial to mesenchymal process. Thus,
the acquisition of a mesenchymal phenotype is associated with a switch from E- to N-cadherin,
the up-regulation of transcriptional repressors of E-cadherin, such as Snail Family Transcriptional
Repressor 1 and 2 (SNAI1 and SNAI2), Zinc Finger E-Box Binding Homeobox 1 and 2 (ZEB1 and
ZEB2), and the down-regulation, among others, of members of the miR-200 family involved in the
maintenance of an epithelial phenotype. Subsequent differentiation to different types of mesenchymal
tissues increases tumor heterogeneity and probably modulates clinical behavior and therapy response.
Keywords: uterine carcinosarcoma; endometrial carcinoma; metaplastic carcinoma; epithelial-to-
mesenchymal transition; clonality; mutation; TP53; PI3K/AKT pathway; gene expression;
miRNA expression
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1. Clinicopathological Characteristics
Endometrial carcinosarcoma (ECS), also known as malignant mixed Müllerian tumor (MMMT), is
a high-grade tumor characterized by a biphasic growth of malignant epithelial (carcinomatous) and
mesenchymal (sarcomatous) components (Figure 1) [1]. ECS is a rare aggressive neoplasm accounting
for approximately 2% to 5% of gynecological carcinomas, but it causes around 16% of all deaths due to
malignancies of the uterine corpus [2,3]. Although ECS shares similar risk factors with endometrial
carcinoma, such as obesity, nulliparity, smoking, and exogenous estrogen use, they present at more
advanced stages and have significantly worse survival than high-grade endometrial carcinomas [3–8].
Figure 1. Morphological and immunohistochemical features of endometrial carcinosarcoma.
(A) Hematoxylin-eosin staining of an endometrial carcinosarcoma showing the epithelial component
surrounded by the heterologous mesenchymal component (chondrosarcoma). (B) Endometrial
carcinosarcoma with homologous sarcoma (H&E). (C) Cytokeratin expression of the case depicted in b.
(D) Vimentin expression in the case depicted in b. (E) p53 overexpression in both the carcinomatous and
sarcomatous components. (F) p53 null pattern in both the carcinomatous and sarcomatous components.
Only occasional normal stromal cells expressed p53. Original magnification 10× for (A,B), and 20×
for (C–F).
Matsuo et al. [9] analyzed the incidence of ECS in the USA during 1973–2013 in 235,849 primary
endometrial carcinomas (ECs) and observed that the proportion of ECS is now significantly higher
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than before and accounts for more than 5% of ECs. There was a significant rise in the proportion of
ECS among primary ECs from 1.7% to 5.6% during this period. Moreover, among 76,118 type II ECs,
the proportion of ECS also increased significantly from 6% to 17.5%; ECS was detected in 11,000 (4.7%)
women. The percentage of black women with ECS was elevated from 11.9% to 20%, whereas the
proportion of white women decreased from 86% to 60.5%. The possible factors associated with the
increase of ECS include the increment in the number of older women and the obese population in the
US, and the global increase in the incidence of breast cancer with a concordant increment in tamoxifen
use [9].
Several studies have demonstrated that tamoxifen use may be associated with an increased
incidence of ECS. In women with breast cancer, the incidence of ECS is 6.35-fold higher in those
treated with tamoxifen [10]. Matsuo et al. [11] reported that ~6% of women with ECS have a
history of tamoxifen use and that tamoxifen-related ECS was significantly associated with a higher
proportion of stage IA disease (48.4% versus 29.9%) and a lower risk of stage IVB disease (7.8% versus
16%) compared to tamoxifen-unrelated ECS. Deep myometrial tumor invasion was less common
in uterine carcinosarcoma related to tamoxifen use (28.3% versus 48.8%). However, in spite of
these favorable tumor characteristics, tamoxifen-related ECS had comparable stage-specific survival
outcomes compared to tamoxifen-unrelated ECS.
From a morphological point of view, the epithelial component of ECS could be endometrioid (most
common in most series) or non-endometrioid (serous, clear cell, undifferentiated, or mixed) [3,4,12–15].
Matsuo et al. [16] reported that among 906 ECS evaluated for histological patterns in their series,
high-grade carcinoma/homologous sarcoma (40.8%) was the most common type followed by high-grade
carcinoma/heterologous sarcoma (30.9%), low-grade carcinoma/homologous sarcoma (18%), and
low-grade-carcinoma/heterologous sarcoma (10.3%). In 75% to 95% of ECS, the epithelial component
was of high grade [16,17]. The mesenchymal component could be minimal or extensive. Sarcoma
dominance (SD) is defined by the presence of more than 50% of the tumor composed by the
sarcomatous component. The mesenchymal component could be subdivided into homologous
(fibrosarcoma, leiomyosarcoma, and endometrial stromal sarcoma) and heterologous, the latter
including skeletal muscle, cartilage, fat, or osteoid, which is present in up to 60% of tumors [3,4,12–19].
Immunohistochemistry may be useful in confirming the presence of a heterologous mesenchymal
component, which, as discussed later, is an adverse prognostic indicator in some series. For example,
nuclear staining with myogenin and Myoblast determination protein 1 (myoD1) helps to confirm the
presence of rhabdomyoblastic differentiation (Figure 2) [20].
Regarding other pathological features, 55% to 60% of ECS show less than 50% of myometrial
invasion at diagnosis. Lymphovascular invasion (LVI) prevalence in ECS seems to be higher than
in other types of endometrial cancer (60.4–62% vs. 26–52%) [21]. Matsuo et al. [21] reported that
among LVI-positive cases, LVIs with a carcinomatous component alone was found in 76.8% and LVI
containing a sarcomatous component with or without a carcinomatous component in the remaining
23.2%. Tumors in the LVI-sarcoma group were more likely to have SD (82.1% vs. 26.4%), heterologous
sarcomatous component (51.3% vs. 37.9%), low-grade carcinoma (42.5% vs. 22.4%), and large tumor
size (81% vs. 70.2%) in the primary tumor site compared with tumors in the LVI-carcinoma group.
Also, the pattern of metastasis differs between the epithelial and mesenchymal parts of the
ECS. Thus, for example, Matsuo et al. [16] analyzed 1096 metastatic sites and showed that carcinoma
components tended to spread lymphatically, while sarcoma components tended to spread locoregionally
(cervix, vagina, etc.).
ECS follows an aggressive clinical course. Patients with International Federation of Gynecology
and Obstetrics (FIGO) stage 1–2 disease have a five-year disease-specific survival of 59%, while those
with stage 3 and 4 disease have a five-year disease-specific survival of 22% and 9%, respectively [2].
The most important prognostic factors in these tumors include FIGO stage and depth of myometrial
invasion [5,7,8,13,15,22]. Other known clinicopathologic features associated with worse outcome are
the grade and histology of the epithelial component and lymphovascular invasion [3,5,8,13]. Although
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the grade and the amount of the sarcomatous component and the presence of heterologous elements
are not related to the overall outcome in some series [6,13,18,22], recent studies have shown the
importance of the sarcomatous component in the prognosis and response to radiotherapy [17,23].
Thus, Matsuo et al. [24] reported that ECS with better prognosis were those composed of a low-grade
carcinoma and homologous sarcoma without SD. In contrast, the worse prognosis corresponded to
ECS composed of a high-grade carcinoma and heterologous sarcoma and SD. This latter type of tumor
tended to occur in older, obese, and Caucasian patients, and they were more likely to have metastatic
implants, large tumor sizes, LVI with sarcoma cells, and higher lymph node ratios. Also, SD seems to be
a prognostic factor in some series [17,23], and it is associated with loco-regional tumor metastasis and
recurrence with sarcoma. In addition, ECS with SD seems more sensitive to radiotherapy compared to
ECS without sarcoma dominance [23]. Finally, different studies have reported a poor prognosis in ECS
with rhabdomyoblastic differentiation [4,17,19].
Figure 2. Endometrial carcinosarcoma with rhabdomyoblastic differentiation. Some cells showed
an intermediate epithelial/mesenchymal differentiation as suggested by the expression pattern of
cytokeratins, myogenin, and desmin. (A) Hematoxylin-eosin staining. (B) Cytokeratin (CK AE1/AE3)
expression. (C) Myoblast determination protein 1 (MyoD1) expression. (D) Desmin expression.
(E) Striated rhadbomyoblasts (H&E). (F) Desmin expression by striated rhadbomyoblasts. Original
magnification 20× for A-D, and 40× for E and F.
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Molecular studies have demonstrated similar genetic alterations in both the carcinomatous and
sarcomatous components of ECS (Table 1). Thus, it is now accepted that most carcinosarcomas are in
fact metaplastic carcinomas, in which the sarcomatous component is derived from the carcinomatous
component as a result of transdifferentiation (epithelial-to-mesenchymal transition—EMT) during
the evolution of the tumor as shown in several studies [25,26]. However, a small percentage of ECS
probably represent real collision tumors, since they are molecularly biclonal and most likely develop
from two independent cell populations [6,27].
Table 1. Comparison of gene mutation frequency among different histological types of endometrial
cancer according to The Cancer Genome Atlas Program (TCGA).
GENE Endometrioid Carcinoma Serous Carcinoma Carcinosarcoma
PTEN 82% 10% 19%
PIK3CA 54% 37% 35%
PIK3R1 36% 11% 11%
CTNNB1 34% 1% 2%
ARID1A 54% 8% 12%
KRAS 24% 3% 12%
CTCF 31% 2% 7%
TP53 21% 88% 91%
FBXW7 17% 24% 39%
PPP2R1A 11% 38% 28%
CHD4 9% 18% 17%
CCNE1 (ampl.) 16% 26% 41%
MYC (ampl.) 14% 24% 21%
MECOM (ampl.) 18% 33% 18%
PIK3CA (ampl.) 10% 22% 11%
ERBB2 (ampl.) 8% 19% 9%
2. Molecular Subtypes of ECS
Four molecular groups have been defined for ECs: the hypermutated (mismatch repair deficiency),
the ultramutated (POLE mutated), the copy-number low, and the copy-number high groups. These
groups not only have different molecular alterations but also different prognoses; patients from the
ultramutated group show the best prognosis, whereas patients in the copy-number high group have
the highest risk of recurrence [28].
Considering the mutational profile (Table 1; see below Section 2. Molecular Subtypes of ECS),
most ECSs are similar to serous-like, copy-number high ECs. Thus, in the study by McConechy et al.,
most tumors had a molecular profile similar to endometrial serous carcinoma (characterized by the
presence of TP53, FBXW7, and PPP2R1A mutations and the absence of ARID1A, CTNNB1, KRAS,
or PTEN mutations), while part of the tumors displayed an endometrioid carcinoma-like mutation
profile characterized by the presence of ARID1A, CTNNB1, KRAS, and PTEN mutations. Based on both
combined genetic and immunohistochemical profiles in their cohort, 18 tumors presented serous-like
and 11 tumors presented endometrioid-like molecular profiles. There was a good correlation between
the histological subtyping (taking into account the morphology of the epithelial component) and
the molecular subtyping in 27 of 29 uterine carcinosarcomas (93%) [29]. More recently Jones et al.,
applied this classification to their set of tumors, and were able to classify 55 out of 57 tumors, of which
22% were endometrioid and 78% serous-like ECS. One sample did not fit in the model due to an
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ultramutated phenotype caused by the POLE mutation, while another had no mutation in the genes
used for classification. Interestingly, all 10 stage IV tumors were serous-like [30].
Most of the endometrioid-like ECSs also showed TP53 mutations, implying that TP53 could be
involved in the progression of part of the copy-number low endometrioid-like carcinomas to ECSs, as
we have previously reported in undifferentiated endometrial carcinoma [31]. Very few ECS belong
to the microsatellite-unstable hypermutated molecular type and the POLE-mutated ultramutated
molecular type used for the classification of endometrial carcinoma. The molecular heterogeneity
present in ECS opens opportunities for targeted therapies.
3. Serous-Like Molecular Alterations in ECS
Previous studies combining aberrant expression of p53 and mutational analysis estimated a TP53
mutation prevalence of 50–60% [3,12,22,27,32–35]. However, subsequent studies using Next Generation
Sequencing (NGS) techniques have shown that the true frequency of TP53 mutation in ECS is very
high, between 64% and 91% [29,30,36–40]. In effect, TP53 mutations are the most frequent molecular
alterations in ECS (Table 1). The lack of nuclear p53 expression is most commonly detected with indel
or nonsense mutations, while missense mutations usually lead to diffuse nuclear p53 immunostaining.
Most of the mutations are located in the DNA binding domain, and very few are present in the
translocation and tetramerization motifs. In the DNA binding domain, 32% of mutations are located on
known hotspot residues, and the most frequent are the R248Q and R273C/H (12% and 7%, respectively)
followed by H179R/D, H193R/Y, and S241Y (5% each), (http://cancergenome.nih.gov/) [41].
The carcinomatous and sarcomatous components show a concordance of 85% for the p53 protein
overexpression and 96% for the TP53 gene mutation, which points to a monoclonal origin of both
components (Figure 1). p16 overexpression (in-block diffuse expression) occurs in about 60% of ECS
simultaneously with TP53 mutations. The concordance of p16 expression between the carcinomatous
and sarcomatous components was about 85% in different series [12,35,42–44]. In addition to TP53, ECSs
show mutations in other genes that are also more frequently affected in endometrial serous carcinoma
(ESC) than in endometrial endometrioid carcinoma (EEC). Accordingly, mutations of FBXW7 and
PPP2R1A have been reported in 19% to 39% and 1% to 38%, respectively, in different series [36–40].
Regarding the BRCA1 and BRCA2 genes, the frequency of ECS in patients carrying germinal
BRCA1/2 mutations has been analyzed in different studies. The estimated relative risk for mutation
carriers is approximately 2% per year, most importantly among serous carcinoma [45–47]. A recent
series has reported that BRCA1/2 were found mutated in 18% and 27%, respectively of ECS [30],
although in the TCGA (The Cancer Genome Atlas Program) series, only BRCA2 mutations were
detected and at a lower frequency (5%) [28]. Carcinosarcoma of the breast and ovary have been
reported in some patients with BRCA1/2 germline mutations [48–50].
Zhao et al. [51] found an excess of mutations in genes encoding histone H2A and H2B, as well
as a significant amplification of the segment of chromosome 6p harboring the histone gene cluster
containing these genes. Thus, mutations in histone H2A/H2B genes were significantly enriched in
carcinosarcomas (CSs) compared with carcinomas (mutations in 21.2% of CSs and 5.2% of uterine and
ovarian epithelial tumor). These findings implicate mutations in histone H2A/H2B genes in ECS.
Le Gallo et al. [40] have reported forkhead box A2 (FOXA2) mutations in 15.1% of ECS. FOXA2 had
not previously been implicated in ECSs and was predominated by frameshift and nonsense mutations.
Sequencing of FOXA2 in 160 primary endometrial carcinomas revealed somatic mutations in 5.7%
of serous, 22.7% of clear cell, 9% of endometrioid, and 11.1% of mixed endometrial carcinomas, the
majority of which were frameshift mutations. Collectively, the findings of the study of Le Gallo et al. [40]
provide evidence that FOXA2 is a pathogenic driver gene in the etiology of primary uterine cancers,
including ECSs.
Similarly to ESC, ECS is characterized by aneuploidy and a high frequency of copy number
variations (CNVs). Analysis of ploidy and whole-genome doubling has established a median ploidy of
3.3 and that 90% of ECS had undergone at least one whole-genome-doubling event. This percentage is
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significantly higher than in serous ovarian tumors, the tumor type with the next highest frequency of
genomic doubling in the TCGA [38].
Recurring focal amplifications reported in the TCGA [38], some of which have also been observed
in other series [51], include those containing known oncogenes such as TERC (3q26.2), FGFR3 (4p16.3),
MYC (8q24.21), KAT6A (10q22.2), MDM2 (12q15), ERBB2 (17q12), CCND1 (11q13), CCNE1 (19q12),
BCL2L1 (20q11.21), and RIT1 (1q22) (Figure 3).
Figure 3. Amplification of oncogenes in endometrial carcinosarcomas analyzed by fluorescence in situ
hybridization (FISH) (A) and (B), MYC proto-oncogene, bHLH transcription factor (MYC) amplification
(C), and (D) Cyclin D1 (CCND1) amplification. Original magnification ×100 for A and C, and ×20
for B-D.
Cyclin D1 (CCNE1) is the most frequently amplified gene in ECS, 41% according to data derived
from TCGA (Table 1). In other tumors, for example, ovarian high-grade serous carcinoma, amplification
of CCNE1 is associated with a worse prognosss and resistance to chemotherapy. According to
Schipf et al., c-MYC amplification had a higher frequency in the carcinomatous compared to the
sarcomatous tumor component. In their data on 30 carcinosarcomas of the ovary and uterus, c-MYC
gene amplification was reported in 78% by fluorescence in situ hybridization (FISH) [52]. However,
the TCGA data showed amplification of c-MYC in only 21% of ECSs [38].
The frequency of ERBB2 amplification in ECS ranged from 3–20% [30,38,53–55]. Thus, ECS patients
with ERBB2 amplification could benefit from anti-HER2 (human epidermal growth factor receptor 2)
therapies, such as Trastuzumab. For patients unresponsive to chemotherapy and Trastuzumab, T-DM1
(Trastuzumab emtansine) may offer an alternative treatment option, as recent studies show how ECS
cell lines and derived xenografts with ERBB2 amplification respond well to T-DM1 [56]. PIK3CA is
amplified in 11% of ECS, further highlighting the importance of the phosphatidylinositol 3-kinase
(PIK3) pathway (see Section 4. Endometrioid-Like Molecular Alterations).
Schipf et al. detected ZNF217 amplification in 87% of gynecological CS [52]. Similarly to c-MYC, in
the TCGA data set the frequency is much lower (9%) [28,38]. Two other frequently amplified oncogenes
in ECS, EGFR, and URI (unconventional prefolding RPB5 interactor 1), have not been found in the
TCGA data set. Biscuola et al. reported EGFR amplification by FISH in 19% of tumors [57], while in
studies with smaller sample size, EGFR (epidermal growth factor receptor) protein overexpression has
been reported in 45% to 82% of ECS, where a higher level of expression was seen in the sarcomatous
component [53,58,59]. URI1 amplification has been reported in 40% of ECS [60]. URI1 amplification
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was also associated with poor survival and reduced response to adjuvant treatment. Likewise, in a
cultured cell model, overexpression of URI1 induced ATM (ATM Serine/Threonine Kinase) expression
and resistance to cisplatin [60]. Recurring GPC5 (Glypican 5) gain/amplification has been detected in a
subset of ECS, mostly in the sarcoma component, and the authors linked the involvement of GPC5
with sarcomatous transformation [61].
4. Endometrioid-Like Molecular Alterations
Mutations in genes encoding for the kinase or regulatory proteins of the PI3K/AKT
(phosphatidylinositol 3-kinase/(Protein Kinase B) pathway have been detected in up to 67% of
ECS [29]. Moreover, multiple PI3K/AKT pathway proteins have been found mutated in one tumor.
PIK3CA mutations have been found in 11% to 40% [29,30,36,38,57,62,63] of the tumors. Unlike for
TP53, with mutations concentrated on HotSpot regions, the mutations in PIK3CA are found scattered
in the different functional domains. In addition to the traditional PIK3CA hotspots in exons 9 and 20, a
smaller portion of ECS has mutations in exon 1, in the adaptor binding domain, helical domain, and
C2 domain which increase kinase enzymatic activity [29,57].
The importance of mutations in this pathway comes from the fact that PI3KCA mutations have been
detected in both the carcinoma and sarcoma components of the primary tumor and also in the metastatic
tumor. This implies that they are important early events in the tumorigenesis of carcinosarcoma and
thus could be targeted with PIK3CA/mTOR (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic
Subunit Alpha /Mechanistic Target of Rapamycin Kinase) inhibitors [29,38]. PIK3CA inhibition has
been applied successfully in advanced endometrial cancers [64].
Phosphatase And Tensin Homolog (PTEN) mutations are not as frequent as PIK3CA, but they are
present in approximately 20% of ECS: 17% and 19% in the series reported by McConechy et al. [29] and
the TCGA [38], respectively. However, Jones et al. reported that 47% of ECS carried PTEN mutation,
but their series included only 17 cases [36]. PTEN and PIK3CA mutations frequently coexist in the
same ECS [29].
Other genes with less frequency of mutations in the PI3K/AKT pathway in ECSs include
Phosphatidylinositol 3-Kinase Regulatory Subunit 1 (PIK3R1) (10–17%), PIK3R2, AKT1, AKT2, and
AKT3 (less than 5% for each gene) [29,36,38,57].
AT-Rich Interaction Domain 1A (ARID1A) and Catenin Beta 1 (CTNNB1) are commonly mutated
in EEC, and ARID1A mutations occur also in 10% to 15% of ECS, leading usually to loss of of protein
expression, while mutations in CTNNB1 are infrequent in ECS [36,38,63]. KRAS mutations were found
in 12% and Cadherin 4 (CDH4) mutations in 18% [38].
Mismatch repair deficiency (MMR-def) and POLE mutations are more common in EEC than in
ESC. MMR-def is due to germline or somatic even affecting mismatch repair genes, most frequently
MutL Homolog 1 (MLH1), MutS Homolog 2 (MSH2), MutS Homolog 6 (MSH6), and Mismatch Repair
Endonuclease PMS2 (PMS2). In sporadic EC, MMR-def is detected in 15–30% of cases [65], although a
higher frequency has been detected among high-grade endometrioid carcinomas (45–63%) [31], most
frequently due to MLH1 promotor methylation. In addition, between 2–6% of endometrial carcinoma
occurs in the context of Lynch syndrome due to germline mutations [66]. The frequency of MMR-def
varies between 3% and 23% in ECS. The higher frequencies come from studies with a small sample
size [36,67], while lower percentages have been observed in a bigger series [37,68]. MLH1 promoter
methylation is probably the major cause for MMR-def in most tumors [68], and accordingly, MLH1
was epigenetically silenced in the two samples with MMR-def in the TCGA series [38].
Mutations in DNA Polymerase Epsilon, Catalytic Subunit (POLE) are present in some ECS, both
of the most common HotSpot-mutations (P286R and V114L) have been identified in individual cases of
ECS [38,69,70]. The most common mutations detected by NGS in recent studies are shown in Table 2.
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Table 2. Comparison of gene mutation frequency among different series of Endometrial carcinosarcoma
(ECS) analyzed by next-generation sequencing.
Gene Cherniack (n = 57) McConechy (n = 30) Jones (n = 361) Zhao (n = 64) * Le Gallo (n = 53)
TP53 91% 80% 67% ~80% 76%
FBXW7 39% 20% ~22% 19%
PIK3CA 35% 40% 22% ~20% 34%
PPP2R1A 28% 13% ~25% 19%
PTEN 19% 27% ~7%
CHD4 17% ~20% 17%
ARID1A 12% 10% ~4%
KRAS 12% 10% ~4%








* approximated % in a combined series of endometrial and ovarian carcinosarcomas.
5. Gene Expression Profiles in ECS
Several studies have analyzed mRNA and microRNA (miRNA) expression profiles in ECS in
comparison to other histological types of EC [71]. Regarding mRNA expression profiles, ECS differs from
other EC histotypes in the expression, among others, of genes modulating epithelial-to-mesenchymal
transition (EMT) and immune response (see Section 9. Immune Response in CS), and in the expression
of cancer-testis antigens (CTA).
There are over 200 CTAs, which are classified into different families according to their sequence
homology. In general, CTA genes are expressed only in normal testis and cancerous tissue. In many
instances, CTA families are formed by clusters of nearly identical genes that are frequently located on
the X-chromosome. A shared regulatory mechanism for related CTA clusters has been suggested as
whole families of CTAs are often co-expressed together in tumors [72,73].
Overexpression of many members of the CTA family, such as melanoma antigen family A (MAGEA)
members (MAGEA6, MAGEA9, MAGEA12), XAGE2, CTCFL, and CTAG1A (cancer/testis antigen 1A)
has been reported in ECS [73]. CTCF, also known as the brother of the regulator of imprinted sites
(BORIS), is an oncogene that deregulates the cancer epigenome, which is a common event in ECS [73,74].
Expression of CCCTC-Binding Factor Like (CTCFL) probably mediates the demethylation of another
CTA gene, thus resulting in activation via repression [74]. Other genes of the CTA family associated
with ECS, include, New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and Preferentially
Expressed Antigen In Melanoma (PRAME) [75,76]. Considering the tissue-restricted expression of
CTA and its immunogenicity, immunotherapy based on CTA vaccines might be beneficial to ECS
patients [73].
The miRNA signature of carcinosarcomas differs from endometrioid and serous carcinomas [77].
The function of miRNAs is to regulate gene expression by silencing. For this, they pair to the
three prime untranslated region (3’UTR) of the target mRNA sequence and thereby direct their
posttranscriptional repression. miRNAs are small noncoding RNAs, which in turn can be regulated by
promotor methylation and transcription factors, or by miRNA processing and stability [78].
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In addition to miRNAs related to EMT (see Section 7. Epithelial-to-Mesenchymal Transition),
miR-20b, miR-301, and miR-487 are up-regulated in carcinosarcomas compared to both endometrioid
and serous tumors, whereas miR-518b is down-regulated. Low expression of miR-20b seems to
inhibit tumor cell growth but then again help the tumor cell to gain resistance to apoptosis in hypoxic
conditions [79]. In another study, miR-888 overexpression was detected in ECS, and the progesterone
receptor was its direct target [80]. Finally, lower cancer-specific survival has been associated with
upregulation of miR-184 and downregulation of let-7b-5p and miR-124 [81].
6. Methylation Profiles in ECS
Similarly to other types of cancers, ECS displays abnormal DNA methylation patterns
including genome-wide hypomethylation and site-specific hypermethylation, associated with
increased expression of DNA methyltransferases (DNMT1, DNMT3a), when compared to the normal
endometrium [38,82]. Regarding global hypomethylation, Li et al. [82] reported that in normal
endometrium, the 80% of analyzed CpGs were methylated, whereas, in ECS samples, this ratio fell to
60% to 70%. In addition, all major classes of genomic transposable elements exhibited global DNA
hypomethylation in ECS, with Long interspersed nuclear elements (LINEs) exhibiting the largest effect
size. This effect was greater in ECS than in other histological types of endometrial carcinomas.
A number of tumor suppressor genes with recurrent hypermethylated promoters has also been
reported in ECS, KLF4, NDN, WT1, PROX1, among others. Promoter hypermethylation of these
genes is also common in other types of EC [38,82]. Interestingly, Cherniak et al. [38] reported that
unsupervised cluster analysis of DNA methylation profiles of ECS grouped the tumors into three main
classes according to their cancer-specific hypermethylation patterns. One group of tumors exhibited a
hypermethylation pattern similar to that of EEC, whereas the others were much more similar to the
ESC. Accordingly, the frequency of PTEN mutations was higher in the first group.
A constant characteristic of ECS is the aberrant DNA methylation of miR-200 genes (see discussion
in Section 7. Epithelial-to-Mesenchymal Transition).
7. Epithelial-to-Mesenchymal Transition
EMT is a biological process that involves the acquisition of a mesenchymal/stem-cell-like phenotype
by the (malignant) epithelial cells, endowing these cells with migratory and invasive properties,
promoting cancer progression, preventing cell death and senescence, and inducing resistance to
chemotherapy [83]. EMT has an important role in cancer, especially in tumor invasion and metastasis.
During EMT, epithelial cells undergo a “cadherin switch” in which expression of N-cadherin is
increased and E-cadherin expression reduced. E-cadherin can be repressed by either zinc-finger
transcription factors (Snail1 (SNAI1), Slug/Snail2 (SNAI2), ZEB2 (SIP1) and ZEB1 (δ-EF1)) or basic
helix–loop–helix transcription factors (E47 (TCF3), E2-2 (TCF4) or Twist). These EMT transcription
factors (EMT-TF) can become activated through activation of different pathways such as Transforming
Growth Factor Beta 1 (TGFβ), tyrosine kinase receptors and Wnt, among others [25].
We have previously suggested that EMT is activated in ECS [65,73,84,85]. Further studies have
confirmed this suggestion [25,38,39,84,86]. For example, we used real-time PCR to measure the
differences in the expression of, E-cadherin, cadherin-11, SPARC, SNAIL, ZEB1, ZEB2, TWIST-1, TCF4,
TGFβ1, and TGFβ2 between the epithelial and mesenchymal components of 23 ECSs. Also, we used
immunohistochemistry to evaluate the expression of E-, P- and N-cadherin, cadherin-11, p120, vimentin,
SPARC, fascin, and caveolin-1 in 76 ECS. In the mesenchymal component, a “cadherin switch” from
E-cadherin to N-cadherin and cadherin 11 was observed. In addition, upregulation of all of E-cadherin
repressors together with overexpression of all mesenchymal markers tested was demonstrated.
Also, High Mobility Group AT-Hook 2 (HMGA2) has a role in EMT as a regulator of SNAI1
expression and of other transcription factors downstream of SNAI1, such as Slug, ZEB1, and ZEB2.
HMGA2 has been proposed to be regulated by the let-7/Lin28B pathway. Accordingly, we have
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previously demonstrated that an increase of Lin28B expression correlated with let-7b down-regulation
and HMGA2 overexpression in ECS [73].
A role of the WNT pathway in the transition from an epithelial to a mesenchymal status is
demonstrated by the fact that up to 23% of ECS showed nuclear β-catenin, not associated with
CTNNB1 mutation, in the sarcomatous but not in the carcinomatous component [57]. Nuclear β-catenin
cooperates with Sox4 and p300 to transcriptionally up-regulate Slug to induce EMT [87].
Similarly to β-catenin, in another study, ALK tyrosine kinase receptor (ALK) was frequently
over-expressed in the sarcomatous components of EC [87]. The authors suggest that ALK-related
cascades could participate in divergent sarcomatous differentiation through the induction of EMT and
inhibition of apoptosis [87]. In contrast, although the expression of L1CAM is a strong predictor of poor
outcome in endometrial cancer and overexpression of L1CAM has been related to EMT in endometrial
cancer cell lines [88], in clinical samples of ECS, only the epithelial component was positive in 65%
of the cases, while no expression was seen in the mesenchymal part. Thus in ECS, L1CAM is not a
marker for the mesenchymal phenotype [89].
MicroRNA signatures associated with EMT and their relationships with EMT markers in human
carcinosarcomas have been studied by us and more recently by Cherniack et al. [25,38,84]. We used
real-time PCR to measure the differences in the expression of 384 miRNAs, between the epithelial and
mesenchymal components of ECS and found that miR-200 family members were down-regulated in the
mesenchymal part of the ECS. The miR-200 family plays a major role in regulating epithelial plasticity,
mainly through its involvement in double-negative feedback loops with the EMT-TFs ZEB1, ZEB2,
SNAI1, and SNAI2, ultimately influencing E-cadherin expression levels [25,84,85]. Down-regulation of
miR-200 family members in ECs is not only due to the transcriptional repression by EMT-TF, but also
to promoter methylation [38,84]. In this sense, experimental studies have demonstrated a major role
of ZEB1 in transcriptional repression and of SNAI1 and, to a lesser extent, SNAI2 in the epigenetic
silencing through DNA hypermethylation of miR-200 genes [84]. Other down-regulated miRNAs in
our studies included miR-23b and miR-29c, involved in the inhibition of mesenchymal markers, and
miR-203 and miR-205 involved in the inhibition of cell stemness [25,84].
8. Beyond EMT: Stemness and Differentiation in ECS
It has been demonstrated that epithelial cells undergoing EMT to acquire mesenchymal features are
more likely to possess stemness. In addition, some studies suggested that stemness can be associated
with cells undergoing a partial EMT and showing a hybrid Epithelial/Mesenchymal phenotype.
Jolly et al. postulated that the core EMT and stemness modules, miR-200/ZEB and Lin28/let7, govern
EMT decision making [90]. According to this hypothesis, not only the miR-200/ZEB EMT module is
active in ECS, as previously discussed, but also, we have previously demonstrated that the expression
of the suppressor of miRNA biogenesis Lin28B was increased in ECS when compared with EEC
samples (62.85-fold change). Moreover, we observed a significant inverse correlation between the
expression of Lin28B and let-7b, supporting the hypothesis that they participate in the same regulatory
pathway [73].
Cells with an Epithelial/Mesenchymal hybrid phenotype evolve to an epithelial or a mesenchymal
phenotype depending on factors acting on the EMT and stemness modules [91]. Both routes would
enable a secondary round of differentiation to specific epithelial or mesenchymal phenotypes [92]. ECS
exemplified well this hypothesis since different types of mesenchymal tissues could develop. This is
illustrated not only by the morphological evidence of striated muscle, cartilage, or bone tissue in ECS
but also by molecular evidence. Thus, the presence of rhabdomyoblastic differentiation in ECS, the most
common heterologous mesenchymal differentiation in ECS, is accompanied by the overexpression of
genes that are characteristic of primary embryonic myocytes [93]. Romero-Perez et al. [73] demonstrated
that in ECS there was an overexpression of the core network of transcription factors that control the
myogenic program in primary myocytes, including Myf5, Myf6, MyoD, and MYOG (myogenin), in
addition to other transcriptional factors involved in this process, such as SIX1 and EYE1/2. Moreover,
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overexpression of genes encoding specialized cytoskeletal proteins, such as slow (Myh7) and embryonic
(Myh3) myosin heavy chains and skeletal α-actin (Acta1), was also observed. Similar to our previous
results, Lu et al. [94] reported that 18 out of 57 ECS reported in the TCGA had a gene expression pattern
enriched in genes involved in muscle development and morphogenesis, myoblast differentiation, and
contraction regulation.
9. Immune Response in CS
The tumor microenvironment has an important role in cancer and immunomodulation of the
microenvironment is a new focus in cancer medicine [95]. Accumulated evidence indicates that ECS is
a rational target for immune therapy. In their study of gene expression, Romero-Peréz et al. found that
over 10% of the genes differentially expressed between ECS and EEC were implicated in the immune
response, suggesting differential immunomodulation between histotypes [73].
Ayers et al. have created a Tumor Inflammation Signature (TIS) using gene expression data from
baseline tumor samples of pembrolizumab-treated patients. The signature includes 18 genes that
reflect a suppressed adaptive immune response (antigen presentation, chemokine expression, cytotoxic
activity, and adaptive immune resistance) and is enriched in tumors with sensitivity to Programmed
cell death 1 ligand 1 (PD-L1) inhibitors [96]. In another study, Danaher et al. concluded that, although
there was only a correlation between TIS and tumor mutational burden (TMB), the tumors could be
classified equally well with either TIS or TMB [97]. Using data from TCGA, we compared the TIS
between endometrioid and serous endometrial and ECS and observed that it is significantly lower in
uterine carcinosarcoma ECS compared to both ECS and ESC (analysis of variance (ANOVA), p < 0.001,
Figure 4). However, TIS varies more within than between tumor types, and although ECS has a
relatively low score on average, more samples need to be studied to see if a group of patients might
show association with prognosis or immunotherapy response prediction. For example in breast cancer,
patients with the highest 10% of the TIS score had a markedly better prognosis [97].
Figure 4. A boxplot histogram of Tumor Inflammation Signature (TIS) scores by endometrial cancer
type in endometrial carcinosarcoma (ECS), endometrial serous carcinoma (ESC), and endometrial
endometrioid carcinoma (EEC). p values from analysis of variance (ANOVA) test are shown for
all comparisons.
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Several studies have demonstrated that EMT contributes to evasion of immune
surveillance [98–105]. PD-L1 has a major role in tumor immune escape and also in the development
of a permissive immune microenvironment [105]. Different studies have observed an association
between PD-L1 expression and mesenchymal characteristics in different tumor types, such as breast,
lung, and pancreatic adenocarcinomas, among others. Also, it has been shown that miR-200 targets
PD-L1. Moreover, the EMT-TF ZEB1 relieves miR-200 repression of PD-L1 on tumor cells, leading to
CD8(+) T-cell immunosuppression and metastasis.
Regarding carcinosarcomas, PD-L1 expression was significantly higher in lung carcinosarcoma
than in conventional non–small-cell lung carcinoma [106], providing a rationale for the potential use of
immunotherapy. In this sense, a significant benefit of Nivolumab treatment in PD-L1 positive metastatic
pulmonary carcinosarcoma has been reported in some patients [107]. In ovarian carcinosarcoma,
PD-L1-positive expression was also observed in about 50% of the tumors, without differences between
the epithelial and mesenchymal components [108]. To the best of our knowledge, there are only
two studies on PD-L1 expression in ECS. Whereas in one study, PD-L1 was expressed in 25% of the
tumors [30], in another, up to 86% of ECS expressed the biomarker [109]. This subset of tumors could
benefit from drugs directed to the PD-1/PD-L1 pathway.
10. Conclusions and Perspectives
Carcinosarcoma is a heterogeneous aggressive endometrial carcinoma that probably represents
the end-stage of the evolution of both endometrioid and serous carcinomas after triggering a stable
EMT program (Figure 5). Molecular observations suggest that, although infrequent, endometrioid
carcinomas associated with mutations in PTEN or PIK3CA are more prone to acquire TP53 mutations
than those associated with MMR-def, POLE, or CTNNB1 mutations. Mutations in TP53 seem to be
essential, but not sufficient, to ECS development, since they are as frequent in ECS as in endometrial
serous carcinoma. Although it is not clear what triggers EMT in tumors with TP53 mutation, a
common characteristic of all ECS is the switching of cadherins, the overexpression EMT-TF, and the
down-regulation of miR-200 genes. Probably, the crosstalk of different EMT-TF and the differential
regulation of miR-200 genes by transcriptional repression or by epigenetic silencing through DNA
hypermethylation play a major role in fixing the mesenchymal phenotype. Subsequent activation of
specific transcription programs could induce differentiation to diverse mesenchymal tissues.
At present, most patients with ECS are not stratified for treatment according to molecular
alterations [110,111]. However, future clinical trials will most likely take into account this data. For
example, a recent report has demonstrated the benefit provided when Traztuzumab is included in the
treatment of ESC with HER2 amplification [112]. Considering the similarities between ESC and ECS, it
is reasonable to think that anti-HER2 therapies would also benefit patients with HER2-positive ECS.
Although the relatively low-frequency of ECS hinders efforts to design specific clinical trials, there
are promising areas of research, such as the use of immunotherapy in tumors with POLE mutations,
MMR-def, and high TMB, and also the use of Poly (ADP-ribose) polymerase (PARP) inhibitors in tumors
with homologous recombination deficiency, especially due to germline or somatic BRCA mutations.
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Figure 5. A proposed model of development of endometrial carcinosarcoma. (A) Evolution of
both endometrioid and serous carcinomas to endometrial carcinosarcoma after eliciting a stable
epithelial-to-mesenchymal transition (EMT) program. Transformation of normal endometrium to
serous endometrial carcinoma is triggered by mutation in TP53. Endometrioid carcinomas with
mutations in genes of the phosphatidylinositol 3-kinase (PIK3) pathway or ARID1A are more prone to
acquire TP53 mutations than those with mismatch repair deficiency or mutations in POLE and CTNNB1.
(B) Endometrial carcinosarcomas are composed by a mixed population of cells representing diverse
EMT states. The relative expression of some factors, such as miR-200 or ZEBs, dictate the specific cell
state: epithelial, hybrid, or mesenchymal (adapted from Ref. 92).
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Abstract: Esophageal squamous cell carcinoma (ESCC) is a common and aggressive malignancy,
with hitherto dismal clinical outcome. Genomic analyses of patient samples reveal a complex
heterogeneous landscape for ESCC, which presents in both intertumor and intratumor forms,
manifests at both genomic and epigenomic levels, and contributes significantly to tumor evolution,
drug resistance, and metastasis. Here, we review the important molecular characteristics underlying
ESCC heterogeneity, with an emphasis on genomic aberrations and their functional contribution
to cancer evolutionary trajectories. We further discuss how novel experimental tools, including
single-cell sequencing and three-dimensional organoids, may advance our understanding of tumor
heterogeneity. Lastly, we suggest that deciphering the mechanisms governing tumor heterogeneity
holds the potential to developing precision therapeutics for ESCC patients.
Keywords: esophageal squamous cell carcinoma; tumor heterogeneity; tumor evolution; precision
medicine
1. Introduction
Esophageal carcinoma is the sixth most lethal cancer type worldwide, responsible for over 400,000
deaths annually [1,2]. Esophageal squamous cell carcinoma (ESCC) is the predominant histological
subtype, accounting for 90% of cases [3,4]. Despite noteworthy advances in both cancer diagnosis and
therapy, the clinical outlook for ESCC patients remains dismal, with a five-year survival rate below
30% [5,6]. A number of lines of evidence have demonstrated that this poor clinical outcome is at least
partially attributed to the substantial intertumor and intratumor heterogeneity in ESCC [7,8].
The concept of tumor heterogeneity contains both intertumor and intratumor forms. Intertumor
heterogeneity concerns the phenotypic and molecular differences among tumors from different
patients, while intratumor heterogeneity refers to biological variations within the same tumor [9–13].
Heterogeneity is an important attribute of cancer and a major contributor to tumor progression.
It manifests at two major levels: genomic (somatic mutations, copy number alterations, chromosomal
rearrangements, etc.) and non-genomic (epigenomic changes, microenvironmental variabilities,
etc.) [14,15]. The degree and complexity of tumor heterogeneity influence the strategy of tumor
biopsy, cancer diagnosis, and treatment planning [7,9,14,16–18]. Increasingly, advances in sequencing
technology and analysis algorithms have substantially promoted the understanding of both intertumor
and intratumor heterogeneity in many cancer types, including ESCC [7,19,20]. However, translation
of the accumulated knowledge on ESCC heterogeneity into clinical practice is still challenging.
A systematic understanding of ESCC heterogeneity with respect to its composition, function, and
implication is therefore urgently needed.
In this review, we summarized the evidence for both genomic and non-genomic sources of ESCC
heterogeneity and discussed their biological and clinical significance in the context of tumor evolution.
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We also described new technologies and methodologies that might further our understanding and
management of ESCC heterogeneity and shared our perspectives on the future of this field.
2. Intertumor Heterogeneity
Taxonomy of cancer subtypes by specific molecular characteristics significantly improves
the conventional histopathological classification and guides subtype-specific precision medicine.
As exemplified in breast cancer (e.g., luminal, basal-like, Her2+), lung cancer (e.g., EGFR+, ALK
fusion+), and gastric cancer (e.g., Epstein–Barr virus+, microsatellite unstable), intertumor heterogeneity
has been widely studied and successfully translated into clinical knowledge in various cancer
types [21–23]. However, the stratification of ESCC patients based on intertumoral molecular
heterogeneity remains comparatively understudied.
In 2017, through an integrative multi-omics analysis, The Cancer Genome Atlas (TCGA) consortium
classified 90 ESCC specimens into three subtypes, designated as ESCC1–3 [4]. ESCC1, mostly Asian
samples, was enriched in genomic alterations in the NRF2 pathway (NFE2L2, KEAP1, CUL3, and
ATG7) and amplifications of SOX2 and/or TP63; ESCC2, mainly Eastern European and South American
samples, was characterized by higher rates of NOTCH1 and ZNF750 mutations, CDK6 amplification,
and inactivation of KDM6A, KDM2D, PTEN, and PIK3R1; only four cases were classified into ESCC3,
which were all from North America and featured in SMARCA4 mutation. Although these subtypes
showed notable geographical trends, their associations with particular biological and/or clinical features
were not extensively elucidated. In addition, because of the relatively small number of samples, these
classifications need further validation in larger cohorts.
In addition to the effort from TCGA consortium, several individual laboratories have attempted to
subgroup ESCC based on transcriptomic data. Upon analyzing tumor samples from African patients,
Liu et al. [24] reported three ESCC subtypes based on their distinct expression patterns of cell cycle and
neural transcripts. In another study, ESCC specimens from 360 East Asian individuals were divided
into four molecular subtypes associated with distinct clinical metrics [25]. Most recently, a new research
work has categorized Asian ESCCs into two subtypes, with subtype I overexpressing genes in immune
response process and subtype II linked to ectoderm development, cell proliferation, and glycolysis
process [26]. Additionally, Tanaka et al. [27] reported the presence of an immune-reactive subtype of
ESCC patients with cytotoxic T-lymphocyte signatures activated by chemoradiotherapy.
Despite the fact that no consensus molecular subtypes of ESCC have been established, the above
subtyping results are sufficient to confirm the existence of extensive intertumor heterogeneity among
ESCC individuals, and further demonstrate heterogeneity amongst different ESCC ethnic groups.
This is in line with the well-established dramatic geographic and demographic features of ESCC [28,29].
It should also be noted that the molecular factors and causes underlying intertumor heterogeneity are
likely similar with those involved in intratumor diversity. In order to fully capture the tumor spectrum,
and to further improve ESCC subclassification and treatment stratification, the molecular features of
ESCC intratumor heterogeneity need to be comprehensively integrated.
3. Intratumor Heterogeneity
In the milestone paper published in 1976, Peter C. Nowell [30] proposed a model for cancer
development: the Darwinian clonal evolution and selection of tumor cells. Since then, this model
has been widely accepted and the phenomenon of intratumor heterogeneity has been highlighted
as a cancer hallmark to reflect the non-uniformity and intricacy within tumor ecosystems [31–33].
To date, it is well established that intratumor heterogeneity is represented by the presence of distinct
cell populations, which can occupy specific microenvironmental niches, behave as communities, and
extensively interact with each other as well as with components of the tumor microenvironment [12].
Therefore, intratumor heterogeneity arises not only from genomic and epigenomic disorders of
tumor cells themselves, but also from the influence of the tumor microenvironment [9]. Importantly,
intratumor heterogeneity exists among different geographical regions of the same tumor (spatial
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heterogeneity), as well as between the primary tumor and subsequent local or distant recurrence in
the same patient (temporal heterogeneity). As a cumulative result, tumor cells display remarkable
variability in numerous phenotypic traits, including clinically important phenotypes such as the ability
to seed metastases and to survive therapy (Figure 1) [34].
Figure 1. Multiple layers of intratumor heterogeneity. Left: Phenotypically distinct cancer cells with
both genomic (DNA color) and epigenomic (cell color) heterogeneity are admixed with diversified
microenvironmental components. Right: A phylogenetic framework helps to understand the nature
and biological significance of tumor spatiotemporal heterogeneity.
3.1. Clonal Evolution of Tumors
According to the clonal evolution hypothesis, cancer arises from a single founder cell, and tumor
progression is accompanied by the resultant succession of clonal expansions that follow the Darwinian
logic [30]. This evolutionary perspective underlines genomic alterations as an essential substrate for
fueling tumor transformation and evolution.
During each cell cycle, regardless of normal or cancer cells, DNA mutations may be acquired.
Thus, the acquisition of mutations is a stochastic and random process. Consequently, innumerable
rounds of cell divisions required for the formation of macroscopic tumors offer plenty of opportunities
for Darwinian selection and emergence of clonal diversity in tumor cell populations. During clonal
evolution, only a few “jackpot” mutations that activate oncogenic pathways and/or inactivate tumor
suppressors are selectively advantageous, allowing the mutant clones to achieve selective sweeps.
These functionally significant mutations are termed “drivers”. In contrast, the vast majority of mutations
are functionally neutral since they do not confer competitive fitness advantage. These mutations are
so-called “passengers” and are mainly responsible for intratumor heterogeneity [35]. Importantly,
clonal evolution often proceeds in a branching rather than in a linear manner, further contributing to
variegated tumor subclones and the complexity of tumor evolution [14]. In fact, many neutral or mildly
deleterious mutations during clonal expansion can be retained in the population, or even undergo
expansions due to the genetic drift [32,35]. Moreover, given the fact that the Darwinian selection is
context-specific, and the evolutionary dynamics of tumor microenvironment and epigenomic events
could translate into heterogeneous selective pressures experienced by tumor cells, the selective effect
of given mutations (either driver or passenger) can change substantially at different stages of tumor
progression [14].
3.2. Spatial Intratumor Heterogeneity
Spatial intratumor heterogeneity has been elucidated at high resolution in many cancer
types [15,36–40]. Recently, several groups have performed multi-regional deep-sequencing, and
have presented a comprehensive heterogeneous landscape of ESCC [41–44]. Through analyzing
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51 sub-tumor regions from 13 ESCC patients, Hao et al. [42] proposed that approximately 40% of
driver mutations were spatially heterogeneous, including oncogenes such as KIT, and members of the
PI3K/MTOR (PIK3CA and MTOR) and NFE2L2 pathways (NFE2L2 and KEAP1). In addition, significant
spatial heterogeneity was observed in copy number alterations, including EGFR amplification and
CDKN2A/B deletions [42]. Furthermore, taking into consideration the multi-step progression of ESCC,
Zeng’s team [43] sequenced different segments of ESCC tumors and their matched dysplasia samples
in a cohort of 20 patients. Their analyses showed that esophagus dysplasia also carried high mutation
load and, remarkably, more heterogeneous mutations were seen in dysplasia than in tumor samples
from each patient. Moreover, through sequencing 682 micro-scale esophageal samples, Yokoyama
et al. [45] reported very recently that pervasive expansions of multiple independent clones were more
commonly present within physiologically normal esophagus in comparison to ESCCs. These seemingly
surprising data indicate that diversified mutational backgrounds were already established in the
precursor lesion or even normal esophageal epithelia, conferring on the esophageal cells the ability to
evade selection pressure during ESCC development. Moreover, the degree and complexity of spatial
heterogeneity was found to be highly correlated with ESCC aggressiveness [44]. Specifically, clinical
stage of ESCC was negatively correlated with the proportion of ubiquitous mutations, and significantly
more heterogeneous mutations were observed in ESCC patients with local metastasis, compared to
those without.
Regionally segregated somatic mutations and copy number alterations have important clinical
implications in ESCC. Firstly, they complicate pathological evaluation of tumor samples. Owing to
potential sampling bias caused by spatial heterogeneity, the representability of tumor regions subject
to pathological assessment is increasingly considered as a key factor. It is possible that diagnostic
and therapeutic targets located in uninspected regions are missed by chance, and the heterogeneous
spectrum of the tumor is inevitably underestimated. Additionally, spatial genomic heterogeneity is an
important determinant for therapeutic responses. Although most cancers initially respond to treatment,
they almost always relapse with the outgrowth of cancer cells that are no longer sensitive to the therapy.
Many cases have demonstrated that resistance to targeted drugs may result from the preexisting
heterogeneous cells. Examples include the impaired efficiency of EGFR inhibitor for lung cancer
patients with heterogeneous driver status [46,47]. Lung cancers initially containing rare mutations
of EGFR, e.g., T790M, or low frequency of MET amplification, are capable of rendering resistance to
targeted therapy [18,31,48,49]. Another well-understood case is chronic myeloid leukemia, in which
mutant forms of the BCR-ABL fusion protein have been implicated in the relapse of disease under
imatinib treatment [50–52]. In ESCC, heterogeneous amplifications of EGFR, FGFR1, and PD-L1 have
been reported [42–44], accounting partially for the unsatisfactory efficacy of targeting such genomic
lesions [53–55]. Spatial genomic heterogeneity, therefore, greatly challenges both accurate diagnosis
and efficient cancer treatment.
In addition to genomic alterations, epigenomic dysregulation also contributes to spatial diversity
within a tumor. Mechanistically, epigenomic heterogeneity may arise from changes in chromatin status
(e.g., DNA methylation, histone modification), deregulation of microRNAs, and transcription regulators,
etc. These alterations potentially provide fitness benefit, leading to intratumor heterogeneity either
independently or in conjunction with genomic alterations [56–64]. For example, DNA methylation
status within promoters of transcription factors SIM2 and SIX1 was strongly correlated with their
heterogeneous expression pattern, which was further associated with ESCC differentiation, progression,
and prognosis [65–67]. Dynamic changes of mutational status and promoter DNA methylation
were also observed in the SWI/SNF chromatin remodeling complex and were shown to involve in
ESCC carcinogenesis [68]. Moreover, epigenomic and genomic heterogeneity have been integratively
analyzed in three ESCC patients [42]. Noticeably, the spatial heterogeneous pattern of DNA methylation
closely recapitulated that of somatic mutations, indicating functional interplay between genomic and
epigenomic alterations in ESCC.
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The tumor microenvironment, consisting of fibroblasts, extracellular matrix, immune cells
(e.g., macrophages, infiltrating lymphocytes), etc., imposes yet another layer of heterogeneity [44,69–75].
Tumor microenvironment can shape tumor cell phenotypes by augmenting both the intrinsic variability
of cancer cells (e.g., by inducing stress responses and genomic instability) and the extrinsic diversity of
microenvironmental contexts (e.g., different densities of blood and lymphatic vasculature, different
numbers and types of infiltrating cells) [7]. In ESCC, the tumor microenvironment itself is indeed
highly heterogeneous, as evidenced by recent reports of intratumor heterogeneity of tumor infiltrating
T and B cells [44,70,75]. Additionally, Yan et al. [44] observed a tight association between genomic
heterogeneity and variation of T cell repertoire in ESCC primary tumors. These results demonstrate
that the intratumor genomic heterogeneity may have clinical relevance in ESCC through affecting
tumor microenvironment. Meanwhile, ESCC cells could also benefit from the microenvironmental
heterogeneity, which supports cellular diversity and influences evolutionary trajectories [14,62,76,77].
3.3. Temporal Intratumor Heterogeneity
Accumulating evidence suggests that intratumor heterogeneity contributes to tumor growth
through a process called branched evolution. This model suggests that tumorigenesis is analogous
to a growing tree, whose trunk gives rise to numerous branches [9,14,78]. Phylogenetic analysis is
a useful approach to delineate such tree structure of cancer evolution [19,38,79–81]. Accordingly, in
the phylogenetic tree, truncal (ubiquitous) events shared by the entire tumor population likely reflect
processes involved before and during tumor initiation and early development, whereas branched
(heterogeneous) events present in only some regions of the tumor reveal factors shaping the genome
during tumor maintenance and progression. Characterization of the relative timing of key somatic
events with possible biological relevance is therefore essential for deciphering the evolutionary
processes of tumors, as well as further improving precision medicine strategies.
In ESCC, driver mutations were significantly more truncal/clonal than passenger mutations,
in accordance with findings in other tumor types. Importantly, the majority of driver mutations in
tumor suppressors (including TP53, KMT2D, ZNF750, etc.) had a tendency to locate in the trunks of
phylogenetic trees, indicating that tumor suppressors are lost as relatively early events during ESCC
development. In contrast, half of the driver mutations in the branches were in oncogenes, including
potential actionable targets, PIK3CA and MTOR, suggesting that they are late events in ESCC [42].
This observation highlights the extra caution needed when considering inhibiting such oncogenic
mutants in ESCC, given previous studies showing that suppressing subclonal drivers could otherwise
lead to outgrowth of non-mutated subpopulations [82].
Esophageal squamous cell carcinoma evolution is a multi-step process that begins from low-grade
dysplasia, high-grade dysplasia, carcinoma in situ to invasive tumor and metastasis [44]. To further
explore the genomic dynamics during this process, recent studies applied multi-region sequencing
on samples covering different stages of ESCC from the same patients and constructed phylogenetic
trees that mapped mutations and copy number alterations chronologically [43,44,83]. Notably, only
a small fraction of total genomic alterations was conserved from squamous dysplasia to ESCC
tumors, implying the distinct evolutionary trajectories taken by precursor and neoplastic cells [43,83].
Phylogenetic analysis confirmed truncal mutations of TP53 and CDKN2A and truncal copy number
alterations of 11q13 (CCND1), 3q27 (SOX2), 2q31 (NFE2L2), and 9p21 (CDKN2A), validating that they
are early changes during esophagus neoplastic transformation [83]. Independently, Chen et al. [43]
also reported early emergence of copy number alterations in precursor lesions of ESCC and highlighted
this phenomenon as a prominent genomic feature distinct from the development of esophageal
adenocarcinoma, another pathological subtype of esophageal cancer. When considering alterations
at pathway level, genes involved in cell cycle regulation (such as TP53, CCND1, CDK6, RB1, and
CDKN2A) were frequently altered in the early stage of ESCC, whereas genes in RTK/RAS/PI3K tended
to undergo alterations throughout the process of ESCC evolution [44].
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Taking into consideration of the timing of metastatic outgrowth and the role of the intratumor
heterogeneity, two distinct models for the derivation of ESCC metastasis have been proposed: the
stepwise progression model and the parallel progression model (Figure 2) [43,44]. The stepwise
progression model was characterized by tumor cells disseminated at the late stages of ESCC. Accordingly,
metastases could be considered as direct descendants of the most malignant and aggressive clones
that dominated primary tumors. This model was also described as the linear spread pattern by
Yan et al. [44]. By comparison, in the parallel progression model, early spread of metastases during
ESCC tumor progression was highlighted. Specifically, divergent evolutionary trajectories were found
between primary tumors and metastatic lesions, as well as among metastatic lesions. This model was
represented as both explosive spread and metastasis-to-metastasis patterns by Yan and colleagues [44].
Figure 2. Phylogenic models for ESCC metastasis. (A) The stepwise progression model, in which
metastases are seeded at the late stages of ESCC progression. This model was also described as the linear
spread pattern by Yan et al. [44]. (B) The parallel progression model, in which tumor dissemination
occurs at the early stages of ESCC progression. In this situation, dissemination of metastases could
happen either (Left) explosively (explosive spread pattern) or via (Right) metastasis-to-metastasis
pattern (T, Tumor; M, Metastasis).
More studies are required to elucidate the clonal relationship between ESCC primary and
metastatic tumor cell populations, which will not only illuminate the evolutionary history of ESCC,
but also create a more solid ground for therapeutic decision making. Ultimately, decoding the extent
of differences between ESCC primary and metastases is crucial for the improved management of
metastatic ESCC patients.
4. New Technologies for the Investigation of Intratumor Heterogeneity
It is with great excitement that we are witnessing novel technologies and methodologies being
developed at a fast pace for the investigation of intratumor heterogeneity. These advances will uncover
the molecular and biological features of intratumor heterogeneity with unprecedented resolution
and they hold the potential to revolutionize our understanding of the complex intrinsic and extrinsic
heterogeneity of ESCC.
4.1. Heterogeneity Studies at the Single-Cell Level
Technical advances in single-cell sequencing have been heralding a new era in resolving tumor
heterogeneity and understanding the dynamics of subclonal architecture during tumor progression [31,
36,84–88]. For instance, single-cell RNA sequencing of glioblastomas revealed that cell-to-cell inherent
variability was evident in regulatory axes central to glioblastoma biology, prognosis, and therapy [88].
Single-cell DNA sequencing of a large number of breast cancer cells unraveled the punctuated evolution
pattern of copy number alterations during tumor development [36,86,87]. In ESCC, single-cell RNA
sequencing has been recently performed on three specimens, and substantial intratumor heterogeneity
contributed by both tumor-intrinsic and microenvironmental alterations has been observed [89].
Nevertheless, more extensive single cell-based studies of ESCC are still lacking.
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Compared to conventional bulk-tissue analysis, single-cell profiling is superior in its robust
sensitivity in detecting subclonal/private genomic alterations at true single-cell resolution. Thus,
single-cell sequencing is of pivotal importance in discovering subtle diversification and rare tumor
clones. Looking to the future, we anticipate that the application of single-cell multi-omics technologies
(e.g., transcriptome, methylome [90,91], and chromatin [92,93] assays) to both cancerous cells and
infiltrating stromal cells will finally provide us with a panoramic view of ESCC heterogeneity.
4.2. Three-Dimensional Organoid Culture
Organoid cultures are three-dimensional multicellular constructs wherein cells can self-assemble
to faithfully represent the physiological states of parent tissues or organs. Derived from patients,
3D organoids are crucial tools for disease modeling, especially cancers. Briefly, the generation of
patient-derived organoids involves disintegration or digestion of the tumor tissue into single-cell
suspensions or cell aggregates, followed by implantation of the cells in growth factor-optimized
media and 3D basement membrane matrix (Matrigel) [94]. Currently, 3D organoids have been
developed for several cancer types and been proven to successfully recapitulate tumor spatiotemporal
heterogeneity [95–100]. Particularly, the generation of clonal organoids from different locations from
the same tumors allows the study of tumor heterogeneity and evolution [100–103]. Specific driver
and passenger mutations could be introduced by the CRISPR-Cas9 genome-editing system with the
resultant organoids valuable for dissecting tumor progression mechanisms [104–107]. Importantly,
organoid technology has also been leveraged to facilitate the development of personalized medicine,
including drug screening and therapy response evaluation, which is in urgent need to overcome tumor
heterogeneity [98,101,108–112].
In ESCC, Kijima and colleagues [113] have successfully generated and characterized 3D organoids
from ESCC patients and provided proof-of-principle regarding their utility as a robust platform for
analyzing cancer cell heterogeneity, evaluating drug sensitivity, and exploring mechanisms of drug
resistance. However, given the importance of the tumor microenvironment, future work will require
the investigation of ESCC-relevant niche factors and optimization of conditions for co-culturing with
stromal and immune cells in the 3D organoids [114]. It also needs to be determined whether the 3D
organoids could faithfully recapitulate the entire heterogeneity of ESCC, and to what extent could the
heterogeneity be maintained after extended ex vivo culture. Additionally, future applications of 3D
organoids in the clinical setting should include analysis of both ESCC precancerous and metastatic
lesions. With such improvements in the organoid system, we believe that 3D organoid culture will
become a powerful tool to model the biological function of intratumor heterogeneity. Through this
tool, we can gain more insights into ESCC evolution in time and space and develop more effective
precision medicine against this deadly disease.
5. Conclusions and Future Directions
It is now clear that heterogeneity is a hallmark of ESCC. However, a significant lag still exists
between the knowledge advance of tumor heterogeneity and its clinical translation regarding to
diagnostic, prognostic, and therapy. Firstly, it is worth investigating whether the heterogeneity
degree by itself could serve as an important biomarker in predicting ESCC progression and guiding
treatment decisions. Notably, the extent of clonal diversity predicts the probability of malignant
progression in Barrett’s esophagus [115]. The quantitative evaluation of cellular diversity has also
been used as a biomarker in breast cancer [116]. These examples suggest that diagnostic value of
heterogeneity may have universal applicability in cancers irrespective of tumor anatomy. Secondly,
given that a heterogeneous tumor is the resulting accumulation of both genomic and non-genomic
diversities, the heterogeneity of both cellular and non-cellular components (e.g., epigenome, tumor
microenvironment) should be more extensively explored, together with their associations with ESCC
biology and clinical outcomes. This entails chronological studies assessing heterogeneity along
disease progression of the same patient, from squamous dysplasia to cancer metastases. Moreover,
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longitudinal studies evaluating intratumor heterogeneity changes during and following therapeutic
interventions are required to support identifying early resistant disease and limiting iatrogenic impacts
of therapy on ESCC evolution. Thirdly, although heterogeneity undoubtedly poses a formidable
obstruction to therapeutic success, there exists a potential to reach drug-sensitive states by strategies of
reducing or even exploiting tumor heterogeneity. Current promising therapeutics include targeting
epigenetic modifications of cancer cells (e.g., histone deacetylase inhibitors), modulating the tumor
microenvironment (e.g., anti-angiogenic therapy, immune therapy), as well as multiplex-targeted
therapy and adaptive therapy. Importantly, there is also a significant progress in the development
of anti-cancer stem cell (CSC) treatments, since CSCs constitute a new research focus in tumor
heterogeneity [117–119]. Particularly, CSCs not only contribute to the phenotypic heterogeneity of
primary tumor but can persist under treatment and provoke drug-resistant recurrence and distant
metastasis. In conclusion, advanced theoretical understanding of the tumor heterogeneity along with
the rapid development of associated technologies will help develop more innovative and effective
precision medicine against ESCC.
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Abstract: Malignant tumors behave dynamically as cell communities governed by ecological
principles. Massive sequencing tools are unveiling the true dimension of the heterogeneity of these
communities along their evolution in most human neoplasms, clear cell renal cell carcinomas (CCRCC)
included. Although initially thought to be purely stochastic processes, very recent genomic analyses
have shown that temporal tumor evolution in CCRCC may follow some deterministic pathways
that give rise to different clones and sub-clones randomly spatially distributed across the tumor.
This fact makes each case unique, unrepeatable and unpredictable. Precise and complete molecular
information is crucial for patients with cancer since it may help in establishing a personalized therapy.
Intratumor heterogeneity (ITH) detection relies on the correctness of tumor sampling and this is
part of the pathologist’s daily work. International protocols for tumor sampling are insufficient
today. They were conceived decades ago, when ITH was not an issue, and have remained unchanged
until now. Noteworthy, an alternative and more efficient sampling method for detecting ITH has
been developed recently. This new method, called multisite tumor sampling (MSTS), is specifically
addressed to large tumors that are impossible to be totally sampled, and represent an opportunity to
improve ITH detection without extra costs.
Keywords: clear cell renal cell carcinoma; tumor evolution; tumor ecology; intratumor heterogeneity;
multisite tumor sampling; targeted therapy
1. Introduction
Clear cell renal cell carcinoma (CCRCC) is nowadays a health problem of major concern in
developed societies. The tumor is an aggressive histologic subtype of renal cancer whose incidence
is expected to be increased in the future due to the increasing rate of obesity and the ageing
population occurring in Western countries [1]. CCRCC shows a well-known resistance to radio-
and chemotherapy [2]. However, anti-angiogenic drugs and immune checkpoint blockade are showing
promising therapeutic results. At present, three therapeutic options have demonstrated an overall
survival improvement: cabozantinib and nivolumab in second or subsequent lines [3], and the
combination of nivolumab and ipilimumab in first line therapy [4].
Pathologists are the medical specialists who handle surgical specimens and decide which parts
of the tumor must be included for microscopic, immunohistochemical (IHC) and molecular analyses.
Tumor representativeness is becoming a critical issue in modern pathology, either when selecting
fragments from large resected tumors or when obtaining tissue cores from tumors prior to surgical
Cancers 2018, 10, 485; doi:10.3390/cancers10120485 www.mdpi.com/journal/cancers231
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resection for diagnostic and/or therapeutic purposes. Increasing evidences are showing in the last
times that current sampling strategies may not be giving a complete information about the histological
and/or molecular alterations that are present in many tumors of different topographies [5–9]. These
inconsistencies rise serious concerns among oncologists [10]. Pathologists, however, seem not to be
aware of this central problem since sampling protocols still remain unmodified in routine work.
Intratumor heterogeneity (ITH) is at the basis of the lack of tumor representativeness in many
tumor samplings. Although well known for decades, the ITH molecular information is having a
significant clinical impact in the last years. The arrival of targeted therapies has increased the need of
very precise information about ITH since it is observed in many tumor types and represents a major
hurdle for effective therapy, provoking therapeutic resistance and metastatic recurrence [11]. In this
sense, Gerlinger et al. [12] unveiled in 2012 to what extent this phenomenon is present in clear cell
renal cell carcinomas, describing the molecular heterogeneity of these tumors across different regions
within the same tumor.
A new tumor sampling strategy has been developed very recently to improve ITH detection
in routine practice [13]. This new method, termed multi-site tumor sampling (MSTS), has been
successfully applied to CCRCC, although it can be applied to any tumor large enough as to make
impossible a total sampling. Interestingly, MSTS outperforms routine sampling protocols in detecting
ITH while keeping the cost fixed [14].
The present paper focuses on the importance of tumor representativeness in modern Oncology.
A correct tumor sampling is mandatory for this purpose. CCRCC is a good example since it is a
well-known paradigm of ITH. More specifically, this paper revisits some basic concepts and applied
clinical issues of CCRCC evolution. Tumor ecology and spatial and temporal evolution constrains are
then reviewed to contextualize the urgent need of an appropriate tumor analysis. Also, this overview
details a more advantageous alternative for tumor sampling supported by a in silico modeling with
clinical validation.
2. Tumors as Dynamic Cell Communities Guided by Ecological Principles
Neoplasia encompasses a number of complex and largely unknown processes with a metabolic
background [15]. Although pathologists risk thinking of tumors under the microscope as static
combinations of cells arranged in different backgrounds organized in varied architectural structures,
malignant tumors are complex communities of cells evolving in time with individuals permanently
interacting each other. The idea of comparing malignant tumors with other biological communities
behaving in a swarm-like manner [16] following similar ecological rules [17,18] is not new. The adaptive
mechanisms of tumor cells to their ever-changing habitat are a crucial issue to survive, grow and
progress. Epithelial-mesenchymal transition (EMT), and its reversal process (mesenchymal-epithelial
transition), are good examples of this dynamic adaptative capacity that can be eventually targeted [19].
A paradoxical effect of EMT is, for example, the development of low-grade metastases in high-grade
CCRCC [20]. This tumor behavior, as defined in Ecology, can be synthesized in four models:
predation, mutualism, commensalism and parasitism [21]. ITH is known to be induced genetically
and epigenetically by interaction with the local tumor microenvironment. Interestingly, tumor
microenvironment changes from tumor to tumor, from organ to organ, and even from region to
region within the same tumor.
Swarming is defined as the collective behavior of a community of individuals without any
centralized guidance or government. This behavior is based essentially on the sum of myriads of
neighbor-to-neighbor communications, and is very common in Nature. Tumor cells reproduce this
behavior when a specific subgroup within a community of malignant cells of a tumor decides to
invade neighbor tissues or metastasize to other organs far away [16]. The collective acquisition of
specific properties of tumor cells composing specific tumor compartments is a well-documented event
in most tumors, CCRCC included [22]. This phenomenon applies also for tumor microenvironment.
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For example, a selective loss of PD-L1 expression has been detected in tumor infiltrating lymphocytes
(TIL) taking part of the vein/caval tumor thrombi compartment of CCRCC [23].
Predation refers to an inter-individual relationship in which one individual benefits the other
killing it. The attack of some T-cells co-localized with tumor cells that is so evident under the
microscope in some CCRCC is a good example of predation. This phenomenon has been investigated
mainly in breast tumors. For example, a high co-localization of immune and tumor cells was associated
to higher 10-year survival in Her2+ breast carcinomas [24]. In the same sense, the pattern of the
PD-1/PD-L1 axis expression in tumor cells and in TIL predicts tumor aggressiveness and survival also
in Her2+ breast cancer [25]. Although PD-1/PD-L1 axis blockade is being used with great promise
for advanced CCRCC treatment, none study of co-localization of immune and cancer cells in these
neoplasms has been published so far.
Cancer cells not always compete for scarce resources. Mutualism applied to cancer refers to
the cooperation of two different cell clones for the same benefit thus favoring tumor growth and
invasion. This process usually implicates extracellular matrix proteins, such as metalloproteinases and
fibronectin, as happens in a zebrafish-melanoma xenograft model [26]. Interestingly, this cooperation
has also been identified between tumor cells and stromal inflammatory cells [27].
Examples of commensalism have also been reported in neoplasia. Commensalism describes the
relationship of two different cell clones for the benefit of one of them, although the other being not
damaged. Also, this process refers to tumor cells and microenvironment cells interactions, for example,
the cooperation between tumor cells and tumor-associated fibroblasts favoring tumor progression and
metastases [28,29]. High levels of fibroblast activation protein (FAP) have been correlated with tumor
size, high grade, high stage and shorter survival in CCRCC, both in primary tumors [30] and in its
paired metastases [31]. In this regard, the IHC detection of FAP in the stromal tumor fibroblasts could
be a potential biomarker of early lymph node metastatic status and therefore could account for the
poor prognosis of FAP positive CCRCC [29]. Even more, recent evidences have shown that tumor
microenvironment may vary in an organ-related way along the multiple disseminated metastases of
the same tumor [32].
In these collective relationships, some situations lead to an individual to benefit from another
damaging it, although not enough so as to destroy it (as happens in predation). In Ecology, this situation
is termed parasitism and also occurs in tumor cell communities, for example, when considering
the systemic damage generated by the local invasiveness and the metastatic spread of a tumor.
This situation could be conceived as a reversal manifestation of the Warburg effect [33], and may
explain the frequent association of tumor desmoplasia and biological aggressiveness that occur in
many neoplasms.
3. Spatial and Temporal Evolution in Clear Cell Renal Cell Carcinomas
As mentioned in previous paragraphs, several researchers have shown how cancer can be
regarded from an ecological perspective that governs tumor evolution [17,34,35]. Obvious ethical
reasons do not allow the analysis of the temporal evolution of any tumor. However, bioinformatic
tools can infer this process by reconstructing the past chronology. Data coming from the molecular
analysis of the tumor tissue obtained from the patient can be phylogenetically analyzed. For example,
a mathematical modeling has recently defined the timing in the evolution of CCRCC showing that
the tumor originates as soon as in the childhood or adolescence of the patient, and remains silent for
decades until appearing symptomatic [36]. More exactly, these early events in CCRCC consist in 3p
loss with concurrent 5q gain as a result of chromothrypsis, a process that occurs only in a few hundreds
of cells [36].
Four models of tumor evolution have been proposed: linear, branched, punctuated and
neutral [37]. With respect to the evolutionary patterns, CCRCC may follow branched or punctuated
models, as reported very recently [38].
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In the linear evolution model, the new sequential driver mutations that appear across the time
vanishes the previous ones due to a strong selective advantage. Such tumor evolution was proposed
long time ago for some examples of colorectal adenocarcinomas [39]. Linear evolution is an example
of Darwinian model.
Branched evolution model has been identified in many human tumors, CCRCC included [12],
and basically consists in a truncal mutation shared by all tumor regions followed by clonal, sub-clonal
and private mutations across the different tumor regions. The resulting evolutionary trees are
shaped by the different accumulative clonal and sub-clonal divergences. Sub-clonal driver mutations
and convergent evolution are two features observed in the branched evolution of CCRCC [12,40].
Interestingly, the coexistence of multiple sub-clones in branched tumors opens the door for the
possibility of some type of sub-clonal cooperation following any of the ecological patterns described
before. Branched evolution also follows a Darwinian model.
Also called the “Big Bang” model [41], the punctuated evolution model is characterized by a large
number of genomic changes occurring at very early stages of tumor evolution. ITH is very high at the
beginning but decreases progressively across the time as a result of the high selective predominance
of very few clones. Typically, tumors developed in a punctuated model display low ITH and high
amounts of single chromosomal rearrangements, a phenomenon termed chromothrypsis present in
several human tumors, including a subset of CCRCC [36]. Punctuated evolution is also a Darwinian
model of tumor evolution.
Neutral evolution is a paradigm of a non-Darwinian model with extremely high ITH in which
natural selection driven by sub-clonal mutations and convergent evolution does no take place.
Most CCRCC follow either branched or punctuated evolution models. In this regard, a recent
multicenter study analyzing 1206 regions from 101 patients has demonstrated that CCRCC display
up to seven distinct evolutionary subtypes [38]. Three of these subtypes (multiple clonal drivers,
BAP1 driven and VHL wild type tumors) followed a punctuated model, were associated to aggressive
clinical behavior and showed early 9p and 14q losses, high chromosomal complexity and low ITH.
By contrast, three other subtypes (PBRM1 → SETD2, PBRM1 → PI3K and PBRM1 → SCNA driven
tumors) followed a branched model and were associated to a less aggressive behavior, with late 9p
and 14q losses, low chromosomal complexity and high ITH. The sub-clonal acquisition of BAP1 or
other mutations linked to clinical aggressiveness marked the inflexion from indolence towards rapid
evolution in this group of CCRCC. Finally, a seventh subtype (VHL mono-driver) was characterized
by low chromosomal complexity and low ITH. Typically, this last subtype did not display 9p or 14q
losses. These molecular subtypes were associated with classic gross (tumor diameter) and histological
(Furhman’s grade, TNM staging, presence of necrosis) parameters and have prognostic implications
for patients [38].
With respect to the development of metastases, CCRCC have shown specific routes in a thorough
analysis of 575 primary and 335 metastatic biopsies in 100 patients with metastatic CCRCC [42].
This multicenter study included three different cohorts of paired primary and metastatic samples of
CCRCC with clinical follow up. The analysis also included samples obtained from the tumor thrombi
in 24 cases. In summary, the aggressive evolutionary subtypes, that is, tumors with high chromosomal
complexity and low ITH displayed a rapid progression to multiple metastases, whereas the opposite,
that is, tumors with low chromosomal complexity but high ITH showed an attenuated temporal
tumor progression, with tendency to develop late single metastasis. Finally, tumors within the seventh
subtype never metastasized.
Although ITH is a main contributor to the development of therapeutic resistance, the mechanisms
that underlie this causal inter-relation provide an example of natural selection through evolutionary
adaptation [43]. Genetic and epigenetic changes contribute to modify and adapt tumor cell fitness to
the new requirements, thus selecting specific clones not only to invade or metastasize, but also to resist
to drugs. Targeted therapies, by definition, select tumor cell populations for resistance, this process
being Darwinian in essence [44]. However, therapeutic resistance does not solely concern tumor cells;
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the local tumor microenvironment also takes part in this process, for example, when the hypoxic status
observed in some regions of many tumors applies additional pressure on tumors and contributes to
the selection of cell clones adapted to survive under the new conditions [45]. Since drug resistances
are a problem of major concern in Oncology and this issue is directly related to regional ITH, a more
efficient sampling method to clarify this problem seems mandatory.
4. The Need for an Updated Tumor Sampling Adapted to Tumor Type
The only way to discover the complex spectrum of ecological relationships and the spatial and
temporal evolution of tumors that have been revisited in previous paragraphs of this narrative is to
improve significantly the tumor representativeness with an affordable sampling. In this sense, total
tumor sampling would be the ideal solution, but it is not sustainable because many tumors are too
large to be analyzed in their entirety. For these cases international accepted protocols were designed.
At least theoretically, an effective sampling strategy must assure getting enough tissue so as to provide
reliable information in a probable subsequent molecular analysis. The benefit of such strategy should
necessarily be balanced with cost in a difficult sustainable equilibrium. At this point the key question
is: How extensive must this sampling be to assure tumor representativeness while keeping the costs
affordable? or, in other words, when to stop sampling? The answer is complex.
The strategy of getting one tissue fragment (roughly a piece of 1 cm2 in dimension) per centimeter
of tumor diameter is a rule applied to all tumors, comes from the early days of Pathology and is still
followed by pathologists worldwide. When, how and why this strategy was chosen is difficult to know.
Although our knowledge about neoplasms has dramatically improved since those days, astonishingly,
nothing has changed in tumor sampling. Instead, pathologists focus their interest on the advances
provided by -omics and other molecular advances brought by sophisticated devices and forget that
the most expensive and advanced technique may miss the target if applied in an inappropriate or
insufficient tissue sample. Once more, the simplest matters.
Internationally accepted protocols of tumor sampling state that one tumor tissue fragment per
centimeter of tumor diameter must be got for histological analysis, plus a fragment of any suspicious
area [46]. As many tumors appear homogeneous to the naked eye when sliced, tumor selection is
usually performed by the pathologist in a blind way and hidden areas of heterogeneity that may be
crucial for the patient are usually overlooked.
MSTS has been recently proposed for CCRCC (Figure 1) [13]. This approach follows the rationale
the more you sample the more you find and applies the divide and conquer algorithm [47]. This algorithm
has been already applied to resolve complex problems in physics [48], biology [49] and medicine [50],
and is based on recursively breaking down a problem in smaller parts (divide) until these are simple
enough to be solved directly (conquer). Then, partial solutions are combined to solve the original
problem. MSTS has proved to outperform routine protocols in a in silico modeling [14] and in a clinical
validation using classic histological parameters [51]. By using MSTS, it is possible to increase the
number of samples while keeping the number of cassettes fixed. For such a purpose, the size of the
samples must be trimmed from 1 cm2 to 3 mm2. This way each cassette can contain 8 small samples
per cassette (80 in total in a tumor of 10 cm in diameter) obtained from very different, distant and
representative regions of the tumor (Figure 2). A straightforward reasoning says that 80 small tissue
fragments have a higher chance for detection of ITH as compared to 10 large samples.
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Figure 1. Schematic representation of routine and multisite tumor sampling (MSTS) concepts in renal
tumors. The scheme shows the routine sampling (left) and the MSTS (right). Red cubes represent
samples at the edges of the tumor (renal sinus, extrarenal extension and interface between non-tumor
and tumor kidney) to detect tumor invasion at these levels. The green cube represents the preceptive
sample of normal kidney. Black cubes represent the tumor sampling in both strategies making use
of the same number of blocks (up to 8 small fragments can be introduced in one cassette in MSTS).
Cassettes containing tumor tissue fragments from MSTS are shown at the bottom of the picture.
Figure 2. Multisite tumor sampling example in a clear cell renal cell carcinoma (CCRCC) showing the
varied spectrum of histologies detected across the eight selected fragments in a single paraffin block,
with clear cell high grade phenotype in sample 1, papillary eosinophilic in samples 2, 3, 4 and 6, solid
eosinophilic in sample 5, and clear cell low grade in samples 7 and 8. (Hematoxylin & Eosin, original
magnification, × 1.5 (large figure) and × 400 (figures 1 to 8)).
If it is accepted that the paraffin block can be the unit of cost in pathology laboratories, it can be
assumed that MSTS is better than routine sampling protocol at the same cost [14]. Finally, this method
allows the inclusion a small fragment of normal renal tissue in each cassette that can be useful as
internal control for immunohistochemistry and/or molecular analyses. The storage of such amount
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of formalin-fixed and paraffin-embedded tumor tissue fragments in pathology laboratories may be
very useful in the future when new technologies allow better analyses. However, pathologists may be
reluctant to use MSTS because it takes a long time to collect 80 small samples in a tumor. The application
of a cutting grid to the tumor slices in the grossing room will shorten significantly the process [52].
Also, an adaptation of MSTS to large tumors arising in hollow viscera has also been proposed,
for example, for cancers arising along the digestive tract. In this particular setting, the anatomical
barrier represented by the muscularis propria leads the tumors to grow with their long axes parallel
to the wall of the viscera forming tumors with plate-like shapes, and not like spheroids as happens
in the kidney, liver or other solid organs. Instead of tissue cubes, the sampling model here gets
tissue bars including the whole thickness (from the lumen to the perivisceral adipose tissue) of the
viscera [53]. MSTS has obtained here also better performances in detecting ITH compared with routine
sampling [53].
As commented in previous paragraphs, temporal evolution in CCRCC follows several
deterministic pathways that have been defined either as branched or punctuated models [37].
The discovering of branched CCRCC would benefit specially from MSTS. This possibility makes
this strategy even more advantageous in these particular cases. Finally, the performance of MSTS to
discover ITH has also proved to be superior at any time of tumor evolution and in all models compared
with routine protocols [54].
Recent evidences, however, have demonstrated that tumor sampling must be adapted to the
tumor type to be efficient because tumor evolution and the spectrum of ITH are in fact very different,
as reflected by the range of evolutionary trees detected across different cancer types [55]. MSTS seems
to be an advantageous approach in large tumors with high ITH because in these cases getting samples
from many tumor regions will give more complete information of the whole mutational landscape.
This happens specially in tumors following branched and neutral models. By contrast, tumors with
low ITH levels, although sometimes more aggressive, apparently will not directly benefit from an
exhaustive sampling across the tumor. This may happen in neoplasms following the linear and
punctuated models.
5. Conclusions
This review is addressed to clinicians and pathologists that are involved in Oncology, and revisits
the complexity of tumor evolution with a special mention to the reasons for which each tumor is
truly unique. The definition of a more efficient method to discover this complexity is an urgent task.
Pathologists, the medical specialists who handle surgical specimens, must reconsider if the currently
accepted protocols for tumor sampling are appropriate enough to offer with reliability the expected
answers that precision medicine needs today. In this regard, new sampling methods could provide
substantial advantages for a more precise diagnosis in a subset of cases. MSTS could be a good option
since it keeps the balance cost/benefit sustainable.
Author Contributions: E.L.-F. and J.I.L. conceived and wrote the review.
Funding: This work has been partially funded by the grant SAF2016-79847-R from Ministerio de Economía y
Competitividad (MINECO), Spain (J.I.L.).
Conflicts of Interest: The authors declare no conflicts of interests.
References
1. Turajlic, S.; Swanton, C.; Boshoff, C. Kidney cancer: The next decade. J. Exp. Med. 2018, 215, 2477–2479.
[CrossRef] [PubMed]
2. Hsieh, J.J.; Purdue, M.P.; Signoretti, S.; Swanton, C.; Albiges, L.; Schmidingen, M.; Heng, D.Y.; Larkin, J.;
Ficarra, V. Renal cell carcinoma. Nat. Rev. Dis. Primers 2017, 3, 17009. [CrossRef] [PubMed]
3. Tannir, N.M.; Pal, S.K.; Atkins, M.B. Second-Line Treatment Landscape for Renal Cell Carcinoma:
A Comprehensive Review. Oncologist 2018, 23, 540–555. [CrossRef] [PubMed]
237
Cancers 2018, 10, 485
4. Wu, B.; Zhang, Q.; Sun, J. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced
renal-cell carcinoma. J. Immunother. Cancer 2018, 6, 124. [CrossRef]
5. Blumenfeld, A.J.; Guru, K.; Fuchs, G.J.; Kim, H.L. Percutaneous biopsy of renal cell carcinoma underestimates
nuclear grade. Urology 2010, 76, 610–613. [CrossRef]
6. Tomaszewski, J.J.; Uzzo, R.G.; Smaldone, M.C. Heterogeneity and renal mass biopsy: A review of its role
and reliability. Cancer Biol. Med. 2014, 11, 162–172. [CrossRef]
7. Beltrame, L.; di Martino, M.; Fruscio, R.; Calura, E.; Chapman, B.; Clivio, L.; Sina, F.; Mele, C.; Iatropoulos, P.;
Grassi, T.; et al. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted
next-generation sequencing: A retrospective study. Ann. Oncol. 2015, 26, 1363–1371. [CrossRef]
8. Bettoni, F.; Masotti, C.; Habr-Gama, A.; Correa, B.R.; Gama-Rodrigues, J.; Vianna, M.R.; Vailati, B.B.;
Sao Juliao, G.P.; Fernandez, L.M.; Galante, P.A.; et al. Intratumoral genetic heterogeneity in rectal cancer. Are
single biopsies representative of the entirety of the tumor? Ann. Surg. 2017, 265, e4–e6. [CrossRef]
9. Ellsworth, R.E.; Blackburn, H.L.; Shriver, C.D.; Soon-Shiong, P.; Ellsworth, D.L. Molecular heterogeneity in
breast cancer: State of the science and implications for patient care. Semin. Cell Dev. Biol. 2017, 64, 65–72.
[CrossRef]
10. Soultati, A.; Stares, M.; Swanton, C.; Larkin, J.; Turajlic, S. How should clinicians address intratumor
heterogeneity in clear cell renal cell carcinoma? Curr. Opin. Urol. 2015, 25, 358–366. [CrossRef]
11. Marusyk, A.; Almendro, V.; Polyak, K. Intra-tumour heterogeneity: A looking glass for cancer? Nat. Rev.
Cancer 2012, 12, 323–334. [CrossRef] [PubMed]
12. Gerlinger, M.; Rowan, A.J.; Horswell, S.; Math, M.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.;
Matthews, N.; Stewart, A.; et al. Intratumor heterogeneity and branched evolution revealed by multiregion
sequencing. N. Eng. J. Med. 2012, 366, 883–892. [CrossRef]
13. López, J.I.; Cortés, J.M. Multi-site tumor sampling (MSTS): A new tumor selection method to enhance
intratumor heterogeneity detection. Hum. Pathol. 2017, 64, 1–6. [CrossRef] [PubMed]
14. López, J.I.; Cortés, J.M. A divide and conquer strategy in tumor sampling enhances detection of intratumor
heterogeneity in pathology routine: A modeling approach in clear cell renal cell carcinoma. F1000Research
2016, 5, 385. [CrossRef]
15. De la Fuente, I.M. Elements of the cellular metabolic structure. Front. Mol. Biosci. 2015, 2, 16. [CrossRef]
[PubMed]
16. Diesboeck, T.S.; Couzin, I.D. Collective behavior in cancer cell populations. BioEssays 2009, 31, 190–197.
[CrossRef] [PubMed]
17. Merlo, L.M.F.; Pepper, J.M.; Reid, B.J.; Maley, C.C. Cancer as an evolutionary and ecological process.
Nat. Rev. Cancer 2006, 6, 924–935. [CrossRef]
18. Horswell, S.; Matthews, N.; Swanton, C. Cancer heterogeneity and the “struggle for existence”: Diagnostic
and analytical challenges. Cancer Lett. 2013, 340, 220–226. [CrossRef]
19. Marcucci, F.; Stassi, G.; De Maria, R. Epithelial-mesenchymal transition: A new target in anticancer drug
discovery. Nat. Rev. 2016, 15, 311–325. [CrossRef]
20. Lopez, J.I.; Mosteiro, L.; Guarch, R.; Larrinaga, G.; Pulido, R.; Angulo, J.C. Low-grade metastases in
high-grade clear cell renal cell carcinomas. A clinicopathologic study of 4 cases with an insight into the role
of mesenchymal-to-epithelial transition process. Ann. Diagn. Pathol. 2016, 20, 13–18. [CrossRef]
21. Nawaz, S.; Yuan, Y. Computational pathology: Exploring the spatial dimension of tumor ecology. Cancer Lett.
2016, 380, 296–303. [CrossRef] [PubMed]
22. Warsow, G.; Hübschmann, D.; Kleinheinz, K.; Nientiedt, C.; Heller, M.; Van Coile, L.; Tolstov, Y.;
Trennheuser, L.; Wieczorek, K.; Pecqueux, C.; et al. Genomic features of renal cell carcinoma with venous
tumor thrombus. Sci. Rep. 2018, 8, 7477. [CrossRef] [PubMed]
23. López, J.I.; Pulido, R.; Lawrie, C.H.; Angulo, J.C. Loss of PD-L1 (SP-142) expression characterizes renal vein
tumor thrombus microenvironment in clear cell renal cell carcinoma. Ann. Diagn. Pathol. 2018, 34, 89–93.
[CrossRef] [PubMed]
24. Maley, C.C.; Koelble, K.; Natrajan, R.; Aktipis, A.; Yuan, Y. An ecological measure of immune-cancer
colocalization as a prognostic factor for breast cancer. Breast Cancer Res. 2015, 17, 131. [CrossRef] [PubMed]
25. Tsang, J.Y.S.; Au, W.L.; Lo, K.Y.; Ni, Y.B.; Hlaing, T.; Hu, J.; Chan, S.K.; Chan, K.F.; Cheung, S.Y.; Tse, G.M.
PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast
cancer patients. Breast Cancer Res. Treat. 2017, 162, 19–30. [CrossRef]
238
Cancers 2018, 10, 485
26. Chapman, A.; del Ama, L.F.; Ferguson, J.; Kamarashev, J.; Wellbrock, C.; Hurlstone, A. Heterogeneous tumor
subpopulations cooperate to drive invasion. Cell Rep. 2014, 8, 688–695. [CrossRef] [PubMed]
27. Sica, A.; Mantovani, A. Macrophage plasticity and polarization: In vivo veritas. J. Clin. Invest. 2012, 122,
787–795. [CrossRef] [PubMed]
28. Hwang, R.F.; Moore, T.; Arumugam, T.; Ramachandran, V.; Amos, K.D.; Rivera, A.; Ji, B.; Evans, D.B.;
Logsdon, C.D. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res.
2008, 68, 918–926. [CrossRef] [PubMed]
29. Zhang, Y.; Tang, H.; Cai, J.; Zhang, T.; Guo, J.; Feng, D.; Wang, Z. Ovarian cancer-associated fibroblasts
contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and
tumor cell invasion. Cancer Lett. 2011, 303, 47–55. [CrossRef]
30. López, J.I.; Errarte, P.; Erramuzpe, A.; Guarch, R.; Cortes, J.M.; Angulo, J.C.; Pulido, R.; Irazusta, J.; Llarena, R.;
Larrinaga, G. Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma. Hum. Pathol.
2016, 54, 100–105. [CrossRef]
31. Errarte, P.; Guarch, R.; Pulido, R.; Blanco, L.; Nunes-Xavier, C.E.; Beitia, M.; Gil, J.; Angulo, J.C.; Lopez, J.I.;
Larrinaga, G. The expression of fibroblast activation protein in clear cell renal cell carcinomas is associated
with synchronous lymph node metastases. PLoS ONE 2016, 11, e0169105. [CrossRef] [PubMed]
32. Jimenez-Sanchez, A.; Memon, D.; Pourpe, S.; Veeraraghavan, H.; Li, Y.; Vargas, H.A.; Gill, M.B.; Park, K.J.;
Zivanovic, O.; Konner, J.; et al. Heterogeneous tumor-immune microenvironments among differentially
growing metastases in an ovarian cancer patient. Cell 2017, 170, 927–938. [CrossRef] [PubMed]
33. Pavlides, S.; Whitaker-Menezes, D.; Castello-Cros, H.; Flomenberg, N.; Vitkiewicz, A.K.; Frank, P.G.;
Casimiro, M.C.; Wang, C.; Fortina, P.; Addya, S.; et al. The reverse Warburg effect: Aerobic glycolysis
in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8, 3984–4001. [CrossRef] [PubMed]
34. Marusyk, A.; Polyak, K. Tumor heterogeneity: Causes and consequences. Biochim. Biophys. Acta 2010, 1805,
105–117. [CrossRef] [PubMed]
35. McGranahan, N.; Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer
evolution. Cancer Cell 2015, 27, 15–26. [CrossRef] [PubMed]
36. Mitchell, T.J.; Turajlic, S.; Rowan, A.; Nicol, D.; Farmery, J.H.R.; O’Brien, T.; Martincorena, I.; Tarpey, P.;
Angelopoulos, N.; Yates, L.; et al. Timing the landmark events in the evolution of clear cell renal cell cancer:
TRACERx Renal. Cell 2018, 173, 611–623. [CrossRef]
37. Davis, A.; Gao, R.; Navin, N. Tumor evolution: Linear, branching, neutral or punctuated? Biochim. Biophys.
Acta 2017, 1867, 151–161. [CrossRef]
38. Turajlic, S.; Xu, H.; Litchfield, K.; Rowan, A.; Horswell, S.; Chambers, T.; O’Brien, T.; Lopez, J.I.;
Watkins, T.B.K.; Nicol, N.; et al. Deterministic evolutionary trajectories influence primary tumor growth:
TRACERx Renal. Cell 2018, 173, 595–610. [CrossRef]
39. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759–767. [CrossRef]
40. Gerlinger, M.; Horswell, S.; Larkin, A.J.; Rowan, A.J.; Salm, M.P.; Varela, I.; Fisher, R.; McGranahan, N.;
Matthews, N.; Santos, C.R.; et al. Genomic architecture and evolution of clear cell renal cell carcinomas
defined by multiregion sequencing. Nat. Genet. 2014, 46, 225–233. [CrossRef]
41. Sottoriva, A.; Kang, H.; Ma, Z.; Graham, T.A.; Salomon, M.P.; Zhao, J.; Marjoram, P.; Siegmund, K.; Press, M.F.;
Shibata, D.; et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 2015, 47, 209–216.
[CrossRef] [PubMed]
42. Turajlic, S.; Xu, H.; Litchfied, K.; Rowan, A.; Chambers, T.; Lopez, J.I.; Nicol, D.; O’Brien, T.; Larkin, J.;
Horswell, S.; et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell
2018, 173, 581–594. [CrossRef] [PubMed]
43. Arnal, A.; Ujvari, B.; Crespi, B.; Gatenby, R.A.; Tissot, T.; Vittecoq, M.; Ewald, P.W.; Casali, A.; Ducasse, H.;
Jacqueline, C.; et al. Evolutionary perspective of cancer: Myth, metaphors, and reality. Evol. Appl. 2015, 8,
541–544. [CrossRef] [PubMed]
44. Pepper, J.W. Darwinian Strategies to Avoid the Evolution of Drug Resistance during Cancer Treatment. Evolutionary
Thinking in Medicine; Alvergne, A., Ed.; Springer: Cham, Switzerland, 2016; pp. 167–176.
45. Lloyd, M.C.; Cunningham, J.J.; Bui, M.M.; Gillies, R.J.; Brown, J.S.; Gatenby, R.A. Darwinian dynamics of
intratumoral heterogeneity: Not solely random mutations but also variable environmental selection forces.
Cancer Res. 2016, 76, 3136–3144. [CrossRef] [PubMed]
239
Cancers 2018, 10, 485
46. Trpkov, K.; Grignon, D.J.; Bonsib, S.M.; Amin, M.B.; Billis, A.; Lopez-Beltran, A.; Samaratunga, H.; Tamboli, P.;
Delahunt, B.; Egevad, L.; et al. Handling and staging of renal cell carcinoma: The International Society
of Urological Pathology Consensus (ISUP) conference recommendations. Am. J. Surg. Pathol. 2013, 37,
1505–1517. [CrossRef] [PubMed]
47. Cormen, T.H.; Leiserson, C.E.; Rivest, R.L.; Stein, C. Introduction to Algorithms, 2nd ed.; MIT Press: Cambridge,
MA, USA, 2001.
48. Ming, D.; Yang, W. A divide and conquer strategy to improve diffusion sampling in generalized ensemble
simulators. J. Chem. Phys. 2008, 128, 094106. [CrossRef]
49. Eisenstein, M. Cell sorting: Divide and conquer. Nature 2006, 441, 1179–1185. [CrossRef]
50. Kristensen, V.N. Divide and conquer: The genetic basis of molecular subclassification of breast cancer.
EMBO Mol. Med. 2011, 3, 183–185. [CrossRef]
51. Guarch, R.; Cortés, J.M.; Lawrie, C.H.; Lopez, J.I. Multi-site tumor sampling (MSTS) significantly improves
the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma.
F1000Research 2016, 5, 2020. [CrossRef]
52. López, J.I.; Cortés, J.M. A multi-site cutting device implements efficiently the divide-and-conquer strategy in
tumor sampling. F1000Research 2016, 5, 1587. [CrossRef]
53. Cortés, J.M.; de Petris, G.; López, J.I. Detection of intratumor heterogeneity in modern pathology: A multisite
tumor sampling perspective. Front. Med. 2017, 4, 25. [CrossRef] [PubMed]
54. Erramuzpe, A.; Cortés, J.M.; López, J.I. Multisite tumor sampling enhances the detection of intratumor
heterogeneity at all different temporal stages of tumor evolution. Virchows Arch. 2018, 472, 187–194.
[CrossRef] [PubMed]
55. McGranahan, N.; Swanton, C. Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell
2017, 168, 613–628. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Exploring Tumor Heterogeneity Using PET Imaging:
The Big Picture
Clément Bailly 1,2, Caroline Bodet-Milin 1,2, Mickaël Bourgeois 1,2,3, Sébastien Gouard 1,
Catherine Ansquer 2, Matthieu Barbaud 2, Jean-Charles Sébille 2, Michel Chérel 1,3,4,
Françoise Kraeber-Bodéré 1,2,4 and Thomas Carlier 1,2,*
1 CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, 44093 Nantes, France
2 Nuclear Medicine Department, University Hospital, 44093 Nantes, France
3 Groupement d’Intérêt Public Arronax, 44800 Saint-Herblain, France
4 Nuclear Medicine Department, ICO-René Gauducheau Cancer Center, 44800 Saint-Herblain, France
* Correspondence: thomas.carlier@chu-nantes.fr; Tel.: +33-240-084-136; Fax: +33-240-084-218
Received: 25 June 2019; Accepted: 28 August 2019; Published: 31 August 2019
Abstract: Personalized medicine represents a major goal in oncology. It has its underpinning in
the identification of biomarkers with diagnostic, prognostic, or predictive values. Nowadays, the
concept of biomarker no longer necessarily corresponds to biological characteristics measured
ex vivo but includes complex physiological characteristics acquired by different technologies.
Positron-emission-tomography (PET) imaging is an integral part of this approach by enabling the fine
characterization of tumor heterogeneity in vivo in a non-invasive way. It can effectively be assessed
by exploring the heterogeneous distribution and uptake of a tracer such as 18F-fluoro-deoxyglucose
(FDG) or by using multiple radiopharmaceuticals, each providing different information. These
two approaches represent two avenues of development for the research of new biomarkers in
oncology. In this article, we review the existing evidence that the measurement of tumor heterogeneity
with PET imaging provide essential information in clinical practice for treatment decision-making
strategy, to better select patients with poor prognosis for more intensive therapy or those eligible for
targeted therapy.
Keywords: PET; heterogeneity; radiomics; radiopharmaceuticals; SUV; nuclear medicine
1. Introduction
Heterogeneity is a concept familiar to pathologists. Phenotypical and functional differences arise
among cancer cells during the course of the disease because of genetic changes [1]. Similarly, the
interactions of cancer cells with their microenvironment or the local variation in angiogenesis and
hypoxia are not uniform in the tumor. Not to mention the perpetual clonal remodeling under the
pressure of microenvironment and treatments. This large biological, cellular, and tissue heterogeneity
exist at the intratumoral level (molecular differences within one tumor), intrapatient level (variation
of tumor features between lesions within one patient), and interpatient level (variation of tumor
features between patients). This heterogeneity conditions tumor aggressiveness and therapeutic
resistance and represents a significant challenge in the design of effective treatment strategies [2]. The
prerequisite for personalized medicine relies on the report of such heterogeneities. Yet, the realization
of multi-region sampling from each tumor of a single patient raises ethical or technical questions.
Positron-emission-tomography (PET) imaging appears as a perfect tool to overcome this obstacle,
providing a whole-body non-invasive method of assessing tumor heterogeneity, through the use of
multiple radiopharmaceuticals, each providing different information. In parallel, the information
derived from the uptakes’ analysis of a tracer such as 18F-fluoro-deoxyglucose (FDG) has enabled
the emergence of a wide variety of PET quantitative metrics including simple semi-quantitative
Cancers 2019, 11, 1282; doi:10.3390/cancers11091282 www.mdpi.com/journal/cancers241
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approaches such as standardized uptake value (SUV) and “high-order metrics” that involve a
segmentation step and supplementary image processing. These parameters, besides their utility for
therapeutic response, should play a key role in the prognostic characterization of tumors, along with
the development of personalized medicine. Radiomics—the high throughput extraction of large
amounts of imaging elements from radiographic images—tackles this challenge and is one of the most
promising strategies [3,4]. The purpose of this short review is to present the latest developments in the
exploration of tumor heterogeneity in PET imaging. Different examples of neoplasias are presented
during the three developed axes. Nevertheless, to emphasize to the reader that these tools can be used
in all diseases, lymphoma is used as a common thread throughout this review.
2. Inter- and Intra-patient Tumor Heterogeneity Exploration through Multiple Tracers PET
Imaging
Nuclear medicine is one of the most dynamic medical fields, in constant evolution over the past
decades. The main strength of this discipline lies in its incredible catalog of radiopharmaceuticals
allowing exploration of virtually every major organ system in the body (Table 1). Personalized medicine
has never been so relevant today and nuclear medicine is on its leading edge, probing deep inside
each patient or tumor to reveal its inner workings. Predictive biomarkers are an essential tool of
precision medicine and individualized treatment. Yet, as mentioned above, tumor heterogeneity
contributes to sampling error, especially for metastatic diseases; target’s expression at one site does
not guarantee expression at all sites. Moreover, target accessibility of drugs is not assessed by biopsy,
and target expression does not provide evidence of targeted-therapy impact on the target. In this
context, PET imaging overcomes many of these limitations exploring target heterogeneity, assessing
target expression and potential accessibility across the whole disease burden, to aid clinical decision
making. A perfect example was recently published by Bensch et al. with the initial results from
the first-in-human imaging with 89Zirconium-labeled atezolizumab [5]. The programmed cell death
protein 1 (PD1)/programmed death-ligand 1 (PD-L1) axis is an important immune checkpoint for T-cell
activation. PD-L1 overexpression is associated with a poor prognosis in a variety of cancers yet these
patients typically have a stronger response to anti-PD-L1 therapy such as atezolizumab [6–9]. The
PD-L1 expression is usually evaluated using immunohistochemistry or RNA sequencing. In Bensch
et al. study, clinical responses were better correlated with PET uptake before treatment than these
two evaluations.
Table 1. Main validated positron-emission-tomography (PET) tracers and their principal indications
(based on [10,11]).
Tracer Metabolic Process Principal Oncological Indications
11C-Methionine Amino acid transport and proteinsynthesis Diagnosis and grading of brain tumors
18F-Choline (FCH) Phosphatidylcholine metabolismand cellular membrane turnover
Biopsy guidance of prostate cancer recurrence/primary
staging in high-risk prostate cancer before surgical
procedures or planning external beam radiation
18F-Fluoro-Deoxyglucose (FDG) Glucose metabolism
Diagnosis/restaging of lung cancer, colorectal cancer, breast
cancer, lymphoma, sarcoma, melanoma, head and neck
cancer
18F-DOPA Dopamine uptake and metabolism Diagnosis of neuroendocrine tumors (NET)/documentedNET metastasis in unknown primary
68Ga-DOTA-Peptides Somatostatin receptors
Identification of primary tumor in patients with
documented NET metastasis/assessment of NET disease
extent before treatment
18F-Fluoroestradiol (FES) Estrogen receptor Status of tumor lesions to determine need for endocrinetherapy in breast cancer
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Table 1. Cont.
Tracer Metabolic Process Principal Oncological Indications
18F-Fluorothymidine (FLT) Cellular proliferation and Differential diagnosis between benign and malignantlesions/lymphoma staging and therapeutic evaluation
18-Sodium Fluoride (NaF) Bone metabolism Detection of bone involvement in tumors with elevatedrisk of bone metastasis
68Ga-Prostate-Specific Membrane
Antigen (PSMA) PSMA expression Localization of tumor tissue in recurrent prostate cancer
Breast cancer also represents a great model for this type of approach [12,13]. Indeed, in this
pathology, 18F-fluoroestradiol (FES) PET has been validated as an accurate method for providing
information on estrogen receptor (ER) status of tumor lesions to determine need for endocrine
therapy [14–17]. Indeed, the uptake of FES has been proven to correlate with ER expression in
biopsy sample [16]. Similarly, several works showed that radiolabeled monoclonal antibodies could
non-invasively identify lesions with positive or over-expression of the human epidermal growth factor
receptor 2 (HER2) and predict response to anti-HER2 antibody-based therapy [18–21]. In particular,
Gebhart et al. recently reported the promising results of the ZEPHIR trial. This work successfully
evaluated two PET imaging as tools to investigate heterogeneity of advanced HER2-positive breast
cancer (PET imaging using trastuzumab radiolabeled with 89Zirconium) and to predict patient outcome
under trastuzumab emtansine (PET imaging with FDG) [22,23]. This innovative study showed the
clear benefit of combining both imaging methods in predicting whether adequate tumor targeting is
followed by sufficient efficacy and cytotoxicity.
Beyond the “simple” search for the expression of a target before initiating a treatment directed
against it, the use of several radiotracers in the same patient can allow to comprehensively assess
disease activity, extent, and heterogeneity. Tumors derived from cells of the neural crest represent
the perfect historical model for this approach [24]. This large group of neoplasms includes a large
variety of tumors, such as gastroenteropancreatic neuroendocrine tumors (GEPs), neuroblastoma,
paraganglioma, pheochromocytoma, medullary thyroid carcinoma, and small cell lung cancer. These
tumors are characterized by similar appearances and expression of different peptides and amines.
Prognostic criteria of this group are generally related to the metastatic extension of the disease but
also to the functional activity, degree of differentiation of the tumor and proliferative indices. These
parameters are essential in the management of these patients. Today, multiple molecular imaging
methods are available to explore these various biologic and histologic characteristics with very high
specificity and can be performed at the whole-body scale [25,26]. Tracers used can be grouped in
three different categories. 123-metaiodobenzylguanidine (123MIBG), an analog of norepinephrine and
18F-fluorodihydroxyphenylalanine (FDOPA), an amine precursor, exploit catecholamine synthesis,
storage, and secretion pathways. 111In-pentetreotide and 68Gallium-labeled somatostatin analog
peptides (68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE) assess the somatostatin receptors
expression. Finally, FDG uptake has been found to correlate with de-differentiation, increasing
aggressiveness and proliferation rate, and poor prognosis. This phenomenon was first described in
differentiated thyroid carcinomas. Indeed, de-differentiated thyroid carcinomas lose their capacity to
capture radioiodine and can be detected by FDG-PET since glycolysis increase at the same time. Thus,
imaging assessment of two or more tracers may yield more clinical information than each alone [27–32]
(Figures 1 and 2).
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Figure 1. An example of a 46-year-old patient with pluri-metastatic intestinal neuroendocrine
tumor (grade 2, ki67 at 4%). 68Ga DOTA-TOC (A), FDG-PET (18F-fluoro-deoxyglucose-
positron-emission-tomography) (B) and FDOPA (18F-fluorodihydroxyphenylalanine) (C) imaging
were realized. MIP (maximum intensity projections) images from the respective PET data sets are
shown. The subject has positive on both FDOPA and somatostatine-receptor imaging, dominant
disease which exhibits no FDG uptake (green arrows). One hepatic lesion was FDOPA-negative
and 68Ga-DOTA-TOC-positive (red arrow) and one gastric lesion was FDOPA-positive and
68Ga-DOTA-TOC negative (blue arrow). Images courtesy of Pr C. Bodet-Milin.
Figure 2. An example of 37-year-old patient with pluri-metastatic paraganglioma. MIP (maximum
intensity projections) images of the realized 123MIBG-scintigraphy (A), FDG-PET (B) and FDOPA-PET
(C) are shown. The subject has a mediastinal lesion, barely seen on 123MIBG-scintigraphy and clearly
positive with the others tracers (red arrows). Pulmonary and skull lesions (green arrows) were only
visible on FDOPA-PET. Images courtesy of Dr C. Ansquer© Catherine Ansquer
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Lymphomas represent another cancer group where multiple tracers’ exploration might allow a
better potential characterization of tumor heterogeneity. Indeed, today, FDG-PET occupies a central
position in accurate staging and therapeutic evaluation of lymphomas [33]. Nevertheless, a certain
number of crucial questions remain regarding its optimal application. While risk-based strategies
may appear to enhance patients’ outcomes for those with Hodgkin’s lymphoma, findings are not so
impressive in non-Hodgkin’s lymphoma [33]. Similarly, novel therapies that may generate an immune
response may lead to false-positive FDG-PET results, requiring the incorporation of these flare-ups
reactions in existing interpretation criteria [34]. Therefore, the development of other radiotracers
with different uptake mechanisms from FDG could be of interest [35]. 18F-fluorothymidine (FLT)
and 11C-methionine (MET), for instance, were both reported to correlate with cellular proliferation
activity and lymphoma histological grade of malignancy, respectively, through the exploration of DNA
and protein synthesis [36,37]. Moreover, FLT showed excellent results in treatment monitoring and
particularly in the setting of early interim evaluation, with more specific and accurate analyses than
FDG [38,39]. In the same way, 18F-fludarabine, an adenine nucleoside analog, owing to its specificity for
lymphoid cells and its absence of uptake in inflammatory tissues, holds great promise for therapeutic
evaluation [40]. Finally, the first in-human study of 68Ga-CXCR4, targeting chemokine receptor
CXCR4, which is frequently overexpressed in various tumor types, showed high lesions’ uptake [41,42].
Moreover, voxel-by-voxel analysis in one patient identified striking inter- and intralesional heterogeneity
in the uptake of 68Ga CXCR4 and FDG, implying that the biological information given by the two
probes may be complementary even in lesions that show avidity for both [42].
Systematic multiple tracers imaging could be used to reveal different profiles with highly different
prognoses. This multiple-tracers imaging associated with an appropriate scoring system might also
influence patients’ management and help selecting between different therapy options [28,43,44].
Indeed, these tumors may be treated with molecular radiotherapy using the same pathways:
131-metaiodobenzylguanidine (131-MIBG) and 177Lutetium-DOTA-TATE. Impressive reports were
reported with these targeted therapies in GEPs and neuroblastoma [45–49]. A theranostic approach,
integrating imaging and therapy in the same system, providing individualized tailored treatment,
despite intratumor and interlesional heterogeneities, is expected to play an increasingly pivotal role in
this large tumor group [50,51].
The theranostic approach indeed represents a formidable field of expansion for nuclear medicine
in an era where targeted therapies have become essential tools in oncology pharmacopoeia [52,53].
As described above in breast cancer and neuroendocrine tumors, it offers a non-invasive method
for quantitatively evaluating target expression in vivo, selecting patients for costly and potentially
toxic treatments, and monitoring responses [50,51,54–56]. In addition, this approach constitutes a
valuable asset in the development of new drugs by pharmaceutical companies. Drug development
being a fairly time-consuming and costly process, it represents an effective solution to rapidly monitor
drug candidates’ pharmacokinetics and biodistribution. This strategy can improve the strength and
effectiveness of early trials by enhancing patient selection, optimizing dose, and rationalizing treatment
reactions [54].
3. Intrapatient Tumor Heterogeneity Exploration through Quantitative Analysis of PET Imaging
FDG-PET has become an essential tool for cancer diagnosis, staging, and therapeutic evaluation.
It has undoubtedly changed the landscape of lymphoma, lung, head and neck or breast cancers
management [57–59]. This spread of the PET imaging technique was particularly enabled by its
quantification ability which allows the use of a reproducible metric for cancer monitoring. The SUV
and particularly SUVmax (defined as the SUV value of the maximum intensity voxel within a region of
interest) is widely used in everyday clinical practice. It is popularly adopted as a surrogate of tissue
accumulation of tracers and particularly as the overall net rate of FDG uptake. It is defined as the
ratio between the radiopharmaceutical concentration (expressed in Bq/mL) and the decay-corrected
injected activity normalized by a given factor (mass of the patient, body surface area or lean body
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mass) [60]. The precise description of underlying technical limitations of this metric is beyond the
scope of this short review and is already largely discussed in the literature [60–62]. Only its use under
clinical situation is highlighted here. Indeed, the computation of intrapatient tumor heterogeneity in
FDG-PET imaging using SUV has been already applied in a wide variety of indications even if not
intentionally or explicitly. FDG uptake heterogeneity may reflect different tumor profiles with different
aggressiveness and consequently prognosis. This contribution offered by the calculation of SUV has
been particularly investigated in lymphoma.
Some histological subtypes of lymphoma such as follicular and mantle cell lymphomas are
heterogeneous diseases with a variety of clinical, genetic, biological features and related different
outcomes. In these pathologies, the intensity of FDG uptake on PET imaging at baseline varies greatly
between patients [33]. Some present barely detectable uptakes while others exhibit very intense
fixations. Yet, this spectrum of SUV, from very low to very high uptakes, provides clinically relevant
information. Indeed, several reports demonstrated that the level of FDG uptake on PET imaging
is largely correlated to lymphoma histology [63,64]. More particularly, indolent disease with low
proliferation rate is generally associated with low uptake, while a more aggressive disease presented
higher FDG uptake. In the same way, very intense FDG uptake associated to a clear uptake gradient
may pertain transformation from indolent to aggressive lymphoma. These findings were confirmed in
a prospective study conducted to evaluate the value of FDG-PET as an accurate guide for biopsies
in suspected transformed tissues [65]. In patients with newly diagnosed indolent lymphoma, low
SUV numbers may reduce the suspicion of transformation in disease sites that were not biopsied.
Conversely, in patients with histologically proven indolent lymphoma, an uncharacteristically higher
than expected SUV may herald an aggressive subtype, warranting a targeted biopsy. Our team reported
similar findings in mantle cell lymphomas. A broad inter-individual tumor cell heterogeneity regarding
FDG avidity was observed in several works with a strong prognostic value on survival of quantitative
parameters such as SUVmax of the lesions with the highest uptake determined at diagnosis [66–69].
This close relationship between high SUVmax values and a more aggressive mantle cell lymphoma
behavior was also supported by the concordance between SUVmax, aggressive variants, and high
percentage (> 30%) of Ki67 positive cells.
This hypothesis that the prognosis of the disease is linked to the most aggressive contingent
corresponding to the lesion with the highest FDG uptake is also reinforced by some studies exploring
the predictive prognostic value of FDG-PET during treatment. Since the development of normalized
criteria for assessment of tumor burden changes, the required number of lesions to consider for response
determination remained a fundamental question [70–72]. The RECIST criteria used for radiological
evaluation recommended the measurement of five target-lesions, selected “randomly,” only on their
suitability for accurate repeated measures [70]. On the contrary, several works using PET imaging
showed that only the most metabolically active lesions, representing the most aggressive portions
of tumors, are critical to consider [73–77]. This approach implies taking the single hottest area as
the reference point on the pre-treatment and post-treatment studies, even if not necessarily the same
area, considering only the worst biologic behaviors of the malignancy. This controversial concept was
explored in many cancers and was applied both in solid tumors with the PERCIST criteria and in
lymphomas. For example, Lin et al. were the first to measure the reduction of SUVmax in the “hottest”
lesion before and during the treatment, in diffuse large B-cell lymphoma (Figure 3). In their study, they
also investigated the FDG uptake changes on interim FDG-PET within the initial hottest tumor site
on baseline FDG-PET (18% of 92 patients) which resulted in more false-negative exams in predicting
PFS [76].
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Figure 3. Selection of regions of interest in 57-y-old patient before chemotherapy. (A) Graded
color-scaled parametric analysis applied in reconstructed coronal PET image shows most active tumor
in upper abdomen. (B) Transverse PET image with a higher scale reveals celiac tumor (T) with activity
profile crossing the hottest point (red spot). (C) Corresponding activity profile in counts-per-pixel.
Isocontours are drawn with lower autocontour threshold of 4500 counts-per-pixel (red isocontour at
inset in B). (D) Normal background tissue (N): two large ROIs are manually selected on gluteal muscles,
avoiding iliac bone marrow activity. This research was originally published in JNM [76]. © SNMMI.
This approach was also recently reported in multiple myeloma patients [78]. In this pathology,
multi-clonal heterogeneity remains one of the main challenges in developing effective strategies.
Multiple myeloma is indeed characterized by spatial differences in the clonal architecture, with
potential non-homogeneous distribution of high-risk disease for which multi-region investigations
appear critical [79–81]. Yet, in a study by our team, the percentage difference of SUVmax between
baseline and interim FDG-PET was a powerful tool to predict long-term outcomes in patients with
FDG-avid multiple myeloma [78]. There again, similar to previous work in lymphomas or in solid
tumors, the hottest lesion in any region was used for comparison even if its location differed from the
initial hottest lesion on PET at diagnosis, to assess the most aggressive portion of the disease on each
PET examination, to free oneself from intrapatient heterogeneity.
4. Intratumor Heterogeneity Exploration through Quantitative Analysis of PET Imaging
In addition to conventional measurements of SUV, a new class of metrics has recently emerged in
PET imaging and is currently being clinically investigated [61]. A simple visual analysis of the FDG
uptake in PET images indeed suggests that the spatial distribution of voxels of different intensities in a
selected region and thus the spatial distribution of the radiotracer can be extremely heterogeneous. And
one can assume that this localized heterogeneity in medical images “partly” reflects heterogeneity on a
lower scale and underlying variations in metabolism, cellular proliferation or necrosis [82]. Advanced
image analysis of a tumor could then capture additional information and some researchers suggested
that genomic, proteomics, and other -omics patterns could be expressed in terms of macroscopic
image-based features [83]. This concept requiring the extraction of a large number of quantitative data
from medical multimodal images has become popular under the term “radiomics” [3,84,85]. In recent
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years, considerable efforts have been made by the medical imaging community to obtain correlations
between these image characteristics and tumor heterogeneity. Those metrics are often referred to
as “textural features” and belong to “high order parameters” (Table 2) along with shape-descriptors
or other descriptors based on fractal analysis or wavelet decomposition [61,86]. They measure the
relationships between groups of two or more voxels in the image (Figure 4). Numerous textural
features can be extracted from medical images, yet only a handful are sufficiently reliable, robust, and
reproducible. Texture analysis remains limited and biased by many methodological and technical
factors inherent to PET images’ acquisition, reconstruction algorithms, or segmentation technique
that can affect the quantification of image heterogeneity [86]. A number of recommendations are
available to help and guide researchers in making the right choices in the calculation and selection of
parameters [86–89].
 
Figure 4. Whole-body 18F-FDG PET scan (A) tumor segmentation (B) and voxel-intensity resampling
(C) allowing extraction of different features (D) by analysis of consecutive voxels in a direction (for
cooccurrence matrices) (a), alignment of voxels with same intensity (b), difference between voxels and
their neighbors (c), and zones of voxels with same intensity (d). This research was originally published
in JNM [90]. © SNMMI.
Table 2. Common imaging heterogeneity parameters. (Based on [61,91]).
Order Matrix Name of the Parameter Description of the Parameter
First Order
SUVmax SUV value of the maximum intensity voxel within aregion of interest (ROI)




SUVmean Average measure of SUV within a defined ROI
Metabolic tumor volume
(MTV) Volume of a defined ROI




Contrast Local variations in the GLCM
Correlation Joint probability occurrence of the specified pixelpairs
Entropy Texture randomness or irregularity
Energy Sum of squared elements in the GLCM




Short run emphasis (SRE) Distribution of short runs
Long run emphasis (LRE) Distribution of long runs
High gray level run emphasis
(HGRE) Distribution of high grey level values runs
Grey-level non-uniformity
(GLNU) Similarity of grey level values throughout the image
Run percentage (RP) Homogeneity and distribution of runs of an image ina specific direction
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Table 2. Cont.





emphasis (HGZE) Distribution of high grey level values zones
Zone length non uniformity
(ZLNU) Similarity of zone length throughout the image
Zone percentage (ZP) Homogeneity and distribution of zones of an imagein a specific direction




Coarseness Granularity within an image.
To date, numerous studies explored the potential value of textural features in PET imaging
with encouraging results in a number of cancers [86,92]. However, only a limited number adopted
rigorous methodological choices with particularly large cohorts of patients and robust statistical
analysis [93,94]. Keeping in mind these limitations, the evidence supporting the additional value of
advanced image features from FDG-PET continues to expand year after year. Several of the most recent
studies have used techniques such as external cohort validation [95–97], or even machine-learning
technique [98,99] and concluded in the usefulness of textural analysis regarding patient management.
Several method were also proposed to minimize the effect of inter-center variability related to textural
features computation [95,100,101] with encouraging results both on a methodological and prognostic
level. One should keep in mind that several hundred, if not thousands of handcrafted features can be
extracted, when the number of patients used to construct the predictive model is often several order of
magnitude lower than the number of features analyzed. The use of machine learning approaches in
this context is thus very useful but opens other issues related to the choice of suitable algorithm for
selecting features and subsequent classifier which were shown to be not unique [102] The use of more
complex approaches relying on deep learning (especially convolutional neural networks) may alleviate
most of the difficulties raised by handcrafted features even if other challenges arise like the number
of data used for training and tuning hyper-parameters of the model. A very good overview of the
available technique that may be potentially clinically efficient in a near future can be found in [103].
Finally, a few studies have investigated the potential combination of image-derived features
from multimodal imaging or associated to clinical data [95,104–106]. One example of a nomogram
construction, published by Desseroit et al. [104], combining tumor and heterogeneity features extracted
from both PET and CT components of routinely acquired FDG-PET scans in non-small cell lung cancers
is shown in Figure 5. Reports in patients with mantle cell lymphoma also successfully applied this
approach [107–109]. In this pathology, as demonstrated in a prospective study [107,108] and confirmed
in a recent work by Mayerhoefer et al. [109], the combination of radiomic features with bio-clinical
scores may possibly improve risk stratification. All these approaches form the basis for future works
investigating the value of textural features in PET imaging and combining these methods will only
reinforce the validity of the studies. In this regard, a recent study focused on this topic and successfully
applied some of these approaches. In this work [95], Lucia et al. validated in two independent external
cohorts of patients previously developed textural features-based models [110] relying on FDG PET
and MRI for prediction of disease-free survival and locoregional control in locally advanced cervical
cancer. Moreover, to adjust for the multicenter effects, they used the ComBat method, derived from
genomic data analysis. They were able to identify two radiomics features indeed associated with worse
outcome, confirming that more heterogeneous tumors have a poorer prognosis [95].
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Figure 5. Workflow of a nomogram construction combining tumor and heterogeneity features extracted
from both PET and CT components of routinely acquired FDG-PET scans in non-small cell lung cancers,
allowing for better stratification among patients with stage II–III, compared to stage I. This research
was originally published in EJNMMI [104]. © Springer.
Radiomic is a promising field. Unlike histological biomarkers derived from invasive biopsy
which sample only a small limited tumor region, as described above, radiomics non-invasively
interrogate the whole tumor. Visualization of tumor heterogeneity is essential in the assessment of
tumor aggressiveness and prognosis. Radiomic has an exceptional potential and may prove critical
toward personalized medicine [83].
5. Conclusions
Nuclear medicine is one of the most dynamic medical fields. Advances in cancer biology
knowledge together with the rise of new imaging techniques (new detection system and progress
in imaging analysis) make this discipline a domain of tremendous and growing evolution. This
dynamism is a real asset as personalized medicine has never been so relevant today. Indeed, PET
imaging appears as an essential tool for non-invasive exploration of intratumoral and interlesional
heterogeneity through the exploration of the distribution and uptake of a tracer or by using multiple
radiopharmaceuticals, each providing different information. There is convincing evidence that the
integration of PET imaging “profiling,” combining these approaches, associated to clinical, biological,
or genomic data could improve tumor characterization and prognosis prediction to allow adequate
patients stratification to therapeutic regimens. By combining at least one metabolic tracer with a
phenotypic one, and by quoting Mankoff et Dehdashti [31], “it may then be possible to show that when
it comes to molecular imaging, 1 plus 1 is greater than 2.”
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Abstract: Tumor DNA mismatch repair (MMR) deficiency testing is important to the identification of
Lynch syndrome and decision making regarding adjuvant chemotherapy in stage II colorectal cancer
(CRC) and has become an indispensable test in metastatic tumors due to the high efficacy of immune
checkpoint inhibitor (ICI) in deficient MMR (dMMR) tumors. CRCs greatly benefit from this testing
as approximately 15% of them are dMMR but only 3% to 5% are at a metastatic stage. MMR status
can be determined by two different methods, microsatellite instability (MSI) testing on tumor DNA,
and immunohistochemistry of the MMR proteins on tumor tissue. Recent studies have reported
a rate of 3% to 10% of discordance between these two tests. Moreover, some reports suggest possible
intra- and inter-tumoral heterogeneity of MMR and MSI status. These issues are important to know
and to clarify in order to define therapeutic strategy in CRC. This review aims to detail the standard
techniques used for the determination of MMR and MSI status, along with their advantages and limits.
We review the discordances that may arise between these two tests, tumor heterogeneity of MMR
and MSI status, and possible explanations. We also discuss the strategies designed to distinguish
sporadic versus germline dMMR/MSI CRC. Finally, we present new and accurate methods aimed at
determining MMR/MSI status.
Keywords: microsatellite instability; colorectal cancer; immune checkpoints; deficient mismatch repair
1. Introduction
There are three major mechanisms in colorectal (CRC) carcinogenesis. The most common is
chromosomal instability (CIN) in 75% of CRCs, the second is an epigenetic modification of DNA
methylation, also called CpG island methylator phenotype (CIMP), in 20% of CRCs, and the third is
microsatellite instability (MSI) or deficiency of DNA mismatch repair system (MMR) which occurs in
approximately 15% of CRCs (Figure 1) [1]. It is worth noting that there is frequent overlap between
CIMP and dMMR/MSI phenotype. CRC carcinogenesis is somewhat more complex, and while rare
overlaps between CIN and CIMP or CIN and MSI phenotypes exist, they will not be developed here [2].
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Figure 1. Simplified molecular subgroups of colorectal cancers. There are three major mechanisms
of colorectal carcinogenesis, 75% of chromosomal instability, 20% of DNA methylation, and 15% of
microsatellite instability or deficient DNA mismatch repair [1]. MSS: microsatellite stability, MSI:
microsatellite instability, CIMP: CpG island methylator phenotype, CIN: chromosomal instability.
Microsatellites (also called “short tandem repeats”) correspond to DNA sequences distributed
throughout the genome (coding or non-coding sequences) with a repetitive structure, i.e., repetition,
a variable number of times, of a single nucleotide or di-, tri-, or tetra-nucleotides. These repetitive
structures are particularly prone to replication errors in the case of deficiency of the MMR system
(dMMR status). An accumulation of errors in the sequence of these microsatellites, called microsatellite
instability, highlights malfunction of the MMR system. Cancers with such phenotypes are said to be
MSI or by extension, MMR-deficient (dMMR), which is the opposite of microsatellite stability (MSS),
also known as MMR-proficient (pMMR).
The MMR system consists of four major proteins called MLH1, MSH2, MSH6, and PMS2.
These proteins identify and correct DNA mismatches caused by DNA polymerase during replication,
which occurs especially in microsatellites. These proteins work two by two, MLH1 with PMS2 and
MSH2 with MSH6, and form the MutLα and MutSa complex, respectively. MutSa recognizes single base
pair mismatch, creates a sliding clamp around DNA, and then binds the second complex, MutLα [3].
This combination interacts with many enzymes, including the DNA polymerase, to perform excision
of the single mismatch and resynthesize the DNA strand (Figure 2). MutSa can also recognize other
error patterns such as insertion and deletion loops and then preferably bind with MutL homologs,
such as MutLβ (MLH1-PMS1) and MutLγ (MLH1-MLH3), thereby achieving error excision [4,5].
Loss of function of one of the four proteins (MLH1, PMS2, MSH2, or MSH6) leads to inactivation of
the MMR system, resulting in a loss of fidelity of the replication and an accumulation of mutations.
This ultra-mutated profile causes dMMR/MSI cancers, including dMMR/MSI CRC.
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Figure 2. Mismatch repair mechanism. (A) Single mismatch, (B) DNA MMR protein sliding clamp,
(C) exonuclease complex, and (D) resynthesis. The complex MutSa recognizes single base pair mismatch
and surrounds the DNA like a clamp and then the MutL complex comes and links to MutSa. Different
enzymes (PCNA and DNA polymerase) then intervene to excise the errors and to resynthesize the DNA.
PCNA: proliferating cell nuclear antigen, ADP: adenosine diphosphate, ATP: adenosine triphosphate,
and MMR: mismatch repair. Proteins from the DNA repair system: MSH2, MSH6, PMS2, and MLH1.
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The dMMR/MSI phenotype can be acquired in sporadic CRC (75%) or constitutively in Lynch
syndrome, due to germline mutation of one of the MMR genes (25%) [6]. Sporadic cases are due in most
cases to a loss of expression of MLH1 caused by hypermethylation of the MLH1 gene promoter. Indeed,
dMMR/MSI detection is of major help to identify Lynch syndrome according to the revised Bethesda
criteria (Table 1). Other clinical impacts of dMMR/MSI determination enter into decision making
regarding adjuvant chemotherapy in stage II CRC and the use of immune checkpoint inhibitor (ICI) in
chemoresistant metastatic dMMR/MSI tumors. About 20% of stage II and III CRCs present a dMMR/MSI
phenotype and are associated with better prognosis than pMMR/MSS tumors [5]. Moreover, stage II
dMMR/MSI CRCs do not benefit from adjuvant fluoropyrimidine chemotherapy [7,8]. Consequently,
in view of a good prognosis for stage II dMMR/MSI CRCs and chemoresistance to fluoropyrimidine,
adjuvant chemotherapy is not recommended. Nevertheless, for high-risk stage II dMMR/MSI CRCs
with very poor prognosis criteria, such as T4 stage and vascular emboli, oxaliplatin-based adjuvant
chemotherapy should be discussed case by case. In metastatic CRCs (mCRC), dMMR/MSI represents
only around 3% to 5% of mCRCs and has been associated with poor prognosis and chemoresistance
to standard treatment [9,10]. Nevertheless, recent series have reported prolonged overall survival
in dMMR/MSI mCRC and a trend toward better outcomes of anti-vascular endothelial growth
factor (anti-VEGF) as compared with anti-epidermal growth factor receptor (anti-EGFR), but no
difference according to chemotherapy regimen, i.e., irinotecan-based chemotherapy as compared with
oxaliplatin-based chemotherapy has been reported [11]. Finally, recent nonrandomized trials suggest
high efficacy of immune checkpoint inhibitor (ICI) in chemoresistant dMMR/MSI metastatic tumors
due to the high tumor mutational burden in these tumors, while the other predictor of response to ICI
is the IHC labeling of the PD-L1 protein (programmed death-ligand 1) [12,13].
Table 1. Revised Bethesda criteria [14].
1. Colorectal cancer diagnosed in a patient less than 50 years of age
2. Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors *, regardless
of age
3. Colorectal cancer with the MSI histology † diagnosed in a patient less than 60 years of age §
4. Colorectal cancer diagnosed in one or more first-degree relatives with an HNPCC-related tumor,
with one of the cancers being diagnosed under age 50 years
5. Colorectal cancer diagnosed in two or more first- or second-degree relatives with HNPCC-related tumors,
regardless of age
*: Hereditary nonpolyposis colorectal cancer (HNPCC)-related tumors include colorectal, endometrial, stomach,
ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome)
tumors, sebaceous gland adenomas and keratoacanthomas in Muir–Torre syndrome, and carcinoma of the small
bowel. †: Presence of tumor-infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring
differentiation, or medullary growth pattern. §: There was no consensus among the workshop participants on
whether to include the age criteria in guideline three above; participants voted to keep less than 60 years of age in
the guidelines.
To conclude, dMMR/MSI testing in CRC is indicated primarily in the following three circumstances:
in stage II CRCs to define indications and modalities of adjuvant chemotherapy, in stage IV to treat
with ICI, and for screening of Lynch syndrome based on the revised Bethesda criteria. However, in
some centers, dMMR/MSI testing is performed in all CRCs given its interest in multiple circumstances.
2. Mismatch Repair System and Microsatellite Instability Testing
The status of dMMR and MSI can be determined by two different methods, molecular MSI testing
based on DNA extracted from tumor tissue and immunohistochemistry (IHC) of the MMR proteins
based on sections of formalin-fixed paraffin-embedded (FFPE) tumor block. Commonly, a tumor is
called dMMR if it presents nuclear loss of expression of at least one of the MMR proteins (MLH1,
PMS2, MSH2, or MSH6), in contrast to pMMR tumor. A tumor is called MSI (or MSI-high, MSI-H) if it
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presents instability (variation in the microsatellite length) of at least 40% of a panel of microsatellites
tested on tumor DNA, in contrast to MSS tumor.
2.1. Microsatellite Instability Testing
Microsatellite instability testing is carried out on tumor DNA extracted from frozen or FFPE
tumor tissue. A specific area with high tumor cellularity (>20%) has to be selected by an experienced
pathologist to avoid false negative results [15]. Microsatellite instability is assessed by analyzing
microsatellite loci, either mononucleotide repeats or a combination of dinucleotide and mononucleotide
repeats as recommended [16].
The first reference panel, referred to as the Bethesda panel, consists of two mononucleotide loci
(big adenine tract BAT-25 and BAT-26) and three dinucleotide loci (D2S123, D5S346, and D17S250) [12].
BAT-25 is found in intron 16 of the c-KIT gene and BAT-26 in the intron 5 of the MSH2 gene. D2S123
(2p16) is telomeric to mismatch repair genes MSH-2 and MSH-6, D5S346 (5q21–22) is close to the locus
for the adenomatosis polyposis coli (APC) tumor suppressor gene, and D17S250 (17q11.2–12) is close to
the locus for the tumor suppressor gene BRCA-1 [17]. As dinucleotide repeats are less sensitive than
mononucleotide repeats for MSI detection, a comparison with non-tumor matching DNA is always
required (DNA extracted from non-tumor tissue from a surgical specimen). When using the Bethesda
panel, tumors with instability of two or more of these loci are considered as MSI (i.e., MSI-high),
and cancers with no instability at any of the five loci are considered MSS. Cancers with only one out
of five unstable loci are interpreted as MSI-low, although it is unclear whether MSI-low represents
a biologically distinct category or whether it simply reflects the inherent limitations of faithfully
replicating these repetitive sequences. For the time being, these tumors are considered as MSS.
The second panel is the pentaplex panel, which consists of the following five consensus
mononucleotide repeats: BAT-25, BAT-26, NR-21 located in the untranslated 5’ region of the SLC7AB
gene, NR-24 located in the untranslated 5’ region of the ZNF-2 gene, and NR-27 (MONO-27) located in
the untranslated 5’ region of the IAP-1 gene. The quasi-monomorphic nature of these microsatellites
facilitates their analysis; they have several repetitions and their size is highly homogeneous in the
Caucasian population [18]. Using the pentaplex panel, a tumor will be called MSI if at least three
markers out of five are unstable (Figure 3B). A tumor with no instability, or one unstable marker,
is classified MSS (Figure 3A). In very rare cases, where two markers are unstable, a healthy tissue
analysis is carried out to confirm or deny instability by comparing healthy and tumor tissue. This panel
has become the new standard, in most international recommendations for MSI testing; contrary to
the Bethesda panel, it does not require comparison with non-tumor tissue for MSI determination in
CRC [19].
Both MSI techniques are based on the simultaneous amplification of five markers in a multiplex PCR.
Amplification products then migrate on capillary electrophoresis, which enables marker distribution
depending on their sizes. Taq polymerase is not faithful enough to reproduce the exact number of
nucleotide repetitions, and therefore, at the expected size of a marker, the electrophoresis profile shows
a multiple peak pattern. The reference size of the marker per sample is given by the main, higher
peak and needs to be compared to its expected size in the general population [16]. If the size of the
marker significantly differs from its expected size, it signifies instability. For non-colorectal tumor
tissue, systematic double testing of tumor tissue and non-tumor tissue is performed for MSI testing.
When compared with non-tumor tissue, the threshold to define MSI is lowered to two unstable markers
out of five [20].
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Figure 3. MSS and MSI profiles using the pentaplex panel. (A) MSS profile of the five consensus
mononucleotide repeats and (B) MSI profile with 5 unstable mononucleotide repeats. Red arrows
indicate microsatellite instability.
2.2. MMR Protein Testing
IHC is a technique detecting protein expression directly from tissue samples. As MMR proteins
(MLH1, MSH2, MSH6, and PMS2) are in the nucleus, only nuclear staining is taken into account in
MMR protein detection. MMR protein loss is defined by the absence of IHC staining in the nucleus of
tumor cells, whereas normal cells remain stained, ensuring the technical validity of the experiment.
Indeed, nuclear staining of non-cancerous stromal cells is considered a good internal positive control,
even in Lynch syndrome, insofar as only one allele is mutated outside the tumor area (germline
mutation of one allele of one MMR gene). A cell develops a DNA repair defect only when its second
copy of the gene also becomes non-functional (Knudson’s two-hit hypothesis) as a result of a random
mutation (somatic mutation of the second allele of the same MMR gene). A loss of MMR protein
expression means genomic alteration (loss of heterozygosity, mutations or epigenetic modifications) of
the corresponding gene. A tumor is considered dMMR if one of the four MMR proteins is lost (absence
of nuclear staining) (Figure 4).
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Figure 4. Immunochemistry of MMR proteins. (A) MMR-proficient (pMMR) tumor, normal colonic
mucosa, no loss of expression of MMR proteins and (B) deficient MMR (dMMR) tumor with loss of
MLH1 and PMS2 expression.
In the MMR system, protein functions are achieved by heterodimers, MLH1 being the PMS2
partner and MSH2 being the MSH6 partner. In their monomeric form, MMR proteins are degraded.
Consequently, the loss of one MMR protein is usually accompanied by the loss of its partner. For instance,
loss of MLH1 or MSH2 proteins will leave PMS2 and MSH6, respectively, in their monomeric forms,
and they will be rapidly degraded. Consequently, loss of MLH1 expression is associated with PMS2
loss and loss of MSH2 expression is associated with MSH6 loss. However, the contrary is not true
insofar as MLH1 and MSH2 proteins, in their monomeric forms, can interact with other proteins of
the MMR system, i.e., MSH3, and thereby avoid degradation [21]. Indeed, isolated loss of PMS2
expression (≈5% to 10% of dMMR CRC [22]) or isolated loss of MSH6 expression (≈5% to 15% of
dMMR CRC [23]) is not rare. In view of both economy and time saving, some pathologists have
analyzed MMR expression of two proteins (MLH1 and MSH2) instead of four but have not been able
to detect isolated loss of PMS2 or MSH6 expression. Indeed, most guidelines recommend performing
IHC of all four MMR proteins to avoid misinterpretation [24].
2.3. Comparison of Molecular MSI Testing and MMR Proteins Immunohistochemistry
The molecular approach (MSI) presents the advantage of studying MMR system dysfunction and
is not limited to protein expression. Indeed, some point mutations allow MMR protein expression
(normal MMR proteins IHC), but without retaining the MMR function (MSI). However, MSI testing
takes somewhat longer and costs a little more than the IHC technique and does not provide information
as to which MMR gene is deficient.
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While both MSI panels, the Bethesda and the pentaplex, use the two microsatellite markers BAT-25
and BAT-26, polymorphisms have been reported for both, especially in African ethnicities [25]. To detect
these polymorphisms and to avoid counting them as unstable markers, it is commonly admitted that
an isolated unstable marker must be validated in comparison with the microsatellite profile of its
matched non-tumor tissue, even for CRC using the pentaplex panel. In this case, MSI exploration will
take longer. Finally, MSI interpretation requires trained molecular biologists, particularly to avoid
misinterpretation of BAT-25 or BAT-26 microsatellites [25,26].
MMR protein IHC is easier and less expensive. Moreover, an isolated loss of MSH6 is not always
responsible for MMR system deficiency, and hence not always detected by MSI technique [27,28].
Indeed, there exists functional redundancy of MMR proteins (PMS2 and PMS1, MSH6 and MSH3)
with MMR protein expression loss at IHC loss, while MSS status is retained due to partial activity of
the MMR system [22]. Moreover, MMR protein IHC can be difficult or misleading as it depends on
staining processes, which are not standardized from one laboratory to another (antigen demasking,
optimal antibody dilution, incubation time, etc.). Indeed, MMR protein IHC requires experienced
pathologists [29]. The technique can give false positive results as a non-functional MMR protein
can remain expressed in tumor tissue and detected by IHC even though the tumor is MSI. Indeed,
although one third of MLH1 mutations are missense mutations coding for non-functional proteins,
MLH1 expression remains detected by IHC [28]. Heterogeneous loss of MMR protein expression has
also been observed for MSH6 due to MSH6 somatic mutations [30].
With regard to sensitivity and specificity of IHC, they vary from 81% to 100% and from 80% to
92%, respectively [31]. MSI analysis sensitivity ranges from 67% to 100% and specificity from 61% to
92% using the Bethesda panel. When using the pentaplex panel, sensitivity is better (89% to 100%)
(no control with non-tumoral tissue) as is specificity (79% to 100%) [32,33].
3. Challenges for Determination of the dMMR/MSI Mechanism
3.1. How to Classify Sporadic versus Germline dMMR/MSI Colorectal Cancer?
MMR deficiency can be acquired in sporadic dMMR/MSI tumors or constitutively in Lynch
syndrome-related dMMR/MSI tumors. About 75% of dMMR/MSI CRCs are sporadic cases. In most
cases, observed loss of MLH1 expression is caused by hypermethylation of its promoter, acquired during
tumorigenesis. This epigenetic modification is developed in the context of senescence with global
hypermethylation of DNA, mainly at CpG islands [34]. CpG islands are regions of DNA that contain
numerous Guanine Cytosine dinucleotides bound together by a phosphodiester and frequently found
in gene promoters. Usually, when the cytosine is methylated in the promoter region, it causes inhibition
of transcription of the gene. CRC with global DNA hypermethylation is called “hypermethylator” or
CpG island methylator phenotype (CIMP). CIMP tumors are frequently associated with BRAF p.V600
mutation (from 77% to 95%) but their interconnections remain unclear [35,36]. Therefore, dMMR/MSI
CRCs with MLH1 loss and BRAF mutation are considered as sporadic dMMR/MSI CRCs. In the case
of dMMR/MSI CRC with MLH1 loss and BRAF wild type status, MLH1 promoter methylation is
determined and a MLH1 promoter hypermethylation signs the sporadic trait of the tumor.
The second group of dMMR/MSI CRCs is primarily related to Lynch syndrome (LS),
i.e., with detectable monoallelic germline mutation in one of the four MMR genes. The LS diagnosis
is a confirmed mutation of one of the MMR genes. The percentage of mutations identified in the
case of suspicion of LS is very variable according to the criteria selected, i.e., more than 90% in the
case of loss of MSH2 or MSH6, about 70% if the Amsterdam II criteria are met, about 40% in case of
loss of MLH1, and about 30% if the revised Bethesda criteria are met [37–39]. Most of the germline
mutations in LS occur in MLH1 or MSH2 genes (90%) (Table 2). MSH6 and PMS2 genes are less
frequently affected (about 10% of cases). In addition, the pathogenicity of PMS2 mutations is more
difficult to establish because of pseudogene interferences [40]. Pseudogenes are usually characterized
by a combination of homology to a known gene and loss of some functionality. Indeed, a PMS2
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non-expressed pseudogene exists and is highly homologous in both intronic and exonic sequences
to the PMS2 gene, hence polymorphisms in this pseudogene can be mistaken for mutations in the
PMS2 gene.
Table 2. The mutation frequencies of mismatch repair gene in Lynch syndrome [37–39].






Constitutional MLH1 epimutation 1–3%
According to the model described by Knudson et al. for tumor suppressor genes such as MMR
genes, one allele of the MMR gene has a germline mutation (first hit) and the second allele of the same
MMR gene is inactivated at the somatic level (second hit) by various alterations (somatic mutation,
genomic rearrangement, promoter hypermethylation, and loss of heterozygosity), which induce
deficiency of the MMR system [41]. International guidelines have defined algorithms to efficiently
identify LS patients among patients with sporadic dMMR/MSI tumors (Figure 5) [42].
Figure 5. dMMR/MSI screening of colorectal cancer (CRC) for suspicion of Lynch syndrome. * According
to the country and the guidelines, universal testing of CRC is recommended only if revised Bethesda
criteria are met. ** A result that is not in favor of diagnosis of Lynch syndrome must be interpreted
according to the patient’s family history and if Lynch syndrome or another genetic predisposition is
suspected, the patients must be referred to oncogenetic consultation. dMMR: deficient mismatch repair,
IHC: immunohistochemistry, LS: Lynch syndrome, MSS: microsatellite stability, MSI: microsatellite
instability, and pMMR: proficient mismatch repair.
3.2. MLH1 Promoter Hypermethylation
In dMMR/MSI CRC with loss of expression of MLH1, identification of the MLH1 promoter
hypermethylation and BRAF p.V600 mutation certifies the sporadic origin [24]. Conversely, if these
alterations are not found, the patient should be referred to oncogenetics for MMR germline testing.
Most teams initially limit their exploration to BRAF status due to cost and the time required for difficult
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MLH1 promoter hypermethylation testing. In the event of dMMR/MSI CRC with loss of expression of
MLH1 and BRAF wild-type status MLH1 promoter hypermethylation testing is performed secondarily.
Nevertheless, about 1% to 2% of LS cases (dMMR/MSI CRC with germline mutation) carry BRAF
mutation [43]. These cases are rare but, at the individual level, the mis-screening of LS can have
major consequences for the patient and his relatives. Indeed, dMMR/MSI BRAF-mutated CRC should
be tested for MLH1 promoter hypermethylation in the case of a high suspicion of LS to confirm,
before germline MMR testing, that it is not a sporadic case.
Determination of somatic versus germline mechanism of dMMR/MSI CRC using methylation
of the promoter of MLH1 gene can sometimes be incorrect. While hypermethylation is mostly
a somatic event, several cases of CRC with constitutional epimutations of the MLH1 gene have been
reported [44–46]. Constitutional MLH1 epimutations cause severe LS phenotype, including young age
of cancer onset and multiple primary tumors [45]. Usually, constitutional MLH1 epimutation arises de
novo with no or non-Mendelian inheritance and the second hit has a genetic, not an epigenetic basis
(somatic mutation or loss of heterozygosity) [46]. Patients with dMMR/MSI CRC with MLH1 promoter
hypermethylation should be screened for constitutional MLH1 epimutations in the case of early onset
CRC (before 50 years) or with multiple tumors before 60 years [47].
3.3. Challenge in Determination of Lynch Syndrome
In approximately 60% to 70% of dMMR/MSI CRCs with suspected LS according to the revised
Bethesda criteria, no mutation is identified (or variants of unknown significance) [48,49]. These tumors
are called Lynch-like syndrome (LLS) and are a challenge for predisposition management of the patient
and his family [48]. Indeed, the risk of colorectal cancer is higher in these families than in the general
population but lower than in LS families [50]. LLS can be due to biallelic somatic inactivation of one
MMR gene (or an allelic somatic mutation associated with loss of heterozygosity of the other allele),
which means that the progeny of the patient has a risk of CRC equal to the general population. Indeed,
upon excluding dMMR/MSI CRC patients with MLH1 promoter hypermethylation and germline
mutations, biallelic somatic inactivation is responsible for approximately 50% of the remaining
dMMR/MSI CRCs [51]. Despite the evident interest of somatic exploration to avoid expensive and
stressful screening protocol for a family with LLS, these tests are not routinely performed. Moreover,
some of them remain unexplained and may be due to genetic alterations that have yet to be identified.
Another issue is the 3′ deletion of the EPCAM gene (epithelial cell adhesion molecule), also called
TACSTD1 (tumor-associated calcium signal transducer 1), which leads to a hypermethylator profile of
its neighbor gene, MSH2 [37]. The latter will not be expressed and a loss of MSH2/MSH6 protein will
be detected by IHC. As no mutation in MMR genes will be detected by germline testing, the tumor
can wrongly be classified as LLS with low cancer risk, whereas it is known that carriers of an EPCAM
deletion have a cumulative risk of CRC similar to carriers of MSH2 mutation [37]. Nevertheless, in most
laboratories, germline EPCAM deletions are now analyzed primarily or secondarily in the absence of
MMR mutation. The incidence of EPCAM deletions has appeared to vary between populations and
may explain at least 1% to 3% of LS [52].
All in all, dMMR/MSI CRCs without evident sporadic mechanisms (i.e., MLH1 promoter
hypermethylation) and without germline mutation of MLH1, PMS2, MSH2, MSH6, deletion of
EPCAM or germline MLH1 promoter hypermethylation are considered unclassified as regards the
molecular mechanism underlying the MMR deficiency, LS versus sporadic cases. This situation
accounts for at least 30% of dMMR/MSI CRC patients with suspected LS [50,53]. These tumors are
mostly 1-loss of MSH6 protein expression without MSH6 germline mutation, 2-loss of MSH2 without
MSH2 germline mutation or EPCAM deletion, 3-loss of PMS2 with no loss of MLH1 and no PMS2
germline mutation, and 4-loss of MLH1 protein expression with no BRAF mutation and no MLH1
promoter hypermethylation and no MLH1 germline mutation. These patients and their first-degree
relatives must be considered as LS and monitored as such.
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4. Discordance Between MMR Immunohistochemistry and DNA Microsatellites Testing
On the basis of the literature, discordances between IHC of MMR proteins and MSI molecular
testing results range from 1% to 10% (Table 3).
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CRC: colorectal cancer, IHC: immunohistochemistry, MMR: mismatch repair, MSI: microsatellite instability, and NCI:
national institute cancer. * Only studies with more than 50 patients were included in the Table.
Studies evaluating discordances between molecular MSI and IHC tests in CRC are limited.
Moreover, it is difficult to compare these studies with each other because the molecular panels used for
MSI testing and the antibodies used for IHC are not the same. It is worth noting that the most frequently
observed discordance was loss of MSH6 expression with MSS status [23]. Indeed, dMMR/MSS CRC
with an isolated loss of MSH6 could be due to the partial redundancy of MSH6 and MSH3 protein
function. When the MSH6 protein is impaired, the MSH2/MSH3 heterodimer continues to operate and
DNA mismatch errors are partially corrected [26].
Unpublished data from our retrospective series of 1085 CRC patients showed 2.3% of discordances
using IHC of the four MMR proteins and the pentaplex panel. Among the 25 discordant cases (2.3%),
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reviewing by expert biologists and pathologists enabled reclassification of seven cases, mostly because
of misinterpretation of IHC due to poor quality of the staining or few tumor cells in the biopsy.
The remaining 18 discordant cases (1.7%) were mainly dMMR/MSS tumors (n = 15/18) with isolated
loss of MSH6 (n = 6). Indeed, pathologist and biologist expertise is crucial for accurate determination of
dMMR and MSI status, as also described by Jaffrelot et al. [61]. They studied 2528 patients with different
types of cancers with a discordance rate of 1.1%, using pentaplex panel for molecular biology and four
proteins for IHC. Cohen et al. studied fewer patients (n = 92) but reported a higher discordance rate
(9.8%) with the same two methods (pentaplex and four proteins) [60].
To avoid these discordances due to technical issues, it is necessary to follow some rules when
performing the tests, mainly to use tumor samples with good quality, more than 20% of tumor cells
and before any treatment, if possible (Table 4). Moreover, in cases of discordance, both tests must be
repeated so as to detect errors or tumor heterogeneity.
Table 4. Main causes of discordances and quality criteria to prevent them.
Causes of Discordance
Quality Criteria to Prevent Discordance
MMR IHC Molecular DNA testing
Low tumor cells [62] Selection of a specific area with thehighest rate of tumor cells
Macrodissection or selection of
tumor sections enriched in tumor
cells (≥20%)
Pre-analytical difficulties [28]
Use formol 4% (not Bouin’s
fixative), protocol standardization




participation in national and
international quality assessment
Non-expert physician [29] Participation in training sessions and request for rereading by expert ifnecessary
Neoadjuvant treatment [63] Testing on pretherapeutic samples
Polymorphisms in non-Caucasian
ethnic groups -
Testing of paired tumor and
non-tumor tissues





MMR: mismatch repair and IHC: immunohistochemistry.
Finally, 1% to 2% of discordances between MMR protein IHC and MSI molecular testing by
pentaplex remain unexplained. In these cases, germline mutation testing of the MMR genes must be
performed if LS is suspected. A diagnostic of LS implies a lifelong cancer screening protocol for the
patient and their relatives. Moreover, a recent report suggests that half of the diagnoses of patients
with mCRC and primary resistance to ICI are due to misinterpretation of the MMR IHC or MSI tests.
Indeed, to avoid false positive of dMMR or MSI tests, both tests are recommended before ICI treatment,
especially in clinical trials (Figure 6). Indeed, most trials with ICI now consider these discordances
during patient inclusion. Whereas in previous studies, either dMMR or MSI status was required for
patient inclusion [65,66], at present, both tests have to be performed with no discordance (dMMR and
MSI) [67,68]. Patients with discordant tests are not eligible for these ongoing trials (pMMR/MSI or
dMMR/MSS).
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Figure 6. dMMR/MSI screening of metastatic CRC for eligibility to immune checkpoint inhibitors.
* If no suspicion of Lynch syndrome. CRC: colorectal cancer, dMMR: deficient mismatch repair, IHC:
immunohistochemistry, LS: Lynch syndrome, MSS: microsatellite stability, MSI: microsatellite instability,
and pMMR: proficient mismatch repair.
Research is ongoing to improve detection of dMMR/MSI cases and to avoid discordant cases,
with particular interest in the use of other microsatellite markers such as HSP110 [69] or an increased
number of microsatellites analyzed using next-generation sequencing (NGS) [70] (see paragraph
“perspective of MSI/MMR testing”).
5. Focus on Tumor Heterogeneity
Although microsatellite instability is considered as an early event in CRC carcinogenesis, several
recent studies have reported that microsatellite instability is not always a homogeneous event
throughout the tumor in sporadic CRC [64,71]. Intra-tumoral heterogeneity is defined as the emergence
of tumor subclones with different genotypes in the same tumor mass and inter-tumoral heterogeneity
consists of the presence of at least two different tumor subclones on different tumor sites. Most studies
in mCRC have reported good concordance in mutational profiles of major signaling pathways, such as
KRAS, TP53, APC, PIK3CA, BRAF, and NRAS, between the primary tumor and its metastases, superior
to 95% [72,73]. However, some recent studies using highly sensitive techniques or microdissection
have identified tumor heterogeneity in CRC. Intra-tumoral and inter-tumoral heterogeneity of KRAS
mutations is now well-known in mCRC and correlates with resistance or reduced efficacy of anti-EGFR
therapies [74]. For instance, the Jeantet et al. study identified a high rate of RAS mutation heterogeneity
in mCRCs with 33% of intra-tumoral heterogeneity and 36% of inter-tumoral heterogeneity [75].
Most articles about tumor heterogeneity have focused on common mutations such as KRAS, TP53,
and PIK3CA while few data are available regarding MSI or MMR IHC tests and intra- and inter-tumoral
heterogeneity, and its possible variations during the tumor growth process.
In Lynch syndrome, microsatellite instability is the primum movens of tumor carcinogenesis and
all tumor cells should be dMMR/MSI with no heterogeneity. By contrast, in sporadic dMMR/MSI CRC
and even if microsatellite instability is considered as an early event, MMR deficiency may emerge
late in tumor progression with intra-tumoral or inter-tumoral heterogeneity. Indeed, according to
Chapusot et al., among 100 sporadic proximal CRCs, eight present an uncommon MMR IHC pattern
with loss of MMR expression (MLH1 and MSH6) restricted to small tumor areas and are MSI. Further
analyses on other tumor areas finally established the presence of intra-tumoral heterogeneity [76].
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Joost et al. collected 14 CRCs with heterogeneous IHC staining patterns that affected at least one of the
MMR proteins, that is, MLH1/PMS2 in three tumors, PMS2 in two tumors, MSH2/MSH6 in 10 tumors
(of which two also expressed heterogeneity for MLH1/PMS2), and MSH6 in one tumor. Analysis
of these 14 sectioned tumor blocks by molecular biology using the pentaplex panel demonstrated
intra-tumoral heterogeneity in three out of 14 tumors [71]. On the one hand, Tachon et al. reported
a case of CRC with heterogeneous MLH1/PMS2 staining pattern in primary tumor confirmed by MSI
testing, MSS in pMMR areas, and MSI in dMMR areas (intra-tumoral heterogeneity) [64]. By contrast,
metastatic lymph nodes were pMMR/MSS. On the other hand, in a cohort of 271 CRC Asian patients,
all MSI samples (n = 39) were dissected into three regions by tumors and analyzed using Bethesda
panel and no intra-tumoral heterogeneity was detected [77].
Although they are rare, due to the prognostic and therapeutic impacts of dMMR and MSI status,
detection of these atypical cases should be undertaken cautiously. Since most of these cases present
atypical staining at MMR IHC, MSI will help to determine the major tumor subclones. In the case
of discordance (dMMR/MSS), it may be useful to test at least two tumor areas of primary tumor or
metastases with both techniques in order to identify tumor heterogeneity. Finally, large prospective
studies are necessary to determine the rate of intra-tumoral and inter-tumoral heterogeneity of
microsatellite instability and their impact on prognosis and treatment efficacy. As of now, there are no
data concerning the efficacy of ICI in mCRC with intra- and inter-tumoral heterogeneity of dMMR and
MSI status. Moreover, to our knowledge, there are no data concerning the dynamic evolution of MMR
and MSI status during tumor progression, especially under treatment selection pressure.
6. Other Markers of Microsatellite Instability and Response to Immune Checkpoint Inhibitors
Finally, while MSI/dMMR reflects tumor genomic instability, it is not the only marker of response
to ICI. Tumor mutational burden (TMB) has been described as predictive of response to ICI, in the
subpopulation of MSI/dMMR mCRC [78], but not exclusively [79]. In dMMR CRC, due to frameshift
mutations leading to abnormal truncated protein products, several immunogenic neoantigens are
generated and explain the high number of tumor-infiltrating lymphocytes in these tumors [80].
For example, cytotoxic T lymphocytes specific to a neoantigen derived from TGFbetaRII frameshift
mutation have been identified in dMMR CRC harboring this mutation [81]. Two triggering signals
are required to initiate adaptive immune response by T cells: MHC-antigen (major histocompatibility
complex) peptide recognition by the T-cell receptor and costimulation via a collection of receptors
interacting with related ligands on antigen-presenting cells (APCs), thereby avoiding T-cell anergy [82].
CD28 is an example of costimulatory (positive) molecules and is constitutively expressed on the T-cell
surface. It binds to B7.1 (CD80) or B7.2 (CD86), which are expressed on APCs and provides the positive
costimulatory signal required for T-cell activation and survival [83]. In contrast, B7 molecules also
interact with cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which is expressed on T cells,
to which it transmits an inhibitory costimulatory signal. In many cancers, especially dMMR/MSI
mCRC, ligands of co-inhibitory immune checkpoint receptors are upregulated in a cancer cell or
tumor microenvironment, leading to T-cell functional exhaustion and unresponsiveness (a state of
anergy), and therefore to loss of tumor growth control (tumor escape). Other well-known immune
checkpoints include PD-L1/PD-1, MHC class II and lymphocyte activation gene 3 (LAG-3), and galectin-9
and mucin domain-containing protein-3 (TIM-3). These interactions allow negative feedbacks and,
using this rationale, several immune checkpoint inhibitors have been developed for cancer treatment
(mAbs blocking co-inhibitory immune checkpoint receptors or their ligands). Indeed, hypermutated
dMMR/MSI mCRCs, i.e., with high neoantigens load, have high sensitivity to immune checkpoint
inhibitors, which reactivate cytotoxic T cells to kill dMMR/MSI tumors cells.
Alteration in POLE gene (DNA polymerase epsilon), observed in ≈0.5% of CRCs [84] can
be detected somatically or constitutionally and is also responsible for tumor genomic instability,
with an ultramutator phenotype and high TMB [85]. POLE encodes the major catalytic and proofreading
subunits of the Polε DNA polymerase enzyme complex. The proofreading (exonuclease) function
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locates and replaces erroneous bases in the daughter strand through failed complementary pairing
with the parental strand. High-fidelity incorporation of bases by POLE, coupled with its exonuclease
proofreading function, ensures a low mutation rate. Clinically, patients in the POLE ultra-mutated
group have been reported to have high sensitivity to ICI [85]. Recent reports suggest an overlap
between dMMR and MSI status and POLE mutation.
A study has evaluated the relationship between MSI/dMMR, TMB, and PD-L1 expression in
approximately 2000 tumor samples (1395 CRCs) [86]. About one-third of the MSI cases, all types of
cancers combined, had TMB-low and only 26% of the MSI cases had positive PD-L1 status. All in
all, only 0.6% of cancers combined the three positive markers (MSI, TMB high, and PD-L1 positive),
although overlaps varied according to tumor type. Only 1.3% of CRCs combined the three positive
markers (MSI, TMB high, and PD-L1 positive) but 5.7% were MSI, 6.7% TMB high, and 7.2% PD-L1
positive. In this CRC population, 5.4% of overlap MSI and TMB high and 1.6% of overlap MSI and
PDL1 positive were observed [86]. For the moment, PD-L1 expression is not a proven biomarker to
select mCRC patients for treatment with ICI [87] and TMB determination is too time-consuming and
expensive for routine clinical practice. In spite of not being perfect, dMMR/MSI remains an established
marker of response to ICI in mCRC and its determination is crucial [12]. Nevertheless, in mCRCs with
discordances between IHC of MMR proteins and MSI, molecular testing determination of TMB could
help to select mCRC patients for treatment with ICI. New biomarkers to select mCRC patients eligible
for ICI are under investigation, especially immunoscore, which is being prospectively evaluated by
our group in the Pochi trial (xelox, bevacizumab plus pembrolizumab in pMMR/MSS mCRC with
high immunoscore).
Finally, molecular alterations associated with dMMR/MSI tumors, other than impairment of
the four core MMR proteins, have recently been described. These alterations mostly impact histone
methyltransferase or demethylase, with examples such as depletion of chromatin regulator SETD2
(set domain containing 2, methyltransferase) or deletion of FANCJ (Fanconi anemia, helicase) or
overexpression of KDM4 (H3K36me2/me3 demethylase), which reduces the abundance of MSH6 [88–90].
In the Awwad et al. study, KMD4 overexpression led to disruption of MSH6 foci formation during
S phase by demethylating its binding site, and resulted in a DNA mismatch repair system [90].
Genes involved in histone modification, such as SETD2, were significantly more mutated in older
patients (≥65 years) and this enzyme modifies histone proteins associated with DNA that control the
regulation of gene expression and DNA replication and prevent the association of MMR proteins with
damaged DNA, thereby preventing DNA mismatch repair [91].
7. Perspectives of MMR Immunohistochemistry and DNA Microsatellites Testing
Aside from multiple tumor area testing and systematic double screening by MMR IHC and MSI
tests, there are other ways to avoid false positives or false negatives, such as exploration of other
microsatellite markers.
7.1. The Role of HSP110 Protein in the Diagnosis of Microsatellite Status
HSP110, a chaperon protein with a T17 mononucleotide repeat located within intron 8, described
in CRC in 2011, shows a remarkably monomorphic profile in non-tumor tissue and is an interesting
candidate for microsatellite instability assessment with IHC and in molecular biology (Figures 7
and 8) [69,92]. Buhard et al. have suggested that HSP110 T17 deletion is present in all true dMMR/MSI
cases and should be used as a complementary test in discordant cases [69]. Indeed, from 70 patients
with CRC considered to be at high risk of LS, 46 displayed unambiguous MSS status with the pentaplex
panel and no aberrant HSP110 was detected in 45 of these 46 tumors (98%). For one patient with
aberrant HSP110, MSI status was confirmed by IHC showing loss of MSH2 expression in the tumor.
By contrast, in the Kim et al. study, 12% (n = 20/168) of MSI CRCs were not associated with instability of
HSP110 T17 [93], however, based on our experience, establishment of HSP110 status by IHC or molecular
technique (HSP110 T17 deletion) does not show 100% correlation and molecular determination of
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HSP110 T17 deletion can be difficult. Finally, while more data are needed before using HSP110 T17 in
routine clinical practice for MSI status determination, HSP110 T17 could be of help in difficult cases.
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Figure 8. Microsatellite instability testing of HSP110 T17. (A) MSS tumor with T16/T16 phenotype
(major peak at 147 bp) and (B) MSI tumor with large deletion of HSP110 T17, patient with a T16/T17
phenotype (peaks at 147 and 148 bps in the polymorphic zone). The major peak selected to determine
size of the deletion is the peak at 147 bps and the black arrow corresponds to a deletion of 4 bps.
7.2. A Larger Panel of Microsatellites for Better Detection of Instability
To improve MSI detection, another way is to analyze a large panel of microsatellites instead of only
five (i.e., pentaplex or Bethesda panels). Next-generation DNA sequencing (NGS), now routinely used
for determination of molecular alterations in most cancers, can allow comprehensive investigation of
multiple microsatellite loci simultaneously, while using appropriate computational tools. Several tools
have been developed and compared to standard procedures [70,94,95]. The mSing method incorporating
from 15 to 2957 microsatellite markers, has demonstrated 96.4% to 100% sensitivity and 97.2% to
100% specificity as compared to the pentaplex panel [94]. MSIsensor and MANTIS (microsatellite
analysis for normal tumor instability), other computational tools for MSI detection with NGS, have also
demonstrated their feasibility, although requiring non-tumor DNA [95,96]. MSIsensors scan a reference
genome to locate homopolymers and microsatellites and then record homopolymers of at least 5 bp
length and microsatellites of maximum repeat unit length five from the reference genome and each site
is saved in a loci file for subsequent analysis. MANTIS uses a set of mono- to penta-nucleotide repeat
microsatellites to detect MSI, by individually computing and aggregating the differences between the
allele length distribution of each locus of matched tumor and normal samples to achieve an average
distance score (zero, fully stable and two, fully unstable); a score threshold of 0.4 is recommended to
diagnose MSI in tumors. MANTIS has displayed superior performance compared to the other tools
(MANTIS, MSISensor, and mSINGS), having the highest overall sensitivity and specificity, even with
loci panels of varying size. Nevertheless, interest in classifying cases with discordant MMR IHC and
MSI results has never been explored. Moreover, NGS experiments are time-consuming and more
expensive than standard MMR IHC/MSI techniques, notably due to the complex bioinformatic analysis
required. The benefit and the place of this technique in this indication, therefore, remain to be precisely
determined [97].
7.3. Tumor Circulating DNA to Overcome Tumor Heterogeneity
As previously highlighted, correct identification of dMMR and MSI status can be impaired by
tumor heterogeneity, samples with few tumor cells or discordance between the two tests. Analysis
of circulating tumor DNA (ctDNA) could be another method likely to easily determine MSI status.
Tumor DNA is released into the bloodstream by exosome, secretion or necrosis and apoptosis. ctDNA
allows direct analysis at a given time of all the molecular alterations present in the tumor and the
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metastases, in a minimally invasive way (blood test). To our knowledge, only two studies have
reported the detection of MSI status using ctDNA [98,99]. In the Deng et al. study, 13 MSI CRCs based
on standard MSI analysis (six mononucleotides: NR-27, NR-21, BAT-26, BAT-25, NR-24, and MONO-27),
were correctly classified “MSI” using the NGS technique on tumoral tissue (analyses of the same
microsatellite loci). On ctDNA of the same 13 patients, the standard MSI technique (by PCR) failed
to detect MSI status while the NGS technique on ctDNA (the same as the one used for the tissue)
correctly identified all MSI cases [98]. In the second study with pan-cancer, ctDNA testing using the
Guardant360 (Guardant Health Clinical Laboratory, Redwood City, CA, US) NGS kit incorporating
99 putative microsatellite loci, accurately detected 87% (71/82) of tissue MSI-H and 99.5% of tissue
microsatellite stability (863/867) with an overall accuracy of 98.4% (934/949) [99].
ctDNA testing allows non-invasive MSI testing at diagnosis and also provides an opportunity to
follow the kinetics of MSI status. Monitoring MSI status at several time-points of tumor progression,
especially at treatment start and at relapse or progression, may be of major interest for monitoring
response to ICI (i.e., selection of pMMR/MSS subclones?) [100]. ctDNA testing could also help with
regard to the tumor heterogeneity issue as it reflects all the tumor subclones at a specific time [101].
Multiple samplings would not be necessary as a single blood sample could detect all major clones
located in the primary tumor and metastases as well. Nevertheless, as of now, we do not know whether
dynamic change of MSI during carcinogenesis exists. Finally, as MMR IHC and MSI discordances
are sometimes caused by insufficient sample quality or tumor cell quantity, ctDNA testing could also
be an interesting substitute [102]. Nevertheless, more data are needed to validate MSI detection by
ctDNA before application in routine clinical practice, which is ongoing in trials using ICI in dMMR/MSI
tumors [98].
New techniques for MSI assessment will probably help to more accurately diagnose dMMR/MSI
CRC and classify discordant cases such as MSI or MMS. However, while increasing the number of
markers to define the MSI status, prognosis of the technique may not significantly improve. On the
contrary, false positives may arise. Detection of cases with a low level of instability may be useful but
can also be without a relevant impact on routine clinical practice. Indeed, one of the urgent questions to
be addressed would be whether discordant cases or those with a low level of microsatellite instability
could benefit from immune checkpoint inhibitor.
8. Conclusions
MMR/MSI screening is crucial not only for LS screening but also in therapeutic management,
especially since the ICI revolution [89]. Indeed, patients with dMMR/MSI tumor have drawn a major
benefit from immunotherapy, whatever the tumor type, with a rate of disease control reaching 80%
and overall survival superior to three years in chemoresistant mCRC cases [10,12,103]. Consequently,
all mCRCs should be tested for MMR and MSI status.
Since ICI is ineffective in pMMR/MSS CRC, as well as expensive and liable to induce severe side
effects, it is essential to avoid false positive dMMR/MSI and false negative pMMR/MSS, and also to
classify discordant cases (pMMR/MSI and dMMR/MSS) [104]. As recommended in recent trials with
ICI, screening for ICI treatment in mCRC can be done by means of one test, MSI or MMR IHC, but in
the case of a positive test or difficulties interpreting the results, the second test should be performed
before treatment with ICI to confirm concordant dMMR/MSI results [67,68].
All the pitfalls of the different techniques must be known and any discordances should be
investigated, in order to achieve the following: 1-control MMR IHC and MSI results, 2-check sample
quality, 3-perform new tests on multiple tumor areas or sites, 4-test other microsatellites or ctDNA if
techniques are available (or else, send sample to an expert team), and 5-perform MMR germline testing
in the case of suspicion of LS. Indeed, rates of “true” discordant cases remain low. New techniques for
MSI assessment (NGS, ctDNA, etc.) will probably help to more accurately diagnose dMMR/MSI CRC,
which is a major challenge for these patients to have access to immunotherapy.
276
Cancers 2019, 11, 1567
Author Contributions: Conceptualization, C.E. and D.T.; validation, C.E., G.T., V.R., L.K.-T., D.T.; investigation,
C.E. and G.T.; resources, D.T.; data curation, C.E., G.T., V.R., L.K.-T., D.T.; writing—original draft preparation, C.E.
and G.T.; writing—review and editing, C.E, G.T, V.R., L.K.-T., D.T.
Funding: This research received no external funding.
Acknowledgments: The authors wish to thank Vanessa Le Berre for her assistance in preparing the
submission of the article and Jeffrey Arsham, an American medical translator, for reviewing our original
English-language manuscript.
Conflicts of Interest: The authors have no relevant affiliations or financial involvement with any organization
or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the
manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony,
grants or patents received or pending, or royalties. Peer reviewers on this manuscript have no relevant financial
or other relationships to disclose.
Abbreviations
ADP adenosine diphosphate




ctDNA circulating tumor DNA
dMMR deficient mismatch repair
ICI immune checkpoint inhibitor
IHC immunohistochemistry
LS Lynch syndrome
mCRC metastatic colorectal cancer





NCI national cancer institute
PCNA proliferating cell nuclear antigen
PCR polymerase chain reaction
PD-L1 programmed death ligand
pMMR proficient mismatch repair
TMB tumor mutational burden
LAG-3 lymphocyte activation gene 3
TIM-3 mucin domain-containing protein-3
References
1. Tariq, K.; Ghias, K. Colorectal cancer carcinogenesis: A review of mechanisms. Cancer Biol. Med. 2016,
13, 120. [CrossRef] [PubMed]
2. Snover, D.C. Update on the serrated pathway to colorectal carcinoma. Hum. Pathol. 2011, 42, 1–10. [CrossRef]
[PubMed]
3. Fishel, R. Mismatch Repair. J. Biol. Chem. 2015, 290, 26395. [CrossRef] [PubMed]
4. Kawasoe, Y.; Tsurimoto, T.; Nakagawa, T.; Masukata, H.; Takahashi, T.S. MutSα maintains the mismatch
repair capability by inhibiting PCNA unloading. Elife 2016, 5, e15155. [CrossRef] [PubMed]
5. Sinicrope, F.A.; Sargent, D.J. Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic,
Predictive, and Therapeutic Implications. Clin. Cancer Res. 2012, 18, 1506–1512. [CrossRef] [PubMed]
6. Hampel, H.; Frankel, W.L.; Martin, E.; Arnold, M.; Khanduja, K.; Kuebler, P.; Clendenning, M.; Sotamaa, K.;
Prior, T.; Westman, J.A.; et al. Feasibility of Screening for Lynch Syndrome Among Patients with Colorectal
Cancer. J. Clin. Oncol. 2008, 26, 5783. [CrossRef] [PubMed]
277
Cancers 2019, 11, 1567
7. Ribic, C.M.; Sargent, D.J.; Moore, M.J.; Thibodeau, S.N.; French, A.J.; Goldberg, R.M.; Hamilton, S.R.;
Laurent-Puig, P.; Gryfe, R.; Shepherd, L.E.; et al. Tumor Microsatellite-Instability Status as a Predictor of
Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. N. Engl. J. Med. 2003, 349, 247.
[CrossRef] [PubMed]
8. Tougeron, D.; Mouillet, G.; Trouilloud, I.; Lecomte, T.; Coriat, R.; Aparicio, T.; Des Guetz, G.; Lécaille, C.;
Artru, P.; Sickersen, G.; et al. Efficacy of Adjuvant Chemotherapy in Colon Cancer with Microsatellite
Instability: A Large Multicenter AGEO Study. J. Natl. Cancer Inst. 2016, 108, djv438. [CrossRef]
9. Venderbosch, S.; Nagtegaal, I.D.; Maughan, T.S.; Smith, C.G.; Cheadle, J.P.; Fisher, D.; Kaplan, R.; Quirke, P.;
Seymour, M.T.; Richman, S.D.; et al. Mismatch repair status and BRAF mutation status in metastatic colorectal
cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies. Clin. Cancer Res.
2014, 20, 5322–5330. [CrossRef]
10. Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.;
Laheru, D.; et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015, 372,
2509–2520. [CrossRef]
11. Tougeron, D.; Sueur, B.; Sefrioui, D.; Gentilhomme, L.; Lecomte, T.; Aparicio, T.; DES Guetz, G.; Artru, P.; De
La Fouchardiere, C.; Moulin, V.; et al. A large multicenter study evaluating prognosis and chemosensitivity
of metastatic colorectal cancers with microsatellite instability. J. Clin. Oncol. 2017, 35, 3536. [CrossRef]
12. Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K.; Lu, S.; Kemberling, H.; Wilt, C.;
Luber, B.S.; et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science
2017, 357, 409–413. [CrossRef] [PubMed]
13. Overman, M.J.; Lonardi, S.; Wong, K.Y.M.; Lenz, H.J.; Gelsomino, F.; Aglietta, M.; Morse, M.A.; Van
Cutsem, E.; McDermott, R.; Hill, A.; et al. Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA
Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J. Clin. Oncol. 2018,
36, 773–779. [CrossRef] [PubMed]
14. Umar, A.; Boland, C.R.; Terdiman, J.P.; Syngal, S.; de la Chapelle, A.; Rüschoff, J.; Fishel, R.; Lindor, N.M.;
Burgart, L.J.; Hamelin, R.; et al. Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer
(Lynch Syndrome) and Microsatellite Instability. J. Natl. Cancer Inst. 2004, 96, 261–268. [CrossRef] [PubMed]
15. Vasen, H.F.A.; Möslein, G.; Alonso, A.; Aretz, S.; Bernstein, I.; Bertario, L.; Blanco, I.; Bulow, S.; Burn, J.;
Capella, G.; et al. Recommendations to improve identification of hereditary and familial colorectal cancer in
Europe. Fam. Cancer 2010, 9, 109–115. [CrossRef] [PubMed]
16. Boland, C.R.; Thibodeau, S.N.; Hamilton, S.R.; Sidransky, D.; Eshleman, J.R.; Burt, R.W.; Meltzer, S.J.;
Rodriguez-Bigas, M.A.; Fodde, R.; Ranzani, G.N.; et al. A National Cancer Institute Workshop on
Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International
Criteria for the Determination of Microsatellite Instability in Colorectal Cancer. Cancer Res. 1998, 58,
5248–5257.
17. Scarisbrick, J.J.; Mitchell, T.J.; Calonje, E.; Orchard, G.; Russell-Jones, R.; Whittaker, S.J. Microsatellite
Instability Is Associated with Hypermethylation of the hMLH1 Gene and Reduced Gene Expression in
Mycosis Fungoides. J. Investig. Dermatol. 2003, 121, 894–901. [CrossRef]
18. Murphy, K.M.; Zhang, S.; Geiger, T.; Hafez, M.J.; Bacher, J.; Berg, K.D.; Eshleman, J.R. Comparison of the
Microsatellite Instability Analysis System and the Bethesda Panel for the Determination of Microsatellite
Instability in Colorectal Cancers. J. Mol. Diagn. 2006, 8, 305–311. [CrossRef]
19. Suraweera, N.; Duval, A.; Reperant, M.; Vaury, C.; Furlan, D.; Leroy, K.; Seruca, R.; Iacopetta, B.; Hamelin, R.
Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and
pentaplex PCR. Gastroenterology 2002, 123, 1804–1811. [CrossRef]
20. Wong, Y.F.; Cheung, T.H.; Lo, K.W.K.; Yim, S.F.; Chan, L.K.Y.; Buhard, O.; Duval, A.; Chung, T.K.H.;
Hamelin, R. Detection of microsatellite instability in endometrial cancer: Advantages of a panel of five
mononucleotide repeats over the National Cancer Institute panel of markers. Carcinogenesis 2006, 27, 951–955.
[CrossRef]
21. Acharya, S.; Wilson, T.; Gradia, S.; Kane, M.F.; Guerrette, S.; Marsischky, G.T.; Kolodner, R.; Fishel, R. hMSH2
forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc. Natl. Acad. Sci. USA 1996, 93,
13629–13634. [CrossRef] [PubMed]
278
Cancers 2019, 11, 1567
22. Liu, W.; Zhang, D.; Tan, S.A.; Liu, X.; Lai, J. Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2
Presenting in a Patient with Synchronous Prostate Cancer with Intact MMR: Diagnosis and Analysis of the
Family Pedigree. Anticancer Res. 2018, 38, 4847–4852. [CrossRef] [PubMed]
23. Verma, L.; Kane, M.F.; Brassett, C.; Schmeits, J.; Evans, D.G.R.; Kolodner, R.D.; Maher, E.R. Mononucleotide
microsatellite instability and germline MSH6 mutation analysis in early onset colorectal cancer. J. Med. Genet.
1999, 36, 678–682. [PubMed]
24. INCA. Tests Somatiques Recherchant une Déficience du Système MMR au Sein des Tumeurs du Spectre du Syndrome
de Lynch; Institut National du Cancer: Boulogne-Billancourt, France, 2016.
25. Pyatt, R.; Chadwick, R.B.; Johnson, C.K.; Adebamowo, C.; de la Chapelle, A.; Prior, T.W. Polymorphic
Variation at the BAT-25 and BAT-26 Loci in Individuals of African Origin: Implications for Microsatellite
Instability Testing. Am. J. Pathol. 1999, 155, 349–353. [CrossRef]
26. Zhang, L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer
patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite
instability testing. J. Mol. Diagn. 2008, 10, 301–307. [CrossRef] [PubMed]
27. Bao, F.; Panarelli, N.C.; Rennert, H.; Sherr, D.L.; Yantiss, R.K. Neoadjuvant therapy induces loss of MSH6
expression in colorectal carcinoma. Am. J. Surg. Pathol. 2010, 34, 1798–1804. [CrossRef] [PubMed]
28. Shia, J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients
at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.
J. Mol. Diagn. 2008, 10, 293–300. [CrossRef] [PubMed]
29. Overbeek, L.I.H.; Ligtenberg, M.J.L.; Willems, R.W.; Hermens, R.P.M.G.; Blokx, W.A.M.; Dubois, S.V.;
van der Linden, H.; Meijer, J.W.R.; Mlynek-Kersjes, M.L.; Hoogerbrugge, N.; et al. Interpretation of
Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting. Am. J.
Surg. Pathol. 2008, 32, 1246. [CrossRef]
30. McCarthy, A.J.; Capo-Chichi, J.M.; Spence, T.; Grenier, S.; Stockley, T.; Kamel-Reid, S.; Serra, S.;
Sabatini, P.; Chetty, R. Heterogenous loss of mismatch repair (MMR) protein expression: A challenge
for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. J. Pathol. Clin. Res.
2019, 5, 115–129. [CrossRef]
31. Snowsill, T.; Coelho, H.; Huxley, N.; Jones-Hughes, T.; Briscoe, S.; Frayling, I.M.; Hyde, C. Molecular testing
for Lynch syndrome in people with colorectal cancer: Systematic reviews and economic evaluation. Health
Technol. Assess. Winch. Engl. 2017, 21, 1–238. [CrossRef]
32. Goel, A.; Nagasaka, T.; Hamelin, R.; Boland, C.R. An Optimized Pentaplex PCR for Detecting DNA Mismatch
Repair-Deficient Colorectal Cancers. PLoS ONE 2010, 5, e9393. [CrossRef]
33. Xicola, R.M.; Llor, X.; Pons, E.; Castells, A.; Alenda, C.; Piñol, V.; Andreu, M.; Castellví-Bel, S.; Payá, A.; Jover, R.;
et al. Performance of Different Microsatellite Marker Panels for Detection of Mismatch Repair–Deficient
Colorectal Tumors. J. Natl. Cancer Inst. 2007, 99, 244–252. [CrossRef] [PubMed]
34. Robertson, K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005, 6, 597–610. [CrossRef]
[PubMed]
35. Weisenberger, D.J.; Siegmund, K.D.; Campan, M.; Young, J.; Long, T.I.; Faasse, M.A.; Kang, G.H.;
Widschwendter, M.; Weener, D.; Buchanan, D.; et al. CpG island methylator phenotype underlies sporadic
microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006,
38, 787–793. [CrossRef] [PubMed]
36. Kambara, T.; Simms, L.A.; Whitehall, V.L.J.; Spring, K.J.; Wynter, C.V.A.; Walsh, M.D.; Barker, M.A.; Arnold, S.;
McGivern, A.; Matsubara, N.; et al. BRAF mutation is associated with DNA methylation in serrated polyps
and cancers of the colorectum. Gut 2004, 53, 1137–1144. [CrossRef] [PubMed]
37. Tutlewska, K.; Lubinski, J.; Kurzawski, G. Germline deletions in the EPCAM gene as a cause of Lynch
syndrome—Literature review. Hered. Cancer Clin. Pract. 2013, 11, 9. [CrossRef]
38. Ward, R.L.; Dobbins, T.; Lindor, N.M.; Rapkins, R.W.; Hitchins, M.P. Identification of constitutional MLH1
epimutations and promoter variants in colorectal cancer patients from the Colon Cancer Family Registry.
Genet. Med. 2013, 15, 25–35. [CrossRef]
39. Crépin, M.; Dieu, M.C.; Lejeune, S.; Escande, F.; Boidin, D.; Porchet, N.; Morin, G.; Manouvrier, S.; Mathieu, M.;
Buisine, M.P. Evidence of constitutional MLH1 epimutation associated to transgenerational inheritance of
cancer susceptibility. Hum. Mutat. 2012, 33, 180–188. [CrossRef]
279
Cancers 2019, 11, 1567
40. Chadwick, R.B.; Meek, J.E.; Prior, T.W.; Peltomaki, P.; de la Chapelle, A. Polymorphisms in a pseudogene
highly homologous to PMS2. Hum. Mutat. 2000, 16, 530. [CrossRef]
41. Knudson, A.G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 2001, 1, 157–162. [CrossRef]
42. Sinicrope, F.A. Lynch Syndrome–Associated Colorectal Cancer. N. Engl. J. Med. 2018, 379, 764–773. [CrossRef]
[PubMed]
43. Parsons, M.T.; Buchanan, D.D.; Thompson, B.; Young, J.P.; Spurdle, A.B. Correlation of tumour BRAF
mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: A literature
review assessing utility of tumour features for MMR variant classification. J. Med. Genet. 2012, 49, 151–157.
[CrossRef] [PubMed]
44. Dámaso, E.; Castillejo, A.; Arias, M.D.M.; Canet-Hermida, J.; Navarro, M.; Del Valle, J.; Campos, O.;
Fernández, A.; Marín, F.; Turchetti, D.; et al. Primary constitutional MLH1 epimutations: A focal epigenetic
event. Br. J. Cancer 2018, 119, 978–987. [CrossRef] [PubMed]
45. Goel, A.; Nguyen, T.P.; Leung, H.C.E.; Nagasaka, T.; Rhees, J.; Hotchkiss, E.; Arnold, M.; Banerji, P.; Koi, M.;
Kwok, C.T.; et al. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new
sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int. J. Cancer
2011, 128, 869–878. [CrossRef]
46. Hitchins, M.P.; Ward, R.L. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for
hereditary non-polyposis colorectal cancer. J. Med. Genet. 2009, 46, 793–802. [CrossRef]
47. Pineda, M.; Mur, P.; Iniesta, M.D.; Borràs, E.; Campos, O.; Vargas, G.; Iglesias, S.; Fernández, A.; Gruber, S.B.;
Lázaro, C.; et al. MLH1 methylation screening is effective in identifying epimutation carriers. Eur. J.
Hum. Genet. 2012, 20, 1256–1264. [CrossRef]
48. Carethers, J.M. Differentiating Lynch-like from Lynch Syndrome. Gastroenterology 2014, 146, 602–604.
[CrossRef]
49. Antelo, M.; Golubicki, M.; Roca, E.; Mendez, G.; Carballido, M.; Iseas, S.; Cuatrecasas, M.; Moreira, L.;
Sanchez, A.; Carballal, S.; et al. Lynch-like syndrome is as frequent as Lynch syndrome in early-onset
nonfamilial nonpolyposis colorectal cancer. Int. J. Cancer 2019, 145, 705–713. [CrossRef]
50. Rodríguez–Soler, M.; Pérez–Carbonell, L.; Guarinos, C.; Zapater, P.; Castillejo, A.; Barberá, V.M.; Juárez, M.;
Bessa, X.; Xicola, R.M.; Clofent, J.; et al. Risk of Cancer in Cases of Suspected Lynch Syndrome without
Germline Mutation. Gastroenterology 2013, 144, 926–932. [CrossRef]
51. Geurts-Giele, W.R.R.; Leenen, C.H.M.; Dubbink, H.J.; Meijssen, I.C.; Post, E.; Sleddens, H.F.B.M.; Kuipers, E.J.;
Goverde, A.; van den Ouweland, A.M.W.; van Lier, M.G.F.; et al. Somatic aberrations of mismatch repair
genes as a cause of microsatellite-unstable cancers. J. Pathol. 2014, 234, 548–559. [CrossRef]
52. Kuiper, R.P.; Vissers, L.E.L.M.; Venkatachalam, R.; Bodmer, D.; Hoenselaar, E.; Goossens, M.; Haufe, A.;
Kamping, E.; Niessen, R.C.; Hogervorst, F.B.L.; et al. Recurrence and variability of germline EPCAM
deletions in Lynch syndrome. Hum. Mutat. 2011, 32, 407–414. [CrossRef] [PubMed]
53. Pearlman, R.; Haraldsdottir, S.; de la Chapelle, A.; Jonasson, J.G.; Liyanarachchi, S.; Frankel, W.L.; Rafnar, T.;
Stefansson, K.; Pritchard, C.C.; Hampel, H. Clinical Characteristics of Colorectal Cancer Patients with Double
Somatic Mismatch Repair Mutations Compared to Lynch Syndrome. J. Med. Genet. 2019, 56, 462. [CrossRef]
[PubMed]
54. Lindor, N.M.; Burgart, L.J.; Leontovich, O.; Goldberg, R.M.; Cunningham, J.M.; Sargent, D.J.;
Walsh-Vockley, C.; Petersen, G.M.; Walsh, M.D.; Leggett, B.A.; et al. Immunohistochemistry versus
microsatellite instability testing in phenotyping colorectal tumors. J. Clin. Oncol. 2002, 20, 1043–1048.
[CrossRef] [PubMed]
55. Hatch, S.B. Microsatellite Instability Testing in Colorectal Carcinoma: Choice of Markers Affects Sensitivity
of Detection of Mismatch Repair-Deficient Tumors. Clin. Cancer Res. 2005, 11, 2180–2187. [CrossRef]
56. Piñol, V.; Castells, A.; Andreu, M.; Castellví-Bel, S.; Alenda, C.; Llor, X.; Xicola, R.M.; Rodríguez-Moranta, F.;
Payá, A.; Jover, R.; et al. Accuracy of Revised Bethesda Guidelines, Microsatellite Instability,
and Immunohistochemistry for the Identification of Patients with Hereditary Nonpolyposis Colorectal
Cancer. JAMA 2005, 293, 1986–1994. [CrossRef]
57. Watson, N.; Grieu, F.; Morris, M.; Harvey, J.; Stewart, C.; Schofield, L.; Goldblatt, J.; Iacopetta, B. Heterogeneous
Staining for Mismatch Repair Proteins during Population-Based Prescreening for Hereditary Nonpolyposis
Colorectal Cancer. J. Mol. Diagn. 2007, 9, 472–478. [CrossRef]
280
Cancers 2019, 11, 1567
58. Yuan, L.; Chi, Y.; Chen, W.; Chen, X.; Wei, P.; Sheng, W.; Zhou, X.; Shi, D. Immunohistochemistry and
microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair
competency. Int. J. Clin. Exp. Med. 2015, 8, 20988.
59. Chen, M.; Chen, J.; Hu, J.; Chen, Q.; Yu, L.; Liu, B.; Qian, X.; Yang, M. Comparison of microsatellite status
detection methods in colorectal carcinoma. Int. J. Clin. Exp. Pathol. 2018, 11, 1431–1438.
60. Cohen, R.; Hain, E.; Buhard, O.; Guilloux, A.; Bardier, A.; Kaci, R.; Bertheau, P.; Renaud, F.; Bibeau, F.;
Fléjou, J.F. 537P Assessment of local clinical practice for testing of mismatch repair deficiency in metastatic
colorectal cancer: The need for new diagnostic guidelines prior to immunotherapy. Ann. Oncol. 2018, 29,
mdy281-083. [CrossRef]
61. Jaffrelot, M.; Laurenty, A.P.; Fares, N.; Staub, A.; Bonnet, D.; Danjoux, M.; Vande Perre, P.; Meilleroux, J.;
Chipoulet, E.; Toulas, C.; et al. Fiabilité de l’étude du phénotype MMR tumoral: Étude à partir d’une cohorte
de 4 948 cas de tests MSI et analyse des phénotypes atypiques. In Proceedings of the JFHOD, Paris, France,
21–24 March 2019.
62. Wang, Y. Differences in Microsatellite Instability Profiles between Endometrioid and Colorectal Cancers.
J. Mol. Diagn. 2017, 19, 57–64. Available online: https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pmc/articles/
PMC5225298/ (accessed on 30 June 2019). [CrossRef]
63. Goldstein, J.B.; Wu, W.; Borras, E.; Masand, G.; Cuddy, A.; Mork, M.E.; Bannon, S.A.; Lynch, P.M.;
Rodriguez-Bigas, M.; Taggart, M.W.; et al. Can Microsatellite Status of Colorectal Cancer Be Reliably
Assessed after Neoadjuvant Therapy? Clin. Cancer Res. 2017, 23, 5246–5254. [CrossRef] [PubMed]
64. Tachon, G.; Frouin, E.; Karayan-Tapon, L.; Auriault, M.L.; Godet, J.; Moulin, V.; Wang, Q.; Tougeron, D.
Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice.
Eur. J. Cancer 2018, 95, 112–116. [CrossRef] [PubMed]
65. Andre, T.; Lonardi, S.; Wong, K.Y.M.; Morse, M.; McDermott, R.S.; Hill, A.G.; Hendlisz, A.; Lenz, H.J.;
Leach, J.W.; Moss, R.A.; et al. Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of
patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic
colorectal cancer (mCRC): CheckMate 142 study. J. Clin. Oncol. 2017, 35, 3531. [CrossRef]
66. Diaz, L.A.; Le, D.T.; Yoshino, T.; Andre, T.; Bendell, J.C.; Koshiji, M.; Zhang, Y.; Kang, S.P.; Lam, B.; Jäger, D.
KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy
for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma. J. Clin. Oncol.
2017, 35, TPS815. [CrossRef]
67. Standard Chemotherapy vs. Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer.
Full Text View. Available online: https://clinicaltrials.gov/ct2/show/NCT03186326 (accessed on 18 August
2019).
68. Interest of iRECIST Evaluation for DCR for Evaluation of Patients with Deficient MMR and /or MSI
Metastatic Colorectal Cancer Treated with Nivolumab and Ipilimumab. Full Text View. Available online:
https://clinicaltrials.gov/ct2/show/NCT03350126 (accessed on 18 August 2019).
69. Buhard, O.; Lagrange, A.; Guilloux, A.; Colas, C.; Chouchène, M.; Wanherdrick, K.; Coulet, F.; Guillerm, E.;
Dorard, C.; Marisa, L.; et al. HSP110 T17 simplifies and improves the microsatellite instability testing in
patients with colorectal cancer. J. Med. Genet. 2016, 53, 377–384. [CrossRef] [PubMed]
70. Zhu, L.; Huang, Y.; Fang, X.; Liu, C.; Deng, W.; Zhong, C.; Xu, J.; Xu, D.; Yuan, Y. A Novel and Reliable Method
to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing. J. Mol. Diagn. 2018,
20, 225–231. [CrossRef] [PubMed]
71. Joost, P.; Veurink, N.; Holck, S.; Klarskov, L.; Bojesen, A.; Harbo, M.; Baldetorp, B.; Rambech, E.; Nilbert, M.
Heterogenous mismatch-repair status in colorectal cancer. Diagn. Pathol. 2014, 9, 126. [CrossRef]
72. Kim, K.; Kim, J.E.; Hong, Y.S.; Ahn, S.M.; Chun, S.M.; Hong, S.M.; Jang, S.J.; Yu, C.S.; Kim, J.C.; Kim, T.W.
Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous
Colorectal Cancer. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2017, 49, 161–167. [CrossRef]
73. Jesinghaus, M.; Wolf, T.; Pfarr, N.; Muckenhuber, A.; Ahadova, A.; Warth, A.; Goeppert, B.; Sers, C.;
Kloor, M.; Endris, V.; et al. Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized
Microsatellite-stable Colorectal Cancer. Am. J. Surg. Pathol. 2015, 39, 1140–1147. [CrossRef]
74. Testa, U.; Pelosi, E.; Castelli, G. Colorectal cancer: Genetic abnormalities, tumor progression, tumor
heterogeneity, clonal evolution and tumor-initiating cells. Med. Sci. 2018, 6, 31. [CrossRef]
281
Cancers 2019, 11, 1567
75. Jeantet, M.; Tougeron, D.; Tachon, G.; Cortes, U.; Archambaut, C.; Fromont, G.; Karayan-Tapon, L. High Intra-
and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. Int. J. Mol. Sci. 2016, 17, 2015.
[CrossRef] [PubMed]
76. Chapusot, C.; Martin, L.; Bouvier, A.M.; Bonithon-Kopp, C.; Ecarnot-Laubriet, A.; Rageot, D.; Ponnelle, T.;
Laurent Puig, P.; Faivre, J.; Piard, F. Microsatellite instability and intratumoural heterogeneity in 100
right-sided sporadic colon carcinomas. Br. J. Cancer 2002, 87, 400–404. [CrossRef] [PubMed]
77. Bai, W.; Ma, J.; Liu, Y.; Liang, J.; Wu, Y.; Yang, X.; Xu, E.; Li, Y.; Xi, Y. Screening of MSI detection loci and their
heterogeneity in East Asian colorectal cancer patients. Cancer Med. 2019, 8, 2157–2166. [CrossRef] [PubMed]
78. Schrock, A.B.; Ouyang, C.; Sandhu, J.; Sokol, E.; Jin, D.; Ross, J.S.; Miller, V.A.; Lim, D.; Amanam, I.; Chao, J.;
et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high
metastatic colorectal cancer. Ann. Oncol. 2019, 30, 1096–1103. [CrossRef] [PubMed]
79. Fabrizio, D.A.; George, T.J.; Dunne, R.F.; Frampton, G.; Sun, J.; Gowen, K.; Kennedy, M.; Greenbowe, J.;
Schrock, A.B.; Hezel, A.F.; et al. Beyond microsatellite testing: Assessment of tumor mutational burden
identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. J. Gastrointest. Oncol.
2018, 9, 610–617. [CrossRef] [PubMed]
80. Tougeron, D.; Fauquembergue, E.; Rouquette, A.; Le Pessot, F.; Sesboüé, R.; Laurent, M.; Berthet, P.;
Mauillon, J.; Di Fiore, F.; Sabourin, J.C.; et al. Tumor-infiltrating lymphocytes in colorectal cancers with
microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod. Pathol.
2009, 22, 1186–1195. [CrossRef]
81. Sæterdal, I.; Gjertsen, M.K.; Straten, P.; Eriksen, J.A.; Gaudernack, G. A TGFβRII frameshift-mutation-derived
CTL epitope recognised by HLA-A2-restricted CD8+ T cells. Cancer Immunol. Immunother. 2001, 50, 469–476.
82. Colle, R.; Cohen, R.; Cochereau, D.; Duval, A.; Lascols, O.; Lopez-Trabada, D.; Afchain, P.; Trouilloud, I.;
Parc, Y.; Lefevre, J.H.; et al. Immunotherapy and patients treated for cancer with microsatellite instability.
Bull. Cancer (Paris) 2017, 104, 42–51. [CrossRef]
83. De Guillebon, E.; Roussille, P.; Frouin, E.; Tougeron, D. Anti program death-1/anti program death-ligand 1 in
digestive cancers. World J. Gastrointest. Oncol. 2015, 7, 95–101. [CrossRef]
84. Müller, M.F.; Ibrahim, A.E.K.; Arends, M.J. Molecular pathological classification of colorectal cancer.
Virchows Arch. 2016, 469, 125–134. [CrossRef]
85. Silberman, R.; Steiner, D.F.; Lo, A.A.; Gomez, A.; Zehnder, J.L.; Chu, G.; Suarez, C.J. Complete and Prolonged
Response to Immune Checkpoint Blockade in POLE-Mutated Colorectal Cancer. JCO Precis. Oncol. 2019, 3,
1–5. [CrossRef]
86. Vanderwalde, A.; Spetzler, D.; Xiao, N.; Gatalica, Z.; Marshall, J. Microsatellite instability status determined
by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Cancer Med. 2018, 7, 746–756. [CrossRef] [PubMed]
87. Marginean, E.C.; Melosky, B. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy
in Colorectal Cancer with Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1
Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. Arch. Pathol. Lab. Med. 2018, 142,
26–34. [CrossRef] [PubMed]
88. Matsuzaki, K.; Borel, V.; Adelman, C.A.; Schindler, D.; Boulton, S.J. FANCJ suppresses microsatellite
instability and lymphomagenesis independent of the Fanconi anemia pathway. Genes Dev. 2015, 29,
2532–2546. [CrossRef] [PubMed]
89. Li, F.; Mao, G.; Tong, D.; Huang, J.; Gu, L.; Yang, W.; Li, G.M. The Histone Mark H3K36me3 Regulates Human
DNA Mismatch Repair through Its Interaction with MutSα. Cell 2013, 153, 590–600. [CrossRef] [PubMed]
90. Awwad, S.W.; Ayoub, N. Overexpression of KDM4 lysine demethylases disrupts the integrity of the DNA
mismatch repair pathway. Biol. Open 2015, 4, 498. [CrossRef] [PubMed]
91. Puccini, A.; Lenz, H.J.; Marshall, J.L.; Arguello, D.; Raghavan, D.; Korn, W.M.; Weinberg, B.A.; Poorman, K.;
Heeke, A.L.; Philip, P.A.; et al. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal
Tumors. Oncologist 2019, 24, 319–326. [CrossRef]
92. Dorard, C.; de Thonel, A.; Collura, A.; Marisa, L.; Svrcek, M.; Lagrange, A.; Jego, G.; Wanherdrick, K.;
Joly, A.L.; Buhard, O.; et al. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy
and improves disease prognosis. Nat. Med. 2011, 17, 1283–1289. [CrossRef]
282
Cancers 2019, 11, 1567
93. Kim, J.H.; Kim, K.J.; Rhee, Y.Y.; Oh, S.; Cho, N.Y.; Lee, H.S.; Kang, G.H. Expression status of wild-type
HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal
cancer. Mod. Pathol. 2014, 27, 443–453. [CrossRef]
94. Salipante, S.J.; Scroggins, S.M.; Hampel, H.L.; Turner, E.H.; Pritchard, C.C. Microsatellite Instability Detection
by Next Generation Sequencing. Clin. Chem. 2014, 60, 1192–1199. [CrossRef]
95. Niu, B.; Ye, K.; Zhang, Q.; Lu, C.; Xie, M.; McLellan, M.D.; Wendl, M.C.; Ding, L. MSIsensor: Microsatellite
instability detection using paired tumor-normal sequence data. Bioinformatics 2014, 30, 1015. [CrossRef]
[PubMed]
96. Kautto, E.A.; Bonneville, R.; Miya, J.; Yu, L.; Krook, M.A.; Reeser, J.W.; Roychowdhury, S. Performance
evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget 2017, 8, 7452.
[CrossRef] [PubMed]
97. Baudrin, L.G.; Deleuze, J.F.; How-Kit, A. Molecular and Computational Methods for the Detection of
Microsatellite Instability in Cancer. Front Oncol. 2018, 8, 621. [CrossRef] [PubMed]
98. Deng, A.; Yang, J.; Lang, J.; Jiang, Z.; Wang, W.; Yuan, D.; Wang, X.; Tian, G. Monitoring microsatellite
instability (MSI) in circulating tumor DNA by next-generation DNA-seq. J. Clin. Oncol. 2018, 36, 12025.
[CrossRef]
99. Willis, J.; Lefterova, M.I.; Artyomenko, A.; Kasi, P.M.; Nakamura, Y.; Mody, K.; Catenacci, D.V.T.; Fakih, M.;
Barbacioru, C.; Zhao, J.; et al. Validation of Microsatellite Instability Detection Using a Comprehensive
Plasma-Based Genotyping Panel. Clin. Cancer Res. 2019. [CrossRef]
100. Cabel, L.; Proudhon, C.; Romano, E.; Girard, N.; Lantz, O.; Stern, M.H.; Pierga, J.Y.; Bidard, F.C. Clinical
potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat. Rev. Clin. Oncol.
2018, 15, 639–650. [CrossRef]
101. Mattos-Arruda, L.D.; Weigelt, B.; Cortes, J.; Won, H.H.; Ng, C.K.Y.; Nuciforo, P.; Bidard, F.C.; Aura, C.;
Saura, C.; Peg, V.; et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of
circulating cell-free tumor DNA: A proof-of-principle. Ann. Oncol. 2014, 25, 1729. [CrossRef]
102. Day, D.; Frentzas, S.; Naidu, C.A.; Segelov, E.; Green, M. Current Utility and Future Applications of ctDNA in
Colorectal Cancer. In Advances in the Molecular Understanding of Colorectal Cancer; Segelov, E., Ed.; IntechOpen:
London, UK, 2019; Chapter 4; ISBN 978-1-78985-060-4.
103. Fader, A.N.; Diaz, L.A.; Armstrong, D.K.; Tanner, E.J.; Uram, J.; Eyring, A.; Wang, H.; Fisher, G.; Greten, T.;
Le, D. Preliminary results of a phase II study: PD-1 blockade in mismatch repair–deficient, recurrent or
persistent endometrial cancer. Gynecol. Oncol. 2016, 141, 206–207. [CrossRef]
104. Cohen, R.; Hain, E.; Buhard, O.; Guilloux, A.; Bardier, A.; Kaci, R.; Bertheau, P.; Renaud, F.; Bibeau, F.;
Fléjou, J.F.; et al. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal
Cancer with Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncol.
2019, 5, 551–555. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Spatiotemporal pH Heterogeneity as a Promoter of
Cancer Progression and Therapeutic Resistance
David E. Korenchan 1 and Robert R. Flavell 1,2,*
1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA
2 Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94143, USA
* Correspondence: Robert.Flavell@ucsf.edu; Tel.: +1-415-353-3638
Received: 21 June 2019; Accepted: 18 July 2019; Published: 20 July 2019
Abstract: Dysregulation of pH in solid tumors is a hallmark of cancer. In recent years, the role of
altered pH heterogeneity in space, between benign and aggressive tissues, between individual cancer
cells, and between subcellular compartments, has been steadily elucidated. Changes in temporal
pH-related processes on both fast and slow time scales, including altered kinetics of bicarbonate-CO2
exchange and its effects on pH buffering and gradual, progressive changes driven by changes in
metabolism, are further implicated in phenotypic changes observed in cancers. These discoveries
have been driven by advances in imaging technologies. This review provides an overview of intra-
and extracellular pH alterations in time and space reflected in cancer cells, as well as the available
technology to study pH spatiotemporal heterogeneity.
Keywords: tumor microenvironment; interstitial pH; acidosis; tumor heterogeneity; magnetic resonance
imaging; hyperpolarized 13C MRI; carbonic anhydrase; lactic acid; positron emission tomography
1. Introduction
In their seminal paper on the hallmarks of cancer [1], Hanahan and Weinberg proposed several
common features of neoplasia, largely caused by genomic changes, that promote tumor development.
Although genetic mutation is a necessary component of tumorigenesis, this must necessarily be
accompanied by disruptions in cellular homeostasis, reflected in changes in metabolism and transport,
which can be adapted according to cellular needs. These modifications both craft what has been
referred to as the 'tumor microenvironment”, an extracellular milieu that further promotes tumor
development and inhibits antitumor immune activity, as well as cell–cell heterogeneity within tumors,
which a growing body of research is supporting as a crucial factor in understanding overall tumor
function [2].
Alterations in pH in cancer represent one of the principal known disruptions in cellular and tissue
homeostasis. While initial interest was sparked by the observation that tumor tissues are significantly
more acidic than their normal counterparts, recent research has delved into how intracellular and
extracellular pH changes play a role in promoting tumor initiation, growth, survival, and metastasis.
The body of research on pH suggests that global measurements of pH do not capture the full story;
rather, the ability of cells to tune pH locally between organelles or between cells, as well as to respond
to kinetic changes affecting pH, plays a crucial role in the development and maintenance of the
cancer phenotype.
In this review article, we will summarize known findings on pH alterations in cancer and
suggest how spatiotemporal heterogeneity in pH works to promote tumor survival and progression.
We will also discuss the available methodologies for measuring pH on spatial and temporal scales,
as well as potential opportunities for further technical development in elucidating how pH influences
tumor behavior.
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2. pH Heterogeneity in Space
Interstitial acidification in cancer has been known for several decades, based upon electrode
pH measurements [3]. More recently, it has been suggested that interstitial acidification may be
accompanied by cytosolic alkalinization. There is also growing interest in the altered pH of subcellular
compartments, including endosomes and lysosomes. Several excellent reviews have summarized
properties and associated phenotypic changes of both intra- and extracellular pH in the context
of cancer [4–6]. Some salient details will be mentioned here. Normal tissue may demonstrate an
intracellular pH (pHi) and an extracellular pH (pHe) of about 7.2 and 7.4, respectively. In cancer, pHe
decreases to 7.0 or lower, leading to a reversal in the pHi–pHe gradient across the cell membrane.
Somewhat more controversial is the claim that pHi significantly increases in the context of cancer,
although in silico models based upon enzymatic pH-dependent activity profiles suggest that an
alkaline pHi confers maximal cell proliferation, upregulated glycolysis, and survival under hypoxia [7].
Changes in pH are closely linked with alterations in membrane transporter expression and function,
which change transport kinetics of protons and small ions including sodium, chloride, bicarbonate,
and lactate [8]. As will be discussed, pHi,e changes can lead to altered protein behavior and are
associated with many phenotypic changes in cancer progression, including invasion, proliferation,
stemness, aggressiveness, immune suppression, vascularization, and metastasis. Figure 1 summarizes
pH-related changes in transporter expression, protein function, and cellular phenotype that are
associated with cancer.
 
Figure 1. Spatiotemporal pH heterogeneity in cancer. Upper right inset: Proton extrusion mechanisms
(red arrows and labels) employed by tumor cells include transport proteins such as monocarboxylate
transporter 4 (MCT4), sodium-proton exchanger 1 (NHE1), or vacuolar-type ATPase. Alternatively,
protons can be titrated with imported bicarbonate (HCO3-), which then diffuses out of the cell as CO2.
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Carbonic anhydrase 9 (CAIX) and potentially other extracellular isoforms catalyze bicarbonate-CO2
exchange in order to reduce CO2 back-diffusion into cells and induce interstitial proton release. High
proton extrusion flux leads to an acidic pHe. Cells may also experience systemic fluctuations in CO2
(green arrows and labels), which induces pHi fluctuations in cells expressing intracellular carbonic
anhydrase isoforms. Upper left inset: Variations in pH lead to alterations in protonation states
of proteins with pH-sensitive amino acid residues, thereby causing structural changes that affect
protein function. Middle inset: Cancer cells may alter pH on a subcellular basis. Intracellular and
extracellular pH spatial heterogeneity can promote focal adhesion formation and/or degradation for
cellular migration. Additionally, altered lysosomal pH can facilitate drug resistance. An acidic pHe is
associated with immune cell anergy, drug localization to the extracellular space, and extracellular matrix
remodeling. Lower section: pH heterogeneity may also exist on the level of tissues. Certain tumor cells
may lower their pHi in order to reduce proliferation and maintain capacity for differentiation. pHe
gradients can be sculpted in a tumor depending on metabolic differences between cells (e.g., glycolytic
vs. oxidative metabolism) in combination with the proton extrusion mechanisms employed. Finally,
systemic CO2 fluctuations can alter pH depending on CA expression and localization.
2.1. Protonation as a Post-Translational Modification
Modulation of protein function based on pH represents a regulatory mechanism that can be rapid
as well as locally constrained. Small changes in local pH can significantly affect the ratio of protonated
versus deprotonated amino acid residues on a protein, depending on the acid dissociation constant
(pKa) of the side chain. Thus, single amino acid mutations in which the side chain pKa moves in
or out of the physiological pH range (e.g., arginine to histidine, or vice versa) can result in either
a gain or loss of protein pH sensitivity. These pH-related changes in function are well-described
for particular proteins in a recent review [9]. A few examples are detailed below. Proteins that
contain pH-sensitive residues or domains affecting activity include calcineurin [10], sodium-proton
exchanger 1 (NHE1) [11], cofilin [12], talin [13], and cancer signaling proteins including endothelial
growth factor receptor (EGFR), and transcription factor p53 [14]. Proteins found in the extracellular
space, notably proteases such as matrix metalloproteinase 3; urokinase-type plasminogen activator; and
cathepsins B, D, and L, also exhibit pH-dependent activity and may in fact only be activated at low pHe
values [15]. Interestingly, arginine-to-histidine mutations feature prominently in a subset of cancers,
including acute myeloid leukemia, colorectal, esophageal, low grade glioma, kidney chromophobe,
medulloblastoma, pancreatic, prostate, stomach, and uterine malignancies, suggesting that these
cancers may have accompanying changes in pHi to regulate protein activity [16]. Thus, by tuning pH
locally and temporally tumors can alter intracellular and extracellular protein functionality.
2.2. Intracellular pH
Generally speaking, interest in pHi changes (including subcellular compartments other than the
cytosol) has surrounded alterations in protein expression and function as a result of protonation state.
We will discuss cellular changes that result from intracellular pH alterations.
2.2.1. Spatial Regulation of Protein Activity via Subcellular pH Heterogeneity
Localized control of pHi within subcellular compartments can be accomplished based upon
expression and localization of proton and other ion transporters. Spatial heterogeneity in pHi can
therefore contribute to phenotypic hallmarks of cancer. During cell migration, a high pHi at the
cell front induces formation of focal adhesion complexes, mitigated in particular by pH-dependent
talin-actin binding [13], whereas a low pHi at the cell rear promotes focal adhesion destabilization as
well as myosin contraction [15]. Localization of NHE1 or MCT4 at the leading edge of migration can
generate the higher pHi required for cellular adhesion. Endosomes and lysosomes have a markedly
reduced pH compared to the cytosol (6.2 and 4.5–5.0, respectively) [17], and the degree of acidity
plays a crucial role in regulating lysosomal protein function. Lysosomal pH within tumor cells may
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therefore provide information regarding chemotherapeutic resistance, as increased vacuolar-type
ATPase (V-ATPase) expression is linked with drug localization in lysosomes [18].
2.2.2. Intercellular pHi Heterogeneity within Tumors
An intriguing area of investigation involves the influence of pHi in cellular heterogeneity within a
tumor. This is because an individual cell’s fate and function can be strongly affected by pHi. Studies of
pHi in the context of eye development in Drosophila melanogaster has revealed that increased proton
efflux and a resultant rise in pHi are sufficient to induce dysplasia, and that proton efflux inhibition in
cancer cell lines induces lethality [19]. Additionally, extracellular ATP was shown to cause intracellular
acidification in prostate cancer cells, leading to growth arrest via disruption of Ca2+ homeostasis [20].
pHi is tightly regulated, and pharmacologic inhibition of proton export significantly reduces tumor
growth [21]. These studies suggest a link between a high pHi and oncogenic events and proliferation in
mammalian cells. However, pHi plays a role in both normal development and oncogenesis. Increases
in pHi were shown to be necessary for the efficient differentiation of both Drosophila follicle cells
and mouse embryonic stem cells. Presumably, cancer stem cells might tend to promote a lower pHi
than surrounding cancer cells in order to prevent differentiation until necessary. Thus, measuring pHi
heterogeneity between cells in a tumor mass could potentially distinguish functional regions of the
tumor for the purpose of designing therapeutic strategies to disrupt intercellular symbiosis.
2.3. Extracellular pH
Far from being merely a side-effect of increased metabolic fluxes, the lower pHe observed in tumors
can also vary spatially, forming gradients within the interstitial space as well as cooperating with the
alkaline pHi to generate a tumor environment favorable for therapeutic resistance and metastasis.
We will briefly discuss the current mechanisms underlying interstitial acidification, then summarize
the effects of pHe spatial heterogeneity on tumors.
2.3.1. Metabolic and Physiological Contributors to Spatial Gradients and Acidic pHe
Interstitial acidification, independent of its tumor-promoting properties, is generally viewed as
a byproduct of altered metabolism coupled with changes in perfusion within tumors. Free protons
diffuse with a diffusion constant of ~1 × 10−4 cm2/s, which is fast enough compared to proton export
rates to diminish the formation of spatial gradients outside the cell. However, proton diffusion through
gels simulating the extracellular matrix has been measured as ~6 × 10−6 cm2/s [22], almost two orders
of magnitude slower than free proton diffusion and on the same order as water diffusion through
biological tissue (~2 × 10−6 cm2/s) [23]. This suggests that protons largely diffuse as mobile buffer
species such as phosphate or carbon dioxide. As a cancer grows and outdistances its local blood supply,
tumor regions become hypoxic, although they remain with diffusive distance of glucose [24]. This has
traditionally been understood to lead to HIF-1α stabilization, which in turn induces overexpression of
glycolytic enzymatic subunits (e.g., LDHA), proton-exporting transporters such as monocarboxylate
transporter 4 (MCT4), and carbonic anhydrase 9 (CAIX). Increased lactate metabolic flux coupled
with proton-lactate co-export via MCT4 is generally accepted to be a major mechanism of interstitial
acidification, with a variety of other mechanisms also contributing (Figure 1). For example, V-ATPase
and MCT4 are both major acidification mechanisms in human breast cancer cell lines [25]. Acidification
has also been shown to occur in glycolysis-deficient Chinese hamster cells [26,27], suggesting that
proton export pathways independent of lactate play a major role in this particular model. Therefore,
depending upon the genetic and metabolic state of the tumor, a variety of mechanisms contribute to
interstitial acidification.
Recent studies have suggested that pHe gradients may be present throughout a tumor mass,
and that these gradients, as well as the pHi–pHe gradient across the cell membrane, promote tumor
growth and survival. Experimental evidence suggests that free proton diffusion through tumor
interstitium is very small and that the majority of proton diffusion takes place by way of mobile
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buffers [22]. It has been hypothesized that various interstitial acidification mechanisms may be
present throughout a tumor mass depending on oxygen/metabolite availability, transporter expression,
and carbonic anhydrase (CA) activity, contributing to a pH gradient throughout the tumor [6].
Additionally, stromal cells near a lesion may shape pHe gradients by forming a syncytium that can take
up acidic byproducts and transport them away from the site of metabolism, as has been demonstrated
in co-cultures of myofibroblasts and colorectal cancer cells [28]. An intriguing area of research is the
contribution of CAIX to gradient sculpting of both pHi and pHe within cell spheroids and in vivo
xenografts. HCT116 human colon carcinoma spheroids transfected to constitutively express CAIX
diminish pHi gradients between the spheroid core and periphery [29] while simultaneously increasing
pHe gradients [30]. When these cells were implanted in a mouse and imaged with a 1H MRSI pH agent,
the resulting tumors only demonstrated voxel pHe values below 6.93, suggesting that CAIX acts as a
“pH-stat” and keeps pHe below a certain level [31]. Another interesting finding is that acid-extruding
bicarbonate transporters such as solute carrier family 4, members 4 and 9 (SLC4A4 and SLC4A9) are
hypoxia-inducible and are therefore likely expressed along with CAIX in hypoxic tumor regions [32].
Mathematical modeling of bicarbonate-CO2 exchange, diffusion, and cellular metabolism predicts
that the effect of CAIX catalysis on pHi and pHe heterogeneity is strongly dependent upon metabolic
pathways and proton transport mechanisms. Whereas cells that mainly produce CO2 or import HCO3−
to titrate intracellular protons benefit greatly from higher CAIX activity, cells which export protons
directly are minimally or even negatively affected by expressing CAIX [33]. Thus, interactions between
cellular metabolism, proton export, CO2 diffusion, and bicarbonate-CO2 interconversion all give rise to
the pHe observed in tumors.
2.3.2. Acidic pHe Can Alter Tumor Metabolism
Interstitial acidification that may be caused by altered metabolism can in turn affect metabolic
pathways. Ippolito et al. discovered in a prostate neuroendocrine carcinoma (PNEC) cell line that
glutamate decarboxylase (GAD) activity in cell lysates increased when the cells were incubated in acidic
media (pH 6.5) and decreased in alkaline media (pH 8.5) [34]. Interestingly, glutamate-ammonia ligase
(GLUL) demonstrated higher activity in both acidic and alkaline media relative to physiologic pH
(pH 7.4). The measured activities correlated with changes in protein expression as well. In a following
study, the group discovered that altering the culture media pH significantly altered metabolic pathways
in the same cell line, with acidic pH favoring oxidative phosphorylation and alkaline pH stimulating
nutrient consumption [35]. In keeping with this finding, they demonstrated that PNEC and human
prostate cancer cell lines were more susceptible to niclosamide inhibition of mitochondrial function at
acid pH and more susceptible to nutrient deprivation at alkaline pH. These findings are intriguing
in that they suggest that pHe measurements can aid in identifying metabolic heterogeneity within a
tumor in order to devise therapeutic strategies against tumor subregions.
2.3.3. Spatial pHe Gradients Promote Healthy Cell Death, Tumor Aggressiveness, and Therapeutic
Resistance
Spatial regulation of tumor pHe has a profound impact upon tumor aggressiveness, survival,
and treatment resistance. The lower tumor pHe forms a gradient with the less acidic interstitium of
normal tissue, promoting a net proton flow that may in turn induce normal cell toxicity [36]. Normal
cells may be unable to cope with the acid load because they are less able to remove intracellular
protons as effectively as tumor cells. The resulting interstitial acidification could activate caspase
activity, leading to apoptosis [37]. Interestingly, loss of p53 in cancer cells seems to protect against
acidic pHe-dependent induction of apoptosis as well [38]. Spatial fluctuations in pHe can affect cellular
migration and invasion. Prior in vivo studies of breast and colon cancer cells implanted in mice have
established that tumors grow preferentially along gradients of decreasing pHe, and that overexpression
of glucose transporter 1 (GLUT1) and NHE1 transporters at the leading edge drives invasion [39].
The high transmembrane pHi–pHe gradient can also act as a defense mechanism against weakly basic
289
Cancers 2019, 11, 1026
chemotherapeutic agents, since these will preferentially protonate in the interstitium, pick up a net
positive charge, and be prevented from cell internalization. This likely explains why extracellular
alkalinization via bicarbonate buffer therapy was shown to enhance doxorubicin (pKa = 7.6) uptake
in MCF-7 xenografts in vivo [40]. Several effects of acidic pHe on antitumor immune cell activity
have been documented. Acid pHe-dependent lactate import can induce anergy in human cytotoxic
T-cells in vitro [41], and pH neutralization in vitro reverses anergy for human and murine infiltrating
T-lymphocytes [42]. Acidosis leads to greater antigen uptake and presentation in dendritic cells
(DCs) [43]; however, tumor-derived lactate could also play a role in inducing a tumor-favorable
phenotype in DCs [44]. Bicarbonate therapy leads to more effective tumor cell killing by natural killer
(NK) cells, suggesting a role for pHe in modulating NK cell activity [45]. Finally, low pHe also affects
cellular differentiation status. Acid pHe promotes the expression of glial stem cell markers [46] and
promotes epithelial-to-mesenchymal transition in Lewis lung carcinoma cells [47].
Because transmembrane proton exporters and CA isoforms play a prominent role in cancer, several
inhibitors have been designed against these targets. A good review on CA inhibitors has been written by
Singh et al. [48]. Other inhibitors include amiloride derivatives against NHE1, proton pump inhibitors
(PPIs) against V-ATPase, and MCT inhibitors such as 4,4′-di-isothiocyanostilbene-2,2′-disulfonate
(DIDS) [49]. Additionally, a large body of literature exists on designing pH-sensitive drug delivery
systems [50] or prodrugs [51] that release the drug or form the active therapeutic agent when they
encounter the acidic tumor microenvironment.
3. pH Heterogeneity in Time
Studying alterations in pH distributions around, between, and within cells does not fully capture
the underlying biological changes in cancer. Alterations in tumor pH happen on various timescales,
ranging from transient, rapid fluctuations to slow, progressive changes. The fast-switching ability of
pH-sensing protons potentially lends itself to respond to rapid changes in pH. Furthermore, tumor
cells are known to undergo hypoxic-normoxic cycles as they outdistance their blood supply [24]. These
cycles likely imply associated changes in pH, which can modulate cell behavior. Additionally, changes
in regulation of carbonic anhydrase isoforms can affect the timescale of transient pH changes and thus
increase or decrease tumor cell sensitivity to pH transients. The study of pH modulation kinetics
represents an intriguing area of tumor biology that is only beginning to be elucidated. Finally, pHi,e in
solid tumors can change over the course of disease progression in order to suit the changing needs
and objectives of tumor cells. The following section highlights salient findings regarding temporal
pH changes.
3.1. Carbonic Anhydrase Kinetics
The changes in protein expression for various isoforms of carbonic anhydrase, notably CAIX, are
well-known for many cancers [52]. As alluded to in Section 2.2.1, CAIX activity can enable higher
metabolic fluxes for rapidly-dividing cancer cells by accelerating HCO3-/CO2-mediated “acid venting”,
which clears away acidic byproducts that might otherwise back up actively-utilized metabolic pathways.
Biological studies and mathematical modeling of lactic acid-producing muscle tissue demonstrate
the role of extracellular carbonic anhydrase in sustaining high metabolic flux and clearance to
blood [53,54]. One of the important features of CAIX in particular is that because its expression is
regulated via HIF1α, it is expressed along with other metabolism-related proteins such as LDHA,
MCT4, and SLC4A4/9. Additionally, although CAIX and other hypoxia-induced proteins can be
expressed through non-canonical HIF pathways, the catalytic activity of CAIX may be enhanced under
hypoxic conditions [55]. As mentioned in Section 2.2.1, CAIX catalysis enhances metabolic fluxes
depending upon the metabolic pathways utilized by cancer cells. Therefore, measuring bicarbonate-CO2
exchange kinetics in vivo could serve as an indicator of metabolic capacity. Gallagher et al. measured
differences in CAIX activity of HCT116 cells with and without constitutive CAIX expression implanted
subcutaneously in mice. Although the CAIX-expressing cells demonstrated a faster rate of conversion
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in vitro, a slower interconversion was observed for these same cells in vivo, which they attributed
to the lower in vivo tumor pHe reducing overall CAIX enzymatic activity [56]. This highlights the
complex phenomena that may contribute to pH regulation in vivo.
3.2. Effects of pHi Transients on Tumor Cells
A very intriguing study was recently performed by Hulikova et al. regarding CA isoforms and
coupling with CO2 fluctuations [57]. The authors discovered that although expression of intracellular
CA isoforms in various cell lines did not enhance proton diffusion throughout the cytosol, they did
sensitize cytosolic pHi to CO2 fluctuations, enabling it to oscillate in response to oscillating pCO2.
Mathematical modeling of pCO2-pHi coupling revealed that the downregulation of intracellular CAi
acted as a sort of low-pass filter, reducing the amplitude of more rapid pHi fluctuations. Intriguingly,
the mammalian target of rapamycin complex 1 (mTORC1) pathway activation as measured by lower
ribosomal protein S6 kinase (S6K) phosphorylation was achievable by exposing HCT116 cells to sharp
pCO2 fluctuations, whereas phosphorylation state did not significantly correlate with the average
pHi. CA inhibition with acetazolamide or knockdown of intracellular carbonic anhydrase 2 (CAII)
significantly altered S6K phosphorylation state. The authors concluded that this coupling between
pCO2 and pHi represents a potent signaling mechanism that can alter cellular activity, particularly
for intracellular CA-expressing tumor cells experiencing rapid pCO2 fluctuations. The authors also
suggested that downregulation of CAi isoforms may confer a survival advantage of tumor cells over
healthy cells, allowing them greater control over pHi as pCO2 fluctuates. At the same time, they
proposed that cancers cells with high CAi activity near aberrant blood vessels experiencing sharp pCO2
fluctuations would experience mTOR-dependent changes in metabolism and perfusion, elicited by
changes in intracellular [Ca2+]. These results suggest that a technique that can measure temporal pHi
fluctuations could identify tumors or tumor regions that are activating particular oncogenic pathways,
thereby facilitating tumor characterization. It also proposes a mechanism by which pH-sensing proteins
could become activated or deactivated by temporal pH changes.
3.3. Tumor pHe Decreases Over Time During Tumorigenesis and Disease Progression
While rapid fluctuations in tumor pHi,e may regulate cancer cell function and metabolism, pHi,e
changes over a slower time scale (e.g., weeks to months) may play an important role in cancer
progression. For example, it has been demonstrated that changes in pancreatic pHe result from chronic
inflammatory pancreatitis and after secretin administration, and it has been hypothesized that this
could drive pancreatic cancer development [58]. This hypothesis is further supported by evidence
that low pHe is associated with local invasion [39] and metastatic disease [59]. Moreover, alterations
in metabolic phenotype, including increased production of lactic acid, are upregulated in disease
progression, thereby inducing a higher degree of acidosis (Figure 1). These indirect lines of evidence
suggest a temporal link between changes in tumor pH and an invasive, metastatic phenotype.
The hypothesis that tumor pHe decreases during disease progression could be directly tested in
spontaneous genetically engineered models (GEM), which allow monitoring of tumors from early
precursors to high-grade, metastatic, lethal tumors [60]. Recently, we have evaluated the pHe of the
Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model in both early- and late-stage
tumors. This is a spontaneous GEM which proceeds from hyperplasia to low-grade tumors, ultimately
progressing to high-grade disease, metastasis, and death [61]. We hypothesized that pHe would
decrease based on prior data indicating increased production of lactic acid in high-grade tumors [62],
as well as the observation that treatment with sodium bicarbonate blocked tumorigenesis in this
model [63]. Supporting the hypothesis, we found that there was a significant decrease in pHe in
mice bearing high-grade tumors compared against low-grade counterparts [64]. Therefore, there is an
accumulating body of both indirect and direct evidence supporting the hypothesis that a temporal
decrease in pHe could represent a biomarker of tumor disease progression.
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4. Techniques to Measure pH Spatiotemporal Heterogeneity
The interstitial acidification that accompanies cancer was first discovered using pH
microelectrodes [3]. Today, many methodologies exist for studying pH changes in time and space,
covering a wide range of modalities, including nuclear methods such as positron emission tomography
(PET) and single-photon emission computerized tomography (SPECT), fluorescence, and magnetic
resonance. The principles underlying chemical agents that detect pH changes are summarized in
Figure 2. These techniques rely on a variety of mechanisms to generate image contrast, and they
operate over a wide range of spatial resolution scales. To the best of our knowledge, the only techniques
that have reported tumor pHe in patients are microelectrodes (5.85–7.68 over many tumor types) [3],
11C-DMO PET (6.88–7.26 in brain tumors/metastases) [65], and acido-chemical exchange saturation
transfer (acidoCEST) MRI (6.58 in metastatic ovarian cancer) [66]. In this section, we will briefly
summarize the range of techniques available for studying pH heterogeneity; these have also been
discussed in a recent review [67].
Figure 2. Mechanisms of pH measurement in cells and tissues. As a general rule, a pH-sensing agent
must contain at least one functional group with a pKa within the physiological range of detection to
generate image contrast. (a) Agents may demonstrate pH-dependent cell binding or uptake. In this
case, a pH decrease can trigger a change in cell permeability, membrane binding, or release of a
prodrug agent which can bind to cells. Importantly, absolute pH quantification is not possible. This
approach is used primarily for pH imaging with positron emission tomography (PET) or single-photon
emission computerized tomography (SPECT). (b) MR-based agents may interact with water protons in a
pH-dependent manner, in which pH induces changes in relaxivity or in exchange (as in acido-chemical
exchange saturation transfer, acidoCEST). (c) The protonated and deprotonated states of an agent may
emit different electromagnetic frequency waves. In this case, the ratio of emission between the two
wavelengths can be used to determine the pH. This approach is relevant to fluorescent-based pH probes
as well as hyperpolarized (HP) [13C]bicarbonate. (d) If the kinetic rate of protonation–deprotonation
is much faster than the absolute frequency difference between emission wavelengths, the agent will
exhibit a frequency shift rather than two distinct emission wavelengths. The observed frequency
depends on the relative populations (ρ) of protonated and deprotonated states, thereby giving the pH.
This approach describes pH imaging with MR spectroscopic techniques (1H, 31P, HP 13C).
4.1. Fluorescence-Based Measurements
Various fluorescent dyes and proteins exhibit a wavelength shift upon protonation, enabling
ratiometric pHi,e calculation by measuring fluorescent output at each wavelength. In general,
fluorescence methods including microscopy have very high spatial resolution (<1 μm), allowing
subcellular measurements of pH gradients, although applications to whole animal and clinical
imaging are limited by low penetration of light through tissue. An exemplary review covering
pH-sensitive fluorescent dyes is Han et al. [68]. Generally, pH imaging studies with fluorescent dyes are
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constrained to 60 minutes in length. One notable approach to pH measurement in various intracellular
compartments involves transfecting cells with a genetic construct encoding a pH-sensitive fluorescent
protein (e.g., pHluorin) modified with a targeting domain that will localize the protein to the desired
organelle [69,70]. This approach also extends the imaging timescale beyond that achievable with
fluorescent dyes. The low depth of tissue penetration for fluorescence in the visible spectrum can be
overcome through the use of agents emitting in the near-infrared range, which have a deeper tissue
penetration compared with visible light [71,72], allowing imaging in murine models. A different way
to overcome the tissue penetration limitations of fluorescence dyes in preclinical in vivo studies is
by constructing a dorsal window chamber. Some studies have demonstrated the use of SNARF-1
fluorescent dye with a dorsal window chamber in order to study proton gradients and flow in tumor
tissue [36] and to observe tumor cell migration along pHe gradients [39]. In theory, a similar approach
could be utilized for intraoperative fluorescence imaging of pH in patients, which has been reported
using other fluorescence molecular imaging probes [73], although this has not been reported to date.
4.2. PET/SPECT-Based Imaging Methods
Several radiolabeled tracers have been developed in order to study pHe in vivo, including
11C-dimethyloxazolidinedione (DMO) [65], 11CO2 [74], and 123I-labeled derivatives of malonic acid [75].
One elegant example of probe design is 64Cu-conjugated pH-low insertion peptide (pHLIP), which
anchors the radioisotope into cell membranes in regions where pHe is below 7.0. We have reported the
synthesis of various caged derivatives of 18F-fluorodeoxyglucose (FDG) that demonstrate pHe-sensitive
localization in vivo by caging group release in acidic pHe followed by uptake via glucose transporters.
By using different amine-containing caging groups varying in pKa, we could tune the pH sensitivity
of FDG uptake [76]. PET/SPECT-based approaches can be readily implemented for in vivo imaging
with good spatial resolution (1–2 mm); however, their primary limitation is that they cannot measure
absolute pHe, but only indicate regions below a certain threshold pHe. Although arterial blood
sampling along with imaging can be fit to a model to estimate pH values [65,74], these pH values have
not been correlated with microelectrode measurements. Nevertheless, these techniques may prove to
be useful in a clinical setting if threshold pH values can be demonstrated to sensitively and selectively
identify or characterize lesions.
4.3. MR-Based Techniques
Magnetic resonance offers spectral sensitivity that enables absolute pH quantification with high
tissue penetration depth, making it a well-studied technique for pHi,e measurement. Major techniques
under investigation include spectroscopic methods and chemical exchange saturation transfer (CEST)
based methodologies.
4.3.1. Chemical Exchange Saturation Transfer (CEST)
CEST approaches represent a rapidly-developing field of study for pHe measurement which has
the advantage of high spatial resolution (0.1–2 mm) but potentially low sensitivity; a comprehensive
review has been written by Chen et al. [77]. Generally, CEST techniques are able to measure pHe by
determining relative rates of protonation and deprotonation, typically for amide functional groups
on either endogenous molecules or administered contrast agents. A recent study demonstrated
more robust and accurate measurement of pHe using the acidoCEST method, which relies upon
exogenous contrast agent administration [78]. In an elegant study, Longo et al. combined CEST
pHe measurements with FDG PET imaging, demonstrating an inverse correlation between tumor
pHe and glucose uptake [79]. It is noteworthy that acidoCEST with the FDA-approved CT contrast
agent iopamidol to measure pHe has been demonstrated in patients with high-grade invasive ductal
carcinoma and with metastatic ovarian cancer [66].
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4.3.2. MR Relaxometry
In this method, paramagnetic contrast agents with a predictable, pH-dependent change in
spin-lattice (T1) relaxation time are administered and used to measure tissue pH. A major strength
of this method is high signal-to-noise ratio and spatial resolution (0.2–2 mm); however, a second,
pH-insensitive contrast agent must also be administered to accurately measure pH. For example,
Gillies et al. used a pH-dependant chelate, GdDOTA-4AmP5−, paired with a pH-independent analog,
GdDOTP5−, to generate high spatial resolution maps of tissue pHe in a rat glioma model [80]. A variety
of other agents have been reported [81,82] for this purpose.
4.3.3. MR Spectroscopic Approaches
Magnetic resonance spectroscopy can be used to measure tumor pHi,e by measuring the chemical
shift of a nucleus in a molecule with a pKa close to the physiological range and determining the pH from a
previously-constructed MR titration curve. This has been described for a variety of chemical compounds
and nuclei, including 31P, 1H, and 19F. 31P MR spectroscopy can be used to measure pHi based on the
chemical shift of the inorganic phosphate peak. Administration of 3-aminopropylphosphonate (3-APP)
followed by 31P MR spectroscopy can be used to measure pHe [83–85]. Similarly, 1H MR spectroscopic
imaging of imidazole-containing compounds, notably (±)2-(imidazol-1-yl)3-ethoxycarbonylpropionic
acid (IEPA) [86] and (±)2-(imidazol-1-yl)succinic acid (ISUCA) [31,87,88], can generate in vivo pHe
maps and therefore be used to study pHe heterogeneity. Similar approaches have been reported
with 19F-containing agents [89]. With the exception of 31P, MR imaging approaches can capture pHe
heterogeneity with acceptable spatial resolution (1–2 mm) and in a reasonable timeframe (10–30 min),
however it cannot measure pHi or capture kinetic pH changes. Both these limitations are linked with
low signal-to-noise or contrast-to-noise ratios.
4.3.4. Hyperpolarized (HP) 13C MR Imaging
The dramatic gain in MR signal attainable through dissolution dynamic nuclear polarization
(d-DNP) [90] provides unique opportunities to capture spatial as well as temporal changes in
pHe. Importantly, the ability to polarize, inject, and image multiple agents simultaneously [91] or
in the same imaging session holds great promise for simultaneously measuring pH and related
metabolic or physiological processes, such as glycolysis and perfusion. pHe mapping with
HP [13C]bicarbonate represents the majority of HP pH imaging and has been demonstrated in
tumors [91–93], perfused lungs [94,95], and other tissues [96,97]. pHi can also be quantified from HP
13CO2 produced from [1-13C]pyruvate in organs with high pyruvate dehydrogenase flux, most notably
the heart [98,99]. Although the short T1 of [13C]bicarbonate/13CO2 (~10 s in vivo [91–93,97,100]) poses
a significant challenge for obtaining sufficient spatial resolution, recent advances in hyperpolarization
approaches, including HP precursor decarboxylation [93,94,101], as well as advanced HP imaging
sequences [96,102,103], can provide significant gains in available HP signal and its effective utilization.
Nevertheless, HP image resolution (2–10 mm) is currently coarser than other modalities and MR
approaches. Figure 3 demonstrates hyperpolarized pHe imaging using an optimized [13C]bicarbonate
method along with HP measures of glycolysis and perfusion in the TRAMP mouse model of prostate
cancer. Other 13C-labeled compounds have also demonstrated pH sensitivity that are potentially
amenable to in vivo pHe imaging, including N-(2-acetamido)-2-aminoethanesulfonic acid (ACES) [104],
diethylmalonic acid (DEMA) [105], zymonic acid [106,107], and amino acid derivatives [108]. Notably,
zymonic acid was applied to pH imaging in kidneys and in a mammary tumor model [106].
Taken together, these data demonstrate robust tumor pHe measurements using a variety of HP
13C MRI methods.
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Figure 3. Hyperpolarized imaging of pHe, lactate conversion, and perfusion can be performed in a
single imaging study. Data are shown for a transgenic adenocarcinoma of the mouse prostate (TRAMP)
animal model displaying a consolidated, high-grade tumor confirmed with histology. HP images of
(a) extracellular pH, (b) lactate-to-pyruvate (Lac/Pyr) ratio, and (c) urea signal intensity are shown
overlaid on 1H anatomical images, enabling voxel-to-voxel correlations in order to study the interplay
between metabolism and acidification.
Importantly, high HP signal gains can also be used to measure kinetic phenomena, such as
CA-catalyzed [13C]bicarbonate-13CO2 exchange, on a sufficiently short timescale (0.1–1 s resolution).
Gallagher et al. studied differences in both pHe and bicarbonate-CO2 exchange within HCT116
xenografts that either overexpressed CAIX or did not [56]. The bicarbonate-to-CO2 forward reaction rate
was quantified by selective saturation of the HP 13CO2 resonance. They found that CAIX-overexpressing
tumors demonstrated a pHe that was 0.15 units lower, similar to results in cell spheroids [30], but
a paradoxically slower exchange rate, which they attributed to a pH-dependent reduction in CAIX
activity. It may be possible to measure both pHe and exchange rate in vivo through MR spectroscopic
techniques similar to the ones employed in this study, although the injected HP [13C]bicarbonate must
be given sufficient time to equilibrate if pHe is to be accurately measured.
HP approaches may also enable in vivo kinetic measurements of pHi, which represents a
tantalizing subject of investigation. One elegant example of this was demonstrated in perfused rat
hearts, where hyperpolarized [1-13C]pyruvate was decarboxylated to form 13CO2, enabling intracellular
measurement of pH by comparison with the bicarbonate resonance. The HP bicarbonate/CO2 data
clearly show differences in measured pHi dynamics with and without CA inhibition, suggesting the
ability to quantify CA-catalyzed intracellular bicarbonate-CO2 interconversion [98]. Similarly, HP
13C-labeled organic phosphates formed from [U-13C,U-2H]glucose, including glyceronephosphate
and 3-phosphoglycerate, have been shown to enable pHi quantification in yeast cells [109]. A similar
approach in which a HP 13C-labeled compound is taken up in mammalian cells and subsequently
phosphorylated to generate a pH-sensing moiety that may be feasible. Additionally, an existing HP pH
agent such as a dicarboxylic acid could be derivatized to form an ethyl ester, as has been demonstrated
with [1-13C]pyruvate to enhance blood–brain barrier crossing [110]. The ester groups could then be
cleaved inside the cell to generate the carboxylic acid moieties and regain pH-sensing ability. Both these
approaches may introduce significant toxicity concerns; nevertheless, these or other HP approaches
could open the way to measuring pHi spatiotemporal fluctuations in vivo.
5. Conclusions
Measuring average pH in tumors provides useful information but fails to describe the complex
dynamics of the tumor microenvironment. The spatial heterogeneity surrounding, among and
within cells plays a major role in driving the aggressive tumor phenotype. Rather than serving as
merely a byproduct of altered metabolism, pH variation throughout a tumor generates the necessary
conditions to alter protein functionality throughout cells, preserve cellular differentiation capacity,
reduce therapeutic uptake, shut down antitumor immune activity, and promote cellular migration and
metastasis. In addition, the kinetic processes that influence pH may hold a great deal of information
295
Cancers 2019, 11, 1026
regarding tumor initiation, metabolism, and cellular maintenance. Many imaging and measurement
techniques have been developed in order to study both pHi and pHe. Hyperpolarized 13C in particular
holds great promise for capturing both spatial and temporal heterogeneity within tumors based on its
ability to estimate kinetic rate constants in an imaging setting. Further development of these and other
in vivo pH measurement techniques will help to reveal the complex role that proton transport plays in
tumor development and therapy.
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